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Abstract 
 
 
 
 
Chromatin remodelling is required for access to occluded sequences of DNA by proteins 
involved in important biological processes, including DNA replication and transcription. There 
is an increasing amount of evidence for chromatin remodelling during DNA repair, although 
this has been mostly focused towards DNA double strand break and nucleotide excision 
repair. At this time there is little evidence for chromatin remodelling in base excision repair 
(BER). BER is a highly conserved DNA repair pathway which processes  spontaneous 
endogenous DNA base damages generated by oxidative metabolism, but also those induced 
by exogenous agents (eg. ionising radiation), to maintain genome stability. The mechanism in 
which the BER repairs damaged bases has been extensively studied and the repair proteins 
involved are well known. However in terms of chromatin, BER is poorly understood. It is 
thought that chromatin remodelling occurs due to accumulating evidence indicating that 
certain BER enzymes are significantly less efficient at acting on sterically occluded sites and 
near the nucleosome dyad axis. At this time the mechanisms and enzymes involved to 
facilitate BER are unknown. Therefore, the study presented in this thesis aimed to identify 
specific histone modification enzymes and/or chromatin remodellers that are involved in the 
processing of DNA base damage during BER. 
 
A method to generate two mononucleosome substrates with a site specific synthetic AP site 
(tetrahydrofuran; THF) was used to measure recombinant AP endonuclease 1 (APE1) activity 
alone, and APE1 in HeLa whole cell extract (WCE) that contained chromatin modifiers. The 
substrates contained either a THF rotationally positioned in the mononucleosome so the DNA 
backbone was facing outwards (THF-OUT) so accessible to APE1, or facing inwards (THF-
IN) towards the histone octamer and so sterically occluded to APE1. I discovered that the 
THF-OUT substrate was efficiently processed by recombinant APE1 alone and by APE1 in 
HeLa WCE. In contrast, recombinant APE1 activity was significantly impeded by THF-IN, but 
which was efficiently processed by APE1 in HeLa WCE in the presence of factors supporting 
ubiquitination. This suggested the presence of a chromatin modifier, predictably E3 ubiquitin 
ligase(s) present in WCE that was increasing THF-IN accessibility to APE1. A sequential 
chromatography approach was utilised to purify these novel activities from HeLa WCE, and I 
identified three separate activities capable of stimulating APE1 activity towards the THF-IN 
mononucleosome. Y-box protein 3 (YBX3) and HECT Domain E3 Ubiquitin Protein Ligase 1 
(HECTD1) were identified by mass spectrometry analysis of active fractions and their 
presence aligned with the APE1 stimulatory activity profile of the THF-IN substrate. Depletion 
of these proteins using siRNA in HeLa cells decreased cell survival following ionising radiation, 
and delayed DNA damage repair in both HeLa cells and in normal lung fibroblasts. Together 
ii 
 
these results suggest that HECTD1 and YBX3 are strong candidates required to facilitate BER 
through histone ubiquitination and/or chromatin remodelling, and provide new mechanistic 
information on the process of BER in cellular chromatin. 
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CHAPTER I 
 
INTRODUCTION  
 
1.1 Genome Stability and Instability 
   
   
The cell is a basic biological, functional and structural building block of most living 
organisms. Most organisms are single cells but others including ourselves are arranged of 
extensive multicellular systems comprising of specialised groups of cells that have their own 
functions but all communicate through elaborate systems. There more than 1013 cells in the 
human body which all originated from one cell. The whole organism is the result of countless 
cell divisions from the original single cell which acts as a carrier of genetic information that 
creates a species. Cells contain the machinery needed and have the ability to use materials 
from the environment to build a copy of the image of itself and genetic information.   
  
Genetic information in all living cells in earth is stored in the form of double stranded molecules 
called deoxyribose nucleic acid (DNA). In human cells identical copies of DNA, genome, are 
distributed between 23 pairs of chromosomes.  Double stranded DNA is a liner unbranched 
polymer made up of four types of monomers; adenine (A), cytosine (C), guanine (G) and 
thymine (T). These monomers are strung together to form a long sequence that encodes for 
the genetic information. Their specific order in DNA forms a code vital to the purpose of DNA. 
A gene is a region of DNA that encodes for a particular protein, the sequence of DNA encodes 
sequences of proteins. Humans have around 20-25,000 genes, although this only represent 
3% of the human genome. 20 different types of amino acid are used to build proteins, which 
type and order of the amino acid sequence is determined by the DNA sequence. Three DNA 
bases (codon) encodes for a specific amino acid within a protein sequence. The relationship 
of DNA sequence to the protein sequence is called the genetic code. Protein molecules are 
made up of long chains of amino acids. Each individual type of protein contains its own unique 
amino acid sequence. Proteins have a vast array of functions including cell mobility and shape, 
enzymes need to produce energy and inter/intra cellular signals.    
  
The DNA sequence can be altered during copying of genetic information, storage and random 
errors occurring chemically (for example from normal cellular metabolism) and by radiation 
from the environment. Damage to DNA can, in some instances, have no significant 
alteration on the cell. However, some however can lead to a change in the sequence of amino 
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acids in protein that may cause an alteration on the proteins structure, function (loss or gain 
of function) and regulation which can have a damaging effect on an organism. To maintain 
genome stability required for an organism’s survival it is important that these damage to DNA 
are repaired before they can have an effect on the whole organism. The significance of DNA 
repair in cells is apparent from the large collection of DNA enzymes that are in cells. Mutations 
in DNA the majority of the time are effectively repaired by DNA repair proteins, however when 
damage is not repaired it can lead to disease. Cancer, neurogenerative disorders and ageing 
are key examples of diseases that are predominantly caused by mutations in DNA. Extensive 
DNA damage (genomic instability) is a marker of almost all cancer cells. Cancer occurs when 
DNA errors are not repaired properly through DNA repair proteins being mutated, inaccuracies 
in repair, or whether there has been a huge increase in DNA damage overwhelming DNA 
repair proteins. This leads to abnormal cellular proliferation and survival due to key proteins 
in these pathways being defective due to mutations in the genes encoding for them or 
their regulators. Currently chemotherapy and radiotherapy are the key treatments for cancer. 
These work by causing extensive DNA damage in cancer cells, overwhelming the ability of 
the cell to repair DNA and so causing cell death. As cancer will affect 1:3 people in their 
lifetimes there is a need to understand more about basic cellular process to identify key drivers 
in the onset and progression of cancers, so these can be targeted for cancer treatment. As 
DNA damage is a hallmark of cancer and used as a frontline treatment it is an important area 
of research for treatment and development of cancers.     
  
1.1.1 Deoxyribose Nucleic acid   
  
DNA is a fundamental feature across all living organisms. The three dimensional structure of 
DNA was discovered to be a molecule comprising of two linear polynucleotide chains made 
up by four different nucleotides. These two polynucleotide chains were found to be held 
together by hydrogen bonds between corresponding nucleotide pairs (1). DNA has a fixed 
backbone that is composed of repeating pentose sugar-phosphate components. Each 
pentose sugar, 2’deoxyribose is connected by two 5’phosphate groups via a phosphodiester 
bond on the 3’hydroxyl residue on the sugar. 2’Deoxyribose sugars are attached to a base, 
there are four possible nitrogenous bases A, T, G, C (Figure 1A). A single unit of the DNA 
polymer is formed when one of this bases is linked to the pentose sugar by a 
covalent glycosidic bond forming a 2’deoxyribonucleoside, this is linked via the 5’ position of 
the pentose sugar to one or more phosphates to become a 2’deoxyribonucleotide (figure 
1B). The 2’deoxyribose molecules are orientated in the same position so each of the DNA 
polymers are polar, consequently the ends of the phosphate backbone are easily discernible; 
5’ phosphate on one end and 3’hydroxl on the other, the bonding between these only occurs 
in the 5’ to 3’ direction. The double helix occurs because of the structural and chemical  
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Figure 1: The chemical structure of the four nitrogenous bases and an example of 
nucleotide structure. (A) The chemical structure of the four main DNA nitrogenous bases, 
the two pyrimidines; C and T, which are composed of a single ring, and the two purines; A and 
G which are composed of 2 fused ring. (B) The nucleotide molecular structure using adenine 
as an example. When a base is attached to a deoxyribose sugar via a glycosidic bond (red 
bond) a nucleoside molecule is formed and which attached to a phosphate group by a 
phosphodiester bond (green bond) and together form the nucleotide. 
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features of the polynucleotide chains. All bases lie within the DNA helix due to the hydrogen 
bonds holding the two polymers together and the pentose sugar-phosphate backbone on the 
outside. A purine, a bulky two-ring base (A and G), is matched with a pyrimidine, a single ring 
base (T and C). A to T and G to C will only pair together due to the structure of bases and 
because of the structure of the DNA backbone. These wind around to form the DNA double 
helix with 10 bases for every 360ᴼ turn. Due to the necessity of base pairing each of the two 
pairs of DNA polymers are complementary to one another, but run antiparallel to one another 
as the polarity of the two strands is opposite and intertwined to form the DNA double helix 
(figure 2). The hydrogen bonds that hold the base pair together are much weaker than covalent 
bonds (such as the C-C or C-N that compose the structures of the bases). These week bonds 
are essential in biochemical systems, in that they are weak enough to be broken apart in 
systems (like transcription to produce RNA from which mRNA is produced by translation the 
messenger molecule that encodes for protein), but still robust enough to stabilise the double 
helix. The stacking of bases on top on each other provided stability to the DNA helix. This is 
achieved by the hydrophobic effect from the hydrophobic bases which group in the centre, 
away from neighbouring water. The polar surfaces however; the DNA backbone which is 
negatively charged is strongly hydrophilic. The stacking of bases on top of each other because 
of this hydrophobic effect attracts bases to one another through van der Waals forces, 
although these forces are weak in the double helix a large proportion of atoms are attracted 
by this force and so the net effect is considerable. Though this rigidity in the construction of 
DNA the storage and protection of genetic information allows its preservation of hereditary 
information.    
  
DNA in cells must be packaged into a small volume so it can be fit in the cell’s nucleus. This 
is achieved by specialised proteins that fold and package DNA in increasingly complex levels 
of organisation that fold nuclear DNA into a series of loops and coils bound to specific proteins 
to form chromatin. This tight organisation of DNA limits the access of proteins involved in DNA 
transcription, replication and repair to DNA. To allow access of these proteins to the target 
DNA sequences loosening of DNA and its protein contacts is required, this occurs by specific 
proteins and epigenetic changes. Arranging DNA into these regulated structures also stops 
DNA becoming an unmanageable jumble and provides protection of DNA from damage for 
the cellular environment by reducing its surface area. Section 3 provides a more in depth 
discussion of chromatin formation and regulation.    
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Figure 2; Bair pairing and the DNA double helix. Image was taken from L A. Pray (2). 
Image shows the molecular structure of DNA and a basic version of the DNA helix is shown 
on the left. The two grey lines running anti parallel are the DNA sugar-phosphate backbone 
which twisted to form the DNA helix and the base pairs in the middle. On opposite ends of the 
DNA backbone there are a 5’ phosphate and 3’hydroxyl group. The zoomed in picture 
describes the molecular structure and bonds which make up DNA, the phosphate, sugar and 
base to form the nucleotide are clearly shown. The two bases G and C are held together by 
three hydrogen bonds and T and A are held by two, the hydrogen bonds are marked as dotted 
red lines. 
 
 
1.1.2 DNA Damage    
 
The structure of DNA makes it well suited to preserve the genetic information it contains. The 
double helix and bases compacted into the centre provides a degree of protection from 
biochemical attacks by guarding the possibly reactive assemblies e.g. the amine side chains 
of bases which are very susceptible to attack.  Under normal physiological settings the N-
Figure from (2), Figure 4 
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linked glycosidic bonds that attach the four bases to the backbone of DNA and phosphodiester 
bonds that make up this backbone are both quite stable. However, DNA despite the clever 
design is frequently broken or chemically modified by endogenous sources such as normal 
metabolism and exogenous sources from environmental factors (3, 4). Damage to DNA can 
block transcription and replication leading to apoptosis or necrosis, and causes genome 
instability which can lead to cancer, ageing and neurodegeneration if not repaired, examples 
will be discussed next. To maintain genome stability cells have developed various DNA repair 
pathways that repair different lesions (5, 6). 
 
 
1.1.3 Endogenous DNA damage   
  
The majority of DNA damaged occurs through intrinsic agents of endogenous 
origin, particularly from water and oxygen from the cell environment (7). DNA damage from 
endogenous sources causes approximately 20,000 lesions per cell per day. 
The simplest form of endogenous damage to DNA is hydrolysis, this occurs to the N-
glycosidic bond that links the DNA base to the 2’deoyribose sugar when produce an array of 
damages to DNA (4). Reactive molecules that are produced in normal cell metabolism can 
also damage DNA, reactive oxygen species (ROS) are produced this way and constantly 
cause damage to DNA (8). Damages can also incur due to errors in normal DNA processing, 
including misincorporation bases during DNA replication.  
  
 
1.1.3.1 Hydrolysis  
  
DNA bases are particularly susceptible to hydrolysis. The N-glycosidic bond 
is extremely vulnerable to acid-catalysed hydrolysis and apurination. Loss of bases to 
produce apurinic/apyrimidinic site (AP-sites) are the result of spontaneous hydrolysis, 
alkylation-induced hydrolysis, but also during base excision repair (BER). These occur 
at an approximate rate of 10,000 per cell per day (4, 9). G and A (purines) are released from 
DNA at comparable proportions; however T and C (apyrimidinic) are released at a 5% lower 
rate (4). At these AP-sites β-elimination occurs within a few days and causes cleavage of the 
DNA as it is weakened (10).  Typically AP site causes base pair substitutions, the most 
common being AP site  T, however they may cause a frameshift of the DNA sequence both 
of which could cause a alternation in the protein they encode for (11).  
  
Hydrolytic deamination of DNA bases containing exocyclic amino groups (NH2) is another 
common reaction concerning hydrolysis. The loss of the amino group in adenine, cytosine, 
guanine and 5’-methylcytosine occur randomly and spontaneously and causes the conversion 
to hypoxanthine, uracil and thymine respectively (7, 12). C and its homologue are the main 
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targets for deamination (4). C to uracil is the most common event and occurs 
at an approximate rate of 100-500 uracil residues per cell per day (7). The deamination of 
purines occurs at a much lower rate for example adenine being deaminated to hypoxanthine 
occurs at only a 2-3% the rate of which cytosine does (13). The GT base pair formed from the 
hydrolysis of 5’methylcytosine is repaired slowly (mismatch repair), as a result these account 
for one third of single base mutations that cause inherited disease and is seen commonly 
mutated in the p53 gene of many different cancers (14).  
  
1.1.3.2 Oxidation  
 
  
Cells are exposed to reactive oxygen during normal cellar aerobic metabolism and this 
provides a large source of damage to the cells genome (4). The most prevalent of these 
reactive molecules are ROS, these are oxygen containing molecules that contain a 
radical making them highly reactive to biomolecules. Oxidative stress is caused by the 
discrepancy in the formation and degradation of ROS, in favour of the formation of ROS. Free 
radicals have a single electron in their orbit, it is this which makes free radicals more reactive 
(8). Examples of oxygen radicals include superoxide, hydroxyl, peroxyl and alkoxyl and the 
non-radicals ozone, singlet oxygen and hydrogen peroxide which are either oxidising or 
are easily changed into radicals (15, 16). ROS are produced constantly in a normal cell as a 
consequence of cellular metabolism and play critical roles in signal transduction, oxidative 
metabolism and killing ingested microorganisms. Although most of the oxygen during oxidative 
metabolism in mitochondria is converted to water up to 2% is converted to ROS (6). Most 
excess ROS is neutralised by superoxide dismutases, glutathione peroxidases and catalases, 
however remaining ROS can damage proteins and DNA. ROS is capable of producing over 
100 oxidative damages to DNA including DNA adducts (e.g. base modification), deoxyribose 
modifications, single/double stranded breaks and DNA crosslinks (17). ROS can contribute to 
the initiation of cancer by causing structural alterations in DNA (such as AP-sites and single 
strand breaks (SSBs)), as they are small molecules that are able to gain access 
to nucleosomal DNA (11). DNA bases, especially G (because of its low redox potential) are 
highly susceptible to oxidation by ROS. The cells response to oxidative damage is DNA repair, 
cell cycle arrest or apoptosis. If these mutations are not reversed then they can contribute to 
tumorigenesis (15, 16). 8-oxoguanine (8-oxoG) is an example of DNA oxidative damage, and 
is used as a marker of oxidative damage in biological systems (18). Reactive nitrogen oxygen 
species (RNS) particularly nitric oxide produce similar array of oxidative adducts in DNA as 
ROS (19). Alkylation is another example of reactive molecules produced endogenously and 
primarily react with oxygen and nitrogen atoms on bases. Examples of alkylating agents are 
the methyl donor S-adenosylmetionine (SAM), methyl radicals produced from lipid 
peroxidation and nitrosated amines (7, 20) 
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1.1.3.3 Errors from DNA Processing  
  
DNA damage can occur through errors resulting from physiological DNA processing. These 
resulting damages such as DNA mis-matches, deletions and insertions are very occasionally 
introduced into DNA. Replicative and translesion synthesis polymerases have a base 
disincorporation rate overall of one for every billion base pair copied (9). Polymerse (Pol) β 
involved in the BER DNA repair pathway has an overall aprromximate error efficiency of 5-
10x10-4, the backup polymerase Polλ in BER has been shown to have a overall error rate 160 
fold higher than Polβ (21, 22). Another source of DNA damage for replication is the 
wrong incorporation of oxidised nucleotide like dUTP and 8-oxo-dGTP by Y family DNA 
polymerases encouraging mutagenesis and facilitating translesion DNA synthesis 
(23). Failed topoisomerase activity (such as topoisomerase II) can cause what is normally a 
transient enzyme-DNA to a permanent double strand break (DSB). This can lead to 
chromosome translocations (such as in mixed lineage leukaemia) and other DNA 
abnormalities (24). DNA repair processes may also introduce errors into DNA. For example 
the repair of double strand breaks can be done via two pathways. Non-homologous end joining 
is an error-prone pathway that causes changes in the sequence near the double strand break. 
Homologous recombination was thought to be an error free process however recent evidence 
has shown that it can be highly mutagenic causing translocations and chromosome 
rearrangements, particularly when large amount of DNA need to be synthesised (25). 
 
 
1.1.4 Exogenous damage 
 
Exogenous damage to DNA is from environmental sources which can be physical or chemical. 
Ultraviolet light (UV) damage is an example of a physical stress from the sun. Ionising radiation 
is another physical agent which occurs both naturally occurring (cosmic radiation) and 
artificially (medical x-rays). Chemical compounds are able to intercalate or covalently bind to 
DNA in numerous ways , examples of chemical compounds are air pollutants (diesel and 
industrial fumes), dietary carcinogens and chemotherapeutic drugs (26, 27). 
 
 
1.1.4.1 UV 
 
The stratospheric ozone layer that shields earth from hazardous solar radiation is constantly 
undergoing depletion due to atmospheric pollutants. Subsequently there is an increase in 
earths exposure to solar radiation.  Solar radiation is a toxic agent to genomic DNA, the 
spectrum of sunlight contains two maxima in the UV spectrum that have mutagenesis 
potential, this is due to DNA bases absorbing UVB protons. UVA is also mutagenic however 
to a smaller degree than UVB due to DNA not being a chromophore for UVA. UV is one of the 
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most damaging exogenous carcinogens that can interact with DNA (26, 28, 29). UV radiation 
provides DNA with enough energy to excite the molecular bonds within to cause covalent 
modifications between pyrimidine nucleotides. Namely cyclobutane pyrimidine (CPD) dimers 
and pyrimidine photoproducts (6-4) both possess an atypical covalent bond between 
pyrimidines and account for 75% and 25% respectively of UV induced damage (26, 30). In 
solar radiation the most energetic form is UVB radiation causes direct absorption of UVB 
photons by DNA nucleotides by primarily pyrimidine thymine, cytosine and 5-methylsctosine, 
however it has been shown that purines are also to absorb photons to a lesser degree. Both 
of these DNA lesions distort the DNA helix by causing a bend of 7 for CPDs and pyrimidine 
photoproducts (6-4) 44° interfering with DNA transcription and replication which can cause 
misreading of the genetic information (30). 
 
 
1.1.4.2 Ionising Radiation  
 
 
Ionising radiation originates from natural sources such as cosmic and gamma radiation and 
artificial sources for example medical X-rays and radiotherapy. Ionising radiation has both 
positive and negative impacts in that may lead to modifications in normal tissues but 
decreases the survival of tumour cells. Ionising radiation causes damages to DNA leading to 
cell death if not repaired. The effect of ionising radiation specifically to bases which is 
accountable to 30-40% of lesions and the free radicals generated from this 60 – 70% (31, 32). 
The most harmful of the DNA lesions produced is DSBs which if not repair can cause 
apoptosis. If they are not repaired correctly genomic rearrangement can take place causing 
genomic instability and so increased mutagenesis. Ionising radiation can also cause damage 
indirectly by the production of ROS through the hydrolysis of water to form hydroxyl radicals 
(33). ROS through ionising radiation produces around 850 pyrimidine lesions such as Tg, 450 
purine lesions for example oxo-7, 8-dihydro-2’-deoxyguanosine, 1000 SSB and 20 – 40 double 
strand break (DSB) per cell (34). 
 
 
1.1.4.3 Alkylation  
 
Alkylating agents are a groups of molecules that transfer an array of alkyl group from one 
molecule to another, modifying the molecules structure and so disrupting its function, they are 
genotoxic and mutagenic. Agents causing alkylation are unavoidable due to the abundance in 
the environment from water, food and constituents in the air and pollutants from sources such 
as industrial and diesel fumes. Despite their adverse effects to health alkylating agents are 
used systemically as cytostatic drugs in cancer patients with the aim of killing cancer cells by 
inducing an overwhelming amount of DNA damage (35, 36). 
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Alkylating agents cause DNA damage by reacting with ring nitrogen’s (N) and extra cyclic 
oxygen (O) in the DNA nucleotide bases causing a broad range of covalent adducts. They can 
comprise genome integrity promoting mutagenesis and cause cell death by blocking DNA 
replication (cytotoxic). Depending on the number of reactive sites on the agent, it’s specific 
reactivity, the type of the alkyl group and DNA substrate the damages can range from the 
addition of modest methyl groups to intricate alkyl add-ons (35, 36). There are two types of 
alkylating agents based on number of reactive sites; monofunctional (one chemical moiety) 
and bifunctional (two chemical moieties) the latter being able to form interstrand crosslinks. 
Based on the specific reactivity of the agent there are SN2 alkylating agents which target 
nitrogen rings and SN1 which alter both the nitrogen rings and the extra cyclic oxygen. N7-
methyl guanine is a primary methylation adduct due to the reactivity of N7 in guanine by 
monofunctional alkylating agents and is noted in 60-80% of all alkylation lesions in DNA. This 
lesion although not mutagenic is susceptible to depurination to a AP-site which is mutagenic. 
N3-methyladenine can also be formed by this agent at a rate of 10-20% of methyl adducts 
(36). This lesion is significantly cytotoxic as it blocks DNA polymerases inhibiting DNA 
synthesis (37). SN1 type alkylating agents are highly reactive to the O6 position in guanine 
resulting in a lesion called O6-methylguanine. This lesion is produced at a much lower rate 
than N-alkyl groups but is important as it is prone to mismatch with thymine during DNA 
replication causing mutagenic and cytotoxic effects (36). Methyl methanesulfonate and 
temozolomide are example of monofunctional alkylating agents used to treat cancer by 
causing alkylation of DNA bases. Bifunctional alkylating agents including nitrogen mustards, 
platinum compounds and mitomycin C cause DNA damage by causing intra/interstrand 
crosslinks (38).  
 
 
1.1.5 Common types of DNA damage 
 
The genome of cell is under constant attack from DNA damaging agents comprising genetic 
stability. These insults can arise from normal cellular processes (endogenous) such as the 
cells normal metabolism and from the environment (exogenous). Many of the lesions that 
caused by these insults result in structural damage to DNA and can modify or disrupt vital 
cellular processes. Common types of DNA damage are as follows DSB, single strand breaks 
(SSB), AP sites, thymine glycol (Tg) and 8-oxoG. 
 
 
1.1.5.1 Double strand breaks 
 
DSB are one of the most dangerous types of DNA damage. They result from exogenous agent 
including ionising radiation and chemotherapy drugs, and endogenously from reactive oxygen 
species (ROS) from the cells environment. Another major form of endogenous damage is 
when DNA replication forks come across DNA lesions causing fork collapse (39, 40). They 
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occur when the phosphodiester bond on complementary strands in the DNA helix are 
simultaneously broken at sites that are suitably close to each other (within 0-20 base pairs) 
so that the hydrogen bonds of the other bases and chromatin structure can keep the DNA 
strands juxtaposed figure 3 (40, 41). This causes the double stranded DNA to become prone 
to dissociation from one another making DNA repair more difficult. DSB are highly cytotoxic 
and mutagenic if it inactivates a vital gene and can cause chromosomal translocations. The 
two key DNA repair pathways that process this type of lesion are homologous recombination 
(HR) and nonhomologous end-joining (NHEJ) (39, 40).  
 
 
Figure 3: DNA Double Strand Break. Schematic diagram shows the formation of DNA DSB 
with DNA bases coded in colour and the phosphodiester back shown in light orange. The 
phosphodiester backbone is broken at opposing sites in DNA but are kept juxtaposed due to 
their close proximity. 
 
 
1.1.5.2 Single strand breaks 
 
SSBs can result from endogenous agents such as ROS and abortive enzyme activity (such 
as DNA topoisomerase 1 (TOP1), and exogenous sources such as ionising radiation. SSBs 
are formed when the phosphodiester bond is broken causing usually loss of a nucleotide and 
damage to either or both the 5’ and 3’ at the SSB site (figure 4). If these are not repaired this 
can lead to genome instability and cell survival. If not repaired a DNA replication forks can 
collapse leaving the site prone to forming a DSB, stall RNA polymerases during transcription 
and cause excessive protein poly(ADP-ribose) polymerase 1 (PARP1) activation. SSBs are 
also a intermediate in BER after incision of the AP-site (42). 
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Figure 4: DNA Single Strand Break. Schematic diagram shows the formation of DNA SSB 
with bases coded for in colour and the DNA backbone in orange. A single strand break is 
formed in one side of the DNA backbone which commonly also causes the loss of the base 
and damage to the 3’ and 5’ ends of DNA.  
 
 
1.1.5.3 AP sites 
 
AP sites are one of the most common types of DNA damage and are estimated to occur at 
10,000 per cell per day, a lesion is classed as a AP-site when there is neither a purine or 
pyrimidine base (43). AP-site are formed by spontaneous, alkylation induced hydrolysis of the 
N-glycosylic bond in nucleotides (figure 5). AP-site are also formed as an intermediate in BER 
by glycosylases when removing a damaged base such as 8-oxoG and Tg. AP site are 
dangerous to cells as thy can cause mutations and they can block DNA replication and 
transcription. AP-sites are processed and repaired by the BER pathway (44). 
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Figure 5: Apurinic/apyrimdinic site in DNA. Schematic diagram shows an AP site in DNA 
with the colours showing the bases and DNA backbone in orange. A AP site is a location in 
DNA where there is no purine or pyrimidine base resulting from DNA damage and 
intermediates in DNA repair.  
 
 
1.1.5.4 8-oxoG 
 
8-oxoG is a common nucleotide modification in cells following oxidative stress from the cells 
environment or ionizing radiation and is used as a marker for oxidative stress (figure 6). It is a 
major source of mutagenesis caused by hydroxyl radicals which add a hydroxyl group to the 
base (4, 8). This lesion is found at higher amounts in animals that have a higher basal 
metabolism due to the increase in ROS production from normal metabolism. The presence of 
this lesion causes GCTA transitions and if not repaired contributes to disease (45). 8-oxoG 
has been found to be increased in premature ageing, neurogenerative disease and cancer  
(8, 45).  
 
 
Figure 6: Molecular of Structure of 8-Oxoguanine. The molecular structure of G (left) and 
8-oxoG (right) are shown. 8-oxoG is a major product of oxidation damage and the difference 
is found on the N8 where oxygen has been added. 
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1.1.5.5 Thymine Glycol 
 
Thymine is the most prone to oxidation from sources such as oxidation stress and ionising 
radiation and Tg being the most stable product of thymine oxidation (figure 7). Tg can also 
form after hydrolytic deamination of 5-methylcytosine glycol which is unstable. It has been 
estimated that 400 Tg lesions occur per cell per day and is used as a marker for oxidative 
stress. Tg lesions can block DNA polymerases in replication and repair which is cytotoxic. Tg 
is not particularly mutagenic as it base pairs with adenine the majority of the time with only 
0.3% T C mutations arising as a result (46).  
 
  
Figure 7; Molecular Structure of Thymine Glycol. The molecular structure of T (left) and 
Tg (right) are shown. Tg is a product of oxidative damage and difference lays on the N5 and 
N6 where oxidation is shown. 
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1.2 DNA Repair   
 
 
Maintaining the genomic integrity of an organism is vital for survival, consequently a high 
fidelity systems are required for both DNA replication and for repairing the numerous lesions 
that occur every day to DNA. Damage that occurs to DNA in a cell can occur from heat, normal 
cellular metabolism, radiation from the environment. Damage to DNA can be as modest as 
a mispaired base or more complex, including chemical cross links or breaks in one or both of 
the phosphodiester backbones. The majority of spontaneous damage to DNA is temporary 
due to their instant rectification by a set of biological process which are mutually called DNA 
repair. There can be serious implications if these lesions are not repaired including cell death 
or transformation, blockage to DNA replication systems, or changes to the DNA sequence that 
might be passed onto upcoming generations and are therefore implicated in the development 
of several human diseases, including premature ageing, neurodegenerative diseases and 
cancer. There are range of DNA repair processes that have evolved to recognise and repair 
specific types of damage to restore DNA to its undamaged state. DSB repair, BER and 
nucleotide excision repair (NER) are the three major DNA repair pathways that are described 
below.     
   
 1.2.1 Double strand break repair    
 
DSB are one of the most cytotoxic forms of DNA damage caused endogenously from cellular 
metabolism (ROS) and exogenously from ionising radiation for example. The repair of DSBs 
it imperative for the cells survival, if left unrepaired they can prompt apoptosis, genome 
rearrangement and initiate carcinogenesis (47, 48). Conversely DSBs are essential 
intermediates which can be beneficial for an organism when controlled in processes that 
require genome rearrangements, such as immune system development and genetic diversity 
in meiosis (47). To neutralise the harmful effects of DSBs two types of DSB repair pathways 
have been identified; non homologous end joining (NHEJ) and homologous recombination 
(HR). NHEJ is the simplest mechanism to repair DSBs and encompasses direct ligation of the 
broken ends of DNA using restricted or no sequence homology to re-join DNA ends and as a 
consequence is error prone. For HR the undamaged homologous sequence from the sister 
chromatid is required to act as a template to repair the two damaged strands ensuring accurate 
repair of the DSB. The choice of pathway is dependent on the structure of the broken DNA 
ends and what cell cycle phase the cell is in (47, 48). NHEJ is the predominant choice of repair 
pathway in humans due to the DSB substrate that is generated (ends in close proximity) and 
because it can be used at any point in the cell cycle. HR is only active during or just after DNA 
replication when the cell is in S and early G2 phases, as the sister chromatid is close to serve 
as a template, it is also able to bind to single strand DNA overhangs which NHEJ can 
inadequately accomplish (48).    
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1.2.1.1 Homologous Recombination   
   
HR repairs DSBs by using genetic information from the sister chromatid or homologous 
chromosome, needing sequence homology to accurately repair constituents. HR is a major 
repair pathway for DSBs in prokaryotes and lower eukaryotes and functions infrequently in 
cells of higher eukaryotes (which use NHEJ predominantly) (49). HRs ability to maintain 
genome stability is demonstrated by the BRCA2 gene which is a tumour suppressor, and  
dysfunctional/mutated BRCA2 causes damaged DNA to not be repaired properly (50). HR 
events are complex and based on research in different organisms and biological 
circumstances and there a various models for precisely how it takes place (40).   
   
A key step in HR is the introduction of a 3’ single stranded DNA tails. The nucleolytic resection 
of DNA DSB acts as a control point for which DSB repair pathway and initiates HR. 
The effectiveness of this resection depends on the MRN complex of RAD50, MRE11 and 
NBS1. Following binding of the of the MRN complex to DSBs the MRE11 subunit initiates 
single strand end resection with the aid of CTiP to produce 3’ DNA single stranded DNA 
overhangs. Both of the 3’ single stranded DNA tails from DSB resection provide a substrate 
for RAD51 filaments (49).  The 3’ single stranded DNA tails are then coated in RPA 
protein which has a higher affinity for single strand DNA than RAD51. RPA stimulates HR by 
neutralising the secondary structure in single stranded DNA (50). RAD51 loading facilitated by 
breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2). BRCA2-PALB2 complex 
recruits and interacts with RAD51 affecting its nuclear localisation and binding properties and 
allow RAD51 to arrange foci at DNA damage sites. BRCA1 is thought to assist in chromatin 
remodelling and so facilitating HR by making DSB more accessible (40). RAD51 then binds 
to 3’single stranded DNA overhangs to produce RAD51 filaments. HR is catalysed by the 
RAD51 protein. RAD52 which is activated by the binding of the p34 subunit of RPA is thought 
to modulate RAD51 actions through its interacting region and RAD52 action to induce (51). 
 The RAD51 nucleoprotein filament interacts with an undamaged homologous duplex and 
catalyses strand exchange events in which one of the 3’ single stranded DNA tails invaded 
the intact DNA duplex and generates a D loop structure by displacing one of the strands, RPA 
also binds to this strand of the D loop (40, 49, 50). The 3’ ends then facilitates DNA synthesis 
using the undamaged DNA as template, the 3’ end of the damage DNA molecule is extended 
by DNA polymerase I leading to the generation of two Holiday junctions (DNA crossovers). 
After migration along the DNA (branch migration)  extending or shrinking the region of 
the heteroduplexed DNA the Holiday junctions are resolved by cleaving the crossed or non-
crossed DNA strands by a resolvase and then ligated by DNA ligase I (40, 49). The HR 
pathway is summarised in figure 8. 
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Figure 8: Homologous Recombination. Homologous recombination pathway. DSBs are 
recognised by the MRN complex which resects DNA to form 3’ single strand overhangs which 
are coated by RPA. RPA is replaced by RAD51 and the RAD51 filament invades the sister 
chromatid to use a template for repair so form a D loop and then  a holiday junction. After 
synthesis the holiday junctions are resolved, based on (40). 
 
 
1.2.1.2 Non-homologous end-joining 
   
NHEJ is a vital DNA repair pathway for the repair of DSB in eukaryotic cells. NHEJ repairs 
damages to DSBs in DNA caused from exogenous and endogenous sources. DSBs are 
also created deliberately in class switch recombination and V(D)J recombination for 
the development of B cells and T cells of which NHEJ plays an essential role. NHEJ does not 
need a homologous template for repair and can process DSB at any point in the cell cycle. It 
processes two termini of any type in a broken DNA molecule so they can be directly ligated. 
Consequently, this can lead to a loss of nucleotides and so comprise genomic integrity. The 
mechanism of NHEJ is broken down into several steps; the recognition and capture of the 
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broken end of DNA, bridging of the molecular ends to bring them back together and the 
religation of the broken DNA ends (52).  
  
The initial step of NHEJ is the recognition and binding of the Ku heterodimer to the DSB. The 
heterodimer is made up of two proteins, Ku70 and Ku80 in a non-sequence dependent 
manner. Ku functions by creating an open ring structure that DNA is threaded onto. When Ku 
is bound to DNA it acts a scaffold for the assembly of the other NHEJ proteins and attracts 
the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to the DSB forming DNA-PK 
holoenzyme (40, 53). DNA-PKcs is a member of the phosphatidylinositol-3 (PI-3) kinase-like 
kinases. The C-terminal domains of this kinase form a crown structure with the N-terminus of 
the protein to produce a pincer structure which modulates its ability to bind to DNA (52). Once 
bound, DNA-PKcs demonstrates serine / threonine kinase activity and its likely substrate 
involved in NHEJ is XRCC4 which it phosphorylates and facilitates NHEJ. It has been 
suggested that DNA-PKcs also helps to bridge the two broken DNA ends, preventing them 
from becoming degraded and helping to relax chromatin to enhance NHEJ efficiency (40). Ku 
directly recruits XRCC4-DNA ligase IV complex to the DNA and facilitates its loading onto 
DNA to stimulate DNA end ligation (40, 52). Figure 9 shows a simplified diagram of NHEJ. 
  
The identity of the DNA polymerases that might be involved NHEJ at the moment is not clear 
(40). It has been proposed that when necessary (depending on the complexity of the DNA 
break being ligated) filling in the gaps in DNA is achieved by X-family of polymerases, 
including   polymerases μ and γ. Pol μ can polymerase across a discontinuous template strand 
when in the presence of Ku and XRCC4/DNA ligase IV (52). The MRE11-RAD50-NBS1 
complex is thought to play a role in NHEJ; the complex has exonuclease, endonuclease and 
DNA unwinding activity primarily when the broken DNA end require processing before ligation. 
There are also suggested candidates for this activity such MRE11 alone or other nucleases 
such as Artemis (40).  
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Figure 9: Non-homologous end joining pathway. Double strand breaks are recognised 
Ku70 and Ku80 heterodimer and form a ring structure which is threaded onto DNA. Ku70/80 
attracts DNA-PKcs to bridge the ends and phosphorylates XRCC4 to facilitate NHEJ. Ku 
recruitment XRCC4-DNA ligase IV complex to DNA to stimulate DNA end ligation, based on 
(40). 
 
  
1.2.2 Nucleotide excision repair   
  
NER is the major DNA repair mechanism for bulky helix-distorting DNA lesions that occur 
through UV radiation, environmental mutagens and some chemotherapy drugs. NER can 
repair a large spectrum of DNA damages including 6-4 pyrimidine-pyrimidone photoproducts 
(6-4PPs), cyclobutane pyrimidine dimers (CPDs) which are formed from UV radiation, many 
bulky adducts, intrastrand cross links by drugs like cisplatin and cyclopurines generated from 
ROS (54, 55). There are two forms of DNA damage detection by NER; global genome NER 
(GG-NER) and transcription-coupled NER (TC-NER). GG-NER as the name suggests repairs 
the global genome with varying efficiencies and TC-NER indirectly detects lesions through its 
ability to detect the blockage of transcription elongation such as CPDs which are poorly 
recognised by GG-NER but interfere with transcription elongation (54, 56). Defective GG-NER 
can promote carcinogenesis, alternatively defective TC-NER can lead to a range of diseases, 
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including xeroderma pigmentusum (XP) an extreme sensitivity to sunlight and serious 
premature ageing such as Cockayne syndrome (54).    
 
  
1.2.2.1 GG-NER Recognition  
 
The initial step in NER is the recognition of lesions. In GG-NER the whole genome is surveyed 
for helix distortions or structural changes which are recognised by XPC. XPC is stabilised 
upon binding with the assistance of RAD23B and centrin 2 (CENT2) (54, 56). XPC is able to 
bind to a range of bulky lesions. This is due to the ability of XPC to bind to the undamaged 
strand of DNA opposite the lesion which is distorted in structure displaying a more single 
stranded DNA character due to the thermodynamic destabilisation by the lesion. RAD23B 
dissociates from XPC upon binding to DNA suggesting it aids in the stability of XPC and the 
delivery of XPC to damaged sites. CENT2 stimulates NER activity, the exact role of the protein 
however remains unknown (55). Certain lesions such as CPD are weak substrates for XPC 
due to the DNA helix only being mildly destabilised. To repair these types of lesions the 
ultraviolet radiation DNA damage binding protein (UV-DDB) complex is employed. The 
complex comprises of DDB1 and DDB2 which are part of the Cullin (CUL)4-regualtor of cullins 
(ROC) ubiquitin ligase complex which ubiquitinates DDB2, XPC (increasing its affinity to DNA 
damage) and histones which are required for efficient NER. Histone removal allows XPC 
recognition to occur. DDB2 binds to these lesions to distort lesions into its binding pocket to 
create single stranded DNA to facilitate XPC binding. Binding of XPC recruits the transcription 
initiation factor IIH (TFIIH) complex to the lesion by direct interaction with XPC-RAD23B (54-
56).   
 
 
1.2.2.2 TC-NER Recognition   
 
The TC-NER indirectly recognises DNA lesions through the blocking of transcription 
elongation. The initial step in TC-NER is the stalled RNA polymerase II (RNAPII) which causes 
the recruitment of Cockayne syndrome protein B (CSB) and Cockayne syndrome WD repeat 
protein A (CSA). CSB binds to RNAPII when blocked by a lesion and wraps the DNA around 
itself, translocating RNAPII, figure 10 (54-56). CSB can then recruit the CSA complex, core 
NER factors (excluding UV-DDB and XPC) and several TC-NER specific factors, and p300 to 
blocked sites. CSB also recruits UV stimulated scaffold protein A (UVSSA) and its partner 
ubiquitin specific processing protease 7 (USP7) which bind to RNAPII after arrest. 
USP7 then deubiquitinates CSB for stabilisation and together UVSSA and USP7 prevent the 
degradation of CSB (54). TFIIH which is a transcription elongation factor is required for the 
recovery of RNA synthesis after DNA damaged and is recruited by CSA. The next steps of 
repair are achieved by XPE and the XPC complex in GG-NER pathway (56).  
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Figure 10: Nucleotide excision Repair. Diagram showing recognition by GG- NER (Left arm) 
and TC-NER (right arm) recognition. Recognition occurs by the XPC/HHR23B (RAD23B 
homolog) in GG-NER or RNA polymerase, CSA and CSB proteins in TC-NER. DNA is opened 
around the lesion by RPA, XPA and the helicase subunits of TFIIH, XPB/XPD allows incision 
of DNA to take place either side of the lesion by ERCC1/XPF and XPG removing the damage 
and the gap is then filled by DNA synthesis, image from (57). 
 
 
1.2.2.3 Incision, excision, gap filling and ligation  
 
The TC and GG recognition sub pathways of NER unite at the point that the TFIIH complex is 
recruited to the damaged site (figure 10) of 10 proteins, two of these are 
bidirectional adenosine triphosphatases (ATPases)/helicases called XPB and XPD which 
Figure from (47), Figure 2a 
22 
 
unwind the DNA to allow for open DNA conformation around the lesion. The ATPase activity 
of XPB is used for the recruitment of the TFIIH complex to the DNA damage site. XPA is 
critical for the 5’-3’ unwinding of DNA to create a 20 – 30 nucleotide bubble (54, 56).  There 
are other constituents of TFIIH also contribute to NER these include, p8, p52 which simulate 
XPB and p44 which then stimulates XPA. Once the pre-incision complex is assembled around 
the lesion XPA, RPA and XPG are employed for thier dual (5’-3’) strand incision of the 
lesion.  XPA binds to the DNA by the 5’ end and recruits ERCC1-XPF which 
has endonuclease activity and RPA protects the single stranded DNA on the opposite side to 
lesion from degradation. XPG interact with TFIIH for structural support and its endonuclease 
activity is triggered once ERCC1-XPF has been recruited (54-56). The lesion excision 
is catalysed by XPG and ERCC1-XPF which leaves a single stranded gap of 22-30 
nucleotides. The DNA replication complex Pol δ/e/κ – PCNA-RFC-RPA is recruited by 
XPA to synthesis a patch of DNA to replace the damaged excised strand. XRCC1-DNA ligase 
IIIα complex is the employed to seal the gap in DNA to leave (usually) a repaired strand of 
DNA (54, 56).  
 
 
1.2.3 Base excision repair  
 
Around 10,000 DNA base lesions are thought to occur in every cell per day from 
endogenous (particularly ROS) and exogenous sources. These types of small base damages 
are commonly the result from oxidation,  hydrolysis, methylation or deamination (4). These 
can lead to DNA base damages including AP sites, alkylated and oxidative base (e.g. 8-oxoG 
and Tg), SSB and misincorporated bases. The BER pathway is a highly conserved DNA 
repair process and is essential to repair the majority of spontaneous endogenous DNA 
damages to maintain genome integrity. These type of lesions to DNA can cause alteration of 
the specific base pairing in DNA causing genomic instability, promoting diseases such as 
cancer, premature ageing and neurodegenerative disorders. The steps and enzymes involved 
in BER are well defined and can be divided into five distinct steps; 1. Recognition and removal 
of the damaged/misincorporated base, 2. AP site incision, 3. Removal of sugar moiety 4. Gap 
filling with the correct undamaged nucleotide, 5. Sealing of the remaining nick. Once BER has 
been initiated repair can take place either by short patch repair or long patch repair figure 11. 
A single nucleotide gap is generated and filled during short patch repair and in long patch a 
gap of 2 to 10bp is created and filled. Short patch repair is the dominant pathway in BER, long 
patch is used after AP-site incision if the 5’ end of the damage site DNA is resistant to end 
processing (58, 59).    
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Figure 11: The Base Excision Repair Pathway. Figure depicting the schematic pathway of 
BER was taken from Parsons and Dianov (59). A DNA-specific glycosylase recognises and 
removes the damaged base to produce an AP site which is then incised by APE1 leaving a 
blocking 5’-deoxyribose phosphate residue. Following the left path of short patch repair at this 
point Pol β removes this blocking residue through its lyse activity and fills the gap with the 
correct base, XRCC1-LigIIIα then seals the nick. If there are non-conventional DNA ends after 
APE1 incision which are resistant to Pol β activity, then BER goes through to long patch repair 
as shown on the right. Pol δ/ε then synthesises from 2 to 8 bases in the repair gap to form a 
5’-flap which is removed by FEN1 which is facilitated by PCNA, Lig I then seals the remaining 
nick. 
 
 
1.2.3.1 Base Removal  
 
The first enzymatic step in BER is conducted by a specific DNA glycosylase which are 
responsible for the search of DNA lesions and catalysis of the cleavage of the N-
glycosidic bond between the damaged base and 2’deoxyribose forming a AP-site, an activity 
universal to all classes of DNA glycosylases. It has been suggested that glycosylases seek 
out lesions by sliding and distributive interactions by gently pinching DNA in a bidirectional 
and random manner (60). Upon damage recognition the glycosylase bends DNA so the 
damaged base is rotated around the phosphodiester backbone axis to 180ᴼ at the damage 
site to produce a broadened and flattened minor grove, promoting the damaged base to flip 
Figure from (59), Figure 1 
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out from the double helix into the binding site of the DNA glycosylase for surveying and protein-
substrate complex formation. This interaction is stabilised by specific amino acids in the DNA 
glycosylase and DNA (58, 61, 62). This mechanism is known ‘base flipping’ common in all 
glycosylases and is required as the active site of glycosylases can only interact 
with extrahelical bases (58). There are 11 distinct DNA glycosylases which recognise 
particular types of base damage or DNA lesions which can be divided into 
four structural families; uracil DNA glycosylases (UNGs), helix-hairpin-helix (HhH) 
glycosylases, endonuclease VIII-like (NEIL) glycosylases and methylpurine DNA 
glycosylases, table 1 summaries the human DNA glycosylases (62). DNA glycosylases are 
classified as either monofunctional or bifunctional dependent on their catalytic mechanism 
and AP lyse strand incision ability, see table 1.  
 
Monofunctional glycosylases have glycosylase activity only (table 1), and so removes the 
damaged base by cleaving the N-glycosidic bond to create an AP-site which is then processed 
by APE1. They do this by utilising a water molecule to act as a nucleophile to assault the C 
aromatic ring of the damaged base which promotes its release and so create a AP-site, which 
is the same as AP-site created from depurination or depyrimidination by ROS (58).  
 
Bifunctional glycosylases have both glycoslase and β-lyase or β, δ-lyase activity (table 1 for 
examples). They are able to remove the damaged base and incise the AP-site to create a 
single strand break. These types of DNA glycosylases have an amine moiety active site which 
acts as a nucleophile to remove the damaged base. The AP-site is then incised by the 
glycosylase between the 3’ phosphodiester linkage to AP-site to create single strand 
break with a blocking irregular residue at the 3’ of the single nucleotide gap. These irregular 
residues can either be phosphor-α,β-unsaturated aldehyde (created through β-elimination) or 
a phosphate group produced by two sequential elimination stages, β, δ-elimination. These 3’ 
blocking residues need to be further processed by specific enzymes AP endonuclease 1 
(APE1) and polynucleotide kinase 3'-phosphatase (PNKP) respectively to become an 
acceptable DNA substrate for Polβ (58, 60, 61).  
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Glycosylase Mono (M) / bi 
(B) functional 
AP Lyase 
activity 
Damaged base 
type 
UNG M No Deaminated 
base 
TDG M No Deaminated 
base 
SMUG1 M No Deaminated 
base 
MBD4 M No Deaminated 
base 
AAG/MPG M No Alkylated base 
MYH M Yes (β)/ No Oxidised base 
OGG1 M/B Yes (β) Oxidised base 
NTH1 B Yes (β) Oxidised base 
NEIL1 B Yes (β, δ) Oxidised base 
NEIL2 B Yes (β, δ) Oxidised base 
NEIL3 M/B Yes (β, δ) Oxidised base 
 
Table 1: Human DNA Glycosylases.  List of the human DNA glycosylases their mono or bi-
functional activity, AP lyase activity and damaged base type, based on tables in (58, 61).  
 
  
1.2.3.2 AP Site Incision  
 
Once the damaged base has been removed by a DNA glycosylase, APE1 incises the DNA 
backbone 5’- to the AP site to produce a single strand break with a 3’- hydroxyl group (59). 
APE1 is the primary AP endonuclease in mammalian cells contributing to approximately 95% 
total AP site incision (63). APE1 incises the DNA phosphodiester bond through a catalysed 
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acid-base reaction which is promoted through the binding of a magnesium ion (Mg2+) which 
stabilises the increasing charge on the oxygen atom in the phosphate group and positioning 
them for nucleophilic attack from aspartate-activated hydroxyl radical (44, 64). There are many 
amino acid interactions that take place that allow APE1 activity and selectivity towards AP-
sites. When APE1 is bound to DNA it bends the DNA to approximately 35° and the helical axis 
kinked to roughly 5Å. APE1 causes this kinking by residues from four loops and one α helix, 
at the 5’- end of the AP site arginine (R) 73, alanine (A) 74 and Lysine (K) 78 interact with 
DNA phosphate on the opposite strand, and tyrosine (Y) 128 and glycine (G) 127 cross and 
widened the minor groove forcing the AP site into the active site of APE1. The catalysis of 
APE1 is facilitated through Asparagine (N) 283- histidine (H) 309 and water (44). The amino 
acid pair N283-H309 form a hydrogen bond which has been suggested to facilitate the H 
residue to act as a base and accept a proton from water which helps to protonation of N210 
to generate a hydroxyl nucleophile (44, 64, 65). The 3’- phosphate group of the AP site forms 
a hydrogen with R177 which penetrates the major groove for stabilisation and so slows APE1 
dissociation from incised DNA. The observation that mutant R177A increased APE1 activity 
by 25%, it was concluded that enzymes in the BER pathway have evolved so rather than 
having maximum activity and so produces many toxic intermediates, the enzymes remain 
associated with intermediate to facilitate the next protein in the pathway (64). The cellular 
levels and activity of APE1 are closely regulated with the level of other downstream BER 
proteins to avoid the production of toxic single strand breaks which can cause blockage of 
DNA replication forks causing collapse and so producing even more toxic DSBs (59). The 
enzyme also processes the 3’- to 5’- exonuclease activity which has been postulated to serve 
as a proofreading mechanism during the synthesis step of BER, removing mismatches or 
damaged nucleotides (66).  
 
 
1.2.3.3 PARP1 and single strand break repair 
 
Following APE1 incision of the AP site it has shown that PARP1 binds to incised AP sites due 
to its high affinity to DNA single strand breaks. PARP1 is considered to be fundamental in 
BER in acute DNA damage (67, 68). PARP1 has been shown to control repair capacity 
through binding to extensive single strand breaks, regulating the access of other repair 
proteins (Polβ and X-ray repair cross-complementing protein 1 (XRCC1) - DNA lig IIIα) when 
they are at adequate levels (68).Single strand break repair is considered a sub-pathway of 
BER. Single strand breaks are recognised by PARP1, a nick sensor and repaired by later 
stage BER proteins; Pol β, Lig IIIα, and XRCC1. PARP1 recruits XRCC1 to single strand 
breaks and together they stabilise the single strand break whilst the DNA ends are processed 
so gap filling synthesis and nick ligation can take place (42, 69). Single strand breaks often 
hold unconventional DNA ends that cannot be processed for complete repair and so need to 
be processed before repair can take place. Single strand breaks can be generated directly 
through ROS or ionising radiation or indirectly e.g. BER intermediates. DNA single strand 
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breaks with modified 5’- and/or 3’- ends are often produced from endogenous sources such 
as oxidative metabolism (ROS), exogenous agents (eg. IR) or indirectly through processes 
such as BER intermediates. These types of single strand breaks can have 3’- phosphate or 
phosphoglycolate ends (oxidised 1’ and 4’ C respectively). Unconventional 3’- residues can 
also result from abortive DNA TOP1 activity which forms single strand breaks and briefly 
remains attached to the 3’- end, however in the presence of DNA lesions it can remain 
attached to the 3’- end. These ends block DNA polymerases and need to be processed before 
DNA repair can take place (42, 70). APE1 and PNKP, as mentioned previously, remove some 
of these unconventional 3’- ends. PNKP has been shown to interact with XRCC1, Pol β and 
Lig IIIα, and furthermore promotes recruitment of XRCC1-Lig IIIα complex to single strand 
breaks (70). PNKP is responsible for processing 5’ end of the blocked TOP1 intermediate 
single strand breaks by its 5’ kinase activity (42). Tyrosyl-DNA phosphodiesterase 1 (TDP1) 
can also process 3’- phosphoglycolate ends however at much lesser extent than APE1 (71). 
Aprataxin which interacts with XRCC1 has been found to be associated with abortive DNA 
ligation intermediates by releasing the 5’- adenylate groups to complete repair (70). 
 
 
1.2.3.4 End Processing 
 
There are a variety of nonconventional 5-’ or 3’- blocking residues from the results of 
bifunctional glycosylases, strand break intermediates, APE1, ionising radiation or ROS. These 
residues hinder the extension by DNA polymerases and nick ligation in downstream BER 
processes and must be processed to allow for efficient repair. Examples of these blocking 
residues are 5’-deoxyribosephosphate, 3’-phosphate, 3’-phosphoglycolate and 3’-phosphor-
α,β-unsaturated aldehyde residues (72). Pol β is primarily involved in the removal of 5’-
deoxyribosephosphate through its dRP lyase activity to produce the required 5’-phosphate 
needed to for nick sealing. DNA Pol λ and ι also have this lyase activity and can remove this 
type of blocking residue (73, 74).  
 
APE1 also has 3’-phosphodiesterase activity and very weak 3‘-phosphatase ability to remove 
3’- blocking moieties such as those produced by bifunctional glycosylases (phosphor-α, β- 
unsaturated aldehydes) and 3’-phosphoglycolate, ROS from normal cellular metabolism and 
IR to produce a 3’-hydroxyl group (59). Blocking 3’-phosphate groups are mostly processed 
by PNKP as APE1 phosphatase activity is very weak. PNKP is bifunctional as it has both a 5’-
kinase and 3’-phosphatase domain. It is able to hydrolyse the 3’ phosphate group to produce 
a 3’ hydroxyl terminus and it’s 5’-kinase activity prepares the nick for ligation by 
phosphorylation of the 5’- hydroxyl to 5’- phosphate (75).  
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1.2.3.5 Gap Filling 
 
To fill the gap during BER cells use polymerases to initiate repair synthesis to insert the correct 
nucleotide, they require at 3’- hydroxyl terminus and an undamaged template so the correct 
nucleotide can be added. Replicative polymerases harbour 3’- to 5’- exonuclease activity 
which is used for proofreading and can remove the incorrect or damaged nucleotide straight 
after phosphodiester bond formation (76). In BER there are considered to be four polymerases 
that act in different sub-pathways, DNA Pol β, δ, ɛ and λ. Pol β is the primary polymerase in 
short patch BER to add the correct nucleotide, however it lacks 3’- to 5’- endonuclease activity. 
Pol β is a small 39 kDa protein with 2 domains, an 8 kDa amino-terminal domain for dRp lyase 
and DNA binding activity and a 31 kDa C-terminal domain for DNA polymerisation. It also 
contains subdomains (thumb, fingers and palm) which facilitate catalysis (77, 78). Pol β is 
recruited to the gap site by interaction with APE1, PARP1 or XRCC1 to a DNA single strand 
break (79, 80). Pol β requires a bend of 90ᴼ in the single strand DNA template at the gap site 
by its 31 kDa domain and stabilised by its 8 kDa domain is needed for Pol β function and may 
increase nucleotide selectivity in DNA repair (78). Pol β also plays a role in long patch BER 
by incorporating the first nucleotide into the gap and so starting this subway of BER (77). Pol 
λ can act as a back-up polymerase for Pol β in some circumstances, and has been suggested 
to be activated in Pol β deficient mouse embryonic fibroblast extracts, however it is 
significantly less efficient at binding to nicked DNA (81).  
 
The choice between either short patch or long patch BER can be determined by the type of 
originating lesion. When Pol β cannot remove the 5’-deoxyribose as the moiety is reduced or 
oxidised, such as the C1’ oxidised AP site lesion 2-deoxyribonolactone, as they are resistant 
to Pol β lyase activity and must be processed by long patch BER which Pol β initiates by 
adding the first nucleotide (82, 83). The cellular adenosine triphosphate (ATP) concentration 
after 5’-deoxyribose removal can also in part determine whether to proceed to long patch or 
short patch BER. When ATP concentration is high the repair pathway is more probable to go 
straight to short patch repair so ligation by DNA Lig IIIα. However when the ATP concentration 
is low long patch repair is more commonly seen as ligation is unfavourable (84). Long patch 
BER integrates 2 -8 bp during the synthesis step conducted by Pol δ and Pol ε with PCNA. 
These two polymerases use strand displacement to synthesis a short nucleotide sequence at 
the 5’- DNA termini creating a flap intermediate. The displaced newly synthesised strand is 
then removed by FEN1 with PCNA to create a DNA substrate which can then be ligated (59, 
85). Uncommonly, Pol η, Pol ι and Pol к which are error prone translesion DNA polymerases, 
can be used in BER to fill the gap leading to the formation of a Schiff base complex with the 
5’-deoxyribose moiety which is a blocking residue and prevents nucleotide incorporation (72, 
86). 
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1.2.3.6 Nick Sealing 
 
The concluding step in BER is to seal the remaining nick to complete repair. Ligases catalyses 
a phosphodiester bond between the 3’- hydroxyl and 5-’ phosphate groups, by using energy 
from phosphoanhydride hydrolysis using ATP or nicotinamide adenine dinucleotide (NAD+) 
(87). Long patch BER is completed by Lig I and short patch BER is completed by 
predominantly LigIII α with its scaffolding protein XRCC1, catalyzing the nick sealing of the 
DNA backbone (59, 88, 89). XRCC1 is required for the stability of DNA Lig IIIα and forms a 
stable complex as seen in XRCC1 deficient cells which have reduced levels of DNA Lig IIIα 
causing a deficiency in repair of single strand breaks and increased sensitivity to DNA 
modifying agents (69, 90, 91). Pol β has been suggested to enhance the recruitment of DNA 
Lig IIIα-XRCC1 complex through an interaction with XRCC1, indeed the presence of this 
complex has been shown to increase the activity of Pol β and overall repair which indicates 
that the interaction between Pol β and XRCC1-Lig IIIα is an essential for proficient repair 
conclusion (92-94).  
 
 
1.2.3.7 Base excision repair and Cancer   
 
BER is a critical pathway for the preservation of genome integrity, which is achieved through 
the processing of DNA base damage and the coordination of each step by the balance of the 
enzymatic activities, both of which are vital for genome integrity and complete repair (95). It 
has long been recognised that defects in DNA repair and consequently increased genome 
instability are linked to cancer susceptibility. An example of this is the oxidative lesion 8-oxoG 
that BER processes has been found in tumour DNA and urine from patients with an array of 
malignancies (5). Currently there is increasing evidence which suggests that cancer cells 
typically either display defects in a DNA repair process (at least one pathway) or have 
increased expression of DNA lesions that are caused by a mutant endogenous source (96). 
In humans DNA repair pathways play a pivotal role in the protection from cancer, this is 
emphasised through the accumulating evidence for the predisposition towards hereditary 
cancers by germ-line mutations in DNA repair genes (97). In BER the connection between 
defective repair and cancer risk is known through the germ-line line biallelic mutation in 
the MUTYH gene that encodes for a DNA glycosylase MYH that is involved in the repair of 
oxidative lesion (5, 97). This mutation causes a predisposition to a rare hereditary form of 
colorectal cancer (97). In the normal human population there are above 100 germ-line single 
nucleotide polymorphisms in numerous BER proteins including DNA glycosylases, APE1, 
XRCC1 and Pol β that are anticipated to change the amino acid sequence of the protein (98). 
Somatic variants (single nucleotide polymorphisms) of BER proteins are also found in sporadic 
cancers, the majority of which are heterozygous suggesting either a dominant phenotype or 
as BER is highly coordinated small alterations could cause genome instability. Variants of 
these proteins cause aberrant BER which if joined with continuous DNA damage over time 
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could produce a mutant phenotype (97, 98). Variants of Pol β are found in approximately 30% 
of tumours which are not in the germ-line (97-99). Somatic mutations of Pol β have been found 
in a number of cancers including gastric, colorectal, prostate, lung, bladder, breast, and 
oesophageal (100). The majority of the somatic mutations observed are point mutants and 
these mutations may only slightly modify the folding of Pol β causing an aberrant phenotype 
(98). It has been suggested that Pol β variants may cause mutations during the gap filling step 
in BER reducing its fidelity such as the K289 methionine (M) and Isoleucine (I)260M variants 
and so increasing genomic instability. In both cases this can lead to DNA repair synthesis 
errors as the fidelity of BER is dependent on the polymerisation stage, this may cause 
imbalances in BER that can lead to a mutator phenotype (5, 77, 99).  
 
There is also accumulating evidence for frequent BER enzymes misregulation in various 
cancers. There are a number of cases of glycosylase overexpression in cancer cells which 
has been suggested to lead to drug resistance (96). Down regulation of OGG1 has been 
implicated in cancer, for example Head and neck squamous cell carcinomas and 
overexpressed in various other cancers (101). PARP1 also has been found to be over 
expressed in some cancer including colon adenoma and carcinoma. APE1 is overexpressed 
in ovarian cancer which promotes the cancer progression (102). High XRCC1 expression in 
head and neck squamous carcinoma is an indicator of poor survival (103). Recently Polβ has 
been found to be overexpressed at mRNA and protein levels in a third of tumour types 
examined in a study, particularly in the ovary, prostate and uterus (104). This highlights the 
possibility of potentially targeting these proteins for cancer therapy.  
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1.3 Chromatin Formation and Dynamics 
  
 
Nearly all DNA in a cell in contained within the nucleus. The double helices of all 46 
chromosomes in human cells if laid out in a line would be approximately 2 meters long. To fit 
this amount of DNA in an around 6μm diameter nucleus, the DNA must be packaged tightly 
in a co-ordinated structure. This is called chromatin which is generated from an array of loops 
and coils by specialised proteins. Despite this compaction of DNA, chromatin is arranged and 
regulated in a way to still make it accessible to protein for biological processes such as DNA 
transcription, replication and repair. In eukaryotes proteins that bind to DNA to shape 
chromosomes are defined as two classifications; histones and non-histone chromosomal 
proteins and together form chromatin. The nucleosome, which is a protein-DNA complex, 
represents the rudimentary form of chromosome packing and form nucleosome arrays, with 
sequences of DNA linking each nucleosome. These are further compacted one of top of the 
other to condense DNA further to form a chromatin fibre. Chromatin not only compacts DNA 
into a small volume it also serves to protect DNA from damage, control gene expression and 
strengthen DNA to allow for mitosis or meiosis when entering anaphase. Tightly packed 
chromatin is termed heterochromatin and encompasses a small number of genes that are 
(the majority of the time) turned off by this compaction. A gene that is frequently expressed is 
typically located in euchromatin which is situated in a relaxed area of 
chromatin. Nucleosomes and chromatin are dynamic, relaxing of the DNA–proteins 
contacts are required for biological processes so proteins can access the DNA sequence to 
accommodate the needs of the cell.  
 
 
1.3.1 Overview of chromatin Structure and Dynamics  
 
In human cells nucleosomes are comprised of two copies of the four core histone proteins H3, 
H4, H2A and H2B forming a histone octamer, which 147bp genomic DNA is wrapped 
around to form the nucleosome core particle and are further processed into densely packed 
chromatin (figure 12).  The nucleosome is a fundamental component of chromatin and formed 
with newly replicated or repaired DNA. This is initiated with the wrapping of DNA around the 
H3-H4 tetramer and followed by the inclusion of two H2A-H2B dimers that help with the 
organisation of the outer wraps of the nucleosomal DNA. Positively charged residues in the 
histone core interact with the phosphate backbone of DNA in the minor grove at regular 10bp 
intervals on each adjacent pseudo two fold axis of symmetry called the dyad axis, (figure 13)  
(16, 105). This provides 14 relatively weak histone-DNA interactions, however all together 
provide positional stability in the nucleosome. Nucleosomes are connected by short segments 
of DNA (linker DNA) and form linear 10nm beads-on-a-string like structures termed 
nucleosome arrays which are packed together to form secondary structure of the 30nm 
chromatin fibre and other more highly ordered tertiary structures (figure 13; (105, 106)). The 
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N-terminal tails of histones contain K residues that protrude out from the nucleosome which 
can be modified through epigenetic post-translational modifications (PTMs); phosphorylation, 
ubiquitination, acetylation, methylation, SUMOylation and PARylation by a multitude of 
different specific enzymes with different biological outcomes and over 100 have been 
identified. This varies chromatin composition and can recruit specific chromatin complexes 
that are able to alter chromatin function (106, 107). Histone variants which have differences 
in their amino acid sequence also regulate chromatin organisation, these variants differ in 
expression throughout the cell cycle and localisation in chromatin and are escorted in and out 
of chromatin by specific histone chaperones. Mostly, histone variants have been identified for 
H2A and H3, the histone variants are highly conserved between species suggesting that they 
accomplish function that cannot be by their non-variant counterparts which has been shown 
with H2A.Z in processes such as transcription (107). Chromatin arrangement is also 
controlled by ATP-dependent chromatin remodelling complexes, these are large multi-subunit 
complexes built around a catalytic ATPase domain.  Chromatin-remodelling complexes and 
PTMs can alter the interaction between nucleosomes and recruit chromatin-binding proteins 
(106). The packaging of DNA into chromatin limits access to DNA for transcription, replication 
and repair, a change in the structure is required to allow factors that facilitate these activities 
to bind. This is thought to occur through PTMs of histone N-terminal tails or the recruitment of 
chromatin remodelling complexes causing chromatin condensation (108).  
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Figure 12; The Primary, Secondary and Tertiary Structure that form Chromatin. Image 
taken from K.Luger et al (106). The primary structure of chromatin is shown at the top which 
is a nucleosome array containing canonical histones (light blue and yellow) and histone 
variants (green, purple and light blue) and all these types of histones vary in the number and 
type of post-translational modifications they endure. Nucleosome – nucleosome interaction 
form chromatin fibres (bottom left) and fibre-fibre (bottom right), the secondary and tertiary 
structures of chromatin respectively. The chromatin fibre on both levels of folding is dependent 
on the primary structure of chromatin (PTMs and histone variants). The secondary and tertiary 
structure of chromatin is stabilised by architectural protein (orange triangle). These three 
states are transitional, indicated to by the arrows by chromatin remodelling factors, histone 
exchange and PTMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure from (106), Figure 1 
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Figure 13; The Nucleosome Core Particle. Image taken from Luger et al (109) detailing the 
first structure of the nucleosome with detailed interactions of DNA and histones to near atomic 
level. Ribbon colour brown and turquoise from the backbone of 147bp DNA and the 8 histones 
which make up the histone octamer; green H4, blue H3, yellow H2A and red H2B. Image 
shows the view down the DNA super helix and vertical to it in the right image. The 2-fold axis 
of symmetry (dyad axis) is associated vertically with DNA at the top in each image.  
 
 
1.3.1.1 Nucleosome structure  
 
Each of the canonical histones H2A, H2B, H3 and H4 (major type histones) are highly 
positively charged have structural similarities, they share a structural domain called the 
histone fold that comprises on 3 α helices; α1, α2 and α3, which are divided using 2 loops; L1 
and L2. This domain is required for the heterodimerisation. Each of these form a motif which 
is termed a ‘handshake’ leading to the two loops coming close together which are essential 
for histone to DNA interaction. The 4 helix bundle then allows for dimerization of the histone 
pairs. In H3 the α-helices allow for the H3-H4 histone pair to come together which forms (H3 
and H4)2 tetramers, the central tetrameric axis of the histone octamer (109). A similar 4 helix 
bundle is formed with H2B and H4 with both copies and so forms the ordered histone octamer. 
H3 – H4 in the octamer are very stable whereas H2A – H2B can be removed or exchange 
more easily (110, 111). The 147bp DNA then forms a tight left handed superhelix 
approximately 1.65 times around the histone octamer to form the nucleosome, (Figure 13, 
(109)). This histone octamer is stabilised by numerous protein, electrostatic interactions and 
hydrogen bonds between DNA and the histone proteins. Interactions with DNA and histones 
Figure from (109), Figure 1 
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are predominately in the structured areas the nucleosome, the histone tails which stretch away 
from DNA are more involved in interaction with other nucleosomes and are the site of most 
PTMs (112-116). 
 
 
1.3.1.2 Histone Variants   
 
Histone protein variants are encoded by genes distinct from their major type equivalent. 
Variant histones are exchanged into nucleosomes by DNA replication independent pathways 
through ATP chromatin remodelling, PTMs and histone chaperones, and are expressed at all 
phases in the cell cycle contrasting to the major type histones. Variants for H2A and H3 are the 
most common and are very conserved which suggests they are needed for certain functions 
that the major histone type cannot achieve (114, 117).   
 
The variant histone H3.3 has a five amino acid difference to its major type, however this does 
not have a significant effect on the nucleosome structure (118). These amino acids are 
involved in the localisation of histone H3.3 by histone chaperones that bind to them (113, 119). 
H3.3 contains areas of DNA for gene promoters, enhancers and gene bodies (120, 121). 
Exchange of H3.3 has been suggested to expose these areas transiently to allow transcription 
factors to bind and function (122). Exchange of H3.3 with gene bodies is linked to an increase 
in transcription suggesting that this exchange is regulated by Pol II and other associated 
factors (123).  
 
H2A.Z is highly conserved between species and is expressed with H2A, its major type, in all 
organisms. H2A.Z has numerous amino acid variations but has little effect on the overall 
structure of the nucleosome (124). There are minor structural changes to the 
nucleosome which alters its stability by affecting the interactions between the H2A.Z – H2B 
dimers due to the steric interference of the L1 loops laying at opposed ends of the dyad 
axis and (H3 – H4)2.(125). This instability of the nucleosome helps with transcription initiation, 
DNA repair and chromosomal domain segregation and this variant is usually found in promotor 
regions (126).  
 
 
1.3.1.3 Nucleosome stability and alternative structures   
 
Chemical alterations of nucleosome components can affect the overall stability of a 
nucleosome through disrupting protein – protein and protein – DNA interactions but without 
altering the structure (127). Thermal denaturation of the nucleosome with nuclease 
accessibility and electron microscopy investigation have revealed that DNA that is towards the 
edges of the nucleosome are more susceptible to dissociation from the histone octamer than 
DNA in the histone core (128). The use of restriction enzyme analysis on incision target sites 
of nucleosomal DNA found that these enzymes could partially cleave DNA in proportion with 
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the distance of the target site and dyad axis i.e. target sites further away were cleaved at 
higher rates than ones closer to the dyad axis. It was thought that DNA on the nucleosome 
edge experiences spontaneous unwrapping and rewrapping, this was also seen in vivo by 
DNA footprinting and transcription studies and allows the binding of transcription factors (129, 
130). Fluorescence resonance energy transfer (FRET) have shown that DNA unwrapping 
occur a number of times a second and can last for approximately 25mS (131). Spontaneous 
unwrapping and wrapping of nucleosomal DNA has associations on the regulation of nuclear 
processes and it explains how some associated proteins can access and so bind to DNA. 
Rates of unwrapping are influenced by DNA sequence and histone variation, for instance the 
PTM acetylation of H3 lysine (Lys) 56 causes an increase rate of site exposure (132). The 
compaction of DNA into chromatin fibres only exhibits small changes in the DNA exposure 
rates proposing that nucleosomes in chromatin experience transient breathing (133).  
 
 
1.3.1.4 Chromatin Secondary Structure 
 
Nucleosomes are attached through linker DNA, H1 binds to this linker DNA and the 
nucleosome dyad stabilises the nucleosome to form high order structures such as nucleosome 
arrays. Nucleosome arrays are compacted to form a three – dimensional higher order 
structure which has been suggested to be facilitated by H1 (134). The secondary structure of 
chromatin is defined as structures from folding a single nucleosome array to form a defined 
fibre; 30nm fibre. The structure of the 30nm fibre is still yet to be resolved and there are at the 
moment two possible models; solenoid and zigzag organisation of nucleosomes on the basis 
of in vivo models. In the one start solenoid model neighbouring nucleosomes are intact by 
linker DNA and follow a superhelical orientation with the bending of linker DNA. Two start zig 
zag model involves two rows of nucleosomes connected by straight linker DNA with the 
alternative nucleosome with straight linker DNA (135). 
 
 
1.3.1.5 Chromatin Tertiary Structures 
 
It has long been regarded that coiling of the 30nm chromatin fibre into increasing higher orders 
of chromatin compacted and at each stage of compaction dependent on the folding and coiling 
of chromatin in the previous step to form chromosomes. The formation and existence of the 
30nm chromatin fibre has been questioned however recently. It has been suggested that 
chromosomes are formed in a much less step wise manner and the idea that a chromosome 
may be similar to a molten globule state as a result of compacted and irregular coiling folding 
of nucleosome arrays (106). Other chromatin organising and compacting proteins are thought 
to play in role in chromatin compaction such as polycomb repressive complex 1 and 2 
(PRC1/2) and myloid, erythroid nuclear termination stage specific protein (MENT), PARP1, 
methyl-CpG-bidning protein 2 (MeCP2) heterochromatin protein 1 (HP1)  (106, 135).  
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1.3.1.6 Regulation of Chromatin Structure 
 
Nucleosomes regulate DNA accessibility to proteins by causing an obstruction so the strength 
and positioning DNA and nucleosome interfaces affect the access to sequences.  Histones 
are dynamic and are regulated to either stimulate or supress biological processes such as 
DNA transcription, replication and repair. Chromatin compaction is regulated by the cell cycle 
through development and external signals. For example in mitosis, chromatin condensation 
occurs, when cells enter interphase chromosomes separate irregularly so that some area 
remain condensed and others relaxed. Factors that target histone octamer- DNA interactions 
are enzymes that modify histones covalently through PTMs, or use ATP to alter nucleosome 
interactions. These are called ATP chromatin remodelling complexes which are recruited by 
PTMs on histones (108). 
 
 
1.3.2 Post Translational Modifications (PTMs) of Histones  
 
PTMs are covalent modifications of a protein which occur during or after protein synthesis. 
They occur on amino acid side chains or at the C or N terminus of the protein and widen their 
chemical functionality by the addition of groups such as phosphate, amide, methyl or ubiquitin 
moieties (136). Over 100 PTMs on histones have been described and common modification 
are shown in figure 14 shows common examples (137). For example phosphorylation, 
ubiquitination, acetylation and methylation occur predominantly on the N-terminal tails and are 
essential in the regulation of chromatin structure and are essential in a wide array of cellular 
processes including regulating transcription, DNA, repair, recombination through meiosis and 
DNA replication scheduling in mitosis (108, 137). A number of PTMs have been reported to 
occur within the histone core, including to 10 - 20 histone modifications that occur between 
the DNA – Histone octamer interface (137). PTMs alter gene expression without changing the 
DNA sequence so are frequently called epigenetic changes although they are not sustained 
over the cell cycle (138). PTMs effect the stability of the nucleosome by changing the chemical 
interactions in the nucleosome or with an adjacent nucleosome changing the compaction of 
chromatin; opening or closing of chromatin (139). PTMs can also regulate biological 
processes, for example during transcription, PTMs can act as scaffolds or binding sites so 
other proteins can bind and can also prevent the binding of proteins to DNA (137, 140, 141). 
These PTMs of histones can also regulate chromatin by the recruitment of ATP dependent 
chromatin remodelling complexes (142). 
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Figure 14: Histone post translational modifications. Common patterns of histone 
modifications in normal and cancer cells. The majority are located on the N-terminal tails, but 
there are also some located in the C-terminal region. Histones undergo a range of PTMs (Ac, 
acetylation; Me, methylation; P, phosphorylation; Ub, ubiquitination) which contribute to global 
and local chromatin condensation or decondensation. Figure has been modified slightly from 
(143).  
 
 
1.3.2.1 Phosphorylation of Histones 
 
Protein phosphorylation is a type of PTM which is the most commonly used for signal 
transduction in all basic cellular processes. This particular PTM has been related chromatin 
structure and function and play a vital part in transcription, apoptosis, DNA repair, 
chromosome condensation (108). Protein kinases utilise ATP to catalyse the addition of a γ-
phosphate group using to specific amino acids (usually Serine (S), Threonine (T) and Y in 
eukaryotes) in a protein. There are in total 518 kinases that make up approximately 1.7% of 
the genome, one of the principal families of genes and it has been estimated that 30% of 
proteins in cells are modified in this way and there around 700,000 sites of possible 
phosphorylation. Kinases are very variable in the number of sites in which they can 
phosphorylate, an example of this is mammalian protein kinase 1 (MEK1) that probably only 
acts on four sites (two in extracellular signal-regulated kinase (ERK) 1 and two in ERK2) in 
contrast to cyclin-dependent kinases (CDKs) which act on hundreds (144). Protein 
phosphatases act by removing phosphate groups, therefore allowing flexible and versatile 
Figure from (143), Figure 2 
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regulation of protein phosphorylation. There are approximately 200 protein phosphatases 
which are be broadly separated into three main families; 40 serine/ threonine, 100 tyrosine 
and 50 dual-specificity phosphatases (144).  
 
Histone phosphorylation is highly dynamic and is involved in chromatin function and structure, 
through (in the majority of cases) modification of S and T amino acids on histone tails. This 
modification on amino acids causes a substantial negative charge on the histone which is 
thought to alter chromatin structure (142). The majority of phosphorylation events occur on 
the N-terminal tails of histone to alter chromatin structure and function, some do occur on the 
C-terminal of certain histones for example phosphorylation of a H4H74 which also causes 
changes in chromatin structures (108, 142). Phosphorylation in the core of the nucleosomes 
also occur such as a H3Y41 (108). H3Y118 phosphorylation at the nucleosome dyad has been 
shown to destabilise the nucleosome altering chromatin structure using mononucleosome 
substrates and has been implicated in DNA transcription and repair (137). The action of 
phosphatases on histones is less well known, but it can be assumed that due to vast amount 
of phosphorylation events that happen there has to be high amount of phosphatases to 
reverse this activity. At mitosis the PP1 phosphatase acts antagonistically in relation to Aurora 
B kinases that induces genome wide H3S10 and H3S28 phosphorylation (142). 
 
 
1.3.2.2 Acetylation of Histones 
 
Histone acetylation involves the transfer of negatively charged acetyl group on to a ε-amino 
group of lysine residue in all core histones. This process is regulated by two opposing families 
of proteins; histone acetyl transferases (HATs) and histone deacetylases (HDACs). HATs 
catalyse the addition of acetyl group by utilising acetyl cofactor A (CoA) as a cofactor. This in 
turn neutralises the positive charge on lysine residues as the acetyl group is negatively 
charged which is thought to weaken the electrostatic interactions between the histone octamer 
– DNA and so relaxes the chromatin to allow for processes such as transcription (142, 145). 
An example of this is acetylation of lysines are H3K115 and H3K122 in the nucleosome dyad 
was found to reduce histone octamer interactions using mononucleosome substrates which 
may facilitate nucleosome repositioning and de/assembly (146). There is an increasing 
amount of evidence of HATs in DNA repair and replication which also require an open 
chromatin structure to operate (147). There are two primary families of HATs; type B which 
acetylate free histones in the cytoplasm such as those synthesised on H4K5 and H4K12 which 
is required for the deposition of histones, and type A which are much more varied. Type A is 
split into three groups; GNAT, MYST and CBP/p300 and can acetylate varies sites on histone 
N-terminal tails (predominantly) and histone core (142). As well as the relaxing chromatin 
acetylation of histones can also be recognised by a number of proteins that contain a 
bromodomain which stabilises the interaction with acetylated histones, which occur in many 
transcription coactivators and SW1/SNF chromatin remodelling factors (108).  
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1.3.2.3 Methylation of Histones 
 
Covalent methylation of histones largely occurs on the side chains of amino acids L and R, 
particularly through the transfer of a methyl group from a S-Adenosyl methionine (SAM) to 
histones H3 and H4. Methylation of histones does not change the charge of histones like its 
other PTM counterparts, phosphorylation and acetylation (108, 148). Lysine residues in 
histones are methylated on the ε-nitrogen by a lysine specific SET domain (130 – 140 amino 
acid motif) lysine histone methyltransferases (HMTases) involved in the methylation of K4, 9 
27 and 36 in H3 and 20 in H4 or non-SET lysine histone methyltransferases which will 
methylate H3K79 (148). Arginine methyltransferases methylate arginine residues 2, 17 and 
26 in H3 and 3 in H4. Lysine methylation can be mono, di and tri methylated while Arginine 
can be mono-methylated, symmetrically or asymmetrically di-methylated. Histone 
modifications by methylation are thought to be a more stable mark than the other PTMs, 
especially histone trimethylation as at the moment there are no known enzyme that can 
remove this type of methylated modification (148). Euchromatin is characteristically marked 
by di and trimethylation on H3K4 by specific HMTases (for example SET1/AS2 and SET7/9). 
This modification stimulates gene expression and a group of co activators including CHD1 
binds to this methyl group and transcriptional machinery can also bind to this residue. In 
contrast methylation on H3K9 is associated with closed chromatin and marks 
heterochromatin.  H3K27 methylation is also associated with closed chromatin and has been 
associated with pluripotency, developmental gene regulation and ESC function, and is 
catalysed by polycomb repressive complexes (PRCs). PRCs are thought to promote the tight 
packaging of chromatin, repress chromatin remodelling and block transcription machinery. 
Polycomb (PcG) proteins have a chromodomain which bind to methylated H3K27 and play a 
vital role in repression of transcription (108). Histone methylation was previously thought to be 
a stable and static PTM until the discovery of the first histone demethylase. Lysine-specific 
demethylase 1 (LSD1) which uses FAD as a cofactor and when in complex with Co-REST 
repressor complex it is able to demethylate nucleosomal histones such as mono and 
demethylated H3K4, when complexed with androgen receptor demethylates H3K9. LSD1 
alone cannot demethylate nucleosomes (142). 
 
 
1.3.2.4 Ubiquitination 
 
Ubiquitination is a very influential and essential mechanism in regulating the majority of the 
features of cell biology. The molecule ubiquitin in a small regulatory protein which is 
conjugated onto proteins either as a monomer or polymer. This PTM affects a range of cellular 
processes including degradation, cellular location, stability or activity of a protein and alter 
protein-protein and protein-DNA interactions.  
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1.3.2.4.1 Ubiquitination pathway 
 
Ubiquitin can be attached to vast array of proteins and different types of ubiquitination can 
have very different effects on the protein as discussed, therefore the ubiquitination process 
requires a high specificity to the substrate. There are 2 E1s, at least 38 E2s and more than 
1000 E3s that the human genome encodes. As the number of enzymes increases in this 
cascade so does the specificity of the next component. Specificity and sensitivity of the 
substrate protein recognition is largely carried out by the E3 ligase either on its own or in 
complex with a E2 (149). 
 
Ubiquitin is a 76 amino acid which is transferred onto a K residue on target protein through a 
step wise process of enzymatic reactions with a E1 activating enzyme, an E2 conjugating 
enzyme and a E3 ubiquitin ligase, which is termed ubiquitination. The enzymatic cascade is 
initiated by a E1 activating enzyme which utilises ATP to form a thioester bond between its 
cysteine (C) in the active site the C-terminus of the G76 residue in ubiquitin. This process 
activates ubiquitin so it can be transferred to a E2 conjugating enzyme. This E1 activating 
enzyme interacts with a E2 conjugating enzyme and catalyses the transfer of ubiquitin from 
the E1 enzyme to the a C residue in the active site E2 enzyme forming a thiol ester bond with 
G 76 ubiquitin. The conjugated E2 then binds to a E3 ubiquitin ligase on which there are two 
different classes. The E3 ligase will either cause the direct transfer of the ubiquitin molecule 
onto a K target protein or onto a K acceptor in the E3 ligase or E3 bound target protein for E3 
mediated ubiquitin transfer on a target protein. This mostly creates an amide isopeptide bond 
between the ε- amino group of a Lys in a target protein and the C-terminal G76 residue of 
ubiquitin (150). The majority of E3 ligases have a really interesting new gene (RING) domain 
or RING related E3s such as the U-box family which mediate the direct transfer of a activiated 
ubiquitin from a E2 enzyme to the target protein. E3 ligase in the homologous to the E6AP 
carboxyl terminus (HECT) domain class conjugate ubiquitin on the C in the active site of the 
E3 creating a thioester intermediate which then transfers ubiquitin onto the target protein. 
Protein targets can be modified by a one ubiquitin on one (monoubiquitination) or more sites 
(multi- monoubiquitination) and repeated addition of ubiquitin molecules to exciting ones to 
form chains of ubiquitin (polyubiquitination) (151). The traditional view of ubiquitination and 
what it is used for primarily is commonly polyubiquitination of proteins primarily as a mark for 
degradation by the 26S proteasome. Protein monoubiquitination has been shown as a vital 
player in regulating essential cellular functions which do not directly include protein 
degradation, such as the regulation of DNA repair, translation, and activation of kinases and 
transcription factors (149, 152). 
 
Proteins can also for marked for ubiquitination and recognised and targeted by E3 ligases. An 
example of this are degrons which simulate the degradation of a proteins that are damaged, 
misfolded or abnormal via the proteasomal degradation pathway. This occurs primarily 
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through the N-end rule pathway and causes destabilisation of the N-terminal residue of a 
protein, termed N- degron. These are then recognised by a E3 ligases that contain a N- 
recognin sequences and with its cognate E2 enzyme polyubiquitinates the N-end rule 
substrates and so sending them to the 26S proteasome (153). Substrate markers for 
ubiquitination can also be generated through PTMs. An example of this in the context of 
nucleosome is CUL4 E3 ligase which binds to histones that are newly synthesised with an 
acetylated H3K56 and ubiquitinates H3K56 and so facilitating hand off H3-H4 from the histone 
chaperone Asf1 to others in nucleosome assembly (154).  
 
DUBs are proteases which remove ubiquitin or ubiquitin like protein residues from target 
proteins and play essential roles in the ubiquitination pathway. DUBs recycle ubiquitin, reverse 
ubiquitin or ubiquitin like modifications of proteins, activate ubiquitin protein precursor and free 
unattached polyubiquitin chains. The human genome encodes for 100 DUBs which are 
separated into five families the ubiquitin C-terminal hydrolases (UCH), the ubiquitin specific 
protease (USP/UBP), the ovarian tumor (OTU), the Josephin domain are papain-like cysteine 
proteases and the fifth family JAB1/MPN/Mov34 metalloenzyme (JAMM) domain zinc-
dependent metalloprotease family.  Deubiquitiniation is a highly conserved and regulated 
process associated with many cellular process including the regulation of cell cycle 
progression, gene expression, DNA repair, kinase activation and proteasomal degradation. 
DUBs require interaction with either a substrate or scaffolding protein to allow for the 
catalytically competent conformation, this prevents DUBs acting on non-specific substrates. 
They are composed of catalytic, protein-protein interaction and ubiquitin binding domains 
which are involved in specificity, binding, localisation and function of DUBs. DUBs form multi 
protein complexes which are required for localisation and substrate specificity so it can 
function within a cell correctly. An example of this is the association of DUBs with E3 ligases 
and so consequently negatively regulating the conjugation of ubiquitin (155).  
 
 
1.3.2.4.2 Ubiquitination of Histones 
 
Ubiquitination of histones occurs mainly in the mono form which is not associated with 
degradation. The understanding of the effect of ubiquitin on histones is not as well understood 
as the other PTMs of histones but they have still be found to have critical functions in DNA 
repair and transcription. In cells H2AK119 and H2BK120 are some of the most ubiquitinated 
proteins in a cell which are high conserved and it has been estimated that 5-15% and 1-2% of 
all H2A and H2B respectively are modified in this way. H3 and H4 can also be ubiquitinated 
for example polyubquitination of these is seen following UV irradiation, however the function 
of this PTM has not been elucidated. Monoubiquitination of H2A and H2B both play a clear 
role in transcription. H2A ubiquitination is associated gene silencing, ubiquitination on K119 
by ubiquitin ligases that were discovered to by transcriptional repressor complexes e.g. PRC1 
and has also been found to repress the methylation of H3K4 which is a transcription marker. 
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DUBs have been found to stimulate gene activation by deubiqutinating H2A. H2B on the other 
hand promote transcription activation through a number of ways by stimulating other PTMs 
and Pol II elongation. In yeast it was shown that ubquitination of H2BK123 enhanced 
methylation of H3K4 which as stated before is a transcription marker. H2B ubiquitination 
facilitates Pol II elongation by stimulating the replacement of H2A/H2B dimers for the 
nucleosome (156, 157).  
 
1.3.2.5 Poly(ADP-ribosyl)ation of Histones 
 
PARPs are a family of enzymes that play vital roles in various cellular processes including 
DNA transcription, replication, repair and the modulation of chromatin structure. PARPs can 
achieve this by catalysing the transfer of ADP-ribose from donor nicotinamide adenine 
dinucleotide (NAD+) onto target proteins post translationally. The enzymatic reaction results 
in the covalent attachment of ADP-ribose to glutamine (Q), arginine (R) or K residues in 
acceptor proteins by a transesterification reaction. There are at least 18 PARPs that are 
encoded by different genes but share homology in a conserved catalytic domain. The 
functions of PARylation have been best identified for only a few PARPS; PARP1, PARP2 and 
tankyrases. There are four subfamilies which include: DNA-dependent PARPs (e.g. PARP1, 
PARP2, and PARP3), the tankyrases (e.g. PARP5B), the Cys-Cys-Cys-His (CCCH) PARPs 
(e.g. PARP7 and PARP12) and the macroPARPs (e.g. B-aggressive lymphoma protein 1) 
(158-160). 
 
PARP1 is involved in the early recruitment of factors for DSB repair. PARP1 deficiency or 
inhibition leads to the delayed activation of DNA damage response proteins such as γH2AX 
and p53 which are recruited to DSBs by ATM. ATM contains poly(ADP)ribose domains and 
its interactions with poly(ADP)ribose polymers stimulates its activity (158).  
 
The poly(ADP-ribosyl)ation of nucleosome arrays has been shown to the relax chromatin 
structure. PARP1 has been shown to modulate the composition of chromatin through 
facilitating the release of H1 and thus cause the recruitment of HGMGB1 and chromatin 
architectural protein to the oestrogen stimulated pS2 promotor (161). PARP1 has been found 
to regulate chromatin structure through preventing the demethylation of H3K4me3 by 
PARylating and inhibiting the recruitment of the K specific demethylase KDM5B and by the 
promoting the exclusion H1, causing the opening of promoter chromatin, thus regulating 
transcription (162). PARP1 activity can be simulated by lipopolysaccharide (LPS) to cause 
ADP-ribosylation of histones which destabilises the histone-DNA interactions in the 
nucleosome and so increasing the accessibility of the DNA promoters to nucleases. LPS 
stimulation induced ADP ribosylation at specific promoters facilitates NF-кB recruitment and 
so the transcription of specific genes in macrophages (163).  PAR chains have been 
suggested to stabilise histones that have been dissociated from DNA. A mesh of PAR chains 
are formed when large scale nucleosome eviction has occurred and so may function as a 
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scaffolding to maintain displaced histones locally. PARylation is also thought to maintain 
chromatin structure, and has been found to maintain heterochromatin and rDNA silencing 
(164).   
 
1.3.3 Histone Chaperones 
 
Histone chaperones are a group of proteins that regulate nucleosome assembly and can also 
dissemble nucleosomes. They are able to do this by binding to histones, there as two groups 
of histone chaperones, ones that bind to H3-H4 or H2A-H2B. However, some histone 
chaperones including facilities chromatin transcription (FACT) are able to bind both of these 
histone dimers. The negative charge of histones chaperones prevents non-specific 
aggregation of highly positively histones charged and negatively charged DNA. They are also 
involved in regulating critical steps when forming the histone octamer with DNA to make the 
nucleosome. Histones and DNA are unable to form nucleosomes on their own as histones 
tend to form aggregates with DNA by binding non-specifically, histone chaperones are 
therefore required for correct folding of the nucleosome (165). In nucleosome assembly firstly 
newly synthesised histones in the cytosol are localised to the nucleus by histones chaperones 
for example (Nucleosome assembly protein 1) Nap1, which are directly implicated in the 
transport of histones on DNA for nucleosome formation. They regulate enzymatic activity of 
histone modifiers with other histone binding proteins such as Anti-silencing factor 1 (Asf1) and 
RbAp46. They also maintain a pool of histones in case of cell stress, for example histone 
chaperones like Nuclear autoantigenic sperm protein (NASP) bind to histones and regulate 
supply of histones.  They play key roles in many biological processes such as transcription, 
recombination, replication, DNA damage response and repair and cell cycle progression 
(166). 
 
 
1.3.4 ATP – dependent chromatin remodelling complexes  
 
ATP-dependent chromatin remodelling complexes alter chromatin organisation by causing the 
displacement of histones by utilising the energy from ATP hydrolysis to remove nucleosomes 
to expose DNA sequences, nucleosome sliding to expose (or bury) a DNA sequence and 
replacing pre-existing histones with specialised histone variants (167). They all share a range 
of similar features; common ATPase domain for remodelling and breaching histone DNA 
interfaces, strong affinity for the nucleosome, domains that recognise PTM of histones and 
utilise ATP hydrolysis to alter histone-DNA contacts. These remodelling complexes are 
divided into four different families which all have a common ATPase domain but are divided 
into different families by their unique flanking domains. The four families include the switching 
defective/sucrose nonfermenting (SW1/SNF), chromodomain, helicase, DNA binding (CHD), 
inositol requiring 80 (INO80) and imitation switch (ISWI) families that have been identified 
(106). All four are specialised for specific purposes and biological settings, by unique domains 
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residing in their catalytic ATPases and also by their unique associated subunits. There 
structures are shown in figure 15. The SWI/SNF family acts by sliding and ejecting 
nucleosomes for many biological processes, but do little in chromatin assembly. However 
ISWI family remodellers optimise the spacing of nucleosomes, thus promoting chromatin 
assembly but repressing transcription. Some CHD remodellers slide or eject nucleosomes to 
stimulate transcription, conversely others have repressive roles. The INO80 family have 
diverse functions including histone variant exchange which comprise promoting DNA repair 
and transcription (167). 
 
 
 
Figure 15: ATP-dependent chromatin remodelling families. All families share a SWI/SNF 
family ATPase subunit characterised by a ATPase domain which is in two sections, HELICc 
(orange) and DExx (red). These families are separated by domains that are within or adjacent 
to the ATPase domain, and are further defined by flanking domains (Bromodomain, helicase-
SANT (HAS), SANT SLIDE module, tandem chromodomains). Figure is from (167). 
 
 
1.3.5 Chromatin Dynamics in DNA repair 
 
Changes in chromatin structure are essential in the response to DNA damage to regulate DNA 
repair and checkpoint signalling. To ensure genome integrity, DNA repair machinery must be 
able to access DNA lesions efficiently no matter what their position is in chromatin. The 
stability of the nucleosome can be altered through a number of ways; histone exchange, 
histone PTMs and the recruitment of ATP-chromatin remodelling complexes. Chromatin 
Figure from (167), Figure 2 
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remodelling in terms of DNA repair has been implicated mostly in the DSB and NER pathways 
which will be discussed in more detail below.   
 
 
1.3.5.1 Histone Modifications  
 
1.3.5.1.1 Histone Phosphorylation  
 
Phosphorylation of H2AX on S 139 is the most established form of epigenetic change that 
occurs as a result of the DNA damage response (DDR). This is an early event which arises 
after DSB by either ataxia telangiectasia mutated (ATM) creating a chromatin mark. In DSB 
repair phosphorylated H2AX (γ-H2AX) is important for the accumulation of different repair 
proteins and signalling molecules, this concentrates repair proteins in small nuclear foci, 
ionising radiation-induced foci (IRIF) (168). The interaction between γ-H2AX and mediator of 
DNA damage checkpoint protein 1 (MDC1), a check point protein which is important for the 
function of γ-H2AX by increasing the levels of γ-H2AX along the chromatin fibre thus acting 
as spatial organiser (169). MDC1 also stabilises NBS1 (which is part of the homologous 
recombination essential MRN complex) and chromatin interaction at DSB (170, 171). MRN 
increases the levels of ATM and so increases the levels of γ-H2AX, this demonstrates a 
positive feedback loop with MDC1 to spread γ-H2AX across chromatin (170, 172). In addition 
when MDC1 and γ-H2AX are bound they act as a platform for other DDR proteins to interact, 
this includes checkpoint kinase 2 (CHK2), Rad51, ring finger protein (RNF)8 and 53BP1 (173). 
As described γ-H2AX functions as a spatial organiser for DSB repair directly and indirectly by 
promoting chromatin remodelling and concentrating repair proteins. DSB repair however is 
only slightly affected by the absence of γ-H2AX, suggesting its role is to cause a concentration 
of repair factors and its function to alter chromatin is not critical for repair. The activation of 
cell cycle checkpoints however is dependent on formation IRIF through γ-H2AX in response 
to low doses of ionising radiation (174) . 
 
Histone H2B has been proposed to be phosphorylated on serine 14 at site where DSBs have 
occurred and form IRIF at late time points after irradiation, it has been suggested that this is 
maybe linked to chromatin condensation and apoptosis (175). Histone H2A in yeast showed 
that mutation of Serine 122 and 129 caused defects during DSB repair, with serine 122 having 
the strongest effect (176). Histone H4 has been suggested to be phosphorylated on serine 1 
in response to DSBs by casein kinase II and phosphorylated H4 regulates chromatin 
acetylation by inhibiting NuA4-mediated acetylation of H4, this is thought to be important for 
normal gene expression and repair (177). 
1.3.5.1.2 Histone Acetylation 
 
Acetylation of histones has been found to be a key regulator of chromatin remodelling. In yeast 
studies investigating patterns of K residues in H4 tails that can be acetylated if mutated was 
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found to inhibit DSB and UV damage repair, this was associated with Esa1 NuA4 HAT 
acetylase complex (178). In DSB repair the TRRAP/TIP60 complex (mammalian homologue 
of NuA4) is thought to be required; studies have found the expression of mutated TIP60 which 
did not have acetyltransferase activity caused defective DSB repair and apoptosis (179). 
Reducing the TRRAP/TIP60 complex subunits caused deficient homologous recombination 
repair, however repair could be rescued by forcing chromatin unwinding, thus suggesting that 
the TRRAP/TIP60 complex was required to induce accessibility of chromatin to repair factors. 
The hyperacetylation of histone H4 is also important for the binding of repair proteins Rad51, 
53BP1 and BRCA1 which require increased chromatin accessibility to bind (180, 181). In a 
study screening for histone modifications in response to DNA damage H3K9 and H3K56 
acetylation was found to be significantly globally reduced (182). 
 
NHEJ is initiated by the acetyltransferases p300 and CREB-binding protein (CBP) which 
accumulates around DSBs, acetylating H3 and H4 and so promoting the recruitment of Ku 
proteins (183). Males absent on the first (MOF), another acetlytransferase, also stimulates HR 
and NHEJ by increasing H4K16 acetylation in response to DSBs which is thought to facilitate 
BRCA1 and 53BP1 recruitment (184, 185). Acetylation of histones in DSB has been shown to 
be transient during different stages of the repair process. Acetylation of K on H3 and H4 during 
HR varies and the HDACs, Rpd3, Sir2 and Hst1 locate to site-specific DSB (186). HDACs 1 
and 2 deacetylate H3 lysine 56 and H4 lysine 16 at DSBs and is required for efficient NHEJ 
repair, and is then followed by hyperacetylation. It has been suggested that deacetylation is 
important to repress transcription so repair is not hindered and that tightly bound chromatin is 
required to stop Ku proteins from slipping away thus keeping them concentrated (187).  
 
In NER, total protein acetylation has been found to increase after UV irradiation and repair is 
boosted in nucleosomes which have been hyperacetylated, this was suggested to be because 
the DNA is made more accessible to repair proteins by histone acetyltransferases (188, 189). 
Changes in chromatin structure maybe induced by acetyltransferases controlling transcription 
of target genes or being attracted to certain DNA sequences following damage, this was 
proved in yeast that the repair and transcription of the MFA2 gene was dependent on GCN5 
acetyltransferase (190). Following UV irradiation, GCN5 acetyltransferase is recruited to sites 
of damage and promotes H3K9 acetylation, H4K16 acetylation also increases however it is 
not known which enzyme catalyses this change but is speculated to be by MOF (184, 191). 
 
Global histone acetylation as a result of DNA damage has been observed to increase 
chromatin accessibility and to increase repair efficiency. Following UV irradiation there is a 
increase in H3K9 and H3K14 in a p53 dependent manner causing chromatin relaxation. This 
is independent from repair proteins that are involved in damage recognition and is mediated 
by p300 acetyltransferase, which is also recruited by p53 to DNA damage (192, 193). The ING 
proteins regulate chromatin acetylation by associating with histone acetylases and 
48 
 
deacetylases, effecting NER. The interaction of p53 and p300 is stimulated by their binding to 
ING2. It has been shown that cells overexpressing inhibitor of growth 1 (ING1) protein, which 
are chromatin acetylation regulators, had an increased repair efficiency after UV damage, and 
its knockdown hindered repair, it was concluded that ING1 is required for global acetylation 
causing chromatin relaxation (194, 195). 
 
 
1.3.5.1.3 Histone Ubiquitination  
 
Ubiquitination of histones is a key process in DDR in DSB repair, and is used to recruit the 
repair proteins 53BP1 and BRCA1. The E3 ubiquitin ligase Ring finger protein 8 (RNF8) which 
accumulates at DSBs, monoubiquitinates H2A and H2AX which then catalyses the K63-linked 
ubiquitin chains with UBC1, that interact with MDC1 to recruit this protein to DNA damage 
sites (196-198). RNF168 another E3 ubiquitin ligase interacts with ubiquitinated H2A/H2AX to 
amplify its ubiquitination at sites adjacent to DSBs. The function of RNF168 is dependent on 
RNF8 to initiate ubiquitination of H2A/H2AXK 13 and 15. RNF168 and RNF8 serves to amplify 
the signal to the threshold level so that 53BP1 and BRCA1 can be recruited by altering the 
accessibility and so facilitating 53BP1 loading (199, 200). The ubiquitin E3 ligase HERC2 also 
localises to repair foci, it functions by binding and facilitating RNF8 and the E2 enzyme Ubc13 
and so promoting Lys 63 polyubiquitin chains (198, 201). Histone H2B is also ubiquitinated as 
a result of DSBs on K120 by the RNF20-RNF40 dimer which is phosphorylated by ATM and 
then recruited to DSB. Without H2B ubiquitination, XRCC4 and Ku80 localisation is disturbed 
which leads to defects in DSB repair (202, 203).  
 
H2A ubiquitination is also seen in NER following UV irradiation, this is dependent on CUL4A-
DDB2 complex and the CAF1 histone chaperone, and as seen in DSB repair RNF8 is recruited 
to UV damage sites by MDC1 and UBC13 mediating ubiquitination. RNF2 knockdown has 
also been shown to perturb H2A ubiquitination after irradiation (204-207).  
 
1.3.5.1.4 Histone methylation 
 
Histone H3K4, 9, 27, 36 and 79 and H4K20 can be either mono, di or trimethylated. These 
types of PTMs are need for 53BP1 retention in chromatin containing DSBs and two have been 
implicated; H3K79 and H4K20 (208, 209). 53BP1 binds to methylated H3K79 and is important 
for RAD9 and RAD53 recruitment and activation, and have been shown to be defective in 
H3K79 and DOT1 methylase mutants. Levels of methylated H3K79 do not change as a result 
of DNA damage and it is suggested that DSBs induce changes in chromatin structure to 
expose methylated H3K79 (210, 211). 
 
Dimethylation of H4K20 is required for 53BP1 accumulation by the Set9 methylase at DNA 
damage sites. Monomethylation in H4K20 mice after knockdown of Suv-20 methyltransferase 
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caused enhanced sensitivity to DNA damage. It has also been suggested that H4K20 
dimethylation levels do not change following DNA damage but become exposed promoting 
53BP1 binding. In a recent study however H4K20 levels increase locally following DSB by 
MMSET methyltransferase to accumulate 53BP1 at DSBs (212-214). 
 
1.3.5.1.5 Histone Poly(ADP-ribosyl)ation 
 
The roles of PARP1 in the DNA damage response have been studied extensively, various 
types of DNA damage cause the recruitment of PARP1 to sites of damage through its DNA 
binding activity. DNA binding induces the catalytic activity of PARP1 which results in the 
formation of PAR chains on itself, histone and non-histone proteins. Histone H2B and H3 are 
the main poly(ADP)ribosylation acceptors in response to DNA damage, minor amounts of H1 
and H4 are also modified (215). 
MOF-induced acetylation of H4K16 is required for the cellular DNA damage response and 
DSB repair. This site can also be poly(ADP)ribosylated by PARP1, crosstalk between these 
two types of modifications could conceivably occur in DSB repair.  PARP1 in vitro is activated 
by oligonucleotides has been shown to be able to modify all 5 histones, the length of the 
poly(ADP)ribose chains was dependent on the NAD+ concentrations. PARP3 has been shown 
to interact with H2B, H3 and H1, poly(ADP-ribosyl)ation of H1 by PARP3 has been suggested 
following DNA DSBs (215). 
In a recent in vitro study histones were found to be specifically modified following DNA DSBs 
by PARP1a and PARP2. PARP1a was found to mono ribosylate H2BE18 and 19. In vitro 
PARP1a was found to mono ribosylate H2BE18 and disruption of this site allowed for the ADP-
ribosylation of H2E19. In vivo studies when generating mutations at these sites found that 
H2BE18 and 19 were the principal sites modified by PARP2 and PARP1a (215, 216).   
 
In the NER pathway UV damage is recognised by XPC and RAD23B which associates with 
the complex DDB1-DDB2 that ubiquitinates the core histones to cause nucleosome 
displacement so repair can be initiated. XPC binds to the chained polymer poly(ADP-ribose) 
sites which is important for its recruitment to UV damage sites. PARP1 binding to DDB2 at 
these damage sites stimulates PARP1 activity, this increase in PARP1 activity causes 
ubiquitination-independent chromatin decondensation to facilitate UV damage repair. DDB2 
stimulated PARylation of histones by PARP1 results in the recruitment of the ALC1 chromatin 
remodelling helicase through its PAR binding domains to further stimulate repair by the further 
recruitment of XPC (215, 217).  
PARP1 has been suggested to facilitate nucleosome disassembly by PARylating histones to 
cause chromatin relaxation. this then causes the recruitment of multiple chromatin remodellers 
such as ALC1, SWI/SNF, SMARCA5 and CHD2 to make DNA accessible to repair. CHD2 
which is recruited to DSBs in a PARP1-dependent manner, triggering the deposition of H3.3 
at these regions to cause chromatin relaxation, promoting efficient repair by NHEJ (158).  
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PARP3 has been shown to nicked mononucleosomes which stimulate PARP3 trans-
ribosylation activity on H2BE2. This suggests PARP3 is a nick sensor in nucleosomes, this 
study the presence of ribosylation of chromatin and DNA single strand breaks (218). 
 
 
1.3.5.1.6 Histone Modifications in BER 
 
There is very little evidence at this time for histone modifications in terms of BER, however 
there have been a couple of published studies which suggest the role of histone modifications. 
Histone acetylation has been suggested as TDG glycosylase interacts with transcriptional 
coactivators CREB binding protein (CBP) and p300 and the subsequent complexes were able 
to acetylate histones and process lesions (219). The DUB enzyme USP7 has been suggested 
to be involved in the regulation of oxidative damage repair through regulating mouse double 
minute 2 homolog (Mdm2) levels and so chromatin accessibility to proteins involved in DNA 
repair. It was suggested that USP7/Mdm2 dependent chromatin remodelling occurs through 
ubiquitination of H2B by Mdm2 to relax chromatin when a DNA lesion is recognised. Further 
investigation suggested that another E3 ligase regulated by USP7 may also be responsible 
for H2B ubiquitination (220). In another study a range of PTMs on histone H3 was analysed 
after DNA damaging agents in U2OS cells. Following methanesulfonate (MMS) a DNA 
alkylating agent, hydrogen peroxide causing DNA strand breaks and alkali labile sites and IR 
treatment there was a reduction in levels of H3S2, H3S28 and H3.3S31 phosphorylation and 
H3K9 and H3K56 acetylation. These findings of changes in H3 phosphorylations and 
acetylations suggest two responses to DNA damage, although this doesn’t directly implicate 
BER, the DNA damaging agents mentioned do causing lesions which are processed by BER 
(182). In a study using mononuleosomes substrates nucleosomes were generated with site 
specific acetylated H3K14 or H3K56 and the rate of repair of uracil and single nucleotide gaps. 
These acetylated sites had no effect on uracil removal but decreased the gap filling ability of 
Polβ near the dyad axis suggesting acetylation of histones may promote alternative gap filling 
pathways (221). 
 
 
 
1.3.5.2 Chromatin Remodelling 
 
The INO80 family of ATP-dependent chromatin remodellers have the most known connection 
with DNA repair. In vitro INO80 is able to slide a mononucleosome from an end to a more 
central location along DNA and it is also involved in nucleosome eviction in vivo (167). In yeast 
studies INO80 is recruited by γ-H2AX to DSBs, and in strains lacking INO80 this hindered the 
5’ – 3’ resection at DSB ends before strand invasion (222)]. Another study however did not 
find this to be the case but found RAD51 and RAD52 loading onto the 3’ ends of the DSB was 
perturbed (223, 224). In mammalian cells however INO80 was not dependent on γ-H2AX but 
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the interaction of it with Arp8 was. Human cells with a knockdown of INO80 have shown 
reduced DSB repair due to its effect on Rad54B and XRCC3 transcription (223, 225). INO80 
knockdown in mammalian cells causes defective HR repair as 53BP1 foci recruitment is 
impaired. It was found that the 5’-3’ resection was impaired but not Rad51 was not affected. 
53BP1 recruitment and resection are also defective in INO80 knockdown cells. Consequently, 
it has been suggested that INO80 participates in the initial stage of DSB end processing as 
the chromatin remodelling produced is necessary for the access the initial repair proteins 
(226). In yeast SWRI (INO80 sub family member) facilitates the localisation of KU proteins to 
damage sites in NHEJ (227). In mammalian cells the initial events of NHEJ is also dependent 
of SWI/SNF chromatin remodelling with the BRM1 subunit required for Ku70 recruitment and 
NHEJ (183). The BRG1 subunit is also required to bind to γ-H2AX nucleosome to cause 
hyperacetylation of H3 K9, K14, K18 and K23. BRG1 therefore increases the accessibility of 
ATM to cause additional H2AX phosphorylation. An interaction between BRCA1 and BRG1 
has also been implicated in HR repair (228, 229).  
 
Using dinucleosome substrates in vitro it was found that the 6-4PP excision was hindered by 
the dinucleosome which suggested that NER needs more room than the space provided by 
linker DNA to operate, and a number of studies have indicated chromatin remodelling activity 
(230). The essential protein CSB in TC- NER contain a SE12/SNF2 ATPase domain which 
has been shown in vitro to alter chromatin structure (231). Using a chromatin model in vitro 
the removal of acetylaminofluorene-guanine adduct near the nucleosome dyad was enhanced 
by SWI/SNF chromatin remodelling which was facilitated by XPA, XPC and RPA (232, 233). 
CPD repair is increased with mammalian SWI/SNF ATPase BRG1 subunit but not 6-4PP, and 
loss of BRG1 results in deregulation of checkpoints and increased apoptosis. The Brg1 
subunit of SWI/SNF is recruited to UV-damage sites through an interaction with XPC (234, 
235). In a yeast study Snf6 and Snf5, which are subunits of SNI/SNF, can be co-purified with 
Rad4 and RAD23, which are the homologues for APC and HR23B respectively and which is 
stimulated by UV induced damage and were required for complete NER (236). INO80 
complexes are involved in NER, they are present at UV damage sites and their deletion 
eliminates the NER protein assembly (237).   
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1.4 BER in Chromatin 
 
 
There is accumulating evidence for chromatin changes through histone modifications and 
chromatin remodellers being an integral part of the DNA DDR, particularly in DSB and NER 
as described above, with a number of histone modifications and chromatin remodelling events 
occurring at these specific lesions sites. Currently, evidence that chromatin changes occur to 
facilitate BER is limited. However, mononucleosome substrates containing site specific DNA 
base damage have been used in vitro to demonstrate that chromatin remodelling events are 
necessary to stimulate BER, particularly in occluded base damage site in the context of the 
nucleosome. Although the identity, mechanisms and enzymes involved in this process remain 
elusive.   
 
 
1.4.1 Mononucleosome Substrates   
 
Chromatin structure and proteins components are ever more linked to biological processes 
including transcription, recombination and DNA repair. Mononucleosome substrates have 
been used to analyse the activity of DNA repair enzymes, histone modifications and chromatin 
remodelling complexes (238-242). Nucleosome organisation regulates a range of cellular 
biological processes including DNA repair. Due to these findings of nucleosome 
dynamics  much effort has put in to replicate these processes in vitro to build our 
understanding, which requires the reconstitution of chromatin components that have 
been utilised extensively. This allows the formation of model chromatin containing a distinct 
DNA sequences and the use of nucleosome positioning sequences for these which are a 
pivotal component of these studies to discover more about gene regulation and nucleosome 
structure and function particularly in DNA repair (243). Previous studies 
with mononucleosome substrates were limited to histones that had been extracted from 
chromatin (244). Histones were extracted from chromatin and were subsequently fractionated 
to purify each histone. However this approach was time consuming and relied on the 
availability of tissue or blood from an organism, histones degraded rapidly and the histone 
pool was very heterogeneous due to isotypes and PTMs of histones. Histones purified from 
recombinant sources (such as Xenopus laevis) however are homogenous (do not contain 
PTMs), are very pure and mutants or isotopes can be expressed. This advancement has 
allowed for resolution of the nucleosome to base pairs and structure of 
the mononucleosome to a high resolution (245, 246).  
 
Variations in the B-DNA structure are sequence dependent and produce a definitive rotational 
and translational orientation, and histone octamer – DNA contacts interact at specific 
locations. Reconstituted nucleosomes have the same structural and physical properties of 
native nucleosomes in eukaryotes (243). Before the identification of 
the Widom 601 nucleosome positioning sequence (245), nucleosome positioning had a 
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somewhat limited positioning ability. A sequence with a preferential orientation may have 
several translational positions within 10bp resulting in a population which is heterogeneous 
with a set of favoured translational positions and no dominant orientation, which caused 
problems with in vitro investigations. The Widom 601 sequence was identified from a random 
DNA pool to bind to the histone octamer to form a nucleosome and has since become a 
standard sequence to use to reconstitute nucleosomes. When reconstituted in the 
nucleosome the 601 sequence has a near identical orientation to 147bp human α-satellite 
DNA nucleosome and the majority of DNA – histone octamer interactions are the same. The 
central 20bp of the 601 sequence and α-satellite nucleosome which conforms around the dyad 
have strikingly very similar conformations, which is related to the vast number of histone 
octamer – DNA interactions. There are some substantial differences however,  the most 
important one being that the 601 sequence forms a 145bp nucleosome compared to α- 
satellite DNA which is 147bp. This is because of differences in the superhelical location at -5 
and +5 where the 601 sequence DNA over coiled causing only 12bp of the 601 DNA in those 
locations instead of 13bp for the α –satellite, which causes some difference in histone octamer 
– DNA interaction at these positions (Figure 16) (247). 
 
 
 
Figure 16; Comparing the Widom 601 Sequence with α-satellite DNA Nucleosome Core 
Particles. Image taken from Makde et al (247). (A) The Widom 601 sequence (blue) was 
aligned against α-satellite DNA (peach) in the context of a nucleosome core particle. The main 
differences between the two were found at the superhelical locations indicated to. The 
difference of the Widom 601 sequence is highlighted to in red and green in (B) and (C) at 
positions -5 and +5 respectively (numbers based on position from the nucleosome dyad.  
 
 
 
 
 
Figure from (247), Figure 4 
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1.4.2 Analysing BER in vitro utilising Mononucleosome Substrates  
 
As most DNA nucleosome positioning sequences exhibit a preferred helical orientation, it is 
now possible to produce distinct model mononucleosomes to explore nucleosome influence 
and dynamics in many biological processes including BER. Several studies have 
reconstituted mononucleosomes with a specifically orientated DNA lesion to examine how 
BER enzymes recognise and process these lesions. It has been made clear through these 
studies that the processing of oxidatively damaged bases and AP sites, by DNA glycosylases 
and APE1 respectively, is dependent on the orientation of lesion and its position in relation to 
the nucleosome dyad. A lesion with the DNA backbone facing outwards away from the 
nucleosome are more efficiently processed by the enzymes than those facing inwards. DNA 
glycosylases and APE1, as previously mentioned, flip the damaged lesion or AP site out of 
DNA helix into a recognition site (64, 248, 249).  In nucleosomes both of these proteins are 
able to process these types of DNA damages as long as the location of this damage is in an 
orientation so it can be flipped out of the helical formation without conflicting with the histone 
octamer. In contrast, DNA base lesions, AP sites and single nucleotide gap sites in occluded 
in regions of the nucleosome are inefficiently processed and are thought to require unwrapping 
of the DNA from the nucleosome to facilitate BER.. Presently it has been suggested that 
spontaneous and reversible unwrapping of nucleosomal DNA containing DNA base damage 
allows access to glycosylases and APE1 to the inwardly facing lesion. Lesions that are located 
in close proximity to the dyad axis are less efficiently processed than those located away from 
the dyad. Increased accessibility is thought to be achieved by currently unknown PTMs of 
histonse and/or chromatin remodelling enzyme to facilitate repair (16). More specific details 
of the effects of chromatin on individual enzyme action are included below.   
 
 
1.4.2.1 Activity of DNA glycosylases on nucleosomes 
 
The efficiency of NTH1 in removing thymine glycol lesions (Tg) in different orientations on 
mononucleosomes has been measured. Outwardly facing Tg lesions were processed at a rate 
similar of that of naked DNA using low concentrations of NTH1. Inwardly facing Tg lesions 
were removed at a 10 fold decreased rate than free DNA, although increasing NTH1 to near 
physiological concentrations progressively increased Tg excision reaching 48 % relative to 
that of naked DNA, supporting the unwrapping hypothesis for inwardly facing lesions. Lesions 
near the dyad axis were only processed 22% as efficiently as naked DNA using the highest 
concentration of NTH1 (250). Increases in NTH1 concentration significantly increased the 
processing of the inwards facing lesions and notably the concentration of NTH1 used to 
efficiently process the inwardly facing Tg lesion was no higher than what was estimated to be 
present in vivo. This was thought to be due to NTH1 high specificity and low non-specific DNA 
binding. Using high NTH1 concentrations to process occluded sites can be linked to 
occurrence and extent of DNA unwrapping events from the nucleosomes to expose occluded 
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lesions (251).  NEIL1 when used at a concentration similar to that expected in vivo was only 
able to excise 10% of Tg lesions facing inwards, compared to 50% when the lesion was facing 
outwards. This was thought to be due to NEIL1 poor specificity and is thought to require other 
proteins to increase its specificity (251).  
 
The repair of 8-oxoG by OGG1 in nucleosomes is greatly impaired in in vitro mononucleosome 
studies. Using model dinucleosomes with a linker H1 proteins 8-oxoG lesions were positioned 
in either the linker DNA or within nucleosome. The absence of H1 in the linker produced similar 
removal rates of 8-oxoG as in free DNA however when H1 was associated with linker DNA 
there was a 10-fold decrease in the activity. In nucleosomal DNA, the processing of 8-oxoG 
was significantly impeded, with or without the linker H1 histone (252). 
 
In a study from the Smerdon group, free DNA (not associated with a histone octamer) and 
mononcleosomes were constructed with G-uracil (U) mismatches. Mononucleosomes were 
constructed using the Widom 601 nucleosome positioning sequence containing a U 
rotationally positioned near the nucleosome dyad and were orientated so the DNA backbone 
was either positioned toward the histone octamer (‘inwards’) or away (‘outwards’). The 
Mononucleosome substrates were compared with each other and with free DNA, analysing 
the activity of UDG and APE1 towards differently positioned and orientated U. Activity of UDG1 
and APE1 was reduced 10-fold in mononucleosome substrates compared to free DNA and 
the U facing outwards was 2-3 fold more efficiently processed than U facing inwards. The next 
step of synthesis by Pol β was totally inhibited at both U orientations (253). In a more recent 
study by Smerdon’s group they assessed the removal of varied translational positioned and 
orientated uracil’s using UDG and APE1 using mononuclesome substrates using the Widom 
601 nucleosome positioning sequence (Figure 17A). U were orientated either inwardly or 
outwardly facing positioned near the nucleosome dyad, and then at two different positions 
away from the nucleosome dyad as flexibility of DNA is thought to increase with distance from 
the nucleosome dyad.  It was found that the rate of uracil removal using outwardly facing 
lesions was 2-10 fold greater than inwardly facing lesions. Inwardly facing lesions although 
not efficiently processed were more readily processed the further they were for the 
nucleosome dyad, outwardly facing lesions near the nucleosome dyad however were 
efficiently processed, see figure 17B. 
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Figure 17; Uracil Rotational Orientation and Translational Position effect on the Activity 
of Glycosylase UDG1 and APE1. Image taken from Smerdon et al (242). (A) The crystal 
structure of the Widom 601 nucleosome core particle showing the translational position 
(numbered with respect of location from the dyad axis which is translational position 0) and 
orientation (DNA backbone outwards facing towards solvent labelled O and DNA backbone 
inwards facing towards the histone octamer labelled I) of U indicated to in black. (B) The 
percentage of incision of nucleosomal DNA following UDG1 and APE1 at different time point. 
Open symbols represent inwardly orientated U at translational positions; red square +4, blue 
circle +25, green circle -29 and purple triangle -49. Filled in shapes represent outwardly 
orientated U at translational positions; blue circle +29, purple triangle -35 and red square +10. 
 
 
1.4.2.2 Activity of APE1 on nucleosomes 
 
The activity of APE1 by has been measured, Hinz et al used mononucleosome substrates 
using the 601 Widom nucleosome positioning sequence with either a glycosylase generated 
AP site or a tetrahydrofluran (THF) AP site analog (synthetic AP-site which is more stable). 
These were placed, which when reconstituted in the nucleosome,  were either inwards, 
outwards or in between inwards and outwards (mid). This study found there was virtually no 
difference in APE1 activity when using glycosylase generated AP sites or the THF AP site 
analog. Mononucleosome substrates with a synthetic AP site facing inwards were much less 
efficiently cleaved than those facing outwards or mid orientation. Association of APE1 with the 
mononucleosome was also found to was greatly reduced compared to free DNA. This was 
also lesion orientation dependent, the inwards facing THF had a much less association with 
APE1 supporting the idea of reduced APE1 activity in occluded lesion sites by the histone 
octamer (254). 
Figure from (242), figure 1a and figure 2a 
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1.4.2.3 Activity of Polβ on nucleosomes 
 
The activity of Pol β has been found to be significantly reduced in the gap facing inwards 
compared to one outwardly facing (242), this has also been seen in other studies with Pol β 
(255). DNA glycosylases induce DNA to bend between 45°-70° (256), however for Pol β to 
function it needs to bend DNA by 90° opposite the single base gap. This severe bending of 
DNA may inhibit Pol β capacity function without altering the histone contacts. It has been 
suggested that Pol β on outwardly facing gaps can achieve its active configuration by 
disrupting enough of the histone contacts, but not when presented with one near the 
nucleosome dyad, where the DNA is tightly packed on both sides, explaining why Pol β has 
virtually no activity in the dyad regardless of orientation. This shows that the histone octamer 
causes varied levels of constraints in BER due to the different requirements of the BER 
enzyme (242). 
 
Polβ activity was analysed following UDG and APE1 treatment using mononucleosome 
substrates where U was either facing outwards or inwards. Pol β activity in this study was 
found to be totally inhibited at both U orientations (253). In another study by the same group 
after UDG and APE1 treatment the gap filling function of Polβ was found to increase 3-fold 
when outwardly facing near the DNA ends than those of the same orientation near the dyad 
axis in the same orientation. This suggests that nucleosome unwrapping events are required 
for BER proteins to access these occluded regions to facilitate BER (242).  
 
 
1.4.2.4 Activity of Lig IIIα-XRCC1 
 
As described previously Polβ activity is significantly impeded by the nucleosome especially in 
the nucleosome dyad where its activity is virtually non-existent.  However, it has been 
found that Lig IIIα-XRCC1 partially enhances the activity of Pol β to repair particularly inwardly 
facing gaps. Lig IIIα-XRCC1 was found to be noticeably active at high concentrations which 
lead to nucleosome disruption. As a result, the Lig IIIα-XRCC1 complex not only increased its 
own activity by nucleosome disruption at a single nucleotide gap site but also that of Pol β. 
This disruption in nucleosome – histone interaction is because DNA ligases function by 
encircling its DNA substrate, so to function in BER Lig IIIα-XRCC1 would require to disrupt the 
DNA- histone contacts (255).  
 
 
1.4.2.5 APE1 activity using nuclear extracts in single and clustered DNA damage site  
 
A characteristic of radiation generated DNA damage is clustered DNA damage which have 
been investigated to be more difficult to process than single lesions due to decreased efficacy 
in BER. In a recent study, mononucleosome substrates were produced using the Widom 601 
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nucleosome positioning sequence with either a single AP site, or two types of clustered sites; 
bistranded AP sites and a AP site with an opposing 8-oxoG lesion within a mononucleosome. 
Purified APE1 activity was significantly impeded in the single AP-site containing 
mononucleosome compared to incubation with the corresponding free DNA, however with 
nuclear extract CHO-K1 incubation the AP site was processed in free and mononucleosomal 
DNA at comparable rates. When analysing the bistranded AP sites mononucleosomse were 
efficiently cleaved using CHO-K1 extracts and the subsequent DSB caused nucleosomal DNA 
dissociation from the histone octamer. Using the 8-oxoG +1 from dyad axis to an AP site 
containing mononucleosome the AP site was efficiently cleaved however 8-oxoG processing 
was significantly impeded (in both the mononucleosome and free DNA), which was suggested 
to be due to OGG1 is unable to bind to when adjacent to a AP site (+1). The increase of APE1 
activity in nuclear extract CHO-K1 was found not to be due to complete unwrapping of 
nucleosomal DNA from the histone octamer to produce free DNA, instead it was suggested 
the presence of a chromatin remodeller facilitates incision of the AP site (257).  
 
 
1.4.3 Chromatin Remodelling factors  
 
Very little is known about the potential histone chaperons and chromatin remodelling enzymes 
that may facilitate BER. SWI/SNF has been reported to stimulate the processing of 8-oxoG by 
each of the repair factors OGG1, APE1 and Polβ in nucleosomes reaching levels as those in 
free DNA. Likewise using oligonucleosome arrays containing a U were incubated with UDG, 
APE1 and Polβ in vitro Polβ activity was found to be significantly impeded, however ISW1 and 
ISW2 from yeast significantly increased Polβ activity (258). In nucleosomes with 8-oxoG 
lesions either positioned in linker DNA or within the nucleosome, the presence of remodels 
structure of chromatin (RSC) part of the SWI/SNF family enhanced the removal of 8-oxoG in 
the linker DNA and the nucleosome (252).  In another study an 8-oxoG lesions was 
incorporated in two moononucleosome substrate near the dyad axis, one containing canonical 
histones and the other with variant H2A.Bbd. In both cases the removal, incision and gap filling 
activity of this lesion was significantly impeded in the mononucleosome compared to free 
DNA. The chromatin remodeller SWI/SNF was found to greatly increase the repair of 8-oxoG 
in canonical nucleosome but had a very weak effect on H2A.Bbd, through altering the DNA -
histone octamer interactions and not mobilisation (nucleosome sliding) of nucleosome (259). 
In a recent study, evidence for histone chaperone activity in facilitating BER was suggested. 
The histone chaperone FACT was found to be released from transcription factors following 
oxidative stress and associate with repair proteins and chromatin remodelling complexes. 
FACT promotes UDG1 in removing uracil in mononucleosome substrates by boosting the 
chromatin remodelling activity of RSC, suggesting the role of these two proteins in facilitating 
the initial step in BER (241). There are very few studies of BER facilitated by chromatin 
remodelling activity in vivo and are mostly indirect. Utilising mutant yeast cells lacking in 
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certain subunits of SWI/SNF and INO80 chromatin remodelling complexes, these cells exhibit 
augmented sensitivity to methyl methanesulfonate (MMS) which suggest their role in 
chromatin remodelling in the presence of alkylated DNA lesions (260-262). In a more recent 
study, the STH1 ATPase subunit of RSC was depleted in yeast and caused an increased 
sensitivity to MMS and considerable inhibition of BER in the GAL1 locus and genome wide. 
Throughout the genome chromatin DNA was found to be less assessable to micrococal 
nuclease digestion without any change in BER gene expression (263). It is conceivable that 
PARP1 may regulate chromatin condensation to facilitate BER as it can ADP-ribosylate 
histones H2B and H1 which could cause nucleosome disruption, relaxing chromatin due to 
the added negative charge. PARP1 also inhibits histone demethylase KDM5B activity to 
create a more open chromatin state, although the roles of PARP in the context of chromatin 
is more associated with transcription regulation at this time (162, 264-266).  
 
Chromatin remodellers involved in BER are significantly understudied, which is impeding our 
knowledge of the mechanism of BER in chromatin that is essential for genome stability and in 
maintaining human health. 
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1.5 Aims 
 
 
 
The mechanism of BER and the major proteins involved are now well defined. However 
despite this knowledge, the epigenetic mechanisms and chromatin remodelling processes 
involved in the cellular response to DNA base damage that is processed by BER are poorly 
understood. Nucleosomes are constructed from 147 bp DNA which is wrapped around a 
histone octamer that comprises of two copies of H2A, H2B, H3 and H4. To access DNA, and 
therefore DNA damage, it is thought that chromatin remodelling is required to support DNA 
damage repair. This is thought to be achieved through histone PTMs on the N-terminal tails 
which contain lysine residues that can be modified through poly(ADP-ribosyl)ation, 
acetylation, methylation or ubiquitination. This then causes chromatin condensation or directly 
recruits chromatin remodelling factors which alter histone contacts though ATP hydrolysis. 
There is accumulating evidence for chromatin changes being an integral part of the DNA 
damage response, particularly in DSB repair and NER, with a number of histone modifications 
and chromatin remodelling events occurring at these specific lesion sites. Relating to BER, 
mononucleosome substrates containing DNA base damage have been used to predominately 
demonstrate that the orientation and translation position of base lesions greatly affects BER 
enzyme activity. However, the chromatin remodelling enzymes, the precise histone 
modifications and the histone modifying enzymes catalysing these that are necessary to 
stimulate BER and the mechanisms involved, remain unknown. 
 
Therefore the study presented in this thesis aimed to identify specific histone modifications, 
the enzymes catalysing these, and the chromatin remodellers that are involved in the 
signalling and/or processing of DNA base damage during BER. In order to achieve this 
overarching aim, three key objectives were identified to drive the progress of this research as 
follows. 
 
I. The generation of mononucleosomes containing site-specific AP-site containing DNA 
damage. 
II. Establishment of in vitro BER assays using mononucleosomal DNA containing site-
specific AP-site DNA damage in different orientations to examine differences in APE1 
activity using purified protein and WCE. 
III. Use of fractionated HeLa cell WCE with mononucleosomal DNA containing site-
specific AP-site DNA damage in order to identify novel enzymatic activities that 
stimulate APE1 activity. 
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CHAPTER II 
 
 
 
MATERIALS AND METHODS 
 
 
2.1 Materials 
 
2.1.1 601 nucleosome positioning sequence 
 
The Windom 601 strong nucleosome positioning was used for mononucleosome experiments 
Windom et al (245). The position of the synthetic AP-site (THF) was determined from the 
crystal structure and sequence published, Rodriguz et al (242). The cloning vector (P-GEM3Z 
with ampicillin resistance) containing the 256bp nucleosome positioning sequence was 
obtained from Prof Peter O’Neil (CRUK/MRC Oxford Institute for Radiation Oncology, 
University of Oxford, UK). 
 
             5’-GCTCGGAATTCTATCCGACTGGCACCGGCAAGGTCGCTGTTCAATACATG   
3’-CGAGCCTTAAGATAGGCTGACCGTGGCCGTTCCAGCGACAAGTTATGTAC  
   
       CACAGGATGGTATATATCTGACACGTGCCTGGAGACTAGGGAGTAATCCC    
         GTGTCCTACCATATATAGACTGTGCACGGACCTCTGATCCCTCATTAGGG  
   
         CTTGGCGGTTAAAACGCGGGGGACCACGCGTTGGTGCGTTTAAGCCGTG    
         GAACCGCCAATTTTGCGCCCCCTGGTGCGCAACCACGCAAATTCGGCAC  
   
         CTGGCGCTTGCTACGACCAATTGAGCGGCCTCGGCACCGGGATTCTCCAG    
         GACCGCGAACGATGCTGGTTAACTCGCCGGAGCCGTGGCCCTAAGAGGTC  
   
         GGCGGCCGCGTATAGGGTCCATCACATAAGGGATGAACTCGGTCTTAAGA 
         CCGCCGGCGCATATCCCAGGTAGTGTATTCCCTACTTGAGCCAGAATTCT  
 
         ATCATGC-3’ 
         TAGTACG-5’ 
     
Figure 18: Double strand 256bp DNA sequence for the 601 nucleosome positioning 
sequence. Figure show nucleotide sequence for the strong Windom 601 nucleosome 
positioning sequence. Nucleotides highlighted in yellow are a restriction digest site for Van91I 
and in green BgII. The nucleosome dyad is indicated to in black bold. The position of the 
tetrahydrofuran (AP site equivalent) is indicated to in red. An THF on the upper strand 
produced an outwards facing THF and when on the lower strand and inwards facing THF 
when reconstituted in the histone octamer.  
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Figure 19: Restriction Digest cut sites and 17bp oligonucleotide insert.  A, shows the 
cuts site from Van91 and BgII and the recognition sequences for each highlighted in yellow 
and green respectively from a sot segment of the 601 nucleosome positioning sequence 
(figure 18). The red lines through the DNA sequence show the specific cut site of each of the 
5’ and 3’ DNA strands in which the enzymes cut to produce the 127bp and 106bp fragments. 
B, 17 bp oligonucleotide sequence which is ligated into the Widom 601 nucleosome 
positioning sequence with 3 base overhangs either the 5’ or 3’ ends depending on the 
orientation of the THF site (THF-OUT and THF-IN). 
 
 
2.1.2 Oligonucleotides 
 
2.1.2.1 Oligonucleotides for preparation of THF containing DNA 
 
Fluorescently tagged primers were used to amplify the 601 nucleosome positioning sequence 
from the P-GEM3Z cloning vector (table 2). Due to the low intensity of IRDYE800 the 
fluorescent tags were set on the opposite forward and reverse primers for the THF facing 
inwards nucleosome (THF-IN). Unlabelled primers were also used to amplify the 601 
nucleosome positioning sequence which was used in the nucleosome reconstitution as a 
carrier DNA to inhibit exonuclease activity in the BER in vitro assay (table 2). Short 
oligonucleotide sequences (table 3) were annealed together and used to introduce a THF 
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(labelled 1) to the nucleosome DNA sequence, this is a stable equivalent of a AP site (as 
shown in Figure 19B)  
 
  
Primer Sequence 
 
THF Facing 
Outwards 
Nucleosome 
(THF-OUT) 
 
Forward.  
5'-IRDYE700-GCTCGGAATTCTATCCGACTGGCACCGGCAAG-3' 
Reverse.        
5'-IRDYE800-GCATGATTCTTAAGACCGAGTTCATCCCTTATGTG-3' 
THF Facing 
Inwards 
Nucleosome 
(THF-IN) 
 
Forward.                        
5'-IRDYE800-GCTCGGAATTCTATCCGACTGGCACCGGCAAG-3' 
Reverse.    
5'-IRDYE700-GCATGATTCTTAAGACCGAGTTCATCCCTTATGTG-3' 
Unlabelled 601 
DNA sequence 
Forward.     
5'-GCTCGGAATTCTATCCGACTGGCACCGGCAAG-3' 
Reverse 5'.     
5’-GCATGATTCTTAAGACCGAGTTCATCCCTTATGTG-3' 
 
 
Table 2: Fluorescently 5’ tagged primers for THF containing site DNA preparation. Table 
shows primer sequences for producing the fluorescently tagged 256bp nucleosome 
positioning sequence. Fluorescently tagged Primers were obtained from Integrated DNA 
technologies (Leuvan, Belgium). The last row shows primer sequences for unlabelled 601 
nucleosome positioning sequence, primers were obtained from Eurogentec (Seraing, 
Belgium). 
 
 
Oligonucleotide Sequence 
 
THF-OUT 
5'-phosTTGGTGC1TTTAAGCCGTGC-3' 
5'-phosCGGCTTAAACGCACCAACGC-3' 
 
THF-IN  
 
 
 
5'-phosTTGGTGCGTTTAAGCCGTGC-3' 
5'-phosCGGCTTAAAC1CACCAACGC-3' 
 
Table 3: Oligonucleotide sequences with a THF (1) which is either outwards or inwards 
facing after nucleosome DNA reconstitution. Sequences shown to create a 17bp 
oligonucleotide with either 5’ or 3’ 3 base overhang, with a THF indicated to as (1), this was 
positioned either on the upper strand THF facing outwards (THF-OUT) or lower strand THF 
facing inwards (THF-IN). Oligonucleotides were obtained from IDT technologies (Leuvan, 
Belgium). 
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2.1.2.2 Real-time PCR primer sequences  
 
Real time (RT) PCR primers (table 4) were used to measure the efficiency of siRNA 
knockdown of 11 E3 ubiquitin ligases in HeLa cells. Actin was used as an expression control 
and all results were normalised to this CT value.  
 
Gene RT-PCR primer Sequence Amplicon (bp) 
CUL4a Forward. 5’-GGACCTCGCACAGATGTACC-3’ 
Reverse. 5’-CGATCGCTGTTCCAAAAGTC-3’ 
104 
RNF8 Forward. 5’-TGTGCTAGAGAATGAGCTCCAA-3’ 
Reverse. 5’-TGTGGGCACAGTTCAAGG-3’ 
77 
RNF168 Forward. 5’-GGCAAGAAAGCTAAGCATTGA-3’ 
Reverse. 5’-GGGTGTAACTGGATCAGATTTTCT-3’ 
94 
DZIP3 Forward. 5’-TGCCCAAGATCTGATACAAGG-3’ 
Reverse- 5’-CTCCAACACACCACCGTACA-3’ 
80 
MSL2 Forward. 5’-CCCTTTCGTGCTGTGTTTG-3’ 
Reverse. 5’-GCCTTTACAAGTTTTGCAGACAT-3’ 
95 
RNF20 Forward. 5’-GGAGGAGCAGATAGAATACCTACAGA-3’ 
Reverse. 5’-CCATTTCAGAGAGGAGTGCTTC-3’ 
77 
RNF2 Forward. 5’-CGGCAGCTGATACCAGAGTC-3’ 
Reverse. 5’-TGCACAGCCTGAGACATTG-3’ 
85 
UBR2 Forward. 5’-CACTTTTCAAGGGCAGAACAG-3’ 
Reverse- 5’-TTTGTCTTTTCAATTTCCGTTG-3’ 
61 
BRCA1 Forward. 5’-TTGTTGATGTGGAGGAGCAA-3’ 
Reverse. 5’-GATTCCAGGTAAGGGGTTCC-3’ 
106 
CUL1 Forward.5’-CCTGGAATTATATAAACGACTTAAGGA-3’ 
Reverse.5’-TTCAGTACACTCTCATCCATCAAAT-3’ 
96 
MULE Forward. 5’-CAGCTCCAGCACTCAGTCAA-3’ 
Reverse. 5’-TGAATGCTCTGGCTGCATAC-3’ 
63 
ACTIN Forward. 5'-AGGCACCAGGGCGTGAT-3' 
Reverse. 5'-CGCCCACATAGGAATCCTTCT-3' 
52 
 
Table 4: Real-time primer sequences for target gene. Primers were obtained from 
Eurogentec (Seraing, Belgium). Table shows target gene, primer sequence for both forward 
and reverse, and length of target sequence of gene.  
 
65 
 
2.1.2.3 SiRNA sequences 
Small interfering mRNA (siRNA) sequences were used to interfere and knockdown the 
expression of specific genes as listed in table 5. A pool of 4 SiRNA sequences were used for 
every gene to increase the efficiency of the knockdown.  
 
Target 
Sequence 
GenBank 
Accession 
SiRNA sequences 
RNF20 NM_019592.6 
 
5'-CCAAUGAAAUCAAGUCUAA-3' 
5'-UAAGGAAACUCCAGAAUAU-3' 
5'-GCAAAUGUCCCAAGUGUAA-3' 
5'-AGAAGAAGCUACAUGAUUU-3' 
  
MSL2 NM_018133.3 
 
5'-GCAGUUCUGUUAUCAAUGG-3' 
5'-UCUCUUAGCCAUAAUGUUU-3' 
5'-CCAGUACACAUGAUGAUAA-3' 
5'-GAGUAUAUAACACAGACUA-3' 
 
 
RNF2 NM_007212.3 
 
5'-GAGGUUAGCUUUAGAAGAA-3' 
5'-GAGAAAUACUGGAAAGUGA-3' 
5'-GCACAGACGAGAUACAUAA-3' 
5'-GAGAAGCAGUAUACCAUUU-3' 
 
 
DZIP3 NM_014648.3 
 
5'-CAAAGUAACUACAGACUAU-3' 
5'-UGACAUAGAUCCUACAGAA-3' 
5'-GAUCAUGGCAUCUGCUUUA-3' 
5'-GAAAUCACACCCUGAGAUA-3' 
 
 
UBR2 NM_015255.2 
 
5'-GAAGUGUUCUGCUUUAUUU-3' 
5'-GCAGAACAAUACUCUAAUA-3' 
5'-GAAGAAAGUACUCCUAAUA-3' 
5'-CAAGAAACCUGGAUUAACA-3' 
 
 
BRCA1 NM_007294.3 
 
5'-CAGCUACCCUUCCAUCAUA-3' 
5'-GGGAUACCAUGCAACAUAA-3' 
5'-GAAGGAGCUUUCAUCAUUC-3' 
5'-CAUGAAAUCUGUUGCUAUG-3' 
 
 
RNF8 NM_003958.3 
 
5'-AGAAUGAGCUCCAAUGUAU-3' 
5'-CAGAGAAGCUUACAGAUGU-3' 
5'-GAGGGCCAAUGGACAAUUA-3' 
5'-CAAUUUGGAUCCUAAGUUG-3' 
 
 
RNF168 NM_152617.3 
 
5'-GGAAGUGGCUGAUGACUAU-3' 
5'-GAAAUUCUCUCGUCAACGU-3' 
5'-AGAAGGAGGUGGAUAAAGA-3' 
5'-GAGUAUCACUUACGCGCUA-3' 
 
 
MULE NM_031407.6 
 
5'-GCAAAGAAAUGGAUAUCAA-3' 
5'-GGAAGAGGCUAAAUGUCUA-3' 
5'-UAACAUCAAUUGUCCACUU-3' 
5'-GAAAUGGAUAUCAAACGUA-3' 
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Target 
Sequence  
GenBank 
Accession 
SiRNA sequences 
CUL1 NM_003592.2 
 
5'-CGACAGCACUCAAAUUAAA-3' 
5'-GGUUAUAUCAGUUGUCUAA-3' 
5'-AGACUUGGAUUUCAGCAUU-3' 
5'-CAACGAAGAGUUCAGGUUU-3' 
 
 
CUL4A NM_001008895.2 
 
5'-GGAAGAGACUAAUUGCUUA-3' 
5'-GAACAGCGAUCGUAAUCAA-3' 
5'-GCAUGUGGAUUCAAAGUUA-3' 
5'-GAACCCAUAUUAUUAGUGA-3' 
 
 
HECTD1 NM_015382.3 5’-GAACUGGACUUCUUUGUAU-3’ 
5’-GAAGAAAUCUACCUUAUGG-3’ 
5’-GGACUUACCUAUUUCUAAA-3’ 
5’-GUUAAUAGCUGUACUAGAA-3’ 
 
YBX1 NM_004559.4 
 
5’-GAGAGACUGUGGAGUUUGA-3’ 
5’-GCGGAGGCAGCAAAUGUUA-3’ 
5’-GCAGACCGUAACCAUUAUA-3’ 
5’-GUAAGGAACGGAUAUGGUU-3’ 
 
YBX3 NM_003651.4 
 
5’-GGAAAUAUCUGCGCAGUGU-3’ 
5’-GGACAGACCUUUGACCGUC-3’ 
5’-AGACGUGGCUACUAUGGAA-3’ 
5’-CAACGUCAGAAAUGGAUAU-3’ 
 
 
Table 5: siRNA pool sequences for knockdowns. SiRNA pools were obtained from 
Dharmacon (Lafayette, Colorado USA). Each SiRNA pool contains 4 individual 
oligonucleotides (5nmol) lyophilised. SiRNA were diluted to 10μM with RNase-free water in a 
Tissue culture hood with laminar flow. SiRNA was mixed on an orbital shaker for 30 minutes 
at room temperature and aliquoted. 
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2.1.3 Antibodies 
 
Antibodies were used to probe for specific proteins in western blotting to confirm their 
presence and levels of expression in protein lysates.  
 
Antibody Reactivity Concentration 
(mg/ml) 
Dilution  Molecular 
weight 
(kDa) 
Source  
Ubiquitinated 
Lys119 
Histone H2B 
Mouse 
monoclonal 
1 1:1000 25 2B Scientific 
Ubiquitinated 
Lys 120 
Histone H2A 
Mouse 
monoclonal 
1 1:1000 25 Millipore 
Actin Mouse 
monoclonal 
26.1 1:20,000 42 Sigma 
Alderich 
APE1 Mouse 
Monoclonal 
1 1:10,000 34 Novus 
Biologicals 
His-tag Mouse 
monoclonal 
0.2 1:1000 N/A Millipore 
CUL4A Rabbit polyclonal 1 1:5,000 88 Abcam 
DDB1 Rabbit polyclonal 0.81 1:2,500 127 Abcam 
Mule Rabbit polyclonal 1 1:2000 482 Bethyl Labs 
CHIP Rabbit polyclonal 1 1:1000 35 Abcam 
HECTD1 Rabbit polyclonal 1 1:1000 280 Bethyl Labs 
YBX1 Rabbit polyclonal 1 1:1000 50 Bethyl Labs 
YBX3 Rabbit Polyclonal 1 1:1000 53 Bethyl Labs 
 
Table 6: Primary Antibodies. Reactivity, concentration, dilution and molecular weight for 
each primary antibody are shown in table. Antibodies were diluted in Odyssey blocking buffer 
(Li-cor biosciences, Lincoln, Nebraska, USA). and 1x Phosphate buffered saline (PBS, Fisher 
scientific UK, Loughborough, UK) 1:1 with 1% tween-20 (Sigma Aldrich, St. Louis, Missouri, 
USA) and applied to Immobilon-FL polyvinylidene diflouride (PVDF) membranes (Sigma 
Aldrich, St. Louis, Missouri, USA). Antibodies were obtained from 2B Scientific (Oxford, UK), 
Abcam, (Cambridge UK), Sigma Aldrich (St. Louis, Missouri, USA), Novus Biologicals, 
(Ontario, Canada), Merck-Millipore (Watford, UK) and Bethyl Labs, (Montgomery, Texas, 
USA). 
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Secondary Antibody 
 
Dilution 
IR Dye 800 goat  
anti-mouse IgG 
1:10,000 
IR Dye 680 goat  
anti-rabbit IgG 
1:10:000 
IR Dye 800 goat  
anti-mouse IgG 
1:10,000 
IR Dye 800 goat  
anti-rabbit IgG 
1:10,000 
 
Table 7: Secondary antibodies. Fluorescently tagged secondary antibodies were applied to 
PVDF membranes (Sigma Aldrich, St. Louis, Missouri, USA) after primary antibody incubation. 
The corresponding reactivity was selected so secondary antibody could bind to primary 
antibody. All secondary antibodies were obtained from Li-cor biosciences (Lincoln, Nebraska, 
USA). 
 
 
2.1.4 Tissue culture reagents 
 
HeLa cells and AG06173 lung fibroblasts were obtained from Dr Grigory L. Dianov, 
CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, UK). All tissue 
culture reagents were obtained from Sigma Aldrich (St. Louis, Missouri, USA) as listed below. 
 
• Dulbecco’s Phosphate-buffered saline (PBS) 
• Trypsin -EDTA solution 0.25% (2.5g porcine trypsin and 0.2g EDTA. 4Na /L of Hank 
balanced salt solution with phenol red)  
• Dulbecco’s Modified Eagle’s Medium (DMEM) with hydroxyethyl 
piperazineethanesulfonic acid (HEPES) modification, 4500mg/L 25mM HEPES and 
sodium bicarbonate, sterile filtered was supplemented with 10% fetal bovine serum 
(FBS, non-USA origin, sterile filtered) 2mM L-glutamine, 100U penicillin, 0.1mg 
streptomycin and 1% MEM Non-essential amino acid solution  
 
 
 
 
 
 
 
 
69 
 
2.2 Transformation of competent cells 
 
DH5α cells (Invitrogen, Waltham, Massachusetts, USA) or Rosetta2(DE3)pLysS) Merck-
Millipore, Watford, UK) were thawed on ice and mixed gently using a pipette tip. DH5α cells 
were transfected with 1ng purified plasmid and incubated on ice for 30 minutes. The cells were 
then heat shocked for 20 seconds at 42°C and then left for a further 2 minutes on ice. 10 times 
warmed lysoeny broth (LB) (2.5 % (w/v) LB granule (Fisher Scientific UK, Loughborough, UK), 
0.5 % (w/v) NaOH, pH 7.2) was then added and the cells incubated at 37°C on a shaking 
incubator for 1 hour. 100μl of cells was removed and spread on LB agar plates (2.5 % (w/v) 
LB granules, 1.5 % (w/v) agar, 0.5 % NaOH and the correct antibiotic (50 μg/ml ampicillin or 
34 μg/ml kanomycin (Fisher Scientific UK, Loughborough, UK)). These were then incubated 
at 37°C overnight. Successfully transformed colonies were selected and grown overnight in 5 
ml LB containing 50 μg/ml ampicillin or 34 μg/ml at 37°C on a shaking platform overnight. 
 
2.2.1 Purifying DNA from bacterial cultures  
 
The overnight cultures were then centrifuged at 5000 x g for 5 minutes to form and pellet and 
supernatant aspirated. DNA was purified following the QIAprep® Spin Miniprep Kit, 
manufacturer’s protocol (Qiagen, Hilden, Germany) and eluted in TE buffer. The concentration 
of the DNA was measured using a Nanodrop ND-1000 spectrometer (software version 
V3.7.1), (Thermo Scientific, Massachusetts, USA) at a wavelength of OD 260nm. 
 
2.3 Polyacrylamide gel electrophoresis (PAGE) 
 
Samples were diluted in 5x EMSA loading buffer (30 % glycerol, 0.25 % xylene cyanol and 
0.25 % bromophenol blue (Fisher Scientific UK, Loughborough, UK) and electrophoresed on 
an 8 % polyacrylamide gel using acrylamide/bis-acrylamide solution 19:1 40 % (w/v) (National 
Diagnostics, Nottingham, UK) with a 1.5 mm 10-well comb inserted in 0.5x TBE (44.5 mM 
Tris, 44.5 mM boric acid and 1 mM EDTA (Sigma Aldrich, St. Louis, Missouri, USA) using the 
HoeferTM SE400 vertical electrophoresis unit (Fisher Scientific UK, Loughborough, UK), 0.4 % 
APS and 0.04 % N,N,N′,N′-Tetramethylethylenediamine (TEMED, Biorad Laboratories Ltd, 
Hercules, California, USA) were used to initiate polymerisation. Samples were 
electrophoresed for 3 hours at 175 V and the unit covered for light protection of the florescent 
tags. The gel was then imaged using the Odyssey image analysis system (DNA gel, 0.75mm 
offset, 680/800 channels). 
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2.4 Denaturing PAGE 
 
A 8 % polyacrylamide denaturing (7 M urea) polyacrylamide gel in 1x TBE (90 mM Tris, 90 
mM Boric acid, 2 mM EDTA) using acrylamide/bis-acrylamide solution 29:1 40% (w/v) 
(National Diagnostics, Nottingham, UK) was prepared fresh on the day of use and the solution 
sterile filtered (0.45 μm syringe filter). The Hoefer SE400 vertical electrophoresis unit was 
used and the solution was poured between glass plates after 0.4 % APS and 0.04 % TEMED 
were used to initiate polymerisation, and a 1.5 mm 15 well comb inserted. Once polymerised, 
the gel was pre run to warm the gel to around 40ᴼC by electrophoresis for 10 minutes at 350 
V, and wells were washed out using 1x TBE prior to sample loading.  Samples were mixed 
1:1 with formamide loading dye (formamide 0.025 % (w/v) (9 5% (w/v) Sigma Aldrich St. Louis, 
Missouri, USA) , heated at 95ᴼC for 5 minutes and loaded onto the 8 % polyacrylamide 
denaturing gel and electrophoresed for 1 hour at 350 V.  
 
 
2.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting 
 
2.5.1 SDS-PAGE 
 
Proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Gels were prepared by mixing the components of the separating gel together 
(377 mM Tris HCl pH 8.8, 0.2 % SDS, 2 mM EDTA, and the appropriate concentration of 
acrylamide/bis solution 30:0.8 (Bio-Rad Laboratories Ltd, Hercules, California, USA). 1 % APS 
and 0.1 % TEMED were added to initiate polymerisation and the gel poured into a 1.5 mm 
empty gel cassette until three quarters full and the gel allowed to set following overlay with 
100 % ethanol. The percentage gel used was dependent on the size of protein being analysed. 
The 5 % stacking gel (62.5 mM Tris HCl pH6.8, 0.2 % SDS, 2 mM EDTA, 5 % acrylamide/bis 
solution 30:0.8 and 10 % APS and 1 % TEMED) was then added to the remaining quarter of 
the gel cassette, following removal of the ethanol, and either a 10-well or 15-well 1.5 mm comb 
added and the gel allowed to set. Samples were diluted in SDS-PAGE loading buffer (25 mM 
Tris pH 6.8, 2.5 % β-mercaptoethanol, 1 % SDS, 5 % glycerol 0.5 mg/ml bromophenol blue, 
1 mM EDTA) and proteins denatured by heating at 95°C for 5 minutes. Electrophoresis was 
performed in 1x Tris-glycine (TGS) SDS buffer, 0.025M Tris, 0.192M glycine and 0.1% SDS, 
pH 8.5 (Fisher Scientific UK, Loughborough, UK) for 2 hours at 125 V (unless otherwise stated) 
in the XCell SureLock Mini Cell (Life Tehnologies). The Precision Plus Protein All Blue Pre-
stained Protein Standards, Bio-Rad Laboratories Ltd (Hercules, California, USA) were used 
as standard markers ranging from 10 kDa to 250 kDa.  
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2.5.2 SDS-PAGE gel protein staining. 
 
The SDS-PAGE gel following electrophoresis (2.5.1) was then rinsed in water and Instant Blue 
(Expedeon, San Diego, California, USA) added so it covered the gel and incubated on a 
rotating platform for >15 minutes. The gel was then imaged using the Odyssey image analysis 
system.  
 
2.5.3 Western Blots 
 
Proteins were separated by SDS-PAGE (see 2.5.1) and transferred onto an Immobilon-FL 
PVDF membrane (Millipore) by electrophoresis at 25 V for 90 minutes in transfer buffer (25mM 
Tris pH 8.3, 192mM glycine (Fisher scientific UK, Loughborough, UK), 20% methanol) using 
the XCell II blot module (Life Technologies, Woolstone, UK). The PVDF membrane was 
blocked in Odyssey blocking buffer which was diluted 1:1 in 1x PBS for 1 hour at room 
temperature. The blocking buffer was removed and the membrane probed with the appropriate 
primary antibody diluted to the relevant concentration (see table 5) in Odyssey blocking buffer 
and 1XPBS (1:1), 0.1 % tween-20 and incubated overnight at 4ᴼC on a rocking platform. The 
membrane was then washed three times for 5 minutes with 1x PBS containing 0.1% tween-
20 and the relevant secondary added diluted to the suggested ratio (see table 6) in Odyssey 
blocking buffer and 1X PBS (1:1) with 0.1% tween-20 for 1 hour at room temperature. The 
membrane was washed as before and an additional final wash was performed with 1x PBS 
prior to imaging using the Odyssey Image Analysis System. 
 
2.6 HeLa whole cell extract preparation  
 
HeLa whole cell extract (WCE) was prepared as previously described (267). HeLa cell pellets 
(Cilbiotech, Mons, Belgium) were resuspended in one packed cell volume of buffer I (10 mM 
Tris-HCl pH 7.8), 200 mM KCl (Sigma Aldrich St. Louis, Missouri, USA), 1 μg/ml of each 
protease inhibitor; aprototin, pepstatin, chymostatin and leupeptin (Sigma Aldrich St. Louis, 
Missouri, USA), 100 μM Phenylmethylsulfonyl fluoride (PMSF) and 1 mM N-ethylmaleimide 
(NEM, Sigma Aldrich St. Louis, Missouri, USA). Following resuspension two pack cell volumes 
of buffer II (10 mM Tris-HCl pH 7.8, 600 mM KCl, 40 % glycerol, 2 mM EDTA, 0.2 % NP-40 
and 1 μg/ml of each of protease inhibitor, 100 μM PMSF and 1 mM NEM) was added and 
thoroughly mixed. Cell suspension was mixed by rotation for 30 minutes at 4ᴼC, centrifuged 
at 72000 x g for 20 minutes at 4ᴼC and supernatant collected and stored at -80ᴼC. 
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2.6.1 Protein Concentration 
 
Prepared HeLa WCE protein concentration was measured using the Bradford assay using the 
protein assay dye reagent (Biorad Laboratories Ltd, Hercules, California, USA) to measure 
the absorbance reading at an optical density of 595 nm using a UV spectrometer. 0.2 mg/ml 
BSA was used as a protein standard for reference for protein concentration calculation below. 
BSA = 0.2/AbBSA = V 
Samples concentration = V X Absample x dilution factor  
 
 
2.7 Preparation of purified APE1 
 
2.7.1 Overexpression of his-tagged APE1  
 
His-tagged pET14b APE1 plasmid (provided by Prof Dianov, Oxford Institute for Radiation 
Oncology) was transformed into Rosetta2(DE3)pLysS bacterial cells, and a colony picked and 
cultured overnight with 5 ml LB with 30 μg/ml kanamycin (Fisher Scientific UK, Loughborough, 
UK) and 34 μg/ml chloramphenicol (following 2.2 transformation). If the culture was turbid 300 
μl culture was added to 30 ml LB with 30 μg/ml kanamycin and 0.1 % glucose and grown at 
37ᴼC at 225 rpm shaking until turbid (OD600 ~ 0.6 to 0.8). The entire culture was expanded to 
300 ml with LB and antibiotic and glucose and incubated with shaking until turbid (OD600 0.6 
to 0.8). Protein expression was induced with 1 mM IPTG and incubated at 30ᴼC with shaking 
for 3 hours. The culture was centrifuged at 5000 x g for 2 minutes, the supernatant aspirated, 
and pellets were then stored at -80ᴼC.  
 
2.7.2 Purification of his-tagged APE1 
 
The bacterial cell pellet containing overexpressed his-tagged APE1 was resuspended in lysis 
buffer (25 mM Tris-HCl (pH8), 0.5 M NaCl, 5 % glycerol, 5 mM imidazole, pH 8 (Sigma Aldrich 
St. Louis, Missouri, USA), 100 mM PMSF and 1 µg/ml of each protease inhibitor; leupeptin, 
chemostatin, pepstatin and aprototin). 2 mg lysozyme was added and the cells were incubated 
on ice for 15 minutes. Cells were lysed by sonication for 3x15 second pulses with 30 seconds 
intervals on ice. Lysates were transferred to 50 ml Oakridge tubes and centrifuged at 23,000 
x g or 20 minutes at 4ᴼC. The supernatant was collected and filtered through a 1 μM syringe 
prefilters, and then a 0.45 μM syringe filter. A 1 ml HisTrap column (GE Healthcare, Little 
Chalfont, UK) was attached to the AKTA purifier FPLC and the column washed in the same 
lysis buffer as above (except 0.1mM PMSF was used). The lysate was added to the column 
and washed thoroughly until no more protein eluted. Bound proteins were collected by 
gradient elution with 20 ml lysis buffer and  elution buffer (25 mM Tris-HCl pH8, 0.5 M NaCl, 
5 % glycerol, 500 mM imidazole and 0.1 mM PMSF) collecting 0.5 ml fractions. Fractions were 
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analysed by SDS-PAGE and western blotting (see 2.5) using anti-His antibodies to select 
fractions with purified his-tagged APE1. 
 
2.8 Immunodepletion of proteins 
 
Protein A magnetic agarose beads (Qiagen, Hilden, Germany) were inverted to resuspend 
beads and 30 μl removed into a fresh 1.5 ml tube for each depletion and control. Beads were 
washed with 500 μl 1X PBS and a magnetic rack used to attract the beads and the PBS 
removed and repeated three more times. Beads were resuspended in 300 μl 1x PBS and 0.5 
μg antibody when immunodepleting APE1 and 10 μg when immunodepleting HECT Domain 
E3 Ubiquitin Protein Ligase 1 (HECTD1) added (see table 6 for concentrations). A control of 
beads without antibody was also prepared for each immunodepetion. Beads were incubated 
at 4ᴼC on an oscillating platform for 3 hours. The magnetic rack was used again to attract 
beads and PBS/unbound antibody removed. Beads were washed in 500 μl buffer (50mM Tris-
HCl pH 8, 50 mM KCl, 1 mM EDTA, 5 % glycerol) and buffer removed using the magnetic rack 
and this was repeated three more times. Cell extract (100 μg) was diluted to 200 μl with buffer 
and added to beads-antibody, and beads alone as a control, and incubated overnight at 4ᴼC 
on a rotator. The magnetic rack was used to attract beads and the immunodepleted extract 
removed into a fresh tube. The protein concentration of the cell extract was measured using 
a Nanodrop ND-1000 spectrometer (software version V3.7.1) at a wavelength of OD 280nm. 
The immunodepleted extract was analysed using SDS-PAGE and Western blotting (see 2.5) 
to check for immunodepletion efficiency.  
 
2.9 Tissue Culture 
 
Tissue culture work was carried out in a class II hood with laminar flow (Esco Global, Barnsley, 
UK) and cleaned with 70 % ethanol thoroughly before and after use. Trypsin, PBS and 
complete DMEM media (containing 10 % FBS, 2 mM glutamine and 1 % pen-strep) were 
warmed in a water bath at 37ᴼC prior to use. All tissue culture work was performed using an 
aseptic technique. All plastics were tissue culture grade and cells were grown in a humidified 
cell culture incubator in 5 % CO2 at 37°C.  
 
2.9.1 Defrosting cells 
 
Vials of cells were removed from liquid nitrogen storage, rapidly defrosted for 1 minute in a 
37ᴼC water bath, centrifuged at 2000 x g for 5 minutes and DMSO removed. The cell pellet 
was then diluted in complete DMEM media to 10 ml and transferred to a T75 flask. Cells in 
the flask were transferred to a humidified cell culture incubator at 5 % CO2 at 37°C. Once cells 
were approximately 80 - 90 % confluent the cells were sub-cultured. 
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2.9.2 Sub Culturing 
 
Once cells had reached approximately 80 % confluence, cells were sub-cultured by aspirating 
DMEM media from the T75 flask, and washing cells with 10 ml PBS. Cells were then treated 
with 1 ml trypsin and incubated for 2 minutes (or until cells had lifted from the tissue culture 
flask base) at 37ᴼC in a tissue culture incubator. Trypsin was neutralised using 9 ml media 
and cells were sub cultured 1:10 for both HeLa and AG06173 lung fibroblasts. Therefore, 1 
ml of cells was transferred to a fresh T75 flask with 25 ml DMEM media and cells cultured in 
a tissue culture incubator. 
 
 
2.9.3 Harvesting Cells 
 
Cells (in 100 mm dishes) were removed from the tissue culture incubator, and plates washed 
with 5 ml cold PBS and aspirated. A further 5 ml of cold PBS was added and cells were 
carefully scraped off using a cell scraper and added to a 15 ml tube, this was repeated again 
with another 5 ml cold PBS. Cells were centrifuged at 2000 x g for 5 minutes at 4°C and the 
supernatant removed. 1 ml cold PBS was used to resuspend the cell pellet which was 
transferred to a 1.5 ml tube and centrifuged for 5 minutes at 3000 xg at 4°C. The supernatant 
was removed and cells pellets frozen at -80°C. 
 
 
2.10 Preparation site-specific THF containing DNA 
 
The plasmid P-GEM3Z containing the Widom 601 nucleosome positioning sequence was 
transformed and purified from DH5α cells (following 2.2 transformation and DNA purification).. 
The 601 sequence was then amplified using polymerase chain reaction (PCR) and the central 
17bp with 3 base pair overhangs either side (5’ or 3’ depending on the THF orientation) was 
removed using a restriction digest and replaced by a duplex oligonucleotide containing a THF 
by sequential ligation. The THF containing DNA was then purified for use in DNA repair assays 
either without (free DNA) or with mononucleosome reconstitution.  
 
2.10.1 Amplification of 601 nucleosome positioning sequence 
 
Polymerase chain reaction (PCR) was used to amplify the 601 nucleosome positioning 
sequence from the P-GEM3Z plasmid. The standard conditions for PCR were 200 μM dNTPS 
(Sigma Aldrich, St. Louis, Missouri, USA), 1x Phusion HF buffer, 2 mM MgCl2, Phusion Hot 
Start II DNA polymerase (Fisher Scientific UK, Loughborough, UK), 0.3 μM of each forward 
and reverse primers (see table 3) and 25 pg/μl P-GEM3Z plasmid made up to 50 μl with 
distilled water. Primers were fluorescently tagged with either IR700 (visualised as red) and 
IR800 (visualised as green) so DNA could be imaged using the Odyssey image analysis 
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system (Li-cor Biosciences, Lincoln, Nebraska, USA). To create enough 256 bp DNA product, 
15 PCR reactions were completed and pooled together. To perform the PCR, 1 cycle of initial 
denaturation was used for 5 minutes at 95°C, this was then followed by 35 cycles of 
denaturation at 98°C for 30 seconds, annealing at 57°C for 30 seconds and extension at 72°C 
for 30 seconds. After this cycling there was a final extension step at 72°C for 5 minutes. The 
256bp nucleosome positioning sequence was checked using a 1.5 % agarose gel (broad 
range agarose) in 1x TAE using a 100 bp DNA ladder and 1X loading buffer (all obtained from 
Fisher Scientific UK, Loughborough, UK) and electrophoresed at 100 V for 1 hour. The 256 
bp substrate was visualised using the Odyssey image analysis system (Li-cor Biosciences, 
Lincoln, Nebraska, USA). 
 
The PCR reactions were pooled and purified using the QlAquick PCR purification kit according 
to manufacturer’s instructions (Qiagen, Hilden, Germany), split across three columns and 
eluted in TE buffer. Eluted DNA was combined into a 1.5 ml amber tube for light protection 
and the concentration measured using Nanodrop ND-1000 spectrometer at a wavelength of 
OD 260nm. 
 
2.10.2 Restriction digests of the 601 nucleosome positioning sequence 
 
The central 17 bp and 3 base overhangs either side (either on the 3’ or 5’ ends depending on 
THF orientation, will just be called 17 bp from here onwards) from the 601 nucleosome 
positioning sequence 256 bp PCR product was removed by restriction digest using 20 U Bgll 
and 50 U Van91I restriction enzymes with 1 x Buffer R (Fisher Scientific UK, Loughborough, 
UK) and incubated overnight at 37ᴼC on a shaking platform. To check the efficiency of the 
restriction digests the digest products, 127bp and 106bp were separated and analysed by 8% 
PAGE (2.3). After efficient restriction digest of the central 17bp from the 601 nucleosome 
positioning sequence, the entire sample was loaded onto an 8 % PAGE to separate the digest 
products and electrophoresed and analysed as before. The digest products were then excised 
from the gel by aligning the Odyssey image analysis system printed image with the gel and 
the 127bp and 106bp removed using a scalpel blade, and sliced into small pieces and placed 
into separate 1.5 ml amber tube. To purify the DNA from gel the freeze/squeeze method (268) 
was used by freezing the gel pieces at -80°C for a minimum of 20 minutes and the DNA 
extracted. 
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2.10.3 DNA Purification from gel pieces  
 
DNA (127 bp and 106 bp separated fragments) in gel pieces following freezing were incubated 
in TE buffer (10 mM Tris, pH 8 and 1 mM EDTA) at 37°C for 3 hours with shaking and the TE 
buffer was removed and filtered through 0.45μM Spin-X columns by centrifugation at 20,000 
x g for 1 minute. The flow through was collected and transferred to 1.5 ml tubes, the 127 bp 
and 106 bp digest products were kept separate. Fresh TE buffer was added to the gel pieces 
and incubated for at least 1 hour and the TE buffer was removed and filtered as before. The 
gel pieces were then added to the Costar Spin-X centrifuge tube filter (0.45μm, Sigma Aldrich, 
St.Louis, Missouri, USA) and centrifuged for 5 minutes to remove any residual TE buffer. The 
filtrates were combined and then concentrated using Amicon Ultra 0.5 ml devices  (10 kDa 
molecular weight cut off (MWCO), EMD Millipore Darmstadt, Germany) for each of the digest 
products to approximately 50 μl and the concentration checked using Nanodrop ND-1000 
spectrometer at a wavelength of OD 260nm. The purification of the two digest products was 
checked and analysed using PAGE (2.3) on an 8 % polyacrylamide gel.  
 
2.10.4 Preparation of duplex oligonucleotide 
 
The duplex oligonucleotide was prepared for ligation by mixing either the two single strands  
(20 bases) DNA sequences for THF-OUT or THF-IN (table 3) at 10 pmol for each with 200 
mM NaCl in TE buffer. The oligonucleotides were then heated at 95°C for 5 minutes in a metal 
heat block and then the heat block was removed from the heater (with the sample still in) and 
allowed to cool to room temperature for approximately 2 hours, this allowed the strands to 
anneal together. After annealing they formed a 17 bp oligonucleotide with 3 base overhangs 
either 5’ for THF-OUT or 3’ for THF-IN, this oligonucleotide will now just be called 17bp duplex 
oligonucleotide from now on.  
 
2.10.5 Sequential ligation of restriction digest products 
 
The 127 bp DNA from the restriction digest was ligated to the 17bp duplex oligonucleotide 
which was added in 3 times excess of the 127 bp DNA with 5 U T4 DNA ligase and 1x T4 
DNA ligase buffer (Thermo Scientific, Massachusetts, USA) and incubated overnight at 4°C . 
The efficiency of the ligation was checked and analysed against the 127 bp DNA using 8% 
polyacrylamide electrophoresed and the 147 bp IR700 tagged ligated DNA visualised. If 
ligation was unsuccessful, then more duplex oligonucleotide DNA and T4 ligase was added 
and ligation repeated. The samples were heated at 65ᴼC for 10 minutes to inactivate T4 DNA 
ligase and denature any duplex oligonucleotide DNA. The DNA was then purified by using the 
MinElute reaction clean-up kit following manufacturer’s instructions (Qiagen, Hilden, 
Germany). DNA was eluted by two sequential elutions with buffer EB into a 1.5 ml amber tube 
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following incubation of the column with this buffer for 1 minute and then centrifugation for 1 
minute at 17,900xg.  
 
For the second ligation, the 147 bp ligated DNA and the remaining 106 bp DNA fragment were 
mixed together with 5 U T4 DNA ligase and 1x T4 DNA ligase buffer and incubated overnight 
at 4ᴼC. The efficiency of the ligation was checked and analysed as with the first ligation and 
the fully ligated 256bp DNA gel purified, extracted from gel pieces, concentrated and purity 
checked as stated previously (2.2.5). The concentration of the final 256 bp DNA containing a 
synthetic THF was determined using Nanodrop ND-1000 spectrometer (software version 
V3.7.1) at a wavelength of OD 260nm and stored at -20ᴼC until required. 
 
2.11 Expression and purification of Recombinant histones 
 
E.coli were transformed with expression vector Xenopus Laevis histones (H2A, H2B, H3 and 
H4) obtained from Professor Karolin Luger  (University of Colorado Boulder, Boulder, USA) 
and histones were overexpressed following Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
induction. The bacteria were harvested, the cells lysed and the recombinant histones purified 
from inclusion bodies by size and ion-exchange chromatography under denaturing condition 
using AKTA-FPLC. Histones were refolded and combined during dialysis to form the histone 
octamer and purified using a high salt buffer using a size exclusion column and a FPLC. The 
purity and stoichiometry of the histone octamer was analysed using SDS-PAGE. Protocol was 
followed from Luger et al (246). 
 
2.11.1 Recombinant Histone Expression 
 
Rossetta2(DE3)pLysS E.coli cells were transformed with 0.25 ng pET-expression vector for 
H2A, H2B and H3, whereas the pET-expression vector for H4 was transformed into 
Rosetta2(DE3) cells (Both Rosetta Competent Cells, obtained from Merck-Millipore (Watford, 
UK)). Cells were incubated on ice for 10 minutes, heat shocked for 30 seconds at 42ᴼC and 
returned to ice for at least 2 minutes. 10 times the volume of cells/plasmid of pre-warmed 2x 
TY media (1 % (w/v) bacto tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl, pH 7 (all Sigma 
Aldrich, St.Louis, Missouri, USA) and incubated on a shaking platform for 1 hour at 37ᴼC. A 
third of the cells were plated onto TYE agar plates (1 % bacto tryptone, 0.5 % yeast extract, 
0.8 % NaCl, 1.5 % (w/v) agar, 50 μg/ml ampicillin and 34 μg/ml chloramphenicol (Fisher 
Scientific UK, Loughborough, UK)) and incubated overnight at 37ᴼC. In four separate universal 
tubes 1 ml 2xTY media (with added 50 μg/ml ampicillin, 34 μg/ml chloramphenicol and 0.1% 
glucose (Sigma Aldrich, St. Louis, Missouri, USA) was inoculated with a single colony from 
each agar plate and incubated at 37ᴼC with shaking until turbid (optical density (OD)600 ~ 0.4). 
0.5 ml was removed from each culture and added to 10 ml 2xTY (supplements added as 
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previously) and incubated with shaking as before until turbid (OD600~0.4). 8 ml of each culture 
added to 500 ml 2xTY (supplements added as before) in 2 litre conical flasks and incubated 
with shaking for a third time until turbid (OD600 ~ 0.4). Histone expression was induced by 
adding 0.2 mM IPTG (Fisher Scientific UK, Loughborough, UK) to each culture and incubated 
at 30ᴼC with shaking for 2 hours. Cells were harvested in 500 ml centrifuge bottles and 
centrifuged at 3000 x g for 10 minutes at room temperature and the supernatant removed. 
Each cell pellet was re-suspended in 10 ml wash buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 
mM EDTA, 5 mM β-mercaptoethanol, 0.3 mM PMSF (Sigma Aldrich, St. Louis, Missouri, USA) 
and transferred to 50ml centrifuge tubes and stored at -80ᴼC. 
 
2.11.2 Inclusion body preparation  
 
The histone proteins are expressed in insoluble form and have to be isolated from inclusion 
bodies following cell lysis. To do this, the bacterial cells in wash buffer were thawed at 37ᴼC, 
10 mg lysozyme (Sigma Aldrich, St.Louis, Missouri, USA) was added and incubated on ice for 
30 minutes. The lysates were then sonicated for 2x30 second pulses with 30 second intervals 
on ice and lysates were transferred to 50 ml Oakridge tubes, (Eppendorf, Hamburg, 
Germany), and centrifuged at 23,000 x g or 20 minutes at 4ᴼC. The supernatant was removed 
and 10 ml wash buffer added (made up as previously with added 1% Triton X-100, (Fisher 
Scientific UK, Loughborough, UK)). Lysates were further sonicated and centrifuged a further 
three times as before, on the final resuspension 10 ml wash buffer was added without Triton. 
H4 was an exception, this protein was only sonicated, centrifuged and re-suspended in wash 
buffer the once as it is prone to lysis. After this final wash step, all histones were centrifuged 
for a final time, the supernatant poured off and stored at -20ᴼC. Histone purification involved 
a two-step purification procedure involving gel filtration followed by ion-exchange 
chromatography using an AKTA fast protein liquid chromatography (FPLC, GE Healthcare, 
Little Chalfont, UK) under denaturing conditions. Each histone protein was purified separately. 
 
2.11.3 Recombinant Histone Purification by gel filtration chromatography  
 
A fresh 9 M urea (Fisher Scientific UK, Loughborough, UK) stock solution was made in water 
with heating and deionised using 1 % amberlite IRN150 mixed bed resin (Sigma Aldrich, St. 
Louis, Missouri, USA) and incubated for 30 minutes at room temperature, prior to filter 
sterilising using a 0.45μm filter. This was used to make up the gel filtration buffer (2 0mM 
sodium acetate pH 5.2, 1 M NaCl, 7 M urea 1 mM EDTA and 5 mM β-mercaptoethanol (Sigma 
Aldrich St. Louis, Missouri, USA)) and cooled to 4ᴼC. A 320ml Sephacryl S-200 gel filtration 
column, (GE Healthcare, Little Chalfont, UK) was attached to an AKTA FPLC purifier and 
equilibrated with gel filtration buffer for 1.5 column volumes at 1.5 ml/min. 400 μl Dimethyl 
sulfoxide (DMSO, Sigma Aldrich, St. Louis, Missouri, USA) was added to one of the histone 
pellets and then minced with a spatula and 10 ml 1x unfolding buffer (7 M guanidinium HCl 
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(Fisher scientific UK, Loughborough, UK), 20 mM Tris pH 7.5, 10 mM Ditiothreitol (DTT, Sigma 
Aldrich, St.Louis, Missouri, USA) was added dropwise and the mixture stirred for 1 hour using 
a magnetic stirrer and stir bar. This was then centrifuged at 23,000 x g for 20 minutes at room 
temperature, the supernatant removed and filtered using syringe prefilters (1 μm). The sample 
was then loaded onto the gel filtration column using a 10 ml superloop (GE healthcare, Little 
Chalfont, UK), at 1.5ml/min. After approximately 85 ml the protein started to elute and 4 ml 
fractions were collected until the UV signal reduced and stabilised so no more protein was 
being eluted. The peak fractions were analysed by 16 % SDS-PAGE and gel staining (2.5.1 
and 2.5.2 respectively) to identify those containing the relevant histones. 
 
2.11.4 Recombinant Histone Purification by FPLC ion-exchange chromatography 
 
Peak fractions from gel filtration chromatography (2.3.3) that contained histones as analysed 
by SDS-PAGE  were dialysed in snakeskin dialysis tubing (35 mm Dry ID, 7 kDa MWCO, 
Thermo Fisher Scientific, Massachusetts, USA) in 2 litres of distilled water containing 2 mM 
β-mercaptoethanol at 4ᴼC for 2 hours. The water was then replaced with fresh water and 2 
mM β-mercaptoethonal and dialysed overnight at 4ᴼC.The dialysed fractions were collected 
and concentrated by Amicon Ultra centrifugal concentrators (3 kDa MWCO, Merck-Millipore, 
Watford, UK) to approximately 1-2 ml. A 1 ml HiLoad 16/10 sepharose high performance 
MonoS column (GE Healthcare, Little Chalfont, UK), was attached to AKTA FPLC and the 
column was equilibrated with cold low salt buffer (20 mM NaAc pH 5.2, 0.1 M NaCl, 7 M urea 
(prepared from 9 M deionised stock), 1 mM EDTA, 5 mM β-mercaptoethanol) for 3 column 
volumes at 1 ml/min. The dialysed histone sample was then loaded onto the column and 
washed until no more protein eluted. Histone proteins were gradient eluted from the column 
using 20 ml low salt buffer and high salt buffer (20 mM NaAc pH 5.2, 1 M NaCl, 7 M urea 
(prepared from 9 M deionised stock), 1 mM EDTA, 5 mM β-mercaptoethanol) at 1 ml/min 
collecting 0.5 ml fractions. The peak fractions were analysed by 16 % SDS-PAGE as previous. 
Fractions identified to contain histones were pooled and dialysed in snakeskin dialysis tubing 
(35 mm Dry ID, 7 kDa MWCO) in 2 litres water with 5 mM β-mercaptoethanol at 4°C overnight. 
This was then replaced with fresh water and 5 mM β-mercaptoethanol for 4 hours, the dialysed 
fractions collected and concentrated to 0.5 ml using Amicon Ultra centrifugal filter (3 kDa 
MWCO). The concentration of the histones was measured Nanodrop ND-1000 spectrometer 
at a wavelength of OD 280nm using molecular weights and extinction coefficients (ɛ) in table 
8. Histones were aliquoted in the following equimolar amounts ready for octamer preparation; 
2mg H2A, 2mg H2B, 2.25mg H3, 1.17mg H4 and stored at -80°C. 
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Histone Molecular weight (kDa) ɛ (cm/M) x 103 
H2A 13.96 4.05 
H2B 13.77 6.07 
H3 15.27 4.04 
H4 11.24 5.4 
 
Table 8: Histone molecular weights and molar extinction coefficients – Molecular weight 
and ɛ was used to determine the concentration of each histone using a nanodrop. 
 
 
2.11.5 Refolding of the Histone Octamer 
 
Each histone aliquot was dissolved to a concentration of 2 mg/ml using 1.25x unfolding buffer 
(25 mM Tris-HCL pH 7.5, 8.75 M guanidinium HCL, 12.5 mM DTT) resulting in a final 
concentration of 1x unfolding buffer. Histones were incubated on ice for 2 hours to allow the 
proteins to unfold. All the histones were then mixed together and an equal volume of 1x 
unfolding buffer added to create a 1 mg/ml solution. Histones were dialysed in snakeskin 
dialysis tubing (35 mm Dry ID, 7 kDa MWCO) in 600 ml refolding buffer (10 mM Tris-HCl 
pH7.5, 2 M NaCl, 1 mM EDTA, 5 mM β-mercaptoethanol) for 6 hours at 4°C and then dialysed 
overnight in fresh refolding buffer. The histones were further dialysed for 4 hours in fresh 
refolding buffer. The dialysed histone octamer was centrifuged at 23,000 x g for 20 minutes at 
4°C and the supernatant collected and concentrated using Amicon Ultra centrifugal 
concentrators (10 kDa MWCO) to 400 μl. This was then loaded on a 24 ml Superdex 200 
10/300GL gel filtration column (GE Healthcare, Little Chalfont, UK), attached to a FPLC and 
previously equilibrated with refolding buffer and 0.5ml fractions collected until the UV signal 
reduced and stabilised. Peak fractions were analysed using 16 % SDS-PAGE and gel staining 
using Instant blue (2.3.4 and 2.3.5) and fractions containing the histone octamer in the correct 
equimolar ratios were pooled and concentrated to 0.5 ml using Amicon Ultra centrifugal 
concentrators (10 kDa MWCO). A Nanodrop spectrometer at a wavelength of OD 280nm was 
then used to check the concentration of the histone octamer was approximately 10 mg/ml 
(absorbance at 0.45 for a 1 mg/ml solution), and then 40 % glycerol and 2 M NaCl was added 
and the histone octamer stored at -20°C.  
 
2.12 Analysing APE1 activity in mononucleosomal and free DNA  
 
Mononucleosome substrates were created with the free THF containing DNA and the histone 
octamer, both prepared as described above. The level of activity of purified, recombinant 
APE1 using mononucleosome substrates with a THF facing either outward or inwards from 
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the nucleosome core was measured and the activity compared between the two substrates. 
These substrates were also incubated with HeLa whole cell extract (WCE). The activity of 
APE1 and HeLa WCE using THF containing free DNA was also used as a control. 
  
2.12.1 Nucleosome Reconstitution 
 
The nucleosome reconstitution mix was prepared by mixing 5 pmol fluorescently–labelled 256 
bp THF DNA, 75 pmol unlabelled 601 nucleosomal DNA sequence (using non fluorescent 
primers (see table 2) but amplified using same PCR reaction and cycles as the preparation of 
THF containing DNA), 50 μg bovine serum albumin (BSA) molecular biology grade (New 
England Biolabs Ltd, Luton, UK), 0.01 % NP-40, 2 M NaCl, 94 pmol Histone Octamer in a final 
volume of 280 μl distilled water. The total volume increased to approximately 300 μl after 
dialysis. All volumes were adjusted if less DNA was used. The mix was then incubated for 10 
minutes at room temperature and transferred to 6.4 mm diameter dialysis tubing 8 kDa MWCO 
(Fisher Scientific UK, Loughborough, UK) which had been rinsed with distilled water and 0.1 
mg/ml BSA prior to use. The nucleosome reconstitution mix was then dialysed in 500 ml of 
decreasing concentrations of NaCl; 1.6 M, 1.2 M, 0.8 M, 0.6 M, 0.2 M, 0.075 M NaCl, with 10 
mM Tris HCl pH 7.4, 1 mM EDTA and 5 mM β-mercaptoethanol for 1.5 hours each and the 
final dialysis left overnight (0.075 M NaCl). The nucleosome reconstitution was removed from 
the dialysis tubing into a 1.5 amber tube and the efficiency of the nucleosome reconstitution 
analysed using a 0.7 % agarose gel in 0.02x TAE buffer and 5 nM SYTO60 red fluorescent 
nucleic acid stain. 50 fmol of the nucleosome reconstitution and free DNA (from preparation 
of free DNA) with 5xloading buffer were loaded onto the agarose gel with a 100 bp DNA ladder 
and electrophoresed at 75 V for 1.5 hours and imaged using the Odyssey Image Analysis 
system. Successful nucleosome reconstitution was visualised as a shift to a heavier molecular 
weight of approximately 700 bp (but not high molecular weight species indicative of protein 
aggregates) to form a mononucleosome substrate with a THF facing either outwards or 
inwards from the nucleosome (depending on which tagged 256 bp THF DNA substrate used). 
The mononucleosome substrate was stored at 4ᴼC. 
 
 
2.12.2 Preparation of Free DNA 
 
Free DNA was prepared as a control, to mimic the conditions of the nucleosome. In this 
instance, 5 pmol labelled 256 bp THF containing DNA was mixed with 75 pmol unlabelled 601 
nucleosomal DNA sequence, 50 μg BSA, 0.075 M NaCl, 10 mM Tris-HCl pH 7.4, 5 mM β-
mercaptoethanol and the volume made up to 300μl with distilled water and stored at 4ᴼC. 
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2.12.3 In Vitro BER Repair Assay and DNA extraction  
 
A reagent mix (Mix A) was prepared on ice containing 1 x BER buffer (40 mM Tris-HCl pH 8, 
5 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT), 2 mM ATP, 1 μg BSA (deacetylated) and 50 fmol 
DNA (either free DNA or mononucleosomal DNA) and made up to 6 μl with distilled water per 
reaction. An enzyme/extract mix (Mix B) was prepared with increasing concentrations of 
purified his-tagged APE1 or HeLa whole cell (WCE) diluted buffer in RWDB buffer (25 mM 
Tris HCl pH 8, 100 mM KCl, 12 mM MgCl2 1 mM EDTA, 17 % glycerol, 2 mM DTT). Where 
indicated, reactions were also supplemented with 5 mM Nicotinamide adenine dinucleotide 
(NAD, Sigma Aldrich St. Louis, Missouri, USA), 0.7 pmol UBE1 activating enzyme, 2.5 pmol 
E2 conjugating enzymes (a combination of 10 different E2s pooled in equimolar ratios; 
UbE2H, Cdc34, UbE2D1, UbE2D2, UbE2D3, UbE2E1, UbE2L3, UbE2L6 and UbE2C) and 
0.6 nmol ubiquitin (Boston Biochemicals, Cambridge, Massachusetts, USA). The His-tagged 
E1 and E2s (UBE1) were prepared by Dr Jason Parsons following overexpression of the 
proteins in bacterial cells, and purified by His-trap chromatography similar to APE1 described 
above (2.4.4.2). Mix A was added to Mix B and incubated at 30ᴼC for set time periods (either 
10 minutes or 1 hour). The reaction was stopped by adding to a final concentration 20 μM 
EDTA and 0.4 % SDS in a final volume of 25 µl with distilled water. 50 μl 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma Aldrich St. Louis, Missouri, USA) was 
further added and the sample was vortexed and centrifuged at 15,000 x g for 1 minute. The 
upper aqueous (DNA containing) layer was removed and transferred to a fresh 1.5ml tube. 50 
μl chloroform:isoamyl alcohol 24:1 (Sigma Aldrich St. Louis, Missouri, USA was then added 
and the sample was centrifuged again and the upper aqueous layer removed, this step was 
then repeated. The aqueous layer was then mixed with 10 μg glycogen, 1/10 volume of 3 M 
NaAc pH 5.2 and 2.5 volumes of cold 100% ethanol. Samples were mixed by inverting the 
tubes 3 to 5 times and incubated at -80% for >1 hour. Samples were centrifuged at 16,000 x 
g for 30 minutes and the supernatant aspirated, 3 volumes of cold 70% ethanol added and 
centrifuged for a further 10 minutes and the supernatant aspirated. Pellets were left to air dry 
for 5 minutes and 10 μl TE buffer added and pellets thoroughly resuspended. Samples were 
analysed by 8% denaturing PAGE (2.4). 
 
 
2.13 HeLa Cell Fractionation  
 
Candidate histone modifiers (eg. E3 ubiquitin ligases, chromatin remodellers) were 
fractionated and purified by sequential chromatography of HeLa cell pellets. Individual 
fractions were analysed using the mononucleosome THF facing inwards substrate, which is 
not efficiently repaired by recombinant APE1 only, utilising the BER assay after each 
chromatography step. Fractions that stimulated recombinant APE1 activity for incision of the 
THF (active fractions) above the threshold value (60 fmol APE1 added which causes ~20 % 
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incision) were pooled and further fractionated by chromatography to further purify histone 
modifiers.  
 
2.13.1 Preparation of HeLa Whole cell extract for Phosphocellulose Chromatography 
 
HeLa WCE was prepared (as shown in (2.6) using 20 g HeLa cell pellets) and dialysed to 
reduce NP-40 and KCl concentrations using snakeskin dialysis tubing (35 mm Dry ID,10 kDa 
MWCO, Thermo Fisher Scientific, Massachusetts, USA) in 3 litres of 150 mM KCL buffer (1 
mM DTT, 100μM PMSF) for 12 hours at 4ᴼC. The WCE was centrifuged at 72000 x g to 
remove precipitated proteins for 20 minutes at 4ᴼC, and the supernatant filtered through a 1 
μM syringe prefilter and then through a 0.45 μM syringe filter. 
 
 
2.13.2 Phosphocellulose Chromatography 
 
A 250 ml phosphocellulose column, prepared using P-11 cellulose and an XK50/20 column 
(GE Healthcare, Little Chalfont, UK), was equilibrated in PC150 buffer (50 mM Tris-HCl pH 8, 
150 mM KCl, 1 mM EDTA, 5 % glycerol, 1 mM DTT, 1 mM PMSF) using an AKTA purifier 
FPLC. HeLa WCE was loaded onto the column and unbound protein were eluted and collected 
until the UV signal stabilised, this was designated the PC150 fraction. Proteins that were 
bound to the column were eluted by PC1000 buffer (50 mM Tris-HCl pH 8, 1000 mM KCl, 1 
mM EDTA, 5 % glycerol, 1 mM DTT, 1 mM PMSF), this was designated the PC1000 fraction.  
 
 
2.13.4 Ion exchange chromatography (MonoQ) 
 
A 20 ml HiLoad 16/10 Q Sepharose high performance column (GE Healthcare, Little Chalfont, 
UK) was equilibrated in Mono Q buffer 1 (50 mM Tris-HCl pH 8, 50 mM KCl, 1 mM EDTA, 5 
% glycerol, 1 mM DTT, 1 mM PMSF) by washing in three column volumes using a AKTA 
purifier FPLC. The PC150 fraction (collected following phosphocellulose chromatography) 
was diluted 1:1 with a no salt buffer (50 mM Tris-HCl pH 8, 1 mM EDTA, 5 % glycerol) and 
passed over the column. Following washing of the column for 3-5 volumes, proteins were 
eluted using a 400 ml salt gradient using Mono Q buffer II (50 mM Tris-HCl pH 8, 1000 mM 
KCl, 1 mM EDTA, 5 % glycerol, 1 mM DTT, 1 mM PMSF) and 4 ml fractions collected. 500 μl 
aliquots from each fraction were concentrated using a Amicon Ultra 0.5 ml devices (10MWCO) 
by centrifugation at 15000 x g to 50 μl and then buffer exchanged (50 mM Tris-HCl pH 8, 50 
mM KCl, 1 mM EDTA, 10 % Glycerol, 1 mM DTT, 1 mM PMSF) prior to analysis of activity 
using concentrated (10 x) fractions. 
 
 
84 
 
2.13.5 Gel filtration 
 
Using an AKTA purifier FPLC, a 24 ml Superdex 200 10/300GL column (GE Healthcare, Little 
Chalfont, UK) was equilibrated in PC150 buffer (see 2.5.2). For each identified activity eluting 
from the MonoQ chromatography, 4 ml fractions were pooled and concentrated using Amicon 
Ultra 15 ml centrifugal concentrators (10 kDa MWCO) to 500 μl at 15000 x g. The concentrated 
samples were then individually loaded onto the gel filtration column and 0.5 ml fractions 
collected until the UV signal stabilised. Fractions were analysed for activity and active fractions 
were pooled for the next chromatography stage. 
 
2.13.6 Final Ion exchange (MonoQ) chromatography  
 
A 1 ml MonoQ 5/50 GL column (GE Healthcare, Little Chalfont, UK) was equilibrated in MonoQ 
buffer I (see 2.13.4). Active fractions from the gel filtration chromatography stage were loaded 
onto the column and the column washed with buffer for 3-5 column volumes. Proteins were 
eluted using a 20 ml salt gradient using Mono Q buffer II (see 2.5.5) in 0.5 ml fractions. 
Fractions were analysed for activity and the most active fraction from each activity was 
analysed by mass spectrometry by Dr Deborah M Simpson (Centre for Proteasome Research, 
University of Liverpool) to identify candidate E3 ubiquitin ligases and/or chromatin 
remodellers. 
 
 
2.14 Seeding cells for RNA interference  
 
2.14.1 Seeding cells for preparation of WCE 
 
Cells were removed from T75 flasks using trypsin (see 2.9.2 above), and following 
neutralisation with complete DMEM media, cells were counted using a haemocytometer. Cells 
were subsequently seeded at 0.5x106 cells per 100 mm dish 10 ml complete DMEM media, 
or 1.5x105 cells per 35 mm dish in 2 ml complete DMEM media. Cells were grown until 70-80 
% confluence before RNA interference.  
 
2.14.2 RNA interference  
 
Cellular protein levels were down-regulated by siRNA-mediated mRNA depletion. siRNA 
primers for target proteins are shown in table 4. Lipofectamine RNAiMAX (Invitrogen, 
Waltham, Massachusetts, USA) was used to transfect cells with siRNA sequences. Cells were 
seeded in either 100 mm or 35 mm dishes until 30-50 % confluent. Per 100 mm dish, 10 μl 
lipofectamine RNAiMAX was added to 0.5 ml DMEM media (no supplements added) and 
separately 40 nM siRNA was added added to 0.5 ml DMEM media (no supplements added), 
these were mixed by inversion 5 times and incubated for 5 minutes. The lipofectamine 
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RNAiMAX mix was added to the siRNA mix, mixed by inversion as before and incubated for 
a further 10 minutes. This 1 ml solution was added drop wise to cells and dishes transferred 
to a tissue culture incubator where they were incubated for 48 hours. For 35 mm dishes, 2.5 
μl Lipofectamine RNAiMAX and 40 nM siRNA was added to cells in 250 μl using the same 
method.  
 
 
2.15 Reverse Transcription and Real-time PCR 
 
The RNesay Mini kit (Qiagen, Hilden, Germany) was used to extract RNA from cell pellets 
following manufacturer’s instructions. Briefly pelleted HeLa cells following siRNA knockdown 
were resuspended in 350 μl buffer RLT and mixed with 350 μl 70% ethanol, the total mixture 
was transferred to a RNeasy Mini spin column and centrifuged at 8000xg for 15 seconds (all 
centrifugations were at this speed and time for the rest of the protocol unless stated).700 μl 
Buffer RW1 was added to column and centrifuged, 500 μl buffer RPE was then added twice 
and centrifuged after each addition. The column was then dried by centrifugation for 1 minute 
and 30 μl RNase free water added and then centrifuged for 1 minute to elute RNA. The 
concentration of RNA was measured using a Nanodrop ND-1000 spectrometer (software 
version V3.7.1) at a wavelength of OD 260nm. The GoScriptTM Reverse Transcription System 
(Fitchburg, Wisconsin, USA) was used to generate cDNA from purified mRNA according to 
manufacturer’s instructions. Briefly up to 5μg RNA (concentrations were kept the same siRNA 
knockdowns and the control) was incubated with 0.5μg Oligo(dT)15   at 70ᴼC for 5 minutes 
and ice for 5 mintues. The reverse transcription mix was made with the following components, 
4 μl GoScriptTM 5x reaction buffer, 1.4mM MgCl2, 0.5mM PCR nucleotide mix, 0.5μl 
Racombinant RNasin ribonucleoase inhibitor, 1μl GoScriptTM reverse transcriptase and made 
up to 15 μl with nuclease free water, the 5μl RNA and primer mix was then added. This mix 
was incubated at 25ᴼC for 5 minutes for annealing, extended by heating at 42ᴼC for 1 hours 
and the reverse transcriptase inactivated by incubation at 70ᴼC for 15 minutes. SYBR® Select 
Master Mix (Thermo Scientific, Massachusetts, USA) was utilised to amplify cDNA using 
primers in table 4 for quantitative Real Time PCR analysis using the 7500 Real Time PCR 
system (Applied Biosystems, Warrington, UK) software version v2.3. A cycle threshold value 
(CT) was provided of the run for the gene/s of interest and the reference gene actin following 
their knockdown by SiRNA. Further calculations (see below) determined relative quantities of 
mRNA (RQ value) and so statistical analysis of knockdown efficiency could be calculated. The 
RQ value allowed us the analyse if successful knockdown of target genes was successful.    
 
ΔCT = CTgene – CT reference gene 
ΔΔCT = ΔCTcontrol – ΔCTtreatment 
RQ = 2ΔΔCT 
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2.16 Clonogenic survival assay 
 
HeLa cells were seeded on 35 mm dishes at 1.5x106 cells and transfected with siRNA targeting 
each of the genes YBX1, YBX3, and HECTD1 and a control (lipofectamine RNAiMAX only) 
as in section 2.6.4. After 48 hours, cells were irradiated at 0-4 Gy using the CellRad X-
ray  irradiator (Faxitron, Tucson, Arizona, USA) at 3 Gy/min. Following irradiation the media 
was aspirated, cells were washed in 1 ml PBS, 200μl trypsin added to the cells which were 
incubated at 37°C until cells lifted of the tissue culture dishes. Trypsin was neutralised in 800 
μl media and cells counted using a haemocytometer. A defined number of cells were seeded 
in 2 ml complete DMEM media at two different cell densities in triplet for each irradiation 
treatment in 6-well plates. Number of HeLa cells seeded per well in a 6 well plate, for 
lipofectamine RNAiMAX only and YBX1 SiRNA; 0 Gy 250 and 500, 1 Gy 500 and 1000, 2 Gy 
1000 and 2000, 4 Gy 2000 and 4000,and for HECTD1 and YBX3 SiRNA; 0 Gy 500 and 1000, 
1 Gy 1000 and 2000, 2 Gy 2000 and 4000, 4 Gy 4000 and 8000 . The cell numbers were 
increased for increasing ionising radiation doses and double the number of cells were used 
for HECTD1 and Y-Box proteins 3 (YBX3) compared to the control and YBX1 which allowed 
for cell plating efficiencies. The plates were incubated in a tissue culture incubator at 37°C, 5 
% CO2 for 7-10 days when colonies were clearly visible (>50 cells/colony). Cells were fixed 
and stained by removing media, washing the cells in PBS, and adding 0.5 % crystal violet in 
6 % glutaraldehyde (bot Fisher Scientific UK, Loughborough, UK) for 1 hour. The dye was 
removed and plates washed in water and allowed to dry overnight. The GelCount colony 
counter (Oxford Optronix, Oxford, UK) was used to accurately count the numbers of colonies. 
The average plating efficiency for the untreated control plate was calculated by the number of 
colonies, divided by how many cells were plated and the average calculated for the two 
seeding density triplicates. To determine the surviving fraction, the surviving counts for each 
condition was divided by the number of cells plated times by the average plating efficiency.  
 
 
2.17 Alkaline COMET assay  
 
The alkaline comet assay was used to study repair kinetics following irradiation as described 
(269). Therefore HeLa cells and AG06173 lung fibroblasts that had been transfected with 
siRNA for either HECTD1 or YBX3 were trypsinised, diluted to 1x105 cells/ml and 250 μl cell 
suspension placed into a 24 well plate. Cells were irradiated with 1.5 Gy using the CellRad X-
ray  irradiator at 3 Gy/min. Following irradiation, 1 ml 1 % low melting point agarose (Fisher 
Scientific UK, Loughborough, UK) in PBS was added to the cell suspension and which was 
then added to a pre-coated microscope slides (800 μl 1 % normal melting point agarose in 
distilled water) which had been allowed to dry overnight. A 22 x 50 mm cover slip was added 
and the slides were kept on ice to allow the agarose with cells to set, and then placed in a 
37°C humidified incubator for a selected length of time to allow for DNA repair. At the end of 
the repair time, coverslips were removed and slides were placed into coplin jars containing 
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cold lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris base, pH 10.5 and containing 10 % 
DMSO and 1 % tween-20 added just before use). Cells were left to lyse for >1 hour at 4°C. 
Slides were transferred to an electrophoresis tank and slides immersed in cold electrophoresis 
buffer (300 mM NaOH, 1 mM EDTA, 1 % DMSO, pH>13). Electrophoresis was performed at 
25 V for 25 minutes ensuring the current was 300 mA by adding or removing buffer. The slides 
were removed and covered with 1 ml neutralisation buffer (500 mM Tris-HCl pH 8) for 5 
minutes and repeated a further two times and slides air dried overnight. Slides were 
rehydrated with distilled water for 30 minutes and 1 ml SYBR Gold (Fisher Scientific UK, 
Loughborough, UK) diluted 1:20,000 diluted in distilled water (pH 8) added for 30 minutes. 
Slides were then air dried overnight. Slides were imaged using the BX61 Olympus microscope 
and 10x magnification (Olympus, Shinjuku, Japan) by taking 10 images per slide, containing 
at least 5 cells per image, using two slides per time point and therefore counting 100 cells in 
total. The experiment was performed in triplicate. Images were analysed using Komet 6.0 
software (Andor Technology, Belfast) in order to calculate % tail DNA values. 
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CHAPTER III 
 
RESULTS I 
 
Generation of the Mononucleosome Containing Site Specific 
Damage 
 
 
3.1 Introduction 
 
Chromatin is a tightly packed unit of DNA, histones and non-histone proteins as described 
previously. Access to occluded sites is facilitated through chromatin remodelling events which 
make DNA more accessible to proteins involved in many biological processes such as DNA 
transcription and replication. This process is also required for DNA repair, however evidence 
for this has mainly been focussed on DSB repair and NER, and that occurring during BER is 
limited. However it is thought that chromatin remodelling occurs due to published studies 
indicating that certain BER enzymes are significantly less efficient at sterically occluded sites; 
particularly when lesions where the DNA backbone is facing inwards and when they are 
located near the dyad axis (94) (242, 254). Nevertheless, the precise mechanisms and 
enzymes involved to facilitate BER by remodelling such are PTM events and chromatin 
remodellers are unknown at this time. I hypothesised that a PTM event by a histone modifying 
enzyme takes place that is either sufficient enough alone to cause chromatin relaxation, or 
actively recruits an ATP-dependent chromatin remodelling complex to cause chromatin 
relaxation allowing access to occluded sites and so facilitating BER.  
 
To look at nucleosome dynamics in vitro during BER, I aimed to firstly mononucleosome 
substrates were generated that contained a synthetic AP site (THF) either with the DNA 
backbone facing inwards (THF-IN) or facing outwards (THF-OUT), which allowed us to 
examine APE1 activity in the nucleosome context. To achieve this the Widom 601 nucleosome 
sequence was used due to its strong nucleosome positioning ability, and the DNA was then 
subsequently engineered to contain a THF lesion within the central 17bp region removed, 
either on the upper DNA strand (5’  3’) or lower strand (3’  5’). The THF was chosen as it 
displays virtually no difference with regards to APE1 activity compared to glycosylase 
generated AP sites, but importantly is much more stable. The histone octamer was made 
using recombinant histone proteins from Xenopus Laevis, which are commonly used to 
generate in vitro mononucleosomes  as the histones are homologous and are of a high purity 
(246). The substrates were designed so that when the THF was located on the upper strand, 
an THF-OUT mononucleosome was formed when the THF site containing DNA was 
89 
 
reconstituted with the histone octamer, Alternatively, an THF-IN containing mononucleosome 
substrate was generated when the lower strand contained a THF (see figure 20 for their 
positions within the crystal structure of the Widom 601 sequence mononucleosome). These 
positions were equivalent to +12 for THF-OUT and +11 for THF-IN when counting from the 
nucleosome dyad axis based on sequences from Smerdon et al (242). These 
mononucleosome substrates were then used to analyse the effect of orientation on APE1 
activity. 
 
 
 
 
Figure 20; Positions of THF sites in the crystal structure of the nucleosome core particle 
containing the Widom 601 nucleosome. Crystal structure PDB ID 3LZ0 obtained and 
modified from (270) orientation 1. The crystal structure of the Widom 601 nucleosome core 
particle showing the translational position (numbered with respect of location from the dyad 
axis which is translational position 0) and orientation (DNA backbone outwards facing towards 
solvent and DNA backbone inwards facing towards the histone octamer labelled) of THF sites 
in reconstituted mononucleosomes indicated to in black circles.  
 
THF site facing 
Inwards (+11) 
THF site facing 
Outwards (+12) 
Dyad Axis (0) 
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3.2 Preparation site specific THF site containing DNA 
 
To produce mononucleosome substrates containing site specific THF sites to analyse APE1 
activity, it was initially important to formulate a method producing a segment of DNA with 
nucleosome interacting properties containing these damaged sites. Two DNA substrates were 
generated containing a site specific THF site either on the upper or lower strand in the central 
area of the DNA sequence. Restriction sites and the location of the THF site can be found in 
Chapter 2 Materials (2.1.1, figure 18 and 19). The Widom 601 sequence was amplified from 
a plasmid using PCR and the central 17 bp removed using restriction enzymes to produce two 
DNA sequence fragments which were purified from one another. A 17 bp duplex 
oligonucleotide containing a THF either on the upper or lower strand was prepared and 
sequentially ligated to each of the purified DNA sequence fragments from the restriction digest 
from the Widom 601 nucleosome positioning sequence. This method resulted in the 
production of two site specific THF site DNA substrates, which when reconstituted with the 
histone octamer, formed mononucleosomes with the DNA backbone containing the THF 
facing either inwards or outwards, figure 21. 
 
 
3.2.1 Amplification of 601 nucleosome positioning sequence  
 
The Widom 601 wild- type nucleosome positioning sequence which has strong nucleosome 
affinity was amplified from the P-GEM3Z plasmid by PCR using primers containing 5’-
fluroescent labelled dye; IRDye800 (green tagged) or IRDye700 (red tagged) on either the 
forward or reverse primers, which was dependent on which type of THF site was generated. 
The IRDye700 was always located on the strand of DNA that contained the THF due to the 
increased signal intensity of this tag so THF incision could be better visualised using the 
Odyssey Image Analysis system. The schematic diagram in Figure 21 shows the process in 
which substrate DNA was created and then wrapped around a histone octamer to reconstitute 
the nucleosome. Following PCR to amplify the 601 nucleosome positioning sequence, a 
restriction digest removed the central 17bp region leaving 127 bp and 106 bp DNA products. 
A 17 bp oligonucleotide with a THF was sequentially ligated to the 127 bp and 106 bp PCR 
products. This produced a DNA fragment of 256 bp containing a THF which could then be 
reconstituted with a histone octamer to form a nucleosome.  
 
Figure 22A shows the 256 bp 601 nucleosome positioning sequence PCR product that was 
produced following PCR in yellow as it contained both IRDye700 and IRDye800 5’ tagged 
ends. PCR reactions were equally efficient whether a 5’-IRDye700 labelled primer was used 
to amplify the upper strand (Figure 22Ai) or whether a 5’-IRDye800 labelled primer was used 
(Figure 22Aii). The fluorescent primers used are also clearly visible underneath each of the 
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PCR products. The 256 bp DNA was subsequently purified using a PCR purification kit and 
the yield was found to be approximately 100 μg for 15 PCR reactions that were pooled. 
 
 
 
 
Figure 21; Schematic diagram showing the formation of the THF containing DNA and 
nucleosome.  The 256 bp Widom 601 nucleosome positioning sequence was amplified from 
a plasmid using PCR using fluorescently tagged primers shown as red and green stars in the 
diagram. The central 17 bp was then removed by utilised a digest to produce a red tagged 
(red star) 127 bp digest product and green tagged (green star) 106 bp digest product (when 
producing a THF-OUT mononucleosome). A 17 bp oligonucleotide (shown in grey) containing 
a THF (blue shape) was then sequentially ligated to the 127 bp and 106 bp DNA producing 
the final 256 bp DNA which was then reconstituted with the histone octamer to form the 
nucleosome.    
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3.2.2 Restriction digest of the 601 nucleosome positioning sequence 
 
Following purification of the 601 nucleosome positioning sequence, the restriction digest 
enzymes Van91I and BgII were utilised to remove to central 17 bp region, the position and 
area these enzymes cut is also shown in Figures 18 and 19 in Chapter 2 Materials (2.1.1). 
These enzymes produce sticky ends which are DNA overhangs that facilitate the subsequent 
ligations (Figure 19). After the Widom 601 nucleosome positioning sequence was treated with 
these enzymes the 100 % efficiency of the digestion was assured producing 106 bp and 127 
bp DNA segments (Figure 22B, lane 2) in comparison to the original PCR product (Figure 22B, 
lane 1). Digestion efficiency was the same whether 5’-IRDye700 labelled primer was used to 
amplify the upper strand (Figure 22Bi) or whether a 5’-IRDye800 labelled primer was used 
(Figure 22Bii). As a result, following digestion the 127 bp DNA segment is either visualised as 
a red band (Figure 22Bi) or a green band (figure 22Bii), and vice versa for the 106 bp segment. 
The 127bp and 106 bp DNA segments were then purified from each other using PAGE 
separation and gel extraction, and their effective purification and quality analysed (Figure 22Ci 
and Cii). 
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Figure 22: DNA Substrate Preparation containing a site specific THF site. A, PCR of 
nucleosome positioning 601 wild-type sequence containing both the IRDye800 and IRDye700 
florescent tags separated by electrophoresis on a 1.5 % agarose gel at 100 V for 1 hour. B, 
Products before (lane1) and after digestion (lane 2) with BgII and Van91 yielding the 127 bp 
and 106 bp products. C, After gel purification of the 127 bp (lane 1) and 106 bp (lane 2) 
products. D, Before (lane 1) and after ligation (lane 2) of the 127 bp band with the 17 bp duplex 
oligonucleotide. E, Before (lane 1) and after the second (lane 2) ligation using the 147 bp and 
106 bp products, producing a 256 bp product containing a THF. DNA substrate preparation 
using either 5’-IRDye700 labelled primer to amplify the upper strand (i) or the lower strand (ii) 
are shown. All PAGE gels (B, C, D and E) contained 8 % polyacrylamide and 0.5x TBE, and 
were run for 2.5 h at 175 V.     
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3.2.3 Sequential ligation of restriction digest products 
 
The 127 bp and 106 bp DNA segments from the 601 nucleosome positioning sequence were 
ligated sequentially to maximise ligation efficiency to a pre-prepared 17 bp duplex 
oligonucleotide with complementary sticky ends, the sequence of these is shown in figure 19B 
and table 3 in Chapter 2 Materials (2.1.2). Two oligonucleotide duplexes corresponding to 
different orientations of the THF site (THF-OUT and THF-IN) were used. The 127 bp was 
initially ligated to the 17 bp oligonucleotide duplex, which was successful as a ligated 147 bp 
DNA segment was observed for both DNA substrates utilising either a 5’-IRDye700 labelled 
(Figure 22Di, lane 2) or a 5’-IRDye800 labelled (Figure 22Dii, lane 2) 127 bp fragment. This 
was purified using the MinElute reaction clean up kit and then ligated to the 106 bp DNA 
segment. Successful ligation was evidenced by the formation of the full 256 bp substrate DNA, 
utilising a 5’-IRDye700 labelled 147 bp segment in combination with a 5’-IRDye800 labelled 
106 bp segment (Figure 22Ei, lane 2). Or of ligation of a 5’-IRDye800 labelled 147 bp segment 
with a 5’-IRDye700 labelled 106 bp segment (Figure 22Eii, lane 2). The full 256 bp substrate 
DNA produced a yellow coloured band, being the combination of both the IRDye700 and 
IRDye800 DNA ends.  This was then purified using gel extraction and used in the nucleosome 
reconstitution with the prepared histone octamer.At this point,  I had now successfully 
developed a method to generate substrate DNA containing a site specific THF site which I 
could use to examine APE1 incision activity rates. Substrates were labelled so the IRDye700, 
the most intense signal when imaging was on the DNA strand which would be incised by APE1 
(so the upper strand for THF-OUT and the lower strand for THF-IN) so the incision rate by 
APE1 could be better visualised.  
 
 
3.3 Expression and purification of recombinant histones for histone octamer 
preparation  
 
E.coli were individually transformed with expression vectors for Xenopus Laevis histones 
(H2A, H2B, H3 and H4) and the proteins overexpressed following IPTG induction. The 
bacteria were harvested, the cells lysed and the recombinant histones purified from inclusion 
bodies by size exclusion and ion-exchange chromatography under denaturing conditions (7 
M urea), using an AKTA purifier FPLC. The histones were then unfolded, combined together 
in equimolar ratios, and refolded to form the histone octamer. The octamer was subsequently 
purified in high salt containing buffer using a size exclusion column and an FPLC.  The strategy 
of the histone purification process is shown in figure 23. 
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Figure 23: Steps of the purification process of histones and refolding of the histone 
octamer. Flow chart shows the stages in the purification process of histones and finally 
refolding of the histone octamer. Firstly each histone was overexpressed in E.coli following 
IPTG induction and bacterial cells were harvested and lysed. Histones were then separately 
purified from inclusion bodies by size exclusion chromatography using a Saphacryl S200 
column eluting at around 14 kDa and ion exchange chromatography using a Mono-S column 
eluting at around 300 mM NaCl, both purification steps were under denaturing conditions (7M 
urea). The presence of histones in fractions was analysed by SDS-PAGE and instant blue 
protein staining. Once purified histones were mixed in equimolar ratios and allowed to refold 
to form the histone octamer. The histone octamer was purified by size exclusion 
chromatography using a Superdex 200 column with a high salt buffer (2 M NaCl) and proteins 
eluted around 108 kDa. The purity adn stoichiometry of the histone octamer was analysed by 
SDS PAGE and protein staining and histone octamer containing fractions pooled. 
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3.3.1 Recombinant Histone Purification by gel filtration chromatography 
 
 
Once individual histones H2A, H2B, H3 and H4 had been expressed in E.coli following IPTG 
induction, bacterial cells were harvested and lysed, and histones purified from inclusion bodies 
under denaturing conditions. This initial step of purification step was by gel filtration 
chromatography using a Sephacryl S200 column in combination with an AKTA purifier FPLC. 
The UV trace and fractions number collected when protein started to elute from AKTA FPLC 
which correlates to the amount of protein that is being eluted are shown for each of the four 
histones; H2A (Figure 24Ai), H2B (Figure 24Bi) H3 (Figure 25Ai) and H4 (Figure 25Bi). In 
general these traces show two major peaks, the first relating to bacterial protein contaminants, 
and the second later peak relating to the histone of interest. The proteins within these fractions 
were separated by SDS PAGE and proteins stained (Figure 24Aii, 24Bii, figure 25Aii and 25Bii, 
for H2A, H2B, H3 and H4, respectively). H2A and H2B have molecular weights of 13.96 and 
13.77 kDa respectively and these proteins were shown to elute in fractions 11-15 for H2A and 
10-14 for H2B (Figure 24Aii and Bii). Note that the upper band are the full length histones and 
the lower band corresponds to histones that are slightly degraded. H3 and H4 have molecular 
weights of 15.27 kDa and 11.24 kDa, respectively. Fractions 8-13 for H3 and fractions 13-19 
for H4 were found to contain these histones (Figure 25Aii and Bii). Of note is the very low 
concentration of H4 in the UV trace and SDS PAGE protein stained gel (Figure 25Bii), which 
has been previously documented (246). Fractions containing the individual histones were 
pooled together for further protein purification by ion-exchange chromatography. 
 
3.3.2 Recombinant histone purification by Ion-exchange chromatography  
 
Pooled fractions for each histone were dialysed in distilled water containing 2 mM β-
mercaptoethanol and then purified by ion-exchange chromatography using a MonoS column 
using an AKTA purifier FPLC, again under denaturing conditions. Fractions were collected 
following salt gradient elution and proteins levels and fraction numbers are shown on the UV 
traces (Figure 26Ai for H2A; Figure 26Bi for H2B; Figure 27Ai for H3; Figure 27Bi for H4). 
Fractions containing protein were separated by SDS PAGE and analysed by protein staining 
(Figure 26Aii for H2A; Figure 26Bii for H2B; Figure 27Aii for H3; Figure 27Bii for H4). Fractions 
13-19 contained protein for H2A and degraded H2A was observed in fractions 8-12 (Figure 
26Aii). Fractions 16-21 contained H2B and degraded H2B was found in fractions 8-15 (Figure 
26Bii). Fractions 14-21 contained full length H3 protein and its degraded form in fractions 10-
13 (Figure 27Aii). Fractions 12-14 had H4 protein present and H4 degradation (lower band) 
based on the SDS-PAGE protein stained gel, although protein levels for H4 were extremely 
low (Figure 27Bii). Fractioning containing individual histones were pooled, dialysed in distilled 
water containing 2 mM β-mercaptoethanol and then concentrated. The protein concentration 
measured for each histone using molecular weights and extinction coefficients were as 
follows; H2A 6 mg, H2B 7 mg, H3 12 mg and H4 1.16 mg per 2 litre bacterial culture. 
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Figure 24: Purification of recombinant histones H2A and H2B by gel filtration 
chromatography. Following protein overexpression, the recombinant histones were initially 
purified by a gel filtration column Sephacryl S-200 for size exclusion chromatography under 
denaturing conditions (7 M urea) and an FPLC. Ai (H2A) and Bi (H2B), UV traces from FPLC 
are shown for histones with the fraction number shown below in red. Aii (H2A) and Bii (H2B) 
fractions were probed for histones using a SDS gel stained with Instant blue for each histone 
(fraction number indicated to in each image) with protein marker for 10 kDa to 250 kDa, the 
fraction designated to in green were pooled. All SDS-PAGE gels contained 16 % 
polyacrylamide and run for 2.5 h at 175 V. 
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Figure 25: Purification of recombinant histones H3 and H4 by gel filtration 
chromatography. Following protein overexpression, the recombinant histones were initially 
purified by a gel filtration column Sephacryl S-200 for size exclusion chromatography under 
denaturing conditions (7 M urea) and an FPLC. Ai (H3) and Bi (H4), UV traces from FPLC are 
shown for histones with the fraction number shown below in red. Aii (H3) and Bii (H4) fractions 
were probed for histones using a SDS gel stained with Instant blue for each histone (fraction 
number indicated to in each image) with protein marker for 10 kDa to 250 kDa, the fraction 
designated to in green were pooled. All SDS-PAGE gels contained 16 % polyacrylamide and 
run for 2.5 h at 175 V.  
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Figure 26: Purification of recombinant histones H2A and H2B by ion-exchange 
chromatography. Following initial histone purification by gel filtration the pooled fractions 
were then separated by an ion exchange column Mono S under denaturing conditions (7 M 
urea) to further purify the histones. Ai (H2A) and Bi (H2B), the UV traces from FPLC are 
shown for each histone with the fraction number shown below in red. Aii (H2A) and Bii (H2B), 
fractions where major UV peaks were seen were probed for histones using a SDS gel stained 
with Instant blue for each histone (fraction number indicated to in each image) with protein 
marker for 10 kDa to 250 kDa, the fractions designated to in green were pooled. All SDS-
PAGE gels contained 16 % polyacrylamide and run for 2.5 h at 175 V. 
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Figure 27: Purification of recombinant histones H3 and H4 by ion-exchange 
chromatography. Following initial histone purification by gel filtration the pooled fractions 
were then separated byan ion exchange column Mono S under denaturing conditions (7 M 
urea) to further purify the histones. Ai (H3) and Bi (H4), the UV traces from FPLC are shown 
for each histone with the fraction number shown below in red. Aii (H3) and Bii (H4), fractions 
where major UV peaks were seen were probed for histones using a SDS gel stained with 
Instant blue for each histone (fraction number indicated to in each image) with protein marker 
for 10 kDa to 250 kDa, the fractions designated to in green were pooled. All SDS-PAGE gels 
contained 16 % polyacrylamide and run for 2.5 h at 175 V. 
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Following purification of each histone, it was found that the concentration of H4 was too low 
for generating the histone octamer and therefore the purification of H4 was repeated, but with 
the modifications as follows. After sonication and centrifugation the subsequent wash steps 
were removed prior to purification by Sephacryl S200 gel filtration. Fractions were collected 
and the UV trace obtained from the FPLC are shown (Figure 28Ai) in addition to separation of 
proteins by SDS PAGE and analysis by protein staining using a protein marker 10 kDa to 250 
kDa (Figure 28Aii). Fractions 12-19 were shown to contain H4, which were then pooled, 
dialysed and then purified by ion-exchange chromatography using a MonoS column. Fractions 
were collected and the UV trace obtained from the FPLC is shown (Figure 28Bi) and the 
fractions separated by SDS PAGE and analysed by protein staining (Figure 28Bii).  A small 
amount of degraded H4 was seen in fractions 8-13, whereas fractions 14-20 contained full 
length H4 protein. Therefore these latter fractions were pooled, and the total yield of H4 
obtained was 18 mg per 2 L bacterial culture. This amount of H4 was sufficient enough with 
the other histones (H2A, H2B and H3) to form the histone octamer.  
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Figure 28: Purification of Histone H4. Following protein overexpression in E. coli, 
recombinant histone H4 was purified by a two-step purification process under denaturing 
conditions (7 M urea) utilising an FPLC as previous, but including a minor modification 
whereby the wash steps following sonication were removed to improve H4 purification yield. 
Ai (H4) UV trace and Aii (H4) SDS PAGE gel stained with Instant blue from FPLC from the 
gel filtration column Sephacryl S-200 for size exclusion chromatography, where the fraction 
numbers indicated in green were pooled. Bi (H4) UV trace and Bii (H4) SDS PAGE gel stained 
with Instant blue from the fractions separated by an ion exchange column Mono S, and where 
the fractions indicated in green were pooled. All SDS-PAGE gels contained 16 % 
polyacrylamide and run for 2.5 h at 175 V. 
103 
 
3.3.4 Refolding of the Histone Octamer 
 
Purified histones were mixed in equimolar ratios in an unfolding buffer, dialysed in refolding 
buffer and the subsequent octamer formed was purified by gel filtration chromatography using 
a Superdex 200 column. Fractions were collected and the UV trace obtained from the AKTA 
FPLC are shown (Figure 29A) in addition to separation of proteins by SDS-PAGE and analysis 
by gel protein staining (Figure 29B). Fractions 28-32 contain H2A and H2B dimers which have 
failed to form the octamer fully with H3 and H4, however fractions 23- 27 show histone octamer 
formation at the expected  molecular weight (~108 kDa). These fractions containing the 
histone octamer were pooled, concentrated and glycerol added to stabilise the octamer prior 
to storage. This octamer preparation acted as a source for use in the nucleosome 
reconstitution with the site specific THF site containing DNA to generate the mononucleosome 
substrates. 
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Figure 29: Refolding of the histone octamer. Histones were mixed together in equimolar 
ratios in unfolding buffer, refolded to form the octamer using a high salt buffer (2 M NaCl) and 
purified using gel filtration chromatography using a Superdex 200 column. A, UV trace from 
FPLC for the histone octamer purification. B, SDS-PAGE gel stained with Instant blue used to 
check for fractions containing the histone octamer. Fractions indicated in green contained the 
histone octamer and fractions indicated in orange contained H2A-H2B dimer. All SDS-PAGE 
gels contained 16 % polyacrylamide and run for 2.5 h at 175 V.  
 
 
3.4 Generation of mononucleosomes containing site-specific DNA damage 
 
Mononucleosomes were reconstituted by incubation of the purified histone octamer with the 
THF site containing substrate DNA (either THF-IN or THF-OUT), using salt gradient dialysis. 
This was achieved by mixing the octamer and DNA in an optimum ratio promoting 
mononucleosome formation, in a high salt (2 M NaCl) containing buffer. The reconstitution 
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was then dialysed in buffers containing reducing concentrations of salt, to stimulate 
mononucleosome substrate formation, which was confirmed by agarose gel electrophoresis 
by a shift in the DNA to a higher molecular weight species.  
 
 
3.4.1 Optimising Nucleosome reconstitution  
 
The optimal substrate DNA: histone octamer ratio was investigated to determine which ratio 
provided the best nucleosome reconstitution, whilst minimising any substantial aggregate 
formation. Nucleosome reconstitutions were analysed by agarose gel electrophoresis using a 
number of different electrophoresis conditions to fully determine the degree of reconstitution. 
This was firstly achieved using nucleosomal DNA that had been directly prepared by PCR 
using the Widom 601 sequence in the presence of unlabelled PCR primers, and which hadn’t 
been modified to contain any THF sites. Gels were stained with SYTO60 Red Fluorescent 
Nucleic Acid stain and visualised using the Odyssey Image Analysis System. The results show 
that the DNA alone (256 bp) runs at the expected molecular weight following analysis by either 
a 0.5 % agarose gel in 0.5 x TAE (Figure 30A, lane 1) or a 0.7 % gel in 0.2 x TAE (Figure 30B, 
lane 1). Following addition of the histone octamer to the DNA for nucleosomal reconstitution, 
a shift to a higher molecular weight (700 bp) species can be observed. When the TAE 
concentration was too high at 0.5X TAE the DNA appeared to be partially stripped from the 
histone octamer (Figure 30A), whereas using a 0.2X TAE concentration appeared to keep the 
nucleosome intact (Figure 30B). Near full nucleosome reconstitution was observed using a 
DNA:octamer ratio of 1:1 (lane 4, Figure 30B), although at 1:1.2 (lane 5), 1:1.4 (lane 6), and 
particularly 1:1.6 (lane 7)  DNA: histone octamer ratios, there appeared to be smearing above 
the mononucleosome band which was indicative of aggregate formation. It was therefore 
concluded that the optimal DNA:octamer ratio for promoting mononucleosome formation, 
whilst limiting aggregate formation, was 1:1. 
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Figure 30: Generation of a Mononucleosome containing unlabelled DNA comparing 
agarose gel conditions and DNA :histone octamer ratio. Nucleosome reconstitution was 
compared to free DNA on agarose gels, whereby a shift from the 256 bp free DNA prep (lane 
1 in all) to high molecular weight species, indicating nucleosome formation (~700 bp). A and 
B, increasing DNA:histone octamer ratios of 1:0.6 (lane 2), 1:0.8 (lane 3), 1:1 (lane 4), 1:1.2 
(lane 5), 1:1.4 (lane 6) and 1:1.6 (lane 7). A, 0.5 % in 0.5xTAE and B, 0.7 % in 0.2x TAE. All 
agarose gels and DNA was separated using electrophoresis at 75 V for 1.5 h. A 100 bp ladder 
was used to identify the size of the DNA 
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3.4.2 Generation of the THF site facing outwards and inwards mononucleosomes 
 
Following optimisation, the 1:1 DNA: histone octamer was used for all subsequent 
nucleosome reconstitutions. Figure 31 show mononucleosome formation for both the THF-
OUT (A) and THF-IN (B) from the nucleosome using the 100 bp DNA ladder. A shift from the 
lower molecular weight of 256 bp for free DNA (from free DNA prep) to a higher molecular 
weight of approximately 750 kDa indicating nucleosome formation is visualised for both the 
THF-OUT and THF-IN generated mononucleosomes.  These successfully generated 
mononucleosomes could then be used in repair assays to measure the activity of APE1 on 
both these substrates.  
 
 
 
 
 
 
 
Figure 31: Generation of a Mononucleosome containing an THF. Nucleosome 
reconstitution was compared to free DNA (lane 1), whereby a shift from the 256 bp free DNA 
prep to high molecular weight species (lane 2), was observed when the nucleosome was 
formed. The 1:1 DNA: histone octamer ratio was used. A, THF-OUT. B, THF-IN. DNA was 
separated using a 0.7 % agarose gel and electrophoresed at 75 V for 1.5 h. A 100 bp ladder 
(right hand lane) was used to identify the size of the DNA  
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3.5 Summary  
 
To investigate the effect of possible histone modifiers or ATP chromatin remodellers on BER 
in chromatin, it was necessary to generate mononucleosome substrates. Two 
mononucleosome substrates were designed to contain THF site lesions in different 
orientations in order to examine the effect of processing by APE1, both in the absence and 
presence of chromatin remodelling activities. According to previously published data, one of 
these synthetic AP site (THF) containing substrates is easily accessible to APE1 as the DNA 
backbone is facing outwards away from the histone octamer, whereas the other with the DNA 
backbone containing the THF site facing inwards towards the histone octamer is thought to 
be more inaccessible. These substrates would allow us to determine if the orientation does 
indeed affect recombinant APE1 activity in vitro as seen in similar previous studies, but more 
importantly to investigate what enzyme/protein factors potentially stimulate APE1 towards the 
more sterically occluded THF site. In this Chapter, I have now shown that a methodology is in 
place to generate mononucleosome substrates containing site-specific THF sites.  
 
The Widom 601 sequence was selected due to its strong nucleosome positioning affinity. This 
was amplified from a plasmid using fluorescently labelled primers so that the DNA could be 
easily visualised using the Odyssey system. The central 17 bp DNA segment was excised by 
restriction enzyme digests and replaced by two sequential DNA ligations with a 17 bp 
oligonucleotide duplex containing a THF either on the upper or lower strand of the DNA. The 
position of the THF in the DNA sequence had been determined using the Widom 601 
nucleosome crystal structure so one sequence would contain a THF in an orientation so the 
backbone was facing outwards, THF-OUT (+12) and the other sequence containing a THF 
facing inwards, THF-IN (+11). This process resulted in producing two substrates containing a 
site specific THF site DNA sequence which could then be used in combination with a histone 
octamer to create a mononucleosome substrate. It should be noted that previously published 
methodology generating substrate DNA has involved using radiolabelled DNA for detection, 
and now our newly designed method completely avoids the use of this harmful radioactivity. 
Instead, our novel method incorporates 5’-fluorescently labelled DNA which is easier and safer 
to work with, but also can be quantitatively analysed using the Odyssey Image Analysis 
System. This is crucial for the analysis of accurate incision rates of the substrate DNA by 
purified enzymes and cell extracts, which will be discussed in subsequent chapters. 
 
The histone octamer was successfully prepared following individual overexpression of each 
Xenopus Laevis recombinant histone in E.coli. Histones were able to be purified using gel 
filtration and ion exchange chromatography under denaturing conditions, and subsequently 
unfolded and refolded to form the histone octamer, as previously reported (246). It had 
previously been noted that histone H4 appeared to be prone to proteolysis, so I made 
modifications to the inclusion body preparation step before gel filtration chromatography to 
prevent this. Indeed, I demonstrated that this was able to successfully increase the yield of full 
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length histone H4. Histone octamer formation was then proven successful, as shown following 
gel filtration chromatography purification, to contain two of each of the histones H2A, H2B, H3 
and H4. Mononucleosome substrates (THF-OUT and THF-IN) were finally prepared by mixing 
AP site containing DNA with the histone octamer, and a 1:1 ratio of DNA:octamer was found 
to be the most efficient. This is consistent with previously reported data (246).  
 
In summary, I have devised and optimised a methodology to generate site specific THF site 
mononucleosome substrates. These can then be used to compare APE1 activity on the two 
different orientations; THF-OUT and THF-IN, in an in vitro repair assay using recombinant 
APE1 and cell extracts which will be presented in the next chapter. This optimised 
methodology could also now be used to generate a wide range of different substrates such as 
a gap, nick or damaged DNA bases so multiple BER activities could be tested in future work.  
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CHAPTER IV 
 
RESULTS II 
 
 
BER in vitro assays using mononucleosomal DNA containing 
site-specific DNA damage in different orientations to examine 
difference in APE1 activity 
 
4.1 Introduction 
 
The short patch BER pathway, the predominant repair pathway for DNA base damage as 
described previously. The mechanisms and DNA repair proteins involved in BER are now well 
established, however the precise mechanism of BER in terms of chromatin is very poorly 
understood. There is accumulating evidence for chromatin remodelling in DNA repair, 
however this has been more directed towards DSB repair and NER.  
Chromatin remodelling is governed by two groups of proteins; histone modifying enzymes and 
ATP-dependent chromatin remodelling complexes, as described. PTMs influence the DNA 
and histone octamer interface causing relaxation (or tightening) of the DNA, causing structural 
changes and manipulating electrostatic interactions. These PTMs of histones can also result 
in the recruitment of a ATP-dependent chromatin remodelling complex. The family of ATP-
dependent chromatin remodelling complexes regulate exposure of DNA by moving (sliding, 
twist or loop), ejecting or exchanging histones through the hydrolysis of ATP. Chromatin 
remodelling factors have been implicated in DNA repair; however at this time specific 
chromatin remodelling factors in BER remain unknown.  
Our current understanding of BER within nucleosomes is that the activity of glycosylases, 
APE1 and Pol β in vitro is dependent on the helical orientation and translational position of the 
particular substrate lesion as described (242, 254, 255, 257, 271). It is thought that partial 
reversible unwrapping of nucleosomal DNA from the histone octamer facilitates access to 
these sterically occluded DNA base damage sites in vivo, achieved by currently unknown 
PTMs of histones and/or chromatin remodelling enzymes that facilitate repair. However 
evidence for the existence of these enzymes, and ultimately of chromatin remodelling required 
for BER in vivo, is lacking. 
Therefore my aim for this chapter was to establish if the occluded THF-IN mononucleosome 
could be more efficiently processed in the presence of factors that could stimulate chromatin 
remodelling events. This was achieved by comparing APE1 incision using either the 
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recombinant form and APE in HeLa WCE which contains chromatin remodelling factors using 
the THF-OUT and THF-IN mononucleosomes. Firstly, it was important to conclude if there 
was any sequence bias between the two oligonucleotide DNA substrates containing a site 
specific THF site using the BER in vitro repair assay in the presence of recombinant APE1 
and APE1 in HeLa WCE. There was minimal difference in incision between the two DNA 
substrates so the THF-IN and THF-OUT mononucleosome were used in the BER in vitro 
assays. Assays were supplemented with ubiquitination supporting factors and NAD to promote 
ubiquitination and poly(ADP)ribosylation events which have both been implicated heavily in 
DNA repair and chromatin remodelling activity in the DDR in DSB and NER, strengthening the 
interest to investigate these two PTMs. This laboratory also has a strong area of interest in 
ubiquitination and strategies to identify E3 ligases using similar techniques as shown in thesis, 
which have been successful (267, 272). Once the correct assay conditions had been 
established and if the THF-IN mononucleosome was more efficiently processed by APE1 
following the addition of these chromatin remodelling factors in HeLa WCE, then HeLa WCE 
would be fractionated to discover the precise proteins that regulate this change in activity of 
APE1 by a chromatin remodelling event. 
 
4.2 BER in vitro assays using free and mononucleosomal DNA containing site-
specific DNA damage; THF-OUT and THF-IN 
 
The first step was to develop an optimised protocol to analyse the in vitro repair of THF-OUT 
and THF-IN in naked DNA (mononucleosome free), as well as that for THF-OUT and THF-IN 
within a mononucleosome. The DNA substrates would largely be incubated with increasing 
concentrations of purified APE1 or with HeLa WCE (in the presence of buffer containing ATP 
and BSA to stabilise proteins), and therefore the DNA would have to be extracted from excess 
protein by phenol chloroform and ethanol precipitation. It was thought that because of the 
presence of chromatin remodellers and/or histone modifiers in HeLa WCE, that the occluded 
THF-IN site would be much more readily processed by APE1 in HeLa WCE compared to just 
purified APE1 alone. Once the DNA was purified, this would have to be separated by 
denaturing (7 M urea) PAGE in order to separate the cleaved 137 bp product for THF-OUT or 
119 bp for THF-IN, from the 256 bp substrate. The location of incision of the substrate THF-
containing DNA by APE1 and the products that are visualised following incision are shown in 
figure 32. Substrates and products were then analysed by using the Odyssey Image Analysis 
System to quantify the degree of THF incision (percentage cleavage).  
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Figure 32: DNA sequence for THF-OUT and THF-IN before and after incision of APE1. 
Figure shows the substrate sequence for THF-OUT with the THF (1) on the upper strand of 
the 256 bp Widom nucleosome positioning sequence and THF-IN with the THF (1) on the 
lower strand. The nucleosome dyad is shown in black bold and the 17 bp oligonucleotide 
insertion is shown in blue bases. The product DNA sequence with the more intense IRDYE700 
fluorescent tag for 137 bp THF-OUT and 116 bp THF-IN are shown.  
113 
 
4.2.1 Optimising gel conditions for denaturing (7 M urea) PAGE 
 
It was firstly important to optimise gel and running conditions so the substrate and product 
bands on the denaturing (7 M urea) PAGE gels could be separated, visualised and ultimately 
quantified with confidence. Optimisations for gel quality were achieved using the free THF-
OUT DNA using recombinant APE1 only. Initially, following phenol chloroform extraction the 
DNA from the BER reactions was ethanol precipitated. This lead to smearing on gels and 
aggregates in the well following incubation of the substrate with an increasing concentration 
of APE1 (0-14.3 fmol; Figure 33A). It was thought that residual phenol in the reactions was 
causing this smearing effect, so a wash step using isoamyl alcohol after phenol chloroform 
extraction was added in an attempt to remove phenol. However again, incubation of free THF-
OUT with increasing concentrations of APE1 (0-3.57 fmol) led to smearing on the gel (Figure 
33B). Therefore a second, additional wash step of isoamyl alcohol was added. This increased 
the quality of the substrate and product bands visually, reduced the amount of smearing and 
no aggregates were seen in the wells of the gel as a consequence of thoroughly removing all 
the phenol from the reaction (Figure 33C). However there was still some minor smearing on 
the gel below the substrate band. As the 8 % denaturing (7 M) acrylamide (19:1 
acrylamide/bis-acrylamide) gel was made from a stock solution, I further examined whether 
making this fresh would improve the using the same increasing concentrations of APE1, and 
indeed when this was performed very little smearing on the gel was observed (Figure 33D). 
Further changing the acrylamide/biacrylamide gel ratio from 19:1 to 29:1, additionally 
improved the substrate and product band quality (Figure 33E). Now that the gel image quality, 
and in particular the product and substrate bands were optimised, substrate DNA from BER 
reactions could be extracted, separated and quantified with confidence and allow us to 
accurately determine the relative activity of both recombinant APE1 and HeLa WCE on THF-
OUT and THF-IN containing DNA. 
 
4.2.2 BER in vitro assays using free THF-OUT and THF-IN DNA 
 
Before looking at THF incision using the THF-OUT and THF-IN mononucleosome substrates, 
it was important to see if there was any sequence specific differences in the incision of the 
free DNA for THF-IN and THF-OUT using recombinant APE1 and HeLa WCE. This is to 
ensure that any potential differences observed in the incision of the THF-IN and THF-OUT 
containing mononucleosomes, was not caused by a different sequence context. The 
percentage cleavage from three independent BER assays using titrations of APE1 and HeLa 
WCE were performed for both the THF-OUT and THF-IN, free DNA substrates. A 
concentration range was selected so a maximum of ~40 % incision was observed. Using 
increasing concentrations of both recombinant APE1 and HeLa WCE had a positive linear 
correlation in the percent incision of the AP sites in both THF-OUT and THF-IN (Figure 34A-
D). THF-OUT free DNA using recombinant APE1 had slightly more percentage incision at all 
concentrations compared to THF-IN substrate, with the biggest difference occurring at highest 
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concentration, suggesting that there is a mild sequence specific effect on incision by APE1 
(Figure 34A and 34C). In contrast, using HeLa WCE at the three lowest concentration points 
showed very minimal difference in percentage incision between THF-OUT and THF-IN, 
although at the two highest concentrations of HeLa WCE there was a slight increase in THF-
OUT incision compared to THF-IN. There does therefore appear to be a very marginal bias 
towards increased AP-site incision of the THF-OUT free DNA, possibly due to the sequence 
surrounding the THF site. As shown in figure 32 the sequence surrounding the THF site for 
the THF-IN is in a GC rich region either side, whereas the THF-OUT neighbours AT. However 
it was predicted that the difference in THF incision between these two THF-OUT and THF-IN 
substrates when reconstituted into mononucleosomes would be more substantial, and that 
this would negate the very slight bias in free DNA substrates.  
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Figure 33: Optimising gel condition for BER in vitro assays using AP-O free DNA and 
purified APE1. For all, 8 % denaturing (7 M) PAGE gels (19:1 acrylamide/bisacrylamide, 
unless stated) in 1X TBE were electrophoresed to separate DNA at 350 V for 1.25 hours and 
visualised using the Odyssey Image Analysis system (IRDYE700). S refers to the substrate 
DNA and P the product DNA after APE1 incision.  A, APE1 concentrations 0, 1.8, 3.6, 7.1, 
14.3 pmol, DNA was extracted by phenol chloroform and then ethanol precipitated. (B-E) 
APE1 concentrations used were 0, 0.35, 0.9, 1.79, 3.57 pmol. B, after phenol chloroform 
extraction, DNA was washed with isoamyl alcohol and then ethanol precipitated. C, Underwent 
two washes with isoamyl alcohol and then ethanol precipitated. D, 19:1 acrylamide/bis-
acrylamide freshly prepared, E, 29:1 acrylamide/bis-acrylamide freshly prepared. 
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Figure 34. In vitro BER assays using Free DNA Substrates containing an AP site for 
either THF-OUT (orange) or THF-IN (blue). For both free DNA substrates, representative 
denaturing (7 M) PAGE gels are shown for various APE1 titrations (0-180 amol) (C, THF-OUT 
and THF-IN free DNA substrates) and HeLa WCE using concentrations (0- 5 ng) D, THF-OUT 
and THF-IN free DNA substrates). These were incubated with the substrate DNA for 10 
minutes at 30ᴼC.  PAGE gels were quantified using the Odyssey Image Analysis system and 
the mean and standard deviation calculated for both substrates. S refers to the substrate DNA 
and P the product DNA after APE1 incision. A, APE1 titration for THF-OUT (orange) and THF-
IN (blue) and B, WCE titration for both THF-OUT (orange) and THF-OUT (blue) DNA 
substrates. All denaturing PAGE gels contained 8 % polyacrylamide, 7M Urea and 1x TBE, 
and run for 1.25 h at 350V. 
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4.2.3 Quantifying APE1 concentration in HeLa WCE   
 
The concentration of APE1 in HeLa WCE was measured using quantitative Western blotting, 
in order to correlate the amount of WCE used in the in vitro BER assays, to that of recombinant 
APE1 only. Therefore known and increasing amounts of HeLa WCE, plus recombinant APE1, 
were separated on a 10 % SDS polyacrylamide gel and probed for APE1 (34 kDa) using anti-
APE1 antibodies. It was found that 300 fmol recombinant APE1 was approximately equivalent 
to 5 μg HeLa WCE, and that the highest concentration used of APE1 (1200 fmol) was equal 
to 20 μg HeLa WCE (Figure 35). So extrapolating backwards, 1 μg HeLa WCE was be 
approximately equivalent to 60 fmol recombinant APE1. From this we could roughly estimate 
how much APE1 in HeLa WCE was causing a certain level of incision and how this compared 
to recombinant APE1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Quantifying APE1 concentration in HeLa WCE. APE1 concentration in HeLa 
WCE was estimated by using known amounts of HeLa WCE and quantifying them against 
known concentrations of purified his-tagged APE1. A 10 % SDS polyacrylamide gel was used 
to separate proteins by electrophoresis at 125 V for 2 h with a 10 kDa to 25 kDa protein marker 
and proteins transferred onto a membrane. APE1 was then detected by Western blotting and 
the Odyssey Image Analysis system was used to visualise and quantify APE1 protein 
concentration.  
 
 
4.2.4 BER in vitro assays using THF-OUT and THF-IN mononucleosome substrates 
 
THF site incision was compared between the THF-OUT and THF-IN mononucleosome 
substrates, using recombinant APE1 and HeLa WCE. The percentage incision from at least 
three independent BER assays using titrations of APE1 and HeLa WCE were performed for 
both THF-OUT and THF-IN mononucleosome substrates. As expected, the concentrations of 
APE1 and HeLa WCE required to cause incision of THF-OUT and THF-IN mononucleosomes 
were much higher (~1000-fold) than what was used to cause incision of free DNA, confirming 
that the nucleosome in general hinders access of APE1 to DNA. I also discovered that the 
THF-IN mononucleosome substrate is much less efficiently cleaved than the THF-OUT 
substrate using recombinant APE1 (Figure 36A and C). Indeed cleavage of THF-IN only 
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reached 20 % with 200 fmol APE1 whereas this was as high as 60 % with THF-OUT. This 
was expected due to the inability of APE1 to access the THF site within the THF-IN 
mononucleosome substrate. However, HeLa WCE displayed a very similar pattern to 
recombinant APE1, in that the THF-IN mononucleosome substrate was much less efficiently 
cleaved than the THF-OUT substrate (Figure 36B and D). Indeed, an approximate 3-fold 
higher concentration of HeLa WCE was required to incise the THF site to a similar efficiency 
in THF-IN versus that in THF-OUT, which was similar to the results with recombinant APE1 
only. This was surprising given that I had hypothesised that WCE (due to the presence of 
histone modifiers and chromatin remodellers) would be able to catalyse the cleavage of the 
THF site both in the THF-IN and THF-OUT substrates to a similar efficiency. Of note are the 
concentrations used of HeLa WCE, which is roughly equivalent to the same amount of 
recombinant APE1 as determined by quantitative Western blotting. Indeed based on figure 
35, 1 µg HeLa WCE is approximately equivalent to 60 fmol of recombinant APE1, which 
means that the graphs are virtually directly comparable to one another. Therefore under these 
conditions, no significant difference was observed in cleaving both substrates when comparing 
APE1 to HeLa WCE (Figure 36A and B). As the reaction conditions contained minimal factors 
required for histone PTMs and chromatin remodelling (only ATP added which promotes 
histone phosphorylation and ATP-dependent chromatin remodellers), I proposed that the 
addition of other factors promoting other histone PTMs would be required to promote APE1 
incision of THF-IN. For example, DNA repair has been shown to be increasingly dependent 
on ubiquitin-dependent processes, so supplementing reactions with factors supporting 
ubiquitination could be one approach. Secondly, reactions had only a short incubation time 
(10 min) so it was thought that this was not sufficient time to allow for remodelling of the 
mononucleosomes following incubation with HeLa WCE specifically. 
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Figure 36: In vitro BER assays using mononucleosome substrates containing an THF-
OUT (orange) or THF-IN (blue). For both mononucleosome substrates percentage incision 
was quantified from denaturing (7 M) PAGE gels using the Odyssey Image Analysis system 
and the mean and standard deviation calculated for both substrates from at least three 
independent experiments. A, Purified APE1 concentration titration (0-229 fmol) using THF-
OUT (orange) and THF-IN (blue) mononucleosomes and C, representative gels shown for 
each. B, HeLa WCE concentration titration (0-4.8 μg) using THF-OUT (orange) and THF-IN 
(blue) mononucleosomes and D, representative gels shown for each.  All denaturing PAGE 
gels contained 8 % polyacrylamide, 7 M Urea and 1x TBE, and run for 1.25 h at 350 V. 
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4.3 BER in vitro assays using HeLa WCE in the presence of ubiquitin and other factors  
 
Due to the observed lack of difference in incision of the THF-IN mononucleosome substrate 
by HeLa WCE, it was predicted that the extracts are potentially deficient in factors stimulating 
histone modifications and/or chromatin remodelling. In the first instance, it was therefore 
assessed whether addition of ubiquitin (therefore promoting histone ubiquitylation) would 
enhance cleavage of the THF-IN mononucleosome substrate, which is more difficult to repair. 
To achieve this, a time course experiment was performed using a defined amount of HeLa 
WCE in the absence and presence of ubiquitin in the BER in vitro assay. Using a time course 
experiment also allowed us to examine whether chromatin remodelling factors needed a 
longer time period (than the 10 minutes used in the first experiments) to catalyse nucleosome 
relaxation events. Secondly the addition of other factors including phosphocreatine (PC) and 
phosphocreatine kinase (PCK; to regenerate ATP concentrations), NAD (to promote ADP-
ribosylation) and E1, E2 enzymes (further supporting ubiquitylation) in promoting AP site 
incision within a mononucleosome was assessed. Cumulatively, this would indicate the 
precise conditions, and ultimately indicate the factors and enzymes, that are necessary for 
chromatin remodelling of THF sites during BER. 
 
 
4.3.1 BER in vitro time course assays using HeLa WCE and ubiquitin with THF-IN and 
THF-OUT 
 
To examine the effect of adding ubiquitin and incubation time on incision of the THF-IN 
mononucleosome substrate by HeLa WCE, a specific concentration of WCE (1.3 µg) which 
caused approximately 10 % incision after 10 min incubation (see Figure 36A) was used, with 
and without supplementary ubiquitin added (0.6 nmol) and the reaction continued up to 1 h. 
Ubiquitination of histones has been shown to be a vital event in the DDR in DSB and NER. 
The percentage incision from at least three individual BER assays for each time course 
experiment was quantified from denaturing (7 M) PAGE gels. Firstly it was noted that 
increasing the incubation time of the THF-IN mononucleosome with WCE from 10-60 min in 
the absence of ubiquitin had a very minimal effect on AP site incision without ubiquitin, only 
increasing incision by <5% from 10 minutes to 1 hour (Figure 37A, light purple line and Figure 
37C). However the percent cleavage of the THF site within THF-IN by HeLa WCE was 
significantly higher in the presence of ubiquitin at all time points compared to when ubiquitin 
was not added (Figure 37A, dark purple line and Figure 37C). Indeed, there was an 
approximate 2.4-fold increase in percentage incision of the THF with ubiquitin added. In the 
presence of ubiquitin, the increase in time seemed to allow possible chromatin remodelling 
factors to have a significant effect on the accessibility of the THF site in the THF-IN 
mononucleosome, increasing incision from ~17 % at 10 min to ~37 % at 1 h.  
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Figure 37:  In vitro BER assays time course using THF-IN and THF-OUT 
mononucleosomes with HeLa WCE plus and minus ubiquitin. THF-IN and THF-OUT 
mononucleosomes were treated with 1.3 μg and 0.04 μg HeLa WCE respectively, plus and 
minus 0.6nmol ubiquitin. Reactions were stopped after 10, 20, 30 and 60 minute and the 
percentage cleavage of the mononucleosome substrates was quantified from denaturing (7 
M) PAGE gels using the Odyssey Image Analysis system and the mean and standard 
deviation calculated. The dark purple (A) and brown (B) represent result with ubiquitin and 
light purple (A) and yellow (B) without ubiquitin. A, THF-IN mononucleosome substrate. B, 
THF-OUT mononucleosome substrate. Representative denaturing PAGE gels are shown plus 
and minus ubiquitin for each Mononucleosome C, THF-IN and D, THF-OUT. All denaturing 
PAGE gels contained 8 % polyacrylamide, 7 M Urea. The percentage incision from at least 
three independent BER assays for each time course.experiment were quantified from 
denaturing (7 M) PAGE gels. 
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To analyse whether this increase in THF site incision activity was specific to the THF-IN 
mononucleosome, the same time course was utilised with the THF-OUT mononucleosome, 
albeit using a lower amount of HeLa WCE as necessary (0.04 μg). The percentage incision 
from at least three and We expected that because the THF site in the THF-OUT 
mononucleosome is already very accessible to APE1 that there wouldn’t be much difference 
in APE1 percentage incision. This was indeed the case as there was virtually no difference in 
incision of the THF-OUT substrate in the presence or absence of ubiquitin (Figure 37B and 
D), and both substrates reached ~25 % incision following 1 h incubation. These data strongly 
suggested that the effect of ubiquitin could be specific to histone modifications and/or 
chromatin remodelling of the THF-IN substrate which is difficult to repair. Therefore, the 
increased activity of APE1 present in HeLa WCE to the THF-IN mononucleosome appears to 
be ubiquitin dependent, and could either to be due to an increase in accessibility from 
dissociation of the DNA from the histone octamer, or because ubiquitination on the N-terminal 
of histones causes relaxation of the mononucleosome structure. 
 
4.3.2 BER in vitro time course assays using HeLa whole cell extract and Ubiquitin with 
THF-IN free DNA 
 
As the addition of ubiquitin was found to stimulate the cleavage of the THF site in THF-IN 
mononucleosome substrate by APE1 present in HeLa WCE, I further examined whether this 
effect was specific to histone modifications and/or chromatin remodelling, and not related to 
modification (ie. ubiquitination) of APE1 protein itself present in the WCE. Therefore the same 
time course was completed using the THF-IN substrate in free DNA. The percentage incision 
from at least three independent BER assays for each time course experiment was quantified 
from denaturing (7 M) PAGE gels. It was found that addition of ubiquitin had no effect on the 
cleavage of the AP site in THF-IN free DNA by HeLa WCE. In fact, incision of the THF site in 
the THF-IN free DNA marginally decreased in the presence (Figure 38A, dark green line and 
Figure 38B) compared to the absence (Figure 38A, light green line and Figure 38B) of 
ubiquitin. Nevertheless, both substrates appeared to reach ~45-50 % incision following 1 h 
incubation This suggested that ubiquitin appears to be having a specific effect on 
mononucleosomal containing DNA damage and not on APE1 itself. 
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Figure 38:  In vitro BER assays time course using free THF-IN DNA substrate HeLa WCE 
plus and minus ubiquitin. THF-IN free DNA was treated with 1 ng HeLa WCE, plus and 
minus 0.6 nmol ubiquitin. Reactions were stopped after 10, 20, 30 and 60 minute and the THF-
IN DNA substrates percentage cleavage was quantified from denaturing (7 M) PAGE gels 
using the Odyssey Image Analysis system and the mean and standard deviation calculated 
from three experiments. A, Graph showing with and without ubiquitin, the dark green represent 
result with ubiquitin and light green without. B, Representative denaturing PAGE gels are 
shown plus and minus ubiquitin for each THF-IN free DNA substrate. All denaturing PAGE 
gels contained 8 % polyacrylamide, 7 M Urea and 1x TBE, and run for 1.25 h at 350 V. 
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4.3.3 BER in vitro time course assays analysing different conditions using HeLa WCE 
with THF-IN mononucleosome 
 
As I established that adding just ubiquitin was able to specifically stimulate incision of THF 
within the THF-IN mononucleosome substrate, I further examined the effect of different 
supplementary components added to the in vitro reaction to optimise the conditions for 
maximal THF cleavage. These included PC and PCK (to regenerate ATP concentrations), 
NAD (to promote ADP-ribosylation) and E1, E2 enzymes in the presence and absence of 
ubiquitin (promoting further ubiquitylation). These conditions were compared against the 
standard reaction (no supplements) using HeLa WCE (1.3 µg) and the THF-IN 
mononucleosome substrate at two incubation time points (30 and 60 min). 
 
The standard reaction containing just HeLa WCE (plus ATP) yielded just 17 % and 21 % THF 
incision at 30 and 60 min incubation time, respectively (Table 9). As seen previously, in the 
presence of ubiquitin the percentage incision increased at both time points (32 % and 30 %, 
respectively), further supporting a dependence on ubiquitination on THF-IN processing. On 
addition of BSA, the percentage incision of the THF-IN mononucleosome substrate only 
marginally increased at 30 and 60 min incubation time (20 % and 26 %) compared to the 
standard reaction (17 % and 21 %), indicating potential stabilisation of protein factors by 
additional protein. The combination of both BSA and ubiquitin together only produced a 
marginal increase in incision of THF-IN (31 % and 37 %), particularly after 60 min incubation, 
compared to ubiquitin alone (32 % and 30 %). The addition of NAD appeared to increase the 
incision of THF-IN mononucleosome substrate reaction (23 % and 31 %) compared to the 
standard reaction alone (17 % and 21 %), suggesting that poly (ADP-ribosylation) stimulates 
THF cleavage. Addition of PC and CPK to facilitate phosphorylation had only a marginal effect 
on incision (18 % and 25 %), although the presence of PC/PCK and NAD significantly 
increased incision by at 30 and 60 min incubation time (39 % and 44 %) in comparison to the 
standard reaction alone (17 % and 21 %). Interestingly, addition of an E1 activating enzyme 
and a pool of ten E2 conjugating enzymes (further supporting ubiquitination) did not cause a 
significant increase in THF-IN incision (22 % and 26 %) compared to reactions containing 
ubiquitin alone (32 % and 30 %). However, when E1/E2 enzymes, ubiquitin and NAD was 
added together to the BER assay, the percentage incision of the THF site in THF-IN 
mononucleosome substrate was significantly increased (56 % and 67 %), suggesting that a 
ubiquitination event in addition to an NAD-dependent process (eg. poly(ADP-ribosyl)ation) 
was taking place to making the AP site more accessible. Lastly, further adding PC and PCK 
to this reaction did not cause any additional increase in THF incision, and in fact this slightly 
decreased APE1 activity (31 % and 42 %). Consequently, these findings suggest that 
components supporting both ubiquitination (E1, E2 and ubiquitin) and poly(ADP-ribosyl)ation 
(NAD) are required for maximal APE1 activity on THF-IN, and could be acting on histone 
proteins making the THF site in the THF-IN mononucleosome substrate more accessible to 
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APE1 within HeLa WCE and this effect was investigated further. In contrast, an ATP 
regenerating system (PC and PCK) does not appear to be essential for the efficiency of the 
THF-IN incision reaction, suggesting that there is sufficient ATP within the reaction to support 
any potential phosphorylation events. 
 
Reaction Conditions Minutes Percent Incision (%) 
Standard Reaction 30 17.0 
 
60 20.5 
0.6nmol ubiquitin 30 32.0 
 
60 30.1 
6μg BSA 30 20.4 
 
60 25.5 
6μg BSA and 0.6nmol Ubiquitin 30 30.7 
 
60 36.5 
5mM NAD 30 23.4 
 
60 30.7 
25mM PC and 10ng CPK 30 18.3 
 
60 25.1 
25mM PC, 0.5μg CPK, 5mM NAD 30 39.1 
 
60 43.8 
0.7 pmol E1, 2.5 pmol E2s and 0.6nmol  30 22.4 
Ubiquitin 60 25.7 
0.7 pmol E1, 2.5 pmol E2s, 0.6nmol Ubiquitin 30 55.7 
and 5mM NAD 60 66.9 
0.7pmol E1, 2.5 pmol E2s, 0.6nmol Ubiquitin,  
30 30.7 
5mM NAD, 25mM PC and 10ng CPK 60 41.5 
 
 
Table 9; BER in vitro time course assays analysing different conditions using HeLa 
WCE with THF-IN Mononucleosome. Reactions were stopped after 30 and 60 min in the 
presence of HeLa WCE (1.3 µg) and the various components, and the THF-IN DNA substrate 
percentage cleavage was quantified from denaturing (7M) PAGE gels using the Odyssey 
Image Analysis system. The standard reaction (HeLa WCE) was supplemented with various 
components to stimulate with ubiquitination (0.7pmol E1, 2.5pmol E2 and/or 0.6nmol 
ubiquitin), phosphorylation via ATP regeneration (25mM PC and 10ng PCK), and poly(ADP-
ribosyl)ation (NAD). The percentage incision for each of these varying condition is shown after 
30 and 60 minutes from one independent experiment. 
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4.3.4 BER in vitro time course assays using both HeLa WCE and purified APE1 in the 
presence of ubiquitin, E1/E2s and NAD using THF-IN mononucleosome substrate 
 
Now that the reaction conditions had been optimised for maximal THF site incision of the THF-
IN mononucleosome substrate, particularly by supplementation with ubiquitin, E1/E2 enzymes 
and NAD, I examined the full time course (0-60 min) of repair of this substrate again using 
both HeLa WCE and purified APE1. I anticipated that stimulation of THF incision activity would 
only be observed with HeLa WCE (containing histone modifiers and chromatin remodellers) 
and not with purified APE1 only. The percentage incision from at least three independent BER 
assays for each time course experiment was quantified from denaturing (7 M) PAGE gels. In 
previous experiments using recombinant APE1 only, the THF-IN mononucleosome substrate 
was only incised to ~20 % with 57-230 fmol APE1 following a 10 minute incubation (Figure 
36A). The addition of ubiquitin, E1/E2 enzymes and NAD to recombinant APE1 (57 fmol) over 
the time course of incision of the THF-IN mononucleosome substrate similarly did not appear 
to dramatically affect THF site incision (Figure 39A, green line and Figure 39B) as this only 
reached ~20 % and ~30 % after 20 min and 60 min incubations, respectively. This suggests 
that ubiquitin, E1/E2 enzymes and NAD are only having a minimal effect on recombinant APE1 
activity. In contrast, THF-IN mononucleosome substrate incision by HeLa WCE in the 
presence of these components was significantly enhanced, especially after 20 min incubation. 
Whilst THF site cleavage was found previous to be only ~12 % and 15 % with HeLa WCE and 
23 % and 37 % with HeLa WCE with ubiquitin after 20 and 60 min incubation, respectively 
(Figure 37A), the addition of ubiquitin, E1/E2 enzymes and NAD increased this to ~45 % and 
67 % (Figure 39A, grey line and Figure 39B). This suggests that this significant difference 
when using HeLa WCE is because of ubiquitination event by a E3 ubiquitin ligase, in 
combination with poly(ADP-ribosyl)ation in the presence of NAD, which was either causing a 
structural change in the mononucleosome through histone PTMs, or is actively recruiting an 
ATP-dependent chromatin remodeller. The effect of these additional factors was further 
analysed using both the THF-OUT and THF-IN mononucleosomes to compare the difference 
in THF incision with either recombinant APE1 or HeLa WCE.  
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Figure 39:  In vitro BER assays time course using THF-IN mononucleosome substrate 
with HeLa WCE or purified APE1 in the presence of ubiquitin, NAD and E1/E2 enzymes. 
Reactions were stopped after 10, 20, 30 and 60 minute and the THF-IN mononucleosome 
substrate with either APE1 or HeLa WCE in the presence of 0.7 pmol E1 and 2.5 pmol E2s 
and 5mM NAD, percentage cleavage was quantified from denaturing (7 M) PAGE gels using 
the Odyssey Image Analysis system and the mean and standard deviation calculated. A, 
Graph showing with 1. 3μg HeLa WCE (grey) and purified 57 fmol APE1 (green). B, 
Representative denaturing PAGE gels for both HeLa WCE and purified APE1 using THF-IN 
mononucleosome substrate. All denaturing PAGE gels contained 8 % polyacrylamide, 7 M 
Urea and 1x TBE, and run for 1.25 h at 350 V. 
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4.3.5 BER in vitro assays with HeLa WCE and purified APE1 in the presence of 
supplementary ubiquitin, E1/E2 enzymes and NAD using THF-OUT and THF-IN 
mononucleosome substrates 
 
APE1 incision was compared between the THF-OUT and THF-IN mononucleosome 
substrates, using titrations of recombinant APE1 and HeLa WCE with all factors required to 
support ubiquitination (ubiquitin, E1/E2 enzymes) and poly(ADP-ribosyl)ation (NAD), which in 
the previous section, I demonstrated caused maximal THF site cleavage of the THF-IN 
mononucleosome substrate. The percentage incision from at least three independent BER 
assays using titrations of recombinant APE1 and HeLa WCE were performed for both THF-
OUT and THF-IN mononucleosome substrates containing the THF site. The dramatic 
difference in incision of the THF-OUT versus the THF-IN mononucleosome substrate by 
recombinant APE1 alone previous shown (Figure 34A), albeit following 10 min incubation, was 
replicated under conditions using increasing concentrations of recombinant APE1 in the 
presence of E1/E2 enzymes, ubiquitin and NAD following 60 min incubation (Figure 40A and 
40C). Indeed APE1 was able to efficiently cleave the THF site in THF-OUT, but was 
significantly impeded by the THF site in THF-IN. At the highest concentration of APE1 (230 
fmol), the percentage difference in incision between THF-OUT and THF-IN was 3.9-fold. 
However, using increasing concentrations of HeLa WCE, THF-IN mononucleosome was much 
more efficiently incised in the presence of E1/E2 enzymes, ubiquitin and NAD, and appeared 
to be approaching the levels of THF site incision of the THF-OUT mononucleosome substrate 
(Figure 40B and D). Indeed, at the final concentration point there was only a 1.2-fold difference 
in cleavage between THF-OUT and THF-IN mononucleosome substrates. Therefore the 
addition of E1/E2 enzymes, ubiquitin and NAD has greatly improved accessibility and incision 
of the THF site in THF-IN compared to HeLa WCE alone (Figure 36B). On direct comparison 
of recombinant APE1 versus the comparative levels of APE1 present in HeLa WCE using the 
THF-IN mononucleosome substrate, recombinant APE1 (57 fmol) produced ~13 % incision, 
however in HeLa WCE (1 μg, equivalent) incision significantly increased to ~52 %. In contrast 
with the THF-OUT mononucleosome substrate at the same concentrations of APE1 and HeLa, 
virtually the same level of incision of the THF site was observed (73% and 75%, respectively). 
These findings provide further strong evidence that the increase in activity of APE1 in HeLa 
WCE on the THF-IN mononucleosome substrate could be due to an increase in accessibility 
from dissociation of the DNA from the histone octamer by PTM (eg. ubiquitination or poly(ADP-
ribosyl)ation) on the N-terminal tails of histones which were either causing a structural change 
or recruiting an ATP-dependent chromatin remodeller.  
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Figure 40: In vitro BER assays using mononucleosome substrates containing an THF-
OUT (orange) or THF-IN (blue) with factors added to support ubiquitination and 
poly(ADP-ribosyl)ation. For both mononucleosome substrates, percentage cleavage was 
quantified from denaturing (7 M) PAGE gels using the Odyssey Image Analysis system and 
the mean and standard deviation calculated for both substrates. Each reaction was 
supplemented with 0.7 pmol E1 and 2.5 pmol E2s, 5 mM NAD and 0.6 nmol ubiquitin. A, 
Purified APE1 concentration titration (0-229 fmol) using THF-OUT (orange) and THF-IN (blue) 
mononucleosomes and C, representative gels shown for each. B, HeLa whole cell extract 
concentration titration (0-1.3 μg) using THF-OUT (orange) and THF-IN (blue) 
mononucleosomes and D, representative gels shown for each. All denaturing PAGE gels 
contained 8 % polyacrylamide, 7 M Urea and 1x TBE, and run for 1.25 h at 350 V. 
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4.4 Analysing structural changes in the THF-IN mononucleosome following BER in vitro 
assay in the presence of additional factors. 
 
The THF-IN mononucleosome was analysed for any structural changes following the BER in 
vitro assay using HeLa WCE in the presence of ubiquitin (plus E1 and E2 enzymes) and NAD. 
It was thought that perhaps the increase of APE1 activity towards THF with these added 
factors was promoting accessibility through a PTM (e.g. ubiquitination or poly(ADP-
ribosyl)ation) on the N-terminal tails of histones causing a structural change or recruiting an 
ATP-dependent chromatin remodeller. The THF-IN mononucleosome was therefore analysed 
to see if the DNA was completely unwrapped from the histone octamer and so making the 
THF site more accessible to APE1, but also whether the histones were being directly 
ubiquitinated.  
 
  
4.4.1 Modifications and structural changes the THF-IN mononucleosome following 
BER in vitro assay in the presence of ubiquitin  
 
To analyse whether the THF-IN monoucleosome substrate DNA following incubation with 
HeLa WCE and ubiquitin was destabilised, thus promoting dissociation of the DNA from the 
histone octamer, the reaction was analysed by agarose gel electrophoresis to see if the 
nucleosome was still fully reconstituted and the structure maintained. The mononucleosome 
was found to still remain intact following incubation with HeLa WCE and ubiquitin when 
compared to free DNA (Figure 41A), suggesting that the nucleosome structure is not 
completely disrupted, and that possibly a partial, localised unwrapping event could be taking 
place. Since the incision of THF-IN by HeLa WCE was ubiquitin-dependent, possible histone 
modifications on the mononucleosome were analysed using Western blotting probing for H2A 
ubiquitination on K119 and H2B on K120, common PTM modifications of histones involved in 
DNA repair. The THF-IN mononucleosome substrate was incubated in the presence and 
absence of HeLa WCE and ubiquitin for 1 h and six reactions of each were pooled and 
separated by SDS-PAGE and analysed by Western blotting. Using the H2A K119 antibodies 
appeared show non-specific binding to a protein (largely at 10 kDa) in HeLa WCE but there 
was no evidence of H2A monoubiquitination appearing at ~25 kDa (Figure 41B). Similarly, the 
appearance of H2B K120 ubiquitination of histones in THF-IN by HeLa WCE was not evident 
(Figure 41C). Whilst this is not conclusive evidence for the lack of histone H2A lysine 119 and 
H2B lysine 120 ubiquitination induced by HeLa WCE, this does suggest that these particular 
PTM associated with DNA repair are not induced in THF-IN. However it should be noted that 
very low amounts of histones (<75 ng) are associated with THF-IN mononucleosome DNA 
which makes them difficult to analyse using this approach and further experimentation is 
necessary.  
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Figure 41: Analysing structural changes and modifications of THF-IN mononucleosome 
substrate. THF-IN mononucleosome substrate was treated with 1.3 μg HeLa WCE and 0.6 
nmol ubiquitin using the BER in vitro assay and incubated for 1 h. A, after incubation the 
nucleosome was analysed using a 0.7 % agarose gel in 0.2x TAE containing SYTO60 using 
50 fmol free DNA as a control and electrophoresed for 1.5 hat 75 V. B and C, Following 
incubation, 6 reactions in the presence (lane 1) or absence (lane 2) of HeLa WCE were pooled 
and electrophoresed on a 16 % SDS polyacrylamide gel with a 10 kDa to 250 kDa protein 
marker at 125 V for 2 h. Following electrophoresis proteins were transferred onto a membrane 
and analysed using western blotting probing for (A) H2A ubiquitination on Lys 119 and (B) 
H2B on Lys 120. Gel and Western blots were visualised using the Odyssey Image Analysis 
system. 
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4.4.2 Structural changes the THF-IN mononucleosome following BER in vitro assay in 
the presence of ubiquitin, E1/E2s and NAD  
 
Following incubation of THF-IN with E1/E2 enzymes, NAD and ubiquitin in the BER in vitro 
assay with the THF-IN mononucleosome substrate, reactions were also analysed by agarose 
gel electrophoresis to examine if the DNA was dissociating from the histone octamer. The 
THF-IN mononcleosome appeared to remain intact following incubation when compared to 
the free DNA (Figure 42). Interestingly, there was an increase in smearing up the gel, 
suggesting a shift in the mononucleosomal DNA above the very defined mononucleosome 
band at 800bp. Whilst the nature of this smear requires further investigation, it does suggest 
that proteins such as ubiquitin or poly(ADP)ribose are binding to the THF-IN mononucleosome 
causing the gel shift, and we speculate that this could potentially be a histone modifier and/or 
chromatin remodeller. 
 
 
 
 
 
Figure 42: Analysing major structural changes in the THF-IN mononucleosome 
substrate with HeLa WCE in the presence of ubiquitin, NAD and E1/E2s. After 60 min 
incubation of the THF-IN mononucleosome substrate with HeLa WCE and ubiquitination 
factors (0.6 nmol ubiquitin, 0.7 pmol E1, 2.5pmol E2s and 5mM NAD), reactions were 
analysed against free THF-IN DNA as a control by 0.7 % agarose gel in 0.2x TAE using 
SYTO60. Agarose gels were electrophoresed at 75 V for 1.5 h and visualised using the 
Odyssey Image Analysis system 
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4.5 Summary  
 
To examine whether PTMs by histone modifying enzymes and/or ATP-dependent chromatin 
remodelling complexes could facilitate APE1 in DNA repair, a BER in vitro assay was 
established to measure the repair of a THF site in THF-OUT which is easily accessible and 
THF-IN which contains an occluded lesion, using recombinant APE1 and HeLa WCE. We 
hypothesised that recombinant APE1 would efficiently incise the THF site in THF-OUT due to 
its increased accessibility but it’s activity towards the THF site in THF-IN would be significantly 
impeded as this site is sterically occluded. However, because HeLa WCE contains possible 
histone modifying enzymes able to induce PTMs on the N-terminal tails of histones and ATP-
chromatin chromatin remodelling complexes that could remodel the nucleosome to make the 
THF site in THF-IN more accessible, it was hypothesised that this would increase incision by 
APE1. A direct comparison between recombinant APE1 and HeLa WCE in this context has 
not previously been reported. 
 
A protocol to analyse the in vitro repair of THF sites in free DNA, as well as a THF site present 
within a mononucleosome at two different orientations, THF-OUT and THF-IN, was 
developed. Initially recombinant APE1 and HeLa WCE was incubated with THF-OUT and 
THF-IN free DNA for 10 min and the percentage incision quantified. This showed a slight bias 
in incision towards to the THF-OUT free DNA compared to the THF-IN free DNA using both 
recombinant APE1 and HeLa WCE, although this difference was very minimal and probably 
due to the THF site being positioned in different sequence contexts. Using the same BER in 
vitro assay, but incorporating the THF-IN and THF-OUT mononucleosome substrates, it was 
found that recombinant APE1 and HeLa WCE (quantified by Western blotting to contain  
roughly the same amount of APE1 as used in comparison to recombinant APE1) were able to 
incise the THF site in the THF-OUT mononucleosome effectively but where both impeded to 
the THF in THF-IN. This was initially surprising as it was thought that the histone modifiers 
and/or chromatin remodellers present in HeLa WCE would cause the THF site in THF-IN to 
become more accessible by remodelling the DNA around the histone octamer. Therefore two 
points were further investigated; the short amount of time that the mononucleosomes were 
incubated (10 min) which is not sufficient time for remodelling to take place, and secondly the 
requirement of additional factors necessary for effective incision of the THF site. To tackle 
these points, the BER in vitro assay using a defined amount of HeLa WCE with the THF-IN 
mononucleosome substrate was analysed in a time course experiment, but also in the same 
experiment, the presence and absence of ubiquitin to promote ubiquitination events was 
investigated and subsequently the percentage incision of the THF site was monitored. In the 
absence of ubiquitin, the THF-IN mononucleosome substrate was still inefficiently processed 
by HeLa WCE up to 1 hour incubation times indicating that the time of the reaction was, at 
least partially, not a contributory factor in the lack of THF site incision. However in the presence 
of ubiquitin, the percentage incision increased dramatically demonstrating that a 
ubiquitination-dependent process was stimulating accessibility and incision of the THF site. It 
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was found that this increase in incision was not due to the DNA completely dissociating from 
the histone octamer as analysed by gel electrophoresis, so it was thought a partial unwrapping 
event could be taking place as a result of ubiquitination, possibly through ubiquitination of one 
of the histones. To rule out the possibility that ubiquitination of APE1 itself was increasing its 
activity, both THF-IN free DNA and the THF-OUT mononucleosome substrate incision was 
analysed using the same time course with HeLa WCE in the presence of ubiquitin. These two 
substrates were incised by HeLa WCE to the same level with and without ubiquitin. This 
suggested that ubiquitination was increasing THF site incision activity not by ubiquitination of 
APE1 itself, but potentially of histone proteins facilitating increased access of APE1 to the 
occluded THF site in THF-IN. 
 
Since ubiquitin was found to stimulate incision of the THF site within the THF-IN 
mononucleosome substrate by HeLa WCE, several other components were added to the BER 
in vitro assay in a small scale experiment designed to optimise the conditions for maximal THF 
site cleavage by HeLa WCE. The concentration of ATP supporting phosphorylation events 
was thought not to be a factor in improving THF site incision as the addition of PC and PCK 
which regenerates ATP had no effect. However, addition of NAD, which is required for 
poly(ADP-ribosyl)ation, plus all factors required to stimulate ubiquitination (ubiquitin, E1/E2 
enzymes) did produce a significant increase in THF site incision in the THF-IN 
mononucleosome substrate. Time course experiments were repeated using HeLa WCE with 
these additional components added using THF-IN mononucleosome substrate, and it was 
observed that the incision of THF-IN was extensively increased compared to reactions in the 
absence of these factors. Further titrations experiments of HeLa WCE (at 1 hour incubation) 
with these factors added using both the THF-IN and THF-OUT mononucleosome substrates 
revealed that in fact the incision of the THF-IN mononucleosome substrate by HeLa WCE was 
approaching the levels of incision of the THF-OUT mononucleosome substrate, which is easily 
accessible. Indeed when comparing relative levels of APE1 in HeLa WCE to recombinant 
APE1 there was found to be a 4-fold increase in incision of the THF-IN mononucleosome 
when using the same amount of APE1 in HeLa WCE compared to recombinant APE1. In 
contrast THF site in the THF-OUT mononucleosome was found to have similar levels of 
incision when using the same amount of APE1 in HeLa WCE and recombinant APE1. This 
strongly indicated that these additional factors supporting ubiquitination and poly(ADP-
ribosyl)ation events were greatly stimulating THF site accessibility using THF-IN by HeLa 
WCE. In contrast, there was still a significant difference in incision of the THF-IN versus THF-
OUT mononucleosomes substrates with recombinant APE1, demonstrating a dependence on 
proteins present within the HeLa WCE. Indeed as incision was largely stimulated by E1/E2 
enzymes and ubiquitin, this suggested the presence of an E3 ubiquitin ligase in the WCE 
which was causing ubiquitination of one of the histone proteins in the histone octamer, which 
was either causing a structural change in the mononucleosome, or recruiting an ATP-
dependent chromatin remodelling complex making the occluded THF site in THF-IN more 
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accessible to APE1. Again, this event was found not to occur through complete unwrapping 
of the nucleosomal DNA from the histone octamer so a partial unwrapping event could be 
taking place. The identity of potential E3 ubiquitin ligase(s) or PARPs that are driving this effect 
in HeLa WCE was then the subject of further experiments.  
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CHAPTER V 
 
RESULTS III 
 
Identification of histone modification/chromatin remodelling 
factors that stimulate APE1 activity towards the THF-IN 
mononucleosome substrate 
 
5.1 Introduction 
 
As discussed in the previous chapter a ubiquitination or poly(ADPribosyl)ation event was 
hypothesised to be taking place on histones causing increased accessibility of the THF-IN 
mononucleosome to APE1 in HeLa WCE with factors to support these two PTMs. At this stage 
I focused on the ubiquitination event that was thought to be taking place. This was partilly due 
to the expertise of this laborator, but more importantly because of its known roles in the DDR 
in DSB repair and NER for chromatin remodelling to facilitate repair. Ubiquitin is a small 
regulatory protein which is covalently added onto substrate proteins, termed ubiquitination, 
which can affect protein stability, activity and protein-protein or protein-DNA interactions, as 
discussed previously. RNF8 and RNF168 have been found to ubiquitinate H2A and H2AX on 
K13 and 15 and form K63-linked chains increasing the accessibility of DSBs and so facilitating 
the loading of 53BP1 (197, 199).  PTM of histones can also recruit ATP-dependent chromatin 
remodelling complexes. For example, INO80 is recruited to DSB by γH2AX to allow access of 
the initial repair proteins by chromatin remodelling to facilitate resection of DSB (226). These 
complexes regulate chromatin by repositioning nucleosomes, removing and expelling histone 
proteins and so altering the accessibility of certain regions of DNA to proteins for biological 
process including DNA damage repair.  
The evidence for the role of histone modifications and ATP-dependent chromatin remodelling 
complexes in BER is limited. Data from other Groups and the data provided in this thesis 
(Chapter IV) show that the orientation and translational position of DNA base damage impacts 
the activity of BER proteins. Indeed, I have shown that a synthetic THF site with the backbone 
facing outwards away from the octamer (THF-OUT) is efficiently incised by APE1 using both 
recombinant APE1 and HeLa WCE. In contrast, a THF site with the DNA backbone which is 
facing inwards toward the histone (THF-IN) is inefficiently cleaved by recombinant APE1, 
although when using HeLa WCE in the presence of factors that stimulate ubiquitination, the 
THF site is more efficiently cleaved. This suggested that there was a ubiquitination-dependent 
event, catalysed by an E3 ubiquitin ligase, occurring on a histone protein within the histone 
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octamer which caused a structural change in the nucleosome, or stimulated the recruitment 
of a ATP-dependent chromatin remodelling complex causing the THF site in THF-IN to 
become more accessible.  
Therefore the aim of this chapter was to identity the E3 ligase and/or the chromatin remodelling 
factors present in HeLa WCE that were stimulating BER. Two approaches were used to 
achieve this goal. Firstly, a candidate approach was used whereby E3 ligases known to be 
involved in other types of DNA repair and histone modifications were depleted by siRNA 
knockdowns in HeLa cells, and the effect of these examined on the incision activity of 
recombinant APE1 on the THF-IN mononucleosome substrate in vitro. Secondly, a 
biochemical fractionation approach was utilised, which is a strong and successful approach in 
Dr Parsons’ laboratory, which involves separation of proteins from HeLa WCE by sequential 
chromatography and testing the activity of individual fractions in stimulating recombinant APE1 
activity towards the THF-IN mononucleosome substrate. Fractions, and ultimately purified 
proteins, were then identified by mass spectrometry. Using both approaches, and once 
candidates have been identified, DNA damage repair kinetics and survival following IR in cells 
could be analysed to further confirm their role in BER during the cellular DNA damage 
response.  
 
5.2 A candidate approach to discover the possible E3 ubiquitin ligase responsible for 
ubiquitinating histones  
 
In the previous chapter, it was discovered that when factors were added to HeLa WCE to 
stimulate ubiquitination (E1, E2s, ubiquitin) but also poly(ADP-ribosyl)ation (NAD) the THF-IN 
mononucleosome substrate was significantly more efficiently incised by APE1 present in 
WCE, compared to recombinant APE1 which had very little activity on the substrate. 
Therefore, it was hypothesised that an E3 ubiquitin ligase was ubiquitinating one or more of 
the histone proteins present in the histone octamer and either destabilising the DNA:histone 
octamer interaction, or causing the recruitment of an ATP-dependent chromatin remodeller, 
either of which could promote the THF site in the THF-IN mononucleosome substrate to 
become more accessible to APE1 in HeLa WCE. To specifically identify the E3 ubiquitin 
ligases involved in this process, eleven enzymes previously associated with other DNA repair 
pathways and histone ubiquitination were selected and their possible effect in stimulating THF 
site cleavage by APE1 was analysed. These enzymes were male-specific lethal-2 (MSL2), 
ubiquitin protein ligase E3 component N-recognin 2 (UBR2), RNF168, ring finger protein 20 
(RNF20), DAZ Interacting Zinc Finger Protein 3 (DZIP3), CUL4A, cullin-1 (CUL1), ring finger 
protein 2 (RNF2), RNF8, Mcl-1 ubiquitin ligase E3 (MULE) and BRCA1, see table 10 for their 
suggested functions. This was achieved by siRNA knockdowns of each of the eleven E3 
ligases for 48 h in HeLa cells. Following siRNA treatment, cells were harvested and cell 
extracts prepared for use in BER in vitro repair assays to quantitatively analyse any difference 
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in the incision by recombinant APE1 of the THF-IN mononucleosome substrate in the absence 
of each E3 ubiquitin ligase or PARP. Assays were performed in the presence of factors to 
support ubiquitination (E1, E2, ubiquitin) and poly(ADP-ribosyl)ation (NAD) and reactions 
were analysed by denaturing (7 M urea) PAGE prior to quantification using the Odyssey Image 
Analysis System to determine the degree of THF site incision for each of the E3 ligase 
knockdowns compared against a Lipofectamine (transfection reagent only) control.  
Ubiquitin E3 
Ligase 
Association with Histones and/or DNA Repair 
 
BRCA1 Key HR factor and ubiquitinates several key proteins at DSBs including 
H2A K127-129 (with BARD1). (273) 
 
CUL1 In complex with SKP1-Cul1-F-box to increase JMJD2/KDM4 histone 
demethylases turnover to regulate chromatin modifications (274) 
 
CUL4A Catalyses the ubiquitination of H3 and H4 in response to UV irradiation 
(275) 
 
DZIP3 Targets H2A K119 ubiquitination (276) 
 
MSL2 Ubiquitinates H2B K34 in vitro and Drosophila. Located on in an 
inaccessible area of nucleosome structure, ubiquitination of this residue 
would likely cause significant alteration of the nucleosome (277) 
 
MULE Regulator of BER. Ubiquitinates histones and likely plays a role in 
chromatin condensation (278, 279) 
 
RNF2 Monoubiquitinates H2A K119 and 120 to help in the recruitment of 
phosphorylated ATM to DSBs, and so reduces γH2AX (280) 
 
RNF8 Ubiquitinates H1 and monoubiquitinates H2A/H2AX  which catalyses 
K63 linked ubiquitin chains with UBC1 to recruit RNF168 (196) 
 
RNF20 Monoubiquitinates H2B on K120 to promote chromatin remodelling a 
HR (203) 
 
RNF168 Ubiquitinates H2A K13 and K15 leading to the recruitment of 53BP1 and 
other DSB repair proteins (204) 
 
UBR2 Ubiquitinates histones H2A and H2B in spermatocytes and somatic cells 
for chromosome stability. UBR2 deficient chromosomes showed defects 
in DSB repair (281) 
 
 
Table 10: Candidate E3 Ligases for stimulation of THF-IN incision. Eleven E3 ligases 
were selected for the mini screen to test for THF-IN incision activity by APE1 in HeLa WCE 
following SiRNA knockdown. E3 Ligases were selected based on their known activity in DNA 
repair and/or histone modifications. 
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5.2.1 Analysing the efficiency of the knockdown for each E3 ubiquitin ligase in HeLa 
cells 
 
Firstly, the efficiency of the siRNA knockdowns were determined using quantitative PCR 
(qPCR). RNA was extracted from HeLa cell pellets and utilised to prepare cDNA. Primers for 
each E3 ubiquitin ligase gene, and actin as the reference gene, were assessed by qPCR and 
a threshold cycle (Ct) value was determined for each gene knockdown. Each knockdown was 
performed in triplicate and averaged before the knockdown efficiency was calculated. The 
majority of siRNA knockdowns for each E3 ubiquitin ligase gene were greater than 85 % (apart 
from DZIP3 which still had a 76 % knockdown) as shown in figure 43. It was concluded from 
this that the E3 ligase knockdowns were successful and so the HeLa cell pellets for each 
siRNA treatment could be utilised for preparing WCE. These extracts could then be used in 
the BER in vitro assay to see if there were any differences in THF site incision of the THF-IN 
mononucleosome substrate in the absence of each of the E3 ubiquitin ligases.  
 
 
Figure 43: Percentage knockdown for each SiRNA candidate E3 Ligases. The 
percentage knockdown for each E3 ligase was quantitated by RT-PCR and the gene levels of 
mRNA (RQ value) calculated from the CT value for the RT-PCR run. Bar chart shows the 
mock (lipofectamine only) normalised to 1 and the relative gene levels after siRNA knockdown. 
Each was done in triplicate and the average CT value calculated. A non template control (just 
primers, no cDNA) was also run for each primer to check for any contamination which could 
alter results.  
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5.2.2 BER in vitro assay with titrations of E3 ubiquitin ligase knockdown HeLa WCE 
with THF-IN mononucleosome 
 
To analyse if there were any differences in incision rates of recombinant APE1 in HeLa WCE 
on the THF-IN mononucleosome substrates, siRNA knockdown of the eleven E3 Ligases in 
HeLa cells were performed, WCE was prepared and two concentration points were analysed 
(0.65 and 1.3 μg) for each E3 ubiquitin ligase knockdown, using Lipofectamine (transfection 
reagent only) as a control. WCE were incubated with the THF-IN mononucleosome substrate 
(1 h at 30°C), and the percentage incision of this substrate from two independent BER assays 
using these concentrations for each E3 ubiquitin ligase knockdown was analysed by 
denaturing (7 M urea) PAGE, quantified using the Odyssey Image Analysis System and 
averaged. I found that there was no dramatic difference in percentage incision of the THF-IN 
mononucleosome substrate between any of the E3 ligase knockdowns compared to the 
control (Figure 44A, 44B and 44C). Using 0.65 μg HeLa WCE, all E3 ubiquitin ligase 
knockdowns lay within a maximum of 8 % range of the control, and at 1.3 μg WCE, this 
difference decreased slightly to 5 %. Only a knockdown of CUL4A or RNF2 appeared to show 
any decrease in incision of THF-IN at the two concentrations of WCE tested. Nevertheless, 
this indicated that there was no significant differences in THF site incision in the absence of 
these selected E3 ligases. To examine whether there may be a delay in the kinetics of APE1 
activity in HeLa WCE following an E3 ubiquitin ligase knockdown, a small time course was 
utilised to see if there were any differences in percent incision of the THF-IN mononucleosome 
substrate.  
 
5.2.3 BER in vitro assay time course with E3 ubiquitin ligase knockdown HeLa WCE 
with THF-IN mononucleosome 
 
A time course was used to analyse if there was any significant difference in the kinetics of 
THF site incision using HeLa WCE (1.3 µg) for each E3 ubiquitin ligase siRNA knockdown, in 
comparison to Lipofectamine (transfection reagent only) as a control. WCE were incubated 
with the THF-IN mononucleosome (10 and 30 min), and the percentage incision of the 
substrate from two independent BER assays using these time points for each E3 ubiquitin  
ligase knockdown was analysed by denaturing (7 M urea) PAGE, quantified using the 
Odyssey Image Analysis System and averaged (Figure 45A, 45B and 45C). After 10 min, the 
percentage incision of the THF-IN mononucleosome substrate for all E3 ubiquitin ligase 
knockdowns (apart from MSL2) were slightly below the control, with the lowest two 
corresponding to RNF8 (figure 45A) and MULE (figure 45C) at 27 % and 28.5 % respectively 
compared to the control at 39 %. However the efficiency of incision of both RNF8 and MULE 
depleted WCE appeared to increase at 30 min, where they were similar to that observed with 
the control WCE. After 30 min, the biggest difference in incision activity compared to the 
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control was with CUL1 knockdown, although this only differed by 8 % (figure 45B). 
Furthermore a depletion of UBR2, RNF168 and DZIP3 (in addition to CUL1) led to consistent 
decreases in the incision of THF-IN at both 30 and 60 min incubation. However, due to these 
minor differences, again it was concluded that there was no significant and dramatic 
decreases in THF site incision of the THF-IN mononucleosome substrate by APE1 present in 
HeLa WCE when these selected eleven E3 ligases, associated with other DNA repair 
pathways, were absent. This could be for several reasons. Firstly, that there were multiple E3 
ubiquitin ligase activities that were compensating for each other when one was depleted and 
so the THF site was still being made accessible to APE1. Secondly, that there were other E3 
ligase(s), or other ubiquitin-dependent activities, that had not been selected for analysis. Due 
to the compleixyt of these results combined with the small changes observed, it was 
determined that a WCE fractionation approach using sequential chromatography was utilised 
to identify and purify potential activities that stimulate APE1 activity towards the THF site in 
the THF-IN mononucleosome substrate.   
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Figure 44: The effect of candidate siRNA E3 ubiquitin ligase knockdowns titrations on 
the BER in vitro assay with THF-IN mononucleosome. The BER in vitro assay was used 
with factors to stimulate ubiquitination (0.7 pmol E1, 2.5 pmol E2 and 0.6 nmol ubiquitin) to 
analyse to the effect of HeLa WCE prepared from each siRNA E3 ligase knockdown on the 
AP site incision of THF-IN mononucleosome using A, B, C, titrations of each HeLa cell extract 
(0.65 μg and 1.3 μg) for 1 h at 30°C. Graphs show the average from two separate experiments 
quantified from denaturing (7 M) PAGE gels contained 8 % polyacrylamide, 7 M Urea and 1x 
TBE, and run for 1.25 h at 350 V. 
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Figure 45: The effect of candidate siRNA E3 ubiquitin ligase knockdowns on the BER 
in vitro assay using a time course with THF-IN mononucleosome. The BER in vitro assay 
was used with factors to stimulate ubiquitination (0.7 pmol E1, 2.5 pmol E2, 0.6 nmol ubiquitin 
and 5mM NAD) to analyse to the effect of HeLa WCE prepared from each siRNA E3 ligase 
knockdown on the AP site incision of THF-IN mononucleosome using, A, B, C, a time course 
(10 and 30 min) following incubation with each of the HeLa WCE (1.3 μg). The key for both A 
and B is shown on the right. Graphs show the average from two separate experiments 
quantified from denaturing (7 M) PAGE gels contained 8 % polyacrylamide, 7 M Urea and 1x 
TBE, and run for 1.25 h at 350 V. 
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5.3 Fractionation of HeLa WCE to identify novel activities that stimulate APE1 activity 
towards the THF site in THF-IN mononucleosome substrate 
 
Candidate histone modifying activities, E3 ubiquitin ligases and potentially ATP-dependent 
chromatin remodelling complexes were aimed to be discovered using sequential 
chromatography of HeLa WCE in combination with the BER in vitro assay containing the THF-
IN mononucleosome substrate. This approach has been very successful in Dr Parsons’ 
laboratory to identify other enzymatic activities, largely E3 ubiquitin ligases, that regulate 
various BER proteins (267, 272, 282, 283). HeLa WCE was therefore fractionated by 
sequential chromatography using, 1. phosphocellulose, 2. ion exchange, 3. gel filtration and 
4. a final polishing ion exchange chromatography step. The 250ml phosphocellulose column 
was used initially to separate DNA and non-DNA binding proteins, this column has a very high 
binding capacity (10mg/ml) so could take up to 2.5g protein. Once the active fraction from the 
phosphocellulose fractionation had been established then this fraction was put over a 20ml 
MonoQ, which also had a very high binding capacity (60mg/ml) so could take up to 1.2g of 
proteins. Active fractions then underwent gel filtration chromatography to help determine the 
molecular weight of the partially purified activity, and the active fractions put over a final 
MonoQ column as a polishing step. We couldn’t use the gel filtration before the first MonoQ, 
as the sample volume for gel filtration needs to be extremely low (<5% of the column volume) 
to improve separation. Following each chromatography step, protein fractions were analysed 
using the BER in vitro assay incorporating the THF site in THF-IN mononucleosome substrate 
in the presence of recombinant APE1, to identify those that stimulate APE1 activity above the 
basal level observed with the protein alone, as a control. Active fractions were pooled and 
were subsequently fractionated by the next chromatography stage until the fractionation was 
performed to completion, at which point fractions were analysed by mass spectrometry. 
Candidates were selected based on how high their Mascot score was, this is the probability 
that the protein is present in the sample based on matching of the sequences identified by 
mass spectrometry with the peptide sequence databases. Therefore the higher the Mascot 
score (which is also related to the number of peptides recognised and the sequence 
coverage), then the more likely the protein is there. Generally proteins with a mascot score of 
~50 or less have low probability. 
 
5.3.1 Phosphocellulose chromatography of HeLa WCE  
 
HeLa WCE was prepared from 20 g cell pellets and was firstly fractionated by 
Phosphocellulose chromatography. Phosphocellulose mimics DNA, particularly being 
negatively charged, and proteins were then eluted into two fractions by salt elution. PC150 
(elution at 150 mM KCl) largely contains non-DNA binding proteins and the subsequent 
generation of PC1000 (elution at 1000 mM KCl) largely contains DNA binding proteins. Due 
to the presence of endogenous APE1 within these fractions that may interfere with analysis of 
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stimulation of THF site incision activity by recombinant APE1, this endogenous protein was 
firstly aimed to be removed by immunodepletion. 
 
5.3.1.1 Immunodepletion of APE1 in HeLa WCE, PC150 and PC1000 
 
APE1 was immunodepleted in HeLa WCE, in addition to the PC150 and PC1000 fractions, to 
attempt to remove/reduce any residual, endogenous APE1 incision activity. Magnetic beads 
bound with APE1 primary antibodies were used for immunodepletion of the extracts which 
was performed overnight at 4°C, prior to analysis by Western blotting following 10 % SDS-
PAGE. It can be seen that endogenous APE1 present in the WCE, is also present in the 
PC1000 fraction as expected, since APE1 displays DNA binding activity (Figure 46A). PC150 
only contains very little/trace amounts of APE1. After immunodepletion, APE1 was 
successfully depleted by ~82 % from HeLa WCE but this had limited success (~20 %) in 
PC1000, which could not be improved. Nevertheless, with this in mind, APE1 immunodepleted 
fractions were examined for stimulation of recombinant APE1 activity using the THF-IN 
mononucleosome substrate. 
 
5.3.1.2 BER in vitro assays to analyse APE1 stimulation in PC150 and PC1000 
 
The BER in vitro assay containing factors added to stimulate ubiquitination (E1, E2, ubiquitin) 
and poly(ADP-ribosyl)ation (NAD) was utilised to analyse THF site incision of the THF-IN 
mononucleosome substrate with HeLa WCE, PC150 and PC1000 after APE1 
immunodepletion, in the absence and presence of recombinant APE1. Reactions were 
incubated for 1 h and analysed by denaturing (7 M urea) PAGE and gels quantified by 
comparing the cleaved 119 bp THF-IN incision product to the 256 bp substrate using the 
Odyssey Image Analysis System for determining the percentage incision of this substrate. 
Purified APE1 only (57 fmol) produced ~20 % incision of the THF site in the THF-IN 
mononucleosome, which was used as a baseline value (Figure 46B and 46C). If after addition 
of recombinant APE1 to the extracts that the incision activity increased above this baseline 
value, then it was predicted that there were histone modifiers (eg. E3 ubiquitin ligases) or 
chromatin remodelling factors (eg.  ATP-dependent chromatin remodelling complexes) that 
were causing the THF site in the THF-IN mononucleosome to become more accessible to 
APE1 and so increasing the percentage incision. A fixed amount of HeLa WCE, PC150 and 
PC1000 (1.3 μg) with THF-IN mononucleosome substrate were then incubated with and 
without recombinant APE1. Incision of THF-IN by HeLa WCE increased from 13 % to 36 % 
when recombinant APE1 was added, an increase of 23 %, which is similar to that for 
recombinant APE1 only. Likewise, addition of recombinant APE1 to PC1000 only increased 
THF site incision by ~13 % (from 33% to 46%). In contrast, THF site incision by PC150 
increased from 0.8 % to 37 % in the absence and presence of recombinant APE1, an increase 
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of ~36 %, This was significantly more than the baseline value observed with recombinant 
APE1 only, suggesting that there are E3 ubiquitin ligase(s) and/or chromatin remodelling 
factors largely in PC150 that are increasing the accessibility of the THF site in THF-IN 
mononucleosome substrate to recombinant APE1. Therefore, the PC150 fraction was further 
fractionated to identify novel activities that stimulate recombinant APE1 activity. 
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Figure 46: Analyses of APE1 stimulation by WCE, PC150 and PC1000 fractions; APE1 
was immunodepleted from HeLa WCE, PC150 and PC1000 and the efficiency of the 
immunodepletion determined by analysis of extracts (10 µg) on a 10 % SDS polyacrylamide 
gel which was probed for APE1 by Western blotting (A). Immunodepleted HeLa WCE, PC150 
and PC1000 in the absence and presence of purified APE1 (57 fmol) were used in the BER 
in vitro assay with THF-IN mononucleosome and incubated for 1 h at 30ᴼC with additional 
factors (0.7 pmol E1, 2.5 pmol E2, 0.6 nmol ubiquitin and 5 mM NAD) (B). Purified APE1 was 
used as a control which produces around ~20-25 % incision of this substrate, which was as 
the threshold value which is shown All other values for HeLa WCE, PC150 and PC1000 have 
had the threshold value deducted to show the stimulation of APE1 above the threshold. 
Percentage incision was quantified from denaturing (7 M) PAGE and the average 
quantifications for two independent experiments are shown and the standard error (C).  
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5.3.2 Ion exchange chromatography of the PC150 fraction of HeLa WCE   
 
The PC150 fraction (~1 g total protein) was fractionated by ion exchange chromatography 
using a 20 ml Mono Q column utilising an increasing salt gradient to elute protein fractions. 
This resulted in the generation of >80 protein fraction, therefore alternate fractions were 
analysed for their ability to stimulate the THF site incision activity of recombinant APE1. Any 
endogenous/residual APE1 activity present in the fractions was also determined by analysis 
of fractions in the absence of recombinant APE1 using the THF-IN mononucleosome 
substrate. Reactions were incubated for 1 h at 30°C with factors to support ubiquitination (E1, 
E2, ubiquitin) and poly(ADP-ribosyl)ation (NAD), separated by denaturing (7 M urea) PAGE 
and gels quantified by comparing the cleaved 119 bp THF-IN incision product to the 256 bp 
substrate using the Odyssey Image Analysis System to quantify the degree of THF site 
incision. 
 
5.3.2.1 Identifying novel activities for stimulation of APE1 activity from ion exchange 
chromatography of PC150 
 
Fractions from Mono Q fractionation of the PC150 fraction of HeLa WCE were buffer 
exchanged to ensure that the level of salt in each fraction was approximately the same (50 
mM KCl). The BER in vitro assay was employed to analyse THF site incision of the THF-IN 
mononucleosome with factors added to support ubiquitination an poly(ADP-ribosyl)ation. 
Recombinant APE1 only (57 fmol) was added to the reactions to examine if protein within the 
fractions could stimulate APE1 activity above the baseline value of ~20 %. Recombinant APE1 
only reactions (but still with ubiquitination/poly(ADP-ribosyl)ation stimulating factors) was 
always completed with every set of reactions as a control, and deducted from the percentage 
incision found in the fractions it was used in. This then showed the increase in incision that 
was not related to recombinant APE1 only, but related to factors stimulating APE1 activity, 
such as E3 ubiquitin ligase(s) and ATP-dependent chromatin remodelling complexes. 
Alternate protein fractions generated from the Mono Q chromatography (Figure 47A) from 
fraction 6 to 76 were analysed for this APE1 stimulating activity (Figure 47B and 47C, blue 
line). Three main stimulatory activities were identified; from fractions 34 – 42 (activity 1; Figure 
47Bi) peaking at fraction 36 at ~37 % incision above the baseline value, fractions 46 – 52 
(activity 2; Figure 47Bii) peaking at fraction 50 at ~36 % incision, and fractions 63 to 76 (activity 
3; Figure 47Biii) the strongest activity with the last six fractions producing up to 40 % incision 
above the baseline value. Their elution position in the FPLC UV trace is shown (Figure 47A). 
A smaller incision activity was noticed between fractions 20 to 28 with the peak fraction being 
at fraction 25 producing ~14 % incision above the baseline value. The BER in vitro assay was 
repeated on the three strongest activities, and although percentage incision did vary for 
activities 1 and 2, there were still three defined activities where the percentage incision above 
the baseline value for activity were observed (Figure 47C, grey line). To determine if these 
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were genuine APE1 stimulating activities, fractions had to be analysed further for any 
residual/endogenous APE1 which could be producing one or more of identified activities and 
so are not directly related to APE1 stimulation. 
 
5.3.2.2 Analysing fractions for residual APE1 incision activity  
 
Fractions were examined for any endogenous/residual APE1 incision activity, by performing 
BER in vitro assays in the absence of recombinant APE1, therefore eliminating any false 
positives in APE1 stimulating activities. Therefore alternate fractions from 18 to 54 and 60 to 
76 (where the major APE1 stimulatory activities were discovered) were tested for THF site 
incision activity with the THF-IN mononucleosome in the BER in vitro assay with factors added 
to stimulate ubiquitination/poly(ADP-ribosyl)ation. Fractions 20 to 22 were found to produce a 
spike in THF site incision activity (~15 % incision above baseline levels; Figure 47C, orange 
line). This appeared to partially overlay with the small activity that was seen with fractions 18 
to 28 in the presence of recombinant APE1 (Figure 47C, blue line) suggesting that this small 
activity was probably accountable to residual, endogenous APE1 in the fractions. At the 
position of the three other identified APE1 stimulatory activities, however, negligible THF site 
activity was observed. Therefore these activities were pooled separately and further 
fractionated separately in order to purify and identify the proteins responsible for stimulating 
APE1 activity.   
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Figure 47; Mono Q chromatography of HeLa PC150. Proteins within HeLa PC150 were 
fractionated by Mono Q chromatography shown is the FPLC UV trace (A). The relative THF 
site incision activity on the THF-IN mononucleosome substrate by protein fractions was tested 
using the BER in vitro assay with additional ubiquitin stimulating factors (0.7 pmol E1, 2.5 pmol 
E2, 0.6 nmol ubiquitin and 5 mM NAD) added in the presence of APE1 (57 fmol) and incubated 
for 1 h at 30°C. Representative gels from three activities identified by denaturing (7 M) PAGE 
gels are shown for activity 1 (Bi), activity 2 (Bii) and activity 3 (Biii). Quantification of these gels 
(blue line) and a repeat analysis on the active fractions (grey line) are also shown (C), where 
threshold incision activity of the purified APE1 only, producing 24 % incision is shown as a red 
dashed line. Fractions that stimulated APE1 activity above this baseline are suspected to have 
chromatin remodelling factors and/or E3 ligases.  
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5.3.3 Further fractionation of the three activities and identifying candidate proteins that 
stimulate APE1 activity 
 
Now that three activities stimulating APE1 activity on the THF-IN mononucleosome substrate 
has been identified, each activity was further fractionated in order to purify protein activity to 
near homogeneity. This was achieved using sequential gel filtration chromatography and a 
final polishing step involving ion exchange chromatography. As above, fractions were 
analysed for stimulation of recombinant APE1 incision activity on the THF-IN 
mononucleosome substrate using the BER in vitro assay, with a focus on identifying incision 
activities above the baseline value obtained using recombinant APE1 only. Reactions were 
incubated for 1 h at 30°C with factors to support ubiquitination (E1, E2, ubiquitin) and 
poly(ADP-ribosyl)ation (NAD), separated by denaturing (7 M urea) PAGE and gels quantified 
by comparing the cleaved 119 bp THF-IN incision product to the 256bp substrate using the 
Odyssey Image Analysis System to quantify the degree of THF site incision. Active fractions 
were pooled after the gel filtration chromatography step and underwent further fractionation 
using the final ion exchange chromatography step. Active fractions at this final step from each 
of the three activities were analysed by mass spectrometry. Candidate proteins in the fractions 
were subsequently analysed for their alignment, as determined by Western blotting, against 
the activity of the fractions at each chromatography step in order to clarify the identification of 
the proteins which are stimulating APE1 through making the THF site more accessible in the 
THF-IN mononucleosome substrate. The most active fraction was also tested with and without 
factors supporting ubiquitination to examine whether the identified activities were dependent 
on ubiquitination or not. The process to identify proteins stimulating APE1 will be discussed 
for each activity separately.  
 
5.3.3.1.1 Gel filtration chromatography of activity 1  
 
Fractions 34 to 42 from the Mono Q chromatography stage equating to activity 1 (Figure 47A) 
were pooled and fractionated using a gel filtration (24 ml Superdex 200) column. Fractions 
were collected (Figure 48A) and subsequently analysed for APE1 stimulatory activity using 
the BER in vitro assay incorporating the THF-IN mononucleosome substrate, with a particular 
focus on identifying fractions containing THF site incision activity above the baseline value of 
recombinant APE1 only. The activities of alternate fractions from 14 to 40 where protein eluted 
were tested. I found that the percentage incision of the THF site was found to exceed the 
baseline value using fractions 16 to 30 by up to 15 % (Figure 48B an 48C). Fractions 16 to 30 
were therefore pooled and further fractionated by ion exchange chromatography. 
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5.3.3.1.2 Ion exchange chromatography of activity 1 
 
Fractions 16 to 30 from the gel filtration stage were fractioned by ion exchange 
chromatography using a 1 ml Mono Q column (Figure 49A). Initially very little APE1 stimulatory 
activity on the THF-IN mononucleosome substrate was observed with these fractions using 
the BER in vitro assay. Fractions were therefore buffer exchanged into a low salt buffer (50 
mM KCl) and concentrated further prior to analysis. On retesting these fractions, an increase 
in THF site incision activity, above the baseline value for recombinant APE1 only, in fractions 
16-17 was observed when alternate fractions were analysed using the BER in vitro assay from 
fractions 8 to 20 (Figure 49B and 49C). Activity was reproducibly higher in these fractions (by 
up to 25 %), despite the activity appearing to reduce between fractionation columns. Fraction 
16 was subsequently analysed by mass spectrometry in order to examine the proteins 
contained within, and particularly to discover whether any candidate E3 ubiquitin ligase(s) and 
ATP-dependent chromatin remodelling complexes were present. 
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Figure 48; Gel filtration chromatography of activity 1. Fractions 34 to 42 from Mono Q 
chromatography were pooled and fractionated using gel filtration (Superdex 200) 
chromatography and the resulting FPLC UV trace is shown (A). The relative THF site incision 
activity of fractions on the THF-IN mononucleosome substrate, in the presence of purified 
APE1 (57 fmol), was tested using the BER in vitro assay with additional ubiquitin stimulating 
factors (0. 7pmol E1, 2.5 pmol E2, 0.6 nmol ubiquitin and 5 mM NAD )added and incubated 
for 1 h at 30°C. Reactions were separated by denaturing (7 M) PAGE and a representative 
gel is shown (B). Quantification of THF site incision from these gels are also shown as an 
average of two independent experiments, where the threshold incision activity of purified 
APE1 only, producing 22 % is shown as a red dashed line (C). 
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Figure 49: Ion exchange chromatography of activity 1. Fractions 18 to 30 from gel filtration 
chromatography were pooled and fractionated using 1 ml Mono Q column and the resulting 
FPLC UV trace is shown (A). The THF site incision activity of fractions on the THF-IN 
mononucleosome substrate, in the presence of purified APE1 (57 fmol), was tested using the 
BER in vitro assay with additional ubiquitin stimulating factors (0.7 pmol E1, 2.5 pmol E2, 0.6 
nmol ubiquitin and 5 mM NAD) added and incubated for 1 h at 30°C. Reactions were 
separated by denaturing (7 M) PAGE gels and a representative gel is shown (B). 
Quantification of THF site incision from these gels are also shown as an average of two 
independent experiments, where the threshold incision activity of purified APE1 only, 
producing 25 % incision has been shown as the red dashed line (C). 
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5.3.3.1.3 Mass spectrometry of fraction 16 from ion exchange chromatography of 
activity 1 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step, fraction 
16, was analysed by mass spectrometry to identify candidate proteins. A selection of the top 
mascot score proteins are shown in table 11 and a full list is provided in Appendix 1. As I 
originally identified that factors supporting ubiquitination (but also poly(ADP-ribosyl)ation) 
were required for improving THF site accessibility to APE1 present in WCE, the major focus 
was predominately on identifying candidate E3 ubiquitin ligases, but also ATP-dependent 
chromatin remodelling complexes that could be recruited after ubiquitination, that were 
present. However, other proteins were not immediately excluded. Interestingly, in this 
particular fraction we discovered that the E3 ubiquitin ligases HECTD1 and Hsc-70-ineracting 
protein (CHIP) were among the top scoring proteins, achieving Mascot scores of 591 and 536, 
respectively. Therefore these candidate enzymes were analysed further, particularly for their 
presence in active fractions, and their alignment with APE1 stimulatory activity.  
Accession Description Mascot Score 
P07900 Heat shock protein HSP90-alpha 3426 
P08238 Heat shock protein HSP90-alpha 3379 
P49736 DNA replication licensing factor 
MCM2 
652 
P33993 DNA replication licensing factor 
MCM7 
645 
Q9ULT8 E3 ubiquitin protein ligase 
HECTD1 
591 
Q9UNE7 E3 ubiquitin protein ligase CHIP 536 
 
Table 11; Mass Spectrometry results for activity 1. Fraction 16, the most active fraction for 
activity 1 purified by the final ion exchange (Mono Q) chromatography column, was analysed 
by mass spectrometry to identify candidate proteins. The top mascot scoring proteins are 
shown in the table and the candidate E3 ligases (HECTD1 and CHIP) are shown in bold.  
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5.3.3.1.4 Alignment of CHIP and HECTD1 with the APE1 stimulatory activity from each 
of the chromatography steps for activity 1 
 
The alignment of the candidate E3 ubiquitin ligases CHIP and HECTD1 against the APE1 
stimulatory activity profile activity profile from each chromatography stage was analysed using 
Western blotting to confirm their presence and levels in fractions compared to the THF-IN 
incision activity profile. Protein fractions were separated by either 6 % (HECTD1) or 10 % 
(CHIP) SDS-PAGE, transferred onto a PVDF membrane and the presence of these proteins 
in fractions were probed for using Western blotting in combination with the Odyssey Image 
Analysis System.  
5.3.3.1.4.1 Ion exchange chromatography alignment of the activity 1 profile to CHIP and 
HECTD1 
 
Alternate fractions 32 to 44 from the initial ion exchange (Mono Q) chromatography stage, 
containing activity 1, were analysed for the presence of HECTD1 and CHIP proteins. Both of 
these candidate proteins were present in the fractions, although the protein levels of CHIP in 
the fractions did not appear to perfectly align with the APE1 stimulatory incision activity profile 
(Figure 50Ai and 50Aii). The highest levels of CHIP were found in fractions 32 and 34 whereas 
the activity was seen predominantly in fractions 36 to 42. Consequently, CHIP was thought 
not to be a major candidate for stimulating APE1 activity on a mononucleosome substrate 
containing a THF site. In contrast, HECTD1 protein levels do appear to correlate well with the 
position of stimulatory incision activity. Levels of HECTD1 are maximal in fraction 38, although 
there is a significant amount of protein present within fractions 34-44 which contains APE1 
stimulatory activity. HECTD1 was therefore further characterised in the subsequent 
chromatography stages. 
5.3.3.1.4.2 Gel filtration chromatography alignment of the activity 1 profile to HECTD1 
 
Alternate fractions 18 to 26 from the gel filtration (Superdex 200) chromatography stage where 
analysed for the presence of HECTD1, and its alignment to the APE1 stimulatory incision 
activity profile. Similar to the previous Mono Q column, HECTD1 was found to be present in 
significant amounts in these active fractions (Figure 50Bii), and the levels of HECTD1 did 
align, to some degree, with the APE1 stimulatory activity profile (Figure 50Bi). The alignment 
of HECTD1 protein was next analysed with the final ion exchange chromatography stage. 
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Figure 50: Alignment of candidate proteins to the activity profiles of activity 1 for each 
of the sequential chromatography stages. CHIP and HECTD1, identified from mass 
spectrometry, were analysed for their alignment to the activity profiles of each chromatography 
step (Ai, Bi, Ci). Protein fractions from active regions were separated by 6 % (for HECTD1) or 
10 % (for CHIP) SDS polyacrylamide gels and transferred onto a PVDF membrane. Fractions 
were analysed for the respective proteins by Western blotting (Aii, Bii, Cii). Figures shows 
protein alignments for the initial ion exchange Mono Q column (Ai and ii), the gel filtration 
Superdex 200 column (Bi and ii) and the final ion exchange Mono Q column (Ci and Cii). The 
activity threshold of APE1 is shown as the red dashed line in each of the graphs. 
158 
 
5.3.3.1.4.3 Final ion exchange chromatography alignment of the activity 1 profile to 
HECTD1 
 
The alignment of HECTD1 protein with the APE1 stimulatory incision activity profile from the 
final ion exchange (Mono Q) chromatography stage was analysed. At this point we would 
expect the alignment to be strong as the activity, and indeed protein, is highly purified. 
Fractions 12 to 20 were analysed for HECTD1 and indeed the protein was found to be present 
in fractions 16 to 20, with a trace amounts in fraction 14 and 15 (Figure 50Cii). The highest 
levels of HECTD1 were found in fraction 16 and this aligned perfectly with the APE1 
stimulatory activity profile where the activity was the strongest in this fraction (Figure 50Ci and 
50Cii). The activity then decreased from fractions 17 to 19, which also matches with a 
decrease in HECTD1 protein. This provided clear evidence that HECTD1 is most likely the 
enzyme that catalyses activity 1. The most active fraction (16) was then analysed for its 
dependence on ubiquitination by removing the ubiquitination supporting factors in the in vitro 
BER assay. 
 
5.3.3.1.4.4 Analysing ubiquitination dependence of activity 1 
 
As HECTD1 was identified as the most likely protein stimulating the activity of APE1 on a THF-
IN mononucleosome substrate (activity 1), and as HECTD1 is an E3 ubiquitin ligase, the 
activity within the purified protein fractions should show dependence on ubiquitination 
supporting factors in the BER in vitro assay. Therefore it was important to assess whether this 
stimulation in APE1 activity was dependent on ubiquitination, which would further support 
evidence that HECTD1 is the enzyme responsible for this effect. Fraction 16 from the final 
Mono Q chromatography stage was titrated into the BER in vitro assay using the THF-IN 
mononucleosome substrate containing APE1 (57 fmol) and ubiquitin (6 nmol), and the assay 
was performed either in the presence or absence of E1/E2 enzyme pool which would support 
ubiquitination. Similar to previous experiments, recombinant APE1 only was used as a control 
under these conditions which was deducted from the percentage THF site incision caused by 
the fraction so that the amount of APE1 stimulation could be directly determined. Whilst the 
THF incision activity was relatively low and quite variable, ubiquitination was found to be 
required for the full activity of purified fraction 16 in stimulating APE1 mononucleosome activity 
on THF-IN (Figure 51A and 51B). Indeed, using volumes of 0.5 μl and 2 μl of fraction 16 the 
activity was significantly increased in the presence of E1/E2 enzymes compared to when 
these were not, as there was a 4-fold and 4.8-fold percentage incision increase, respectively. 
The effect of removing HECTD1 from fraction 16 by immunodepletion was attempted as we 
would expect that when HECTD1 is depleted, then the APE1 stimulatory activity would 
decrease. 
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5.3.3.1.4.5 The effect of HECTD1 immunodepletion from fraction 16 of activity 1 
 
HECTD1 was attempted to be immunodepleted from the active final Mono Q chromatography 
fraction 16, containing activity 1, to see if its removal from the fraction decreased the observed 
stimulation in APE1 activity on the THF-IN mononucleosome substrate. This is due to my 
hypothesis that HECTD1 ubiquitinates histones to make the THF site in THF-IN more 
accessible to APE1 and so stimulates its activity. To achieve this, HECTD1 antibody was 
bound to magnetic beads, and fraction was added and incubated overnight with the antibody 
magnetic beads, with beads alone used as a control. Immunodepletion of HECTD1 from the 
fraction was analysed by 6 % SDS-PAGE and Western blotting for HECTD1. Unfortunately, 
despite several attempts, the best immunodepletion result attained was only ~25 % 
immunodepletion of HECTD1 (Figure 52A). Nevertheless, the control and HECTD1 
immunodepleted extracts were analysed in the BER in vitro assay using the THF-IN 
mononucleosome substrate with factors added to stimulate ubiquitination/poly(ADP-
ribosyl)ation in the presence of recombinant APE1 using a reaction time course (0-80 min). A 
slight decrease in percentage incision of the THF site by APE1 was observed, especially at 
the last two time points (60 and 80 min) which saw a decrease of ~17 % and ~9 % respectively 
(Figure 52B and 52C). This correlated with a lack of efficient immunodepletion of HECTD1, 
although no further conclusions could be established from this result. Therefore in order to 
examine HECTD1 further, an siRNA knockdown of HECTD1 in cultured cells was used to 
analyse if the enzyme was having effect on DNA damage repair kinetics and survival following 
IR. 
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Figure 51: Analysing the ubiquitination dependence of activity 1. Fraction 16 from the 
final Mono Q chromatography stage from activity 1 was analysed for its dependence on 
ubiquitination using the BER in vitro assay to analyse the repair activity on the THF-IN 
mononucleosome substrate. Fraction 16 (0.5-2 µl) was incubated with APE1 (57 fmol) and 
ubiquitin (0.6nmol) with and without the E1/E2 enzyme pool, and the THF-IN substrate 
incubated for 1 h at 30°C. Percentage substrate incision was averaged from two separate 
experiments (A), and a representative denaturing (7 M) PAGE gels (B) is shown. Incision with 
the APE1 only control threshold is shown as the red dashed line. 
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Figure 52: HECTD1 immunodepletion from fraction 16 from the final ion exchange 
chromatography. Following immunodepletion (IP) of HECTD1 from fraction 16 using 
HECTD1 antibody with magnetic beads, and using beads alone as a control, the fractions was 
separated on by 6 % SDS-PAGE, proteins transferred onto a PVDF membrane which was 
then analysed for HECTD1 by Western blotting to check the efficiency of HECTD1 IP (A). 
Fractions were then used in the BER in vitro repair assay to analyse the repair of the THF-IN 
mononucleosome substrate at different time points (with 0.6 nmol ubiquitin, 0.7 pmol E1, 2.5 
pmol E2s and 5 mM NAD) (0-120 min). The percentage THF site incision quantification (B) 
and the denaturing (7 M) PAGE gel that was quantified (C) are shown.  
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5.3.3.2.1 Gel filtration chromatography of activity 2 
 
Active fractions 46–52 containing activity 2 from the first ion exchange Mono Q 
chromatography stage (Figure 47A) were pooled and fractionated using the gel filtration (24 
ml Superdex 200) column (Figure 53A). Fractions were collected and analysed for APE1 
stimulatory activity on the THF-IN mononucleosome substrate using the BER in vitro assay 
by examining activity above the baseline value of recombinant APE1 only in the presence of 
ubiquitination/poly(ADP-ribosyl)ation factors. Alternate fractions from 14 to 40 were tested for 
APE1 stimulatory activity. I found that percentage incision of the THF in THF-IN exceeded the 
baseline value in fractions 14 to 28 (Figure 53B and 53C). APE1 stimulatory activity appeared 
to be maximal using fractions 18-26, where it reached ~20 % incision above that using 
recombinant APE1 alone. Therefore fractions 16 to 26 were pooled and fractionated by ion 
exchange chromatography. 
5.3.3.2.2 Ion exchange chromatography of activity 2 
 
Fractions 16-26 from the gel filtration (Superdex 200) chromatography stage were fractioned 
by ion exchange chromatography using a 1 ml Mono Q column (Figure 54A). Alternate 
fractions 10 to 32 were analysed using the BER in vitro assay containing the THF-IN 
mononucleosome substrate in the presence of recombinant APE1 and 
ubiquitination/poly(ADP-ribosyl)ation factors. Maximal APE1 stimulatory activity appeared to 
be around fraction 21, which was ~20 % above baseline levels (Figure 54B and 54C). 
Therefore this fraction was chosen for analysis by mass spectrometry to identify candidate E3 
ubiquitin ligase(s) and ATP-dependent chromatin remodelling complexes. 
5.3.3.2.3 Mass spectrometry of fraction 21 from ion exchange chromatography of 
activity 2 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step, fraction 
21, was analysed by mass spectrometry to identify candidate proteins. A selection of the top 
mascot score proteins are shown in table 12 and a full list is provided in Appendix 2. As factors 
to promote ubiquitination (but also poly(ADP-ribosyl)ation) were initially found to stimulate 
APE1 activity by WCE on the THF-IN mononucleosome substrate, the identification of 
candidate E3 ubiquitin ligase(s) was of interest, in addition to any ATP-dependent chromatin 
remodelling complexes that could be recruited after ubiquitination. However, other proteins 
that were identified were not completely excluded. In this particular fraction, the E3 ubiquitin 
ligases MULE and the DNA damage-binding protein 1 (DDB1) which is a core component of 
the cullin (CUL4A and CUL4B) E3 ubiquitin ligase complex had high mascot scores of 1041 
and 167, respectively. In fact CUL4A was also identified in the mass spectrometry results, 
however it had a lower mascot score of 42. MULE and DDB1 were therefore analysed for their 
presence and alignment in purified fractions containing APE1 stimulatory activity.  
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Figure 53: Gel filtration chromatography of activity 2. Fractions 46 to 52 from the first ion 
exchange (Mono Q) chromatography stage were pooled and fractionated using gel filtration 
(Superdex 200) chromatography and the resulting FPLC UV trace is shown (A). The repair 
activity of fractions on the THF-IN mononucleosome substrate using the BER in vitro assay 
with ubiquitin factors (0.7 pmol E1, 2.5 pmol E2, 0.6 nmol ubiquitin and 5 mM NAD) added in 
the presence of APE1 (57 fmol) was performed by incubation for 1 h at 30°C. Reactions were 
separated by denaturing (7 M) PAGE gels and a representative gel is shown (B). 
Quantification of THF site incision from the average of two independent experiments of these 
gels are also shown, where incision activity of the activity threshold purified APE1 only, 
producing 27% incision is shown as the red dashed line (C). 
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Figure 54; Ion exchange chromatography of activity 2. Fractions 16 to 26 from gel filtration 
(Superdex 200) chromatography were pooled and fractionated by ion exchange 
chromatography using 1 ml Mono Q column and the resulting FPLC UV trace is shown (A). 
The repair activity of fractions on the THF-IN mononucleosome substrate using the BER in 
vitro assay with ubiquitin factors (0.7pmol E1, 2.5pmol E2, 0.6nmol ubiquitin and 5mM NAD) 
added in the presence of APE1 (57 fmol) were performed by incubation for 1 h at 30°C. 
Reactions were separated by denaturing (7 M) PAGE gels and a representative gel is shown 
(B). Quantification of AP site incision from these gels are also shown as an average of two 
independent experiments, where incision activity of the activity threshold purified APE1 only, 
producing 30 % incision is shown by the red dashed line (C). 
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Table 12: Mass Spectrometry results for activity 2. Fraction 21, the most active fraction for 
activity 2 purified by the final ion exchange (Mono Q) chromatography column, was analysed 
by mass spectrometry to identify candidate proteins. The top mascot scoring proteins are 
shown in the table and the candidate E3 ligases are shown in bold.  
  
Accession Description Mascot Score 
O15355 Protein phosphatase 1G 1581 
Q7KZ85 Transcription elongation factor SPT6 1446 
P49792 E3 SUMO-protein ligase RanBP2  1138 
Q7Z6Z7 E3 ubiquitin-protein ligase MULE 1041 
Q86VP6 Cullin-associated NEDD8-dissociated 
protein 1  
241 
Q16531 DNA damage-binding protein 1 167 
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5.3.3.2.4 Alignment of MULE and DDB1 with the activity from each of the 
chromatography steps for activity 2 
 
The alignment of the candidate E3 ubiquitin ligase proteins MULE and DDB1 to the APE1 
stimulatory activity profile for activity 2 from each of the chromatography stages was analysed 
using Western blotting to confirm their presence and levels in fractions compared to the activity 
profile. Protein fractions were separated on a 6 % (MULE) and 10 % (DDB1) SDS-PAGE gel, 
transferred onto a PVDF membrane and the presence of each of these proteins in fractions 
were probed for using Western blotting in combination with the Odyssey Image Analysis 
System.  
5.3.3.2.4.1 Ion exchange chromatography alignment of the activity 2 profile to MULE 
and DDB1 
 
Alternate fractions 46 to 56 from the initial ion exchange (Mono Q) chromatography stage 
containing activity 2 were analysed for the presence of MULE and DDB1. Indeed significant 
amounts of both of these candidate proteins were found to be present in the fractions (Figure 
55Ai and 55Aii). However their elution profile did not appear to align well with the APE1 
stimulatory activity profile of activity 2. Both proteins appear to peak at fraction 46 (and 
possibly earlier) and then decreased across the fractions, especially MULE, whereas THF-IN 
stimulatory incision activity peaked at fraction 50 and decreased either side of this. Although 
the alignment of proteins to the activity profile didn’t match completely, MULE and DDB1 
alignment was still further characterised in the subsequent chromatography steps. 
 
5.3.3.2.4.2 Gel filtration chromatography alignment of the activity 2 profile to MULE and 
DDB1 
 
Alternate fractions 16 to 30 from the gel filtration (Superdex 200) chromatography of activity 2 
were analysed for the presence of MULE and DDB1, and for their alignment to the APE1 
stimulatory incision activity profile. From the activity profile, the highest APE1 stimulatory 
activity on THF-IN seemed to be within fractions 18 to 26 where they appeared relatively the 
same intensity (Figure 55Bi). MULE was found to be present in fraction 18, albeit at a low 
concentration, peaks at fraction 20 and then reduces in quantity up to fraction 28 (Figure 
55Bii). DDB1 also follows a similar trend to MULE being present in low amounts in fraction 18, 
although the levels appear to stay the same in fractions 20 to 26 and then reducing at fraction 
28. Both proteins again do not appear to align greatly with the activity profile, particularly as 
activity is largely maximal in fraction 18 where the amounts of both proteins are low. However 
despite this, the alignment of these proteins in the final ion exchange chromatography step 
was analysed.  
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5.3.3.2.4.3 Final ion exchange chromatography alignment of the activity 2 profile to 
MULE and DDB1 
 
Every fraction from fraction 17 to 25 from the final ion exchange (Mono Q) chromatography of 
activity 2 was probed for MULE and DDB1, but also CUL4A, for completion. CUL4A was found 
to be present in the mass spectrometry results at a low mascot score, but it is well known to 
form E3 ubiquitin ligase complexes with DDB1. The peak fraction for APE1 stimulatory activity 
was fraction 21, with the two fractions either side of it showing some degree of THF-IN 
stimulatory incision activity (Figure 55Ci). The protein levels of MULE did not appear to 
correlate with the alignment of activity, as its highest presence appeared to be in fractions 19 
and 20. DDB1, however, was present in all fractions from 17 to 24 but peaked at fraction 21, 
and fractions either side of it (20 and 22) also had higher levels of DDB1 protein compared to 
the other fractions (Figure 55Cii). This showed some degree of alignment with APE1 
stimulatory activity, although not greatly particularly as DDB1 was found in fractions 17-19 
where there is no activity, although this activity may be dependent on protein abundance. As 
expected, CUL4A showed a similar elution profile to DDB1 given that they form protein 
complexes. These data largely suggest that neither MULE or DDB1 align extremely well with 
APE1 stimulatory activity on a THF-IN mononucleosome substrate, although CUL4A and 
DDB1 should not be excluded entirely. Therefore, it was important to analyse whether the 
stimulatory activity in these fractions had any dependence on ubiquitination.  
168 
 
 
Figure 55: Alignment of candidate proteins to the activity profiles of activity 2 for each 
of the sequential chromatography stages. MULE and DDB1, identified from mass 
spectrometry, were analysed for their alignment to the activity profiles of each chromatography 
step (Ai, Bi, Ci). Protein fractions were separated on a 6 % (for MULE) or 10 % (for DDB1 and 
CUL4A) SDS polyacrylamide gels, transferred onto a PVDF membrane and analysed by 
Western blotting for the respective proteins (Aii, Bii, Cii). Figure shows protein alignments for 
the initial ion exchange (Mono Q) column (Ai and ii), gel filtration (Superdex 200) column (Bi 
and ii) and the final ion exchange (MonoQ) chromatography column (Ci and Cii). The activity 
threshold of APE1 is shown as the red dashed line in each of the graphs. 
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5.3.3.3.4.4 Analysing ubiquitination dependence of activity 2 
 
The two candidate proteins MULE and DDB1 identified from mass spectrometry of activity 2 
showed poor alignment to the activity profile for APE1 stimulation on a THF-IN 
mononucleosome substrate. This raised the possibility that this activity may not be 
ubiquitination/E3 ubiquitin ligase dependent and that a different method to stimulate APE1 
incision (eg. phosphorylation of histones, chromatin remodelling) may be responsible. Since 
we used ubiquitination supporting factors in the BER in vitro assay, it was important to assess 
whether this stimulation in APE1 activity was dependent on these factors. Active fraction 21 
from the final ion exchange (Mono Q) chromatography stage was titrated into the BER in vitro 
assay using the THF-IN mononucleosome substrate containing recombinant APE1 (57 fmol) 
and ubiquitin (0.6 nmol) in the absence and presence of the E1/E2 enzyme pool, to see if 
ubiquitination was key for this activity. The average THF site incision from two experiments 
was determined, and as previous, recombinant APE1 only was used as a control which was 
deducted from the percentage incision using the fraction so that the amount of stimulation 
could be determined. Interestingly, and in contrast to activity 1, the activity of fraction 21 from 
activity 2 was found not to be dependent on ubiquitination. Indeed the level of APE1 
stimulation of incision of THF-IN was virtually the same in the absence and presence of E1/E2 
enzymes (Figure 56A and 56B). It was therefore decided that this activity, at this point, would 
not be followed further as this would potentially require extensive further analysis of mass 
spectrometry data and subsequent testing of alternative candidate enzymes involved in other 
PTM events. 
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Figure 56: Analysing the ubiquitination dependence of activity 2. Fraction 21 from the 
final ion exchange (Mono Q) chromatography stage of activity 2 was analysed for the 
dependence on ubiquitination. The fraction (0.5-2 µl) was tested in the BER in vitro assay 
using the THF-IN mononucleosome substrate with APE1 (57 fmol) and ubiquitin (0.6 nmol), 
with and without the E1/E2 enzyme pool, which was incubated for 1 h at 30°C. Percentage 
substrate incision was averaged from two separate experiments (A), and a representative 
denaturing (7 M) PAGE gels (B) is shown. Incision with the APE1 only control activity threshold 
is shown as the red dashed line. 
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5.3.3.3.1 Gel filtration chromatography of activity 3  
 
Active fractions 63 to 76 from the initial ion exchange (Mono Q) chromatography stage (Figure 
47) were pooled and fractionated using the gel filtration (24 ml Superdex 200) column (Figure 
57A). Fractions were collected and analysed for APE1 stimulatory activity on the THF-IN 
mononucleosome substrate using the BER in vitro assay by examining activity above the 
baseline value of recombinant APE1 only. Alternate fractions 14 to 38 where protein eluted 
were tested for APE1 stimulatory activity. The percentage incision of THF in the THF-IN 
mononucleosome substrate was found to exceed the baseline value using fractions 16 to 32 
(Figure 57B and 57C). The peak of activity was at fraction 18 which caused an ~25 % increase 
in incision above the baseline value using recombinant APE1 only. Fractions 16 to 24, where 
the highest activity was seen, were pooled and fractionated by ion exchange chromatography. 
 
5.3.3.3.2 Ion exchange chromatography of activity 3 
 
Fractions 16 to 24 from the gel filtration (Superdex 200) chromatography stage were pooled 
and fractioned by ion exchange chromatography using a 1 ml MonoQ column (Figure 58A). 
Every fraction from 25 to 31 was then analysed for APE1 stimulatory activity by the BER in 
vitro assay using the THF-IN mononucleosome substrate. This showed that activity was 
predominantly present in fractions 28 and 29 (Figure 58B and 58C). Indeed the highest 
increase in THF site incision percentage was ~10-15 % and therefore fraction 29 was analysed 
by mass spectrometry to identify potential candidate E3 ubiquitin ligase(s) and ATP-
dependent chromatin remodelling complexes. 
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Figure 57: Gel filtration chromatography of activity 3. Active fractions 63 to 76 from the 
first (Mono Q) chromatography stage were fractionated using gel filtration (Superdex 200) 
chromatography and the resulting FPLC UV trace is shown (A). The repair activity of fractions 
on the THF-IN mononucleosome substrate using the BER repair assay with APE1 (57 fmol) 
and ubiquitin (0.6 nmol) added was performed for 1 h at 30°C. Reactions were separated by 
denaturing (7 M) PAGE gels and a representative gel is shown (B). Quantification of AP site 
incision from these gels are also shown as an average of two independent experiments, where 
incision activity of purified APE1 only, the threshold activity, producing 30 % incision is shown 
by the red dashed line (C). 
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Figure 58: Ion exchange chromatography of activity 3. Active fractions 16 to 24 from gel 
filtration (Superdex 200) chromatography stage were pooled, fractionated using ion exchange 
(Mono Q) column and the resulting FPLC UV trace is shown (A). The repair activity of fractions 
on the THF-IN mononucleosome substrate using the BER repair assay with APE1 (57 fmol) 
and ubiquitin (0.6 nmol) added was performed for 1 h at 30°C. Reactions were separated by 
denaturing (7 M) PAGE gels and a representative gel is shown (B). Quantification of THF site 
incision from these gels are also shown as an average of two independent experiments, where 
incision activity of purified APE1 only, the threshold value, producing 30 % incision is shown 
by the red dashed line(C). 
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5.3.3.3.3 Mass spectrometry of fraction 29 from ion exchange chromatography of 
activity 3 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step from 
activity 3, fraction 29, was analysed by mass spectrometry to identify candidate proteins. A 
selection of the top mascot score proteins are shown in table 13 and a full list is provided in 
appendix 3. As factors used to promote ubiquitination (but also poly(ADP-ribosyl)ation) were 
initially found to increase APE1 incision of the THF-IN mononucleosome substrate, the 
identification of any E3 ubiquitin ligases were of interest, as were the presence of any ATP-
dependent chromatin remodelling complexes that could be recruited after ubiquitination. 
Surprisingly, none of these types of proteins were identified from mass spectrometry. In fact 
two Y-Box binding proteins (YBX), were the top two proteins identified from mass 
spectrometry, which were nuclease-sensitive element-binding protein 1 (YBX1) and Y-box 
binding protein 3 (YBX3) with Mascot scores of 917 and 459, respectively.  Therefore, YBX1 
and YBX3 were analysed for their presence and alignment in fractions containing APE1 THF-
IN stimulatory activity.  
 
Accession Description Mascot 
Score 
P67809 Nuclease-sensitive element-binding 
protein 1 (YBX1) 
917 
P16989 Y-box binding protein 3 (YBX3) 459 
P68363 Tubulin alpha-1B chain 345 
P07437 Tubulin beta chain 293 
 
Table 13: Mass Spectrometry results for activity 3. Fraction 29 the most active fraction for 
activity 3 purified from the final ion exchange (Mono Q) chromatography stage was analysed 
by mass spectrometry to identify candidate proteins. The top mascot scoring proteins are 
shown in the table and the interesting candidate proteins are shown in bold.  
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5.3.3.3.4.1 Ion exchange chromatography alignment of the activity 3 profile to YBX1 and 
YBX3 
 
Alternate fractions 64 to 76 from the initial ion exchange (Mono Q) chromatography stage 
where APE stimulatory activity was discovered were analysed for the present of YBX1 and 
YBX3 by Western blotting. Both of these candidate proteins were present in the fractions, 
although the antibodies for YBX3 were not of particularly good quality (Figure 59Ai and 59Aii). 
However it appeared as though the signal for YBX3 does not align particularly well with the 
activity profile as the protein appeared the most abundant in fractions 64-66 and decreased 
thereon, whereas APE1 stimulatory activity on the THF-IN mononucleosome substrate 
appeared to increase from fractions 64 to 74. The protein levels of YBX1 also appeared higher 
in fractions 64 and 66, which then decreases in the other fractions (68 to 76), although this 
seemed to occur to a lesser extent than with YBX3. Nevertheless, the alignment of YBX1 and 
YBX3 were further characterised in the subsequent chromatography steps 
 
5.3.3.3.4.2 Gel filtration chromatography alignment of the activity 3 profile to YBX1 and 
YBX3 
 
Every fraction from fractions 17 to 25 from the gel filtration (Superdex 200) chromatography 
stage were examined for the presence of YBX1 and YBX3 by Western blotting, and for their 
alignment to the APE1 stimulatory incision activity profile on the THF-IN mononucleosome 
substrate. From the activity profile the highest activity appeared to be in fractions 18 to 24 with 
the peak activity at fraction 18 (Figure 59Bi). YBX1 and YBX3 were again found to present in 
all active fractions from 17 to 25. The levels of both proteins peaked at fraction 17 and 18, and 
then decrease to fraction 25 which aligns, to some degree, with the APE1 stimulatory activity 
profile (Figure 59Bi and 59Bii). As both proteins appeared to display some alignment with the 
activity profile, this was further assessed in the final ion exchange chromatography step.  
 
5.3.3.3.4.3 Final ion exchange chromatography alignment of the activity 3 profile to 
YBX1 and YBX3 
 
Every fraction from fraction 25 to 33 from the final ion exchange (Mono Q) chromatography 
stage where APE1 stimulatory activity was present were examined for YBX1 and YBX3 by 
Western blotting. The two fractions that produced APE1 stimulatory activity on the THF-IN 
mononucleosome substrate were fractions 28 and 29 (Figure 59Ci). YBX1 was found to be 
present in fractions 27 to 29 and YBX3 largely present in fractions 27 and 28. Interestingly the 
antibodies for YBX3 detected the protein well in these fractions, indicating that YBX3 is indeed 
increasing in abundance following purification. However, both of these were proteins appear 
to be present in fraction 27, where little APE1 stimulatory activity was seen, and activity was 
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also observed in fraction 29 there was very little YBX3 (Figure 59Ci an 59Cii). Therefore, it 
was difficult to conclude whether YBX1 or YBX3 are or are not causing the APE1 stimulatory 
activity observed. The dependence of fraction 29 for ubiquitination was therefore examined 
further.  
 
5.3.3.3.4.4 Analysing ubiquitination dependence of activity 3 
 
The two candidate proteins, YBX1 and YBX3, identified from mass spectrometry of the final 
ion exchange (Mono Q) chromatography stage showed some degree of alignment to the 
activity profile for APE1 stimulatory activity on the THF-IN mononucleosome substrate. It was 
thought that either these proteins were stimulating APE1 activity on their own, or acting in 
concert with another as yet unidentified enzyme present in the purified fraction thereby making 
the THF site in the THF-IN mononucleosome substrate more accessible to APE1. As we used 
factors (E1, E2, ubiquitin) but also poly(ADP-ribosyl)ation (NAD) in the BER in vitro assay, it 
was important to assess whether this stimulation in APE1 activity was particularly 
ubiquitination dependent. Fraction 29 from the final ion exchange (Mono Q) chromatography 
column was titrated into the BER in vitro assay using the THF-IN mononucleosome substrate 
with APE1 (57 fmol) and ubiquitin (0.6 nmol), in the absence or presence of the E1/E2 enzyme 
pool to examine if ubiquitination was key for this for this activity. The average THF site incision 
within THF-IN from two experiments was calculated and recombinant APE1 only was used as 
a control which was deducted from the percentage incision by the fractions so that the amount 
of stimulation could be determined. Interestingly, ubiquitination was found to greatly stimulate 
this activity as there was a dramatic reduction in THF incision in the absence of the E1/E2 
enzyme pool (Figure 60A and 60B). As this activity was found to be largely ubiquitination-
dependent, and that YBX1 and YBX3 are not known as E3 ubiquitin ligases, it was predicted 
that these proteins maybe facilitating ubiquitination of histones by an associated E3 ligase 
present in the fractions that makes the AP site more accessible. It was therefore interesting to 
examine the effect of an siRNA knockdown of YBX1 and YBX3 in cells to analyse if these 
proteins are controlling DNA damage repair kinetics and survival following IR. 
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Figure 59: Alignment of YBX1 and YBX3 to the activity profiles of activity 3 for each of 
the sequential chromatography stages. YBX1 and YBX3, identified from mass 
spectrometry, were analysed for their alignment to the activity profiles of each chromatography 
step (Ai, Bi, Ci). Protein fractions were loaded onto 10 % SDS polyacrylamide gels, transferred 
onto a PVDF membrane and analysed by Western blotting for the respective proteins (Aii, Bii, 
Cii). Figures show protein alignments for the initial ion exchange (Mono Q) column (Ai and ii), 
the gel filtration (Superdex 200) column (Bi and ii) and the final ion exchange (Mono Q) 
chromatography column (Ci and Cii). The activity threshold of APE1 is shown as the red 
dashed line in each of the graphs.  
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Figure 60: Analysing the ubiquitination dependence of activity 3. Fraction 28 from the 
final ion exchange (Mono Q) chromatography stage of activity 3 was analysed for the 
dependence on ubiquitination. The fraction (0.5-2 µl) was tested in the BER in vitro assay 
using the THF-IN mononucleosome substrate with APE1 (57 fmol) and ubiquitin (0.6npmol), 
with and without the E1/E2 enzyme pool, which was incubated for 1 h at 30°C. Percentage 
substrate incision was averaged from two separate experiments (A), and a representative 
denaturing (7 M) PAGE gels (B) is shown. Incision with the APE1 only control, the threshold 
value, is shown by the red dashed line. 
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5.4 Analysing IR-induced DNA damage repair kinetics and cell survival following siRNA 
knockdown of candidate proteins  
 
The results shown previously suggest that the candidate proteins identified (HECTD1, YBX1 
and YBX3) maybe stimulating APE1 activity by increasing the accessibility of sterically 
occluded AP sites through histone modifications and/or chromatin remodelling. If these 
proteins were required in cells to promote DNA repair and were thus depleted, this should 
reduce the ability of the cells to repair DNA damage and also sensitise the cells to DNA 
damaging agents (eg. ionising radiation (IR)). IR was selected as a DNA damaging agent due 
to its use in cancer therapy and so making this work more translational. IR does have its 
disadvantages however, it causes a range on DNA damages; base damages, SSBs and DSBs 
and so is not specific to BER. MMS is a specific base damaging agent, due to its ability as a 
DNA alkylating agent but using this would have little translational impact to cancer therapy. 
The candidate proteins were therefore knocked down in cells using siRNA prior to irradiation. 
Cell survival was then measured using clonogenic assays, whereas the comet assay was 
used to analyse DNA damage repair kinetics following individual candidate protein 
knockdowns. 
 
5.4.1 Knockdown of HECTD1, YBX1 and YBX3 in HeLa cells 
 
HeLa cells were treated with siRNA (40 nM) for each of the candidate proteins HECTD1, YBX1 
and YBX3 with Lipofectamine RNAiMAX for 48 h, in addition to a control using the transfection 
reagent only, so the knockdown efficiency could be compared. Cells were harvested, lysed 
and protein concentration measured. The efficiency of knockdown for each protein compared 
to the control was assessed by SDS-PAGE and Western blotting for each of the candidate 
proteins using the Odyssey Image Analysis System (Figure 61A-C). This revealed that all 
three candidate proteins were efficiently knocked down by siRNA in HeLa cells, by ~88 %, 
~84 %, ~92 %, and for HECTD1, YBX3 and YBX1 respectively. The same conditions were 
therefore used prior to the clonogenic assay and comet assay. 
 
5.4.2 Analysing IR-induced cell survival after YBX1, YBX3 and HECTD1 knockdown 
 
To assess whether the siRNA knockdown of YBX1, YBX3 and HECTD1 separately in HeLa 
cells affected cell survival in response to IR-induced DNA damage, the clonogenic assay was 
utilised. Following a 48 h knockdown of each of these proteins, using transfection reagent only 
as a control, the cells were irradiated with increasing doses of x-rays (0-4 Gy). Cells were then 
trypsinised and a defined number of cells seeded in triplicate in 6-well plates for each siRNA 
knockdown and irradiation condition. The cell numbers were increased for increasing radiation 
doses and double the number of cells were used for HECTD1 and YBX3 siRNA treated cells, 
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compared to the control and YBX1 treated cells, to allow for cell plating efficiencies. Cells were 
incubated for ~7 days, and cells fixed and stained as long as there were more than >50 
cells/colony. Colonies were then counted using the GelCount colony analyser and the relative 
colony formation (surviving fraction) of each siRNA knockdown condition compared to the 
untreated control was determined. 
 
 
 
Figure 61: Knockdown of HECTD1, YBX1 and YBX3 in HeLa cells. HeLa cells were treated 
with siRNA (40 nM) for either HECTD1, YBX1 or YBX3 for 48 h, or using Lipofectamine 
RNAiMAX only as a control. Cells were harvested, lysed and protein concentration was 
measured using the Bradford assay. Cell lysates (10 µg) were separated on SDS 
polyacrylamide gels (6 % for HECTD1 and 10 % for YBX1 and YBX3), transferred onto a 
PVDF membrane and analysed by Western blotting for the respective proteins. The efficiency 
of the knockdown was quantified and normalised to the loading control (β-actin).  
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Figure 62: The effect of YBX1, YBX3 and HECTD1 on cellular sensitivity to IR. HeLa cells 
were grown in 3 cm dishes for 24 h to 30–50% confluency and then treated with Lipofectamine 
RNAiMAX transfection reagent in the presence of HECTD1 siRNA, YBX1 siRNA, YBX3 siRNA 
or RNAiMAX alone (as a control) for 48 h. Clonogenic survival of cells was analysed following 
treatment with increasing doses of ionising radiation (0–4 Gy) (A, B, C). Shown is the surviving 
fraction with standard error of the mean from at least three independent experiments. SnF is 
shown as * p = <0.01 and ** p= <0.001. 
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It was found that a YBX1 knockdown had no effect on HeLa cell survival compared to the 
control, suggesting that YBX1 is not essential for the cellular response to IR (Figure 62A). In 
contrast, YBX3 knockdown did sensitise cells particularly following 2 Gy and 4 Gy x-ray 
irradiation. Using a one way ANOVA statistical test at 2 Gy compared to the control this was 
found to be significant (significance factor (SnF) p = < 0.001) and a 4 Gy (SnF p<0.01 (Figure 
62B). A HECTD1 knockdown also sensitised cells to IR, but was only statistically significant 
after 4 Gy x-ray irradiation (SnF p = <0.01) (Figure 62C). These results suggest that YBX3 is 
required for cell survival in response to IR, and predictably this effect is through modulating 
DNA damage repair. HECTD1 only appears to be controlling cell survival, and thus DNA 
damage repair, at high doses of radiation, suggesting that it could be having an effect on 
specific types of DNA damage or that there is a particular threshold for increased 
radiosensitivity. Therefore IR-induced DNA damage repair kinetics following these protein 
knockdowns was assessed in HeLa cells, but also normal lung fibroblasts, to see if there was 
any delay in DNA damage repair using the alkaline comet assay.  
 
5.4.4 Analysing IR-induced cellular DNA damage repair kinetics following knockdown 
of YBX1, YBX3 and HECTD1 
 
As YBX3 and HECTD1 (to some extent) appear to be required for HeLa cell survival following 
IR, we analysed whether this was caused by changes in DNA damage repair kinetics by 
utilising the alkaline single cell gel electrophoresis (comet) assay. The alkaline comet assay 
measures collectively DNA single strand breaks, double strand breaks and alkali labile sites. 
This was initially analysed in HeLa cells. In control cells (transfection reagent only), the 
majority of IR-induced DNA damage was repaired by 60-120 min post-irradiation, with a 
gradual decrease in % tail DNA observed from 10-60 min post-irradiation (Figure 63; blue 
bars). Following YBX3 siRNA, there appeared to be a delay in DNA damage repair, particularly 
at these later time points (60 and 120 min) and indeed after 120 min there a statistically 
significant difference in DNA damage levels compared to control transfected cells (p<0.05; 
Figure 63; green bars). Interestingly, there was also a significant increase in the basal levels 
of DNA damage in unirradiated cells following YBX3 knockdown in comparison to control 
transfected cells. A significant difference in DNA damage repair kinetics was also seen 
following HECTD1 siRNA, compared to control transfected cells, and particularly this was 
statistically significant at 120 min post-irradiation (p<0.01; Figure 63; yellow bars). However in 
the absence of HECTD1, there was no significant difference in the % tail DNA in unirradiated 
controls. These data suggest that both YBX3 and HECTD1 appear to play a role, albeit 
differing roles, in the repair of IR-induced DNA damage in HeLa cells. 
 
Since HeLa cells are cervical cancer cells, it was also interesting to examine whether YBX3 
and HECTD1 play a role in normal cells in response to DNA damage. Therefore normal human 
lung fibroblasts (AG06173) were used in a similar experiment. Similar to that observed with 
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HeLa cells, in control fibroblasts (transfection reagent only), the majority of IR-induced DNA 
damage was repaired by 60-120 min post-irradiation, with a gradual decrease observed from 
15-60 min post-irradiation (Figure 64; blue bars). Following YBX3 knockdown, there was a 
significant delay in DNA damage repair at all the time points investigated (15-120 min), 
suggesting that YBX3 is playing a critical role in the response to IR-induced DNA damage in 
normal cells (Figure 64; green bars). There was also defective DNA damage repair in the 
absence of HECTD1 in normal fibroblasts, although this was only significant at 30-120 min 
post-irradiation (Figure 64; yellow bars). It should also be noted that depletion of HECTD1 or 
YBX3 also caused a significant accumulation of DNA damage in the unirradiated controls. 
 
 
 
 
 
Figure 63; Analysing ionising radiation-induced DNA damage repair kinetics following 
siRNA knockdown of YBX1, YBX3 and HECTD1 in HeLa cells. HeLa cells were irradiated 
(1.5 Gy) and DNA single/double strand breaks and alkali labile sites measured at various time 
points post-irradiation (0-120 min) by the alkaline single cell gel electrophoresis (comet) assay. 
Shown is the % tail DNA with standard deviations from at least three independent 
experiments. *p<0.05 and **p<0.01, as analysed by a one sample t-test. 
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Figure 64; Analysing IR-induced DNA damage repair kinetics following siRNA 
knockdown of YBX1, YBX3 and HECTD1 in normal lung fibroblasts. Normal lung 
fibroblast cells (AG06173) were irradiated (1.5 Gy) and DNA single/double strand breaks and 
alkali labile sites measured at various time points post-irradiation (0-120 min) by the alkaline 
single cell gel electrophoresis (comet) assay. Shown is the % tail DNA with standard 
deviations from at least three independent experiments. *p<0.05, **p<0.01 and ***p<0.001, as 
analysed by a one sample t-test 
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5.5 Summary  
 
In Chapter 4, I revealed evidence suggesting that the increase in the activity of APE1 towards 
the THF-IN mononucleosome substrate caused by WCE was thought to be due to a E3 
ubiquitin ligase(s) or PARPs, as when factors were added to stimulate ubiquitination or 
poly(ADPribosyl)ation in the BER in vitro assay, the substrate showed increased incision. 
Ubiquitination was selected as the primary PTM to follow up due to the expertise of this 
laboratory and more importantly it’s heavy implication in chromatin remodelling during DSB 
repair and NER. To attempt to discover the potential E3 ubiquitin ligase(s) responsible for the 
increase of activity of APE1, two approaches were used. Initially a candidate approach was 
used, screening selected E3 ligases (11 in total) that are known to be involved in different 
types of DNA damage repair pathways. These E3 ligase(s) were knocked down using siRNA 
in HeLa cells, and WCE were then used in the BER in vitro repair assay with factors to support 
ubiquitination (and poly(ADP-ribosyl)ation) to assess APE1 activity towards the THF-IN 
mononucleosome substrate. It was found that there was no dramatic and significant difference 
in APE1 incision activity between the control and the siRNA knockdowns for MSL2, UBR2, 
RNF168, RNF20, DZIP3, CUL4A, CUL1, RNF2, RNF8, MULE and BRCA1 using either an 
extract titration or a reaction time course. Whilst the sensitivity of the assay could be 
questioned, and there appeared to some candidates that caused a minor reduction in the 
efficiency of THF incision (eg. UBR2, RNF168, DZIP3 and CUL1), arguably it appears as 
though these enzymes alone are not absolutely essential for the repair of the THF-IN 
mononucleosome substrate. Alternatively, there could be multiple overlapping activities which 
may be able to compensate for the lack of one of these enzymes. Therefore a different 
approach was used to identify potential E3 ubiquitin ligase(s) and/or chromatin remodellers 
that were stimulating APE1 incision activity towards the THF-IN mononucleosome substrate. 
A fractionation approach was used to purify and ultimately identify novel activities that 
stimulate APE1 activity towards the THF-IN mononucleosome substrate. This approach has 
been used successfully in Dr Parsons’ laboratory to identify E3 ubiquitin ligases that regulate 
the cellular levels of BER proteins, although this is the first time that this approach has been 
used in combination with mononucleosome substrates and the BER in vitro assay. This 
approach involves sequential chromatography of HeLa WCE over four separate 
chromatography columns. After each fractionation, protein fractions were analysed for APE1 
stimulatory activity on the THF-IN substrate which was above the basal activity of recombinant 
APE1 only, which was added to the BER in vitro assay. This sequential approach purifies the 
protein(s) responsible so that they can be easily identified by mass spectrometry. Firstly a 
Phosphocellulose column was used to separate HeLa WCE into two protein fractions; PC150 
and PC100 that largely contain non-DNA and DNA binding proteins, respectively. APE1 was 
then immunodepleted from these two fractions, and from the full HeLa WCE, as much as 
possible in order to remove any endogenous APE1 present that may elevate THF site incision. 
This was largely successful in the WCE and PC150 fractions, although the PC1000 fraction 
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still contained substantial amounts of APE1. Nevertheless, these cell extracts were then used 
in the BER in vitro assay with and without added recombinant APE1, which alone caused 
around ~20 % incision of the THF-IN mononucleosome substrate. This was the baseline value 
we set for examining any significant increases in THF site incision, therefore any difference 
above this value indicated that there were factors in the fraction that were stimulating APE1 
activity. The PC1000 fraction didn’t increase APE1 incision above this baseline value 
suggesting that this fraction lacked proteins that we have shown to stimulate APE1 incision 
activity towards the THF-IN mononucleosome substrate. The PC150 fraction however 
increased APE1 incision by ~40 % above this baseline value, indicating that there were factors 
in this fraction that made the THF site in THF-IN mononucleosome more accessible to APE1. 
Predictably these were thought to be E3 ubiquitin ligase(s) and/or chromatin remodellers, that 
were increasing the incision activity of APE1 towards this substrate, as originally the WCE 
activity was found to be highly dependent on ubiquitination. As the PC150 fraction contained 
APE1 stimulating activity this fraction was further separated by sequential chromatography.  
In the second chromatography step, which used an ion exchange (Mono Q) column, 
surprisingly three novel APE1 stimulatory activities were identified which increased APE1 
incision of the THF-IN mononucleosome substrate above the baseline value. As previously, 
the BER in vitro assay was used with factors to stimulate ubiquitination and poly(ADP-
ribosyl)ation. Residual, endogenous APE1 protein was identified in the fractions from the 
Mono Q column, however this did overlap with any of the three identified, major activities. 
Fractions for the three separate activities were pooled and purified over another two columns; 
gel filtration (Superdex 200) and a final ion exchange (Mono Q) column separately using the 
same approach as before to identify active fractions. The most active fraction after the final 
ion exchange fractionation was analysed by mass spectrometry to identify candidate E3 
ligases and/or chromatin remodelling complexes that were potentially stimulating APE1 
activity by changing the structure of the mononucleosome to make the THF site in THF-IN 
mononucleosome more accessible to APE1. Mass spectrometry identified several candidate 
proteins; activity 1 HECTD1 and CHIP, activity 2, MULE and DDB1 and activity 3 YBX1 and 
YBX3.  
For activity 1, the presence of CHIP protein in the fractions did not appear to align well with 
the initial ion exchange activity profile of APE1 stimulation on THF-IN, however HECTD1 
showed a strong alignment and this was shown throughout all activity profiles for each of the 
chromatography steps. As HECTD1 is an E3 ubiquitin ligase, the most active fraction from the 
final chromatography step was analysed for its dependence on ubiquitination by removing 
factors (E1/E2 enzymes) that supported ubiquitination. When these factors were removed, the 
activity of APE1 incision of the THF-IN mononucleosome substrate decreased, giving more 
evidence and confidence that this novel APE1 stimulating activity was accomplished by 
HECTD1. For activity 2, MULE and DDB1 showed only some degree of alignment towards the 
activity for each of the fractionation steps. CUL4A which is known to for multiple E3 ligase 
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complexes with DDB1, was also analysed at the final ion exchange (Mono Q) stage and 
indeed aligned with DDB1, and again to some degree with the APE1 stimulatory activity profile 
for THF-IN. However, the most active fraction from the final ion exchange chromatography 
was found to be not dependent on ubiquitination, suggesting that this novel activity was not 
caused by MULE or DDB1, so this activity was not analysed further at this stage. For activity 
3, the Y-box proteins YBX1 and YBX3 were found in high abundance in the fractions and 
again these proteins appeared to align, to some degree, with the APE1 stimulatory activity 
profile for THF-IN all the subsequent chromatography steps. Interestingly this activity was 
found to be dependent on ubiquitination, and whilst YBX1 and/or YBX3 have no known E3 
ubiquitin ligase activity, this suggested that these proteins could be facilitating an E3 ubiquitin 
ligase present in the fraction to stimulate APE1 activity towards the THF-IN mononucleosome 
substrate. However, no E3 ubiquitin ligases were discovered to be present in these active 
fractions by mass spectrometry. 
Since HECTD1, YBX3 and YBX1 proteins appeared to be good follow up candidates from the 
fractionation strategy, it was decided to examine their effect on cell survival and DNA damage 
repair kinetics in response to IR. If these candidate proteins were stimulating APE1 activity by 
histone modifications and/or chromatin remodelling, it can be expected that cells would be 
unable to repair occluded DNA damage sites, and that DNA damage persistence could cause 
cell sensitivity to IR. Following YBX3 siRNA in HeLa cells, it was discovered that there was 
significantly reduced cell survival at 2 Gy and 4 Gy doses of IR. HECTD1 siRNA, however, 
only appeared to significantly affect cell survival at the highest dose used (4 Gy). These data 
would suggest that both YBX3, and to some extent HECTD1, play roles in controlling cell 
survival in response to IR. The roles of these proteins specifically in DNA damage repair in 
HeLa cells was discovered by a delay in IR-induced DNA damage repair as visualised by the 
comet assay, compared to the untransfected control, largely at later times (60 and 120 min) 
post-irradiation. This delay in repair would appear to correlate with increased sensitivity of 
cells in the absence of YBX3 and HECTD1 following irradiation. Lastly since HeLa cells were 
used for analysis, which are cervical cancer cells, I also acquired exploratory data examining 
the role of HECTD1 and YBX3 in DNA damage repair in normal human lung fibroblasts. An 
siRNA knockdown of either YBX3 and HECTD1 also reduced IR-induced DNA damage repair 
kinetics in normal fibroblasts compared to the untransfected control, at several time points 
post-irradiation. This suggests that HECTD1 and YBX3 not only play a role in HeLa (cancer) 
cells, but are also essential proteins in normal cells required in the cellular response to IR-
induced DNA damage. 
In summary, both HECTD1 and YBX3 identified in this study appear to be strong candidates 
required for BER, which I predict is catalysed through histone ubiquitination and chromatin 
remodelling. I propose that these proteins make sterically occluded DNA damage (eg. AP 
sites) more accessible to BER proteins (eg. APE1) and thus facilitate efficient DNA damage 
repair. 
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CHAPTER VI 
 
DISCUSSION 
 
 
6.1 Overview 
 
 
Damage to DNA occurs frequently through endogenous sources such as normal cellular 
metabolism and exogenous sources so it is important that cells repair the damage to maintain 
genome stability. Indeed it is thought that around 10,000 DNA base lesions are generated in 
every cell per day from ROS from cellular metabolism. BER is highly conserved and is 
essential for the repair of the majority of endogenous DNA base damages to maintain genome 
integrity. If DNA base damages are not repaired the integrity of the genome can be 
compromised, stalling replication and transcription which can lead to diseases including 
cancer, premature aging and neurodegeneration (5, 6). This highlights the importance of 
increasing our understanding of the response and repair of DNA lesions which are processed 
by BER, as proteins associated with the repair pathway can be potentially harnessed to 
produce new therapies for diseases such as cancer. A good example of this is the use of 
inhibitors targeting PARP-1 for the treatment of BRCA-deficient tumours. It is therefore of 
interest to discover novel proteins involved in chromatin remodelling during BER as it is a 
source of potential therapeutic targets to treat human diseases. 
 
DNA in cells is packaged tightly into chromatin, generated in a vast array of loops and coils in 
a co-ordinated manner. Chromatin is arranged and regulated so that DNA can still be 
accessed by proteins for important biological processes, including transcription, replication 
and repair. Chromatin at its most basic level is organised of nucleosomes which link together 
to form nucleosome arrays. Nucleosomes consist of two copies of each of histone H2A, H2B, 
H3 and H4 forming the histone octamer and approximately 147 bp genomic DNA is wrapped 
around the octamer (16). Nucleosome arrays are packed together to form the chromatin fibre, 
which are coiled and looped into increasingly higher orders of chromatin with the assistance 
chromatin regulator proteins to form chromosomes (106). 
 
Chromatin and nucleosomes form an obstruction to proteins required for important biological 
processes requiring access to genomic DNA, depending on the DNA to nucleosome interface. 
This is overcome by the dynamic properties of histones, and are regulated in such a way to 
either stimulate or repress biological processes. Histones have N-terminal tails which protrude 
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out of the nucleosome and specific residues can be modified through PTMs including 
acetylation, poly(ADPribosyl)ation, ubiquitination, methylation and phosphorylation. These 
can alter the chromatin structure in a number of ways including; manipulating the electrostatic 
interactions between the DNA and the histone octamer, disturbing protein-protein and protein-
DNA interactions, histone exchange and causing the recruitment of ATP-dependent chromatin 
remodelling complexes (106-108, 127). These alterations on histones can ultimately lead to 
chromatin condensation and so sterically obstructed sequences of DNA can be accessed by 
proteins in order for biological processes can take place (107). Fluctuations in chromatin 
structure is essential in the DNA damage response to regulate checkpoint signalling and DNA 
repair and therefore to maintain genome integrity. DNA repair proteins must be able to access 
DNA lesions so repair can take place regardless of the location within chromatin. Evidence for 
chromatin remodelling in DNA repair is increasing, although in contrast to BER, at this time 
chromatin remodelling has generally been connected to DSB (HR and NHEJ) and NER (174). 
Histone modifications and chromatin remodelling in response to damaged DNA bases to 
facilitate BER is poorly understood. Chromatin remodelling is thought to be necessary based 
on evidence from mononucleosome substrates which have been utilised in several published 
studies. These substrates have shown that BER enzymes are significantly less efficient at 
sites where the base lesion is sterically occluded, with the DNA backbone facing towards the 
core of the histone octamer or located close to the dyad axis of the nucleosome. In contrast, 
base lesion sites that are away from the dyad axis and the DNA backbone is orientated so it 
faces outwards are efficiently processed by BER enzymes. To maintain genome integrity, 
sterically occluded base lesions must be repaired suggesting that chromatin relaxation events 
need to take place to slide, unwind or remove histones so that base lesions are accessible for 
repair (16, 242, 252, 254, 256, 257, 284, 285). The precise mechanisms by which these 
occluded sites are regulated to facilitate BER enzymes are currently largely unknown. 
 
The study presented in this thesis using mononucleosome substrates, aimed to identify 
specific histone modifiers and/or the chromatin remodellers that are involved in the processing 
of DNA base damage during BER. The results show that the sterically occluded THF-IN site 
can be more efficiently processed by APE1 present in HeLa WCE in largely a ubiquitination-
dependent event, predictably by a E3 ligase, but not by recombinant APE1 only. This is 
thought to be by causing a structural change in the mononucleosome through histone PTMs 
or causing the recruitment of ATP-dependent chromatin remodelling complexes. A sequential 
chromatography approach of proteins purified from HeLa WCE was used to purify and identify 
the E3 ubiquitin ligase HECTD1, and the DNA binding protein YBX3, in active fractions that 
stimulated THF-IN incision by APE1. I found that depletion of these proteins in HeLa cells and 
in normal human lung fibroblasts (AG06173) delayed DNA damage repair following IR. 
Furthermore, depletion of HECTD1 and YBX3 in HeLa cells sensitised cells to IR. Therefore I 
hypothesise that both YBX3 and HECTD1 appear to be strong candidates required for 
improving the efficiency of BER through histone ubiquitination and/or chromatin remodelling.  
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6.2 Mononucleosomes as substrates for BER  
 
Several published studies have used mononucleosomes to monitor the repair of differently 
orientated base lesions and intermediates by purified BER enzymes. It has been well 
established and documented from these investigations that base lesions located near the dyad 
axis and/or orientated so the backbone is facing towards the histone core cause a significant 
decrease in the efficiency of repair by purified BER enzymes (16, 242, 252, 254, 256, 257, 
284, 285). However, the efficiency of repair of these substrates by BER proteins present within 
cell extracts, which contain histone modifiers and chromatin remodellers, has not previously 
been reported in such detail. Therefore, I uniquely used mononucleosome substrates to 
examine any possible effect of histone modification enzymes present in WCE in facilitating 
APE1 activity at sterically occluded THF sites, in comparison to recombinant APE1 only, with 
the eventual goal of purifying and identifying these enzymes. Two mononucleosome 
substrates were designed containing THF in two different site-specific regions; THF-OUT at 
+12 and THF-IN +11 from the nucleosome dyad, in order to investigate this. The orientation 
of the THF when reconstituted to form the mononucleosome was determined from the crystal 
structure of the Widom 601 nucleosome positioning sequence and from previously published 
work (242). The Widom 601 nucleosome sequence was selected for its near identical 
orientation when reconstituted in a nucleosome compared to human DNA and has strong 
nucleosome affinity properties (247). This is a standard sequence for use when reconstituting 
nucleosomes and has been used by previous studies examining BER enzymes in 
mononucleosomes (242, 257, 271). A THF was used as an alternative to an AP-site as it is 
significantly more stable, and exhibits virtually no difference in APE1 activity compared to AP-
sites generated by glycosylases (254). The method in which the two site specific THFs were 
introduced into the Widom 601 nucleosome positioning has been previously reported (257), 
involving cloning of duplex oligonucleotides containing THF into the 601 sequence. However, 
we modified this methodology by utilising IRDye700 or IRDye800 primers to generate 
fluorescently labelled DNA which could be accurately detected and quantified using the 
Odyssey Image Analysis System. Other similar studies utilise radiolabelling to visualise DNA 
in this context, and so this is the first study to use fluorescently tagged primers to study BER 
enzyme activities in a mononucleosome context, providing a safer alternative which can be 
easily and reliably quantified. Following PCR cloning, the substrates were bound with Xenopus 
Laevis recombinant histone octamer, which are commonly used as they can be easily 
expressed in bacterial systems to high purity and are highly homologous to human histones 
(245, 246). Each histone was firstly overexpressed in E.coli, purified from inclusion bodies by 
gel filtration and ion exchange chromatography (under denaturing conditions) and refolded to 
form the histone octamer, as previously shown (246). The THF-OUT and THF- IN 
mononucleosome substrates were prepared using a 1:1 ratio of substrate DNA and histone 
octamer to achieve optimum reconstitution. The optimised methodology described in this 
thesis can be used in the future to study a variety of different BER steps (eg. DNA glycosylase 
excision of damaged DNA bases and Polβ gap filling activity) and so has the potential to 
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investigate if there are different chromatin modifications taking place to facilitate independent 
activities of BER enzymes. 
 
Before analysing the incision of the THF mononucleosome substrates by recombinant APE1 
versus WCE, it was important to examine whether there was any sequence bias towards to 
the two different THF-sites in free DNA. There was a slight bias towards free DNA of THF-
OUT compared to THF-IN, the difference however was very minimal. This bias was thought 
to be because of the sequence context of THF-site. The THF-site for THF-IN has CG either 
side, whereas THF-OUT has CG and TA either side. CG rich regions because of the 
presence of three hydrogen bonds are more stable than AT regions which have two and so 
this maybe having an impact on the slight bias towards to THF-OUT in free DNA. This minimal 
difference in sequence bias by APE1 has been reported previously (286). The same BER in 
vitro assay was expanded to incorporate the THF-OUT and THF-IN mononucleosome 
substrates. As previously mentioned, mononucleosome substrates have been used 
successfully in number of published studies to analyse the activity of BER enzymes to 
numerous lesions at different translational and rotational positions (242, 254, 257). Using 
mononucleosome substrates do have their limitations as they are just a single nucleosome 
and so lack the full chromatin structure which may produce different histone dynamics and 
chromatin remodelling activity. They are however a much better substrate than just using free 
DNA alone, which would not give any insight into nucleosome dynamics during DNA repair. 
There has been progression of the mononucleosome to dinucleosomes containing linker DNA 
and H1 in a recent study examining 8-oxo-G removal (252). Furthermore in the future, there 
could be more complex chromatin structures created, such as vast nucleosome arrays or 
chromatin fibres, however at this stage mononucleosome substrates appear to be the best 
models for investigating nucleosome dynamics during BER.  
 
 
6.3 APE1 in HeLa WCE can efficiently incise THF-IN  
 
I discovered that recombinant APE1 activity was significantly impeded to the sterically 
occluded THF site in THF-IN compared the THF site in THF-OUT which (as expected) was 
efficiently processed by APE1 (~3-fold difference in incision) as seen in previous studies (254). 
The same was result was initially found using HeLa WCE, which we hypothesised that histone 
modifiers and/or chromatin remodellers would make this site more accessible to APE1, 
facilitating its activity. However, largely because of the short amount of time THF-IN was 
incubated with HeLa WCE (10 mins) but also the requirement of additional factors necessary 
to stimulate any possible remodelling event due to very low concentration of HeLa WCE used, 
it was decided that the BER in vitro assay would be revised. Initially by increasing the length 
of time THF-IN was incubated with HeLa WCE, this had no dramatic effect on APE1 activity, 
suggesting that time (partially) was not a contributing factor to the lack of any potential 
chromatin remodelling activity. Ubiquitination is a strong area of interest in this laboratory, but 
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more importantly ubiquitination of histones has been shown to be a vital event in the DDR in 
DSB repair and NER further strengthening the interest to investigate this PTM event (196, 
204, 273, 287, 288). I discovered that the presence of supplementary ubiquitin in the BER in 
vitro reaction using a time course experiment significantly increased APE1 activity in HeLa 
WCE towards THF-IN. This indicated that a ubiquitination-dependent process could be taking 
place which is increasing the accessibility of the THF site to APE1. This was thought to be 
due to a partial unwrapping event as the mononucleosome structure itself was found to remain 
intact following gel analysis. Additional ubiquitin had no effect on the activity of recombinant 
APE1 alone towards the free DNA substrates, or of WCE for the THF site in THF-OUT, 
suggesting that this stimulatory effect is specifically required for accessing THF-IN. It also 
rules out the possibility that APE1 itself was undergoing ubiquitination thus increasing its 
activity, and the specificity to increase APE1 activity in HeLa WCE towards THF-IN and not 
THF-OUT suggested that histones were being ubiquitinated facilitating access of APE1 to 
THF-IN. A trial experiment was performed to analyse the optimum conditions for the BER in 
vitro assay, maximising THF-IN incision. I discovered that the combined addition of NAD 
required for poly(ADP-ribosyl)ation and all factors required for ubiquitination (ubiquitin, E1/E2 
enzymes) produce a significant increase in incision by APE1 in HeLa WCE in the THF-IN 
mononucleosome substrate. Of note, although ATP supporting phosphorylation events with 
the addition of PC and PCK to regenerate ATP had no additive effect on APE1 activity in 
combination with ubiquitination supporting factors, these factors alone did produce a mild 
increase in THF-IN mononucleosome incision. This suggested that a phosphorylation event 
may play a minor role in facilitating APE1 activity. Subsequently in a full time course 
experiment using the BER in vitro assay with factors added to stimulate ubiquitination 
(ubiquitin, E1/E2 enzymes), the degree of THF-IN incision by APE1 present in HeLa WCE 
increased to almost the same efficiency as cleavage of the THF-OUT mononucleosome 
substrate. On comparison of recombinant APE1 alone and in HeLa WCE, these additional 
factors caused an approximate 4-fold increase in incision of THF-IN by APE1 in HeLa WCE. 
On the other hand THF-OUT was incised to a similar degree using the same concentrations 
of APE1 alone and in HeLa WCE. 
 
My data therefore strongly indicate novel evidence that additional supporting factors 
stimulating ubiquitination and poly(ADP-ribosyl)ation events cause the THF site in THF-IN to 
become more accessible to APE1 in HeLa WCE. Whilst the importance of poly(ADP-
ribosyl)ation (predictably via PARP-1) cannot be dismissed, the fact that stimulatory activity 
was largely observed with ubiquitin only suggested that potentially an E3 ubiquitin ligase is 
capable of ubiquitinating histones and either causing a structural change in the 
mononucleosome structure or is actively recruiting an ATP-dependent chromatin remodeller 
making the THF site in THF-IN more accessible to APE1. As mentioned above, I found no 
evidence that a total unwrapping of DNA from the histone octamer was being induced since 
the mononucleosome structure remained intact following gel analysis, and would appear to 
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suggest that a partial unwrapping event is taking place. Nevertheless, to our knowledge, this 
is the first evidence suggesting that BER of sterically occluded DNA damage sites in a 
chromatin model are stimulated by ubiquitination.  
 
This finding that BER can be stimulated to sterically occluded site by ubiquitination relates to 
other work in the DNA repair field, particularly related to DSB repair and NER. For example, 
H2AK119 and H2AK120 monoubiquitylation by the Polycomb E3 ligase complex BMI1–
RING1B has been shown to be important for efficient DSB repair (273). RNF8, which 
accumulates at DSBs, monoubiquitinates H2A and H2AX which then catalyses the K63-linked 
ubiquitin chains with UBC1, that interact with MDC1 to recruit this protein to DNA damage 
sites (198). This monoubiquitination of histones causes the recruitment of RNF168 to initiate 
H2A/H2AX K13 and K15-dependent polyubiquitination. The ubiquitination of histones allows 
the recruitment of 53BP1 and BRCA1 by altering chromatin accessibility, so facilitating 53BP1 
loading (199). In NER although the exact ubiquitination sites of H2A, H3 and H4 have yet to 
be identified, their ubiquitination by CUL4-DDB-ROC1 ubiquitin ligase destabilises 
nucleosomes, facilitating the release of DDB2/XPE and may also enable NER proteins to 
access lesions (289, 290).  In this context, BER stimulation at occluded DNA damage sites by 
ubiquitination could be increasing the accessibility of BER proteins to the lesions, and so 
increasing their activity (241). To examine this in more detail, we could study histone 
ubiquitination directly by using mononucleosome substrates in the in vitro BER assay and 
examining common histone ubiquitination sites (e.g. H2A K13, K15 or K119 and H2B K120) 
by western blotting. We could mutate specific residues in histones which form 
mononucleosomes such as a K to R to observe if there is any observed lack of stimulation of 
APE1 activity to incise the THF-site in THF-IN which would show that if this site specific 
ubiquitination is required.  
 
There is evidence for nucleosome unwrapping during DNA repair, particularly during NER and 
DSB repair. A study has shown that UV photoproducts enhanced the unwrapping of the DNA 
from histones increasing the exposure of DNA lesions to NER proteins (291). To allow protein 
access to DSBs, it has been suggested that the p400 SWi/SNF ATPase and histone 
acetylation by Tip60 destabilises nucleosomes causing a reduction in nucleosome array 
packing causing a more open conformation (292). RAD51 nucleoprotein filament during HR 
has also been shown to cause the unwrapping of DNA from core histones through ATP-
hydrolysis (293). Specifically related to BER it has been suggested, although not proven in 
detail, that the repair of 8-oxo-G lesions by OGG1 in BER is stimulated by SWI/SNF by either 
chromatin remodelling or sliding to allow for efficient repair (259). Another study analysing the 
same lesion in a dinucleosome found that removal of H1 by NAP-1 allowed for the complete 
remodelling of dinucleosomes by RSC for efficient removal of 8-oxo-G (252). FACT and RSC 
are also thought to act in concert to facilitate BER, their presence increased nucleosome 
mobility (sliding) to increase excision of DNA lesions. In this study nucleosome mobility was 
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measured using native PAGE to measure centrally and end-positioned nucleosomes (241). 
Therefore it would be interesting to use a similar approach to examine whether there is any 
nucleosome sliding in our experimental system utilising THF-IN and HeLa WCE. 
 
 
6.4 HECTD1 and YBX3 are possible candidates for chromatin modelling activity to 
facilitate BER 
 
Since I discovered that the activity of APE1 in HeLa WCE towards the THF-IN 
mononucleosome substrate was being stimulated by ubiquitination, I began the search for an 
E3 ubiquitin ligase capable of performing this role. Initially, an siRNA screening approach was 
utilised whereby eleven E3 ubiquitin ligase enzymes known to catalyse histone ubiquitination 
were individually depleted in HeLa cells and WCE prepared. These WCE were then analysed 
in the presence of ubiquitination and poly(ADP-ribosyl)ation stimulating factors for their ability 
to efficiently process THF-IN. Predictably, depletion of the specific E3 ubiquitin ligase for this 
substrate would reduce the ability of APE1 to incise THF-IN, however this candidate approach 
showed no difference in THF-IN incision by APE1. This could mean either two results. Either 
these specific E3 ubiquitin ligases are not implicated in chromatin remodelling of THF-IN and 
necessary for APE1 activity, or that there are many overlapping activities to compensate for 
the lack of one of these enzymes. Therefore a different strategy was employed using a 
fractionation approach that has been successfully utilised on a number of occasions to identify 
E3 ubiquitin ligases that regulate cellular levels of BER enzymes in this laboratory (267, 272, 
282, 283). However, for the first time, this approach was used in combination with 
mononucleosomes and the BER in vitro assay. Therefore proteins from HeLa WCE were 
sequentially fractionated over four separate chromatography columns, and after each 
fractionation step, fractions were individually analysed using the BER in vitro assay 
incorporating THF-IN to identify activities stimulating the basal activity of recombinant APE1 
only (which was added to all fractions). As in the siRNA screening above, factors supporting 
ubiquitination and poly(ADP-ribosyl)ation were added in order to maximise THF-IN incision. 
The PC150 fraction, containing largely non-DNA binding proteins, was able to increase the 
basal level of incision activity of recombinant APE1 against the THF-IN mononucleosome 
using the BER in vitro assay. The PC150 fraction was further fractionated by ion-exchange 
chromatography which identified three separate activities stimulating APE1 incision of THF-
IN, above the basal level of recombinant APE1 only. These three activities were individually 
purified over two further chromatography columns (gel filtration and ion exchange) again to 
identify active fractions towards THF-IN. Following completion of this process, mass 
spectrometry analysis of the most active fraction from each of the purifications the last stage 
of the fractionation was performed and a list of proteins present were generated. Since activity 
of APE1 in HeLa WCE towards THF-IN was largely ubiquitin-dependent, we particularly 
focussed on known E3 ubiquitin ligases with high mascot scores present in the respective 
activities. Active fractions were then probed by Western blotting using antibodies against the 
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candidate proteins, to examine their alignment with the activity profiles for each of the 
fractionation stages. The E3 ubiquitin ligase scaffold proteins CUL4A and DDB1 showed some 
degree of alignment to the activity profiles of APE1 activity towards THF-IN from activity 2. 
However, it was discovered that the stimulatory activity of APE1 towards THF-IN using purified 
fractions from this activity was actually not dependent on the presence of ubiquitination 
factors, suggesting another mechanism was taking place to make THF-IN more accessible. 
At this point, this particular activity was not followed any further. The E3 ubiquitin ligase 
HECTD1 showed a strong alignment to activity 1 profiles for each fractionation step, and 
furthermore the most active fraction from the final chromatography step was found to be 
dependent on ubiquitination factors in simulating APE1 activity towards the THF-IN 
mononucleosome. The mass spectrometry results for activity three did not identify any E3 
ligases. However, Y-Box proteins YBX1 and YBX3 were found to be in high abundance and 
the proteins aligned to some degree to the activity 3 profiles of APE1 stimulatory activity in all 
chromatography steps. Surprisingly, this activity was also found to be dependent on 
ubiquitination, although YBX1 and YBX3 have no known E3 ligase activity.  
 
HECTD1, YBX1 and YBX3 proteins were therefore examined further for their effect on cellular 
survival and DNA damage repair kinetics using clonogenic assays and alkaline comet assays, 
respectively. If these proteins were stimulating APE1 accessibility to AP sites by histone 
modifications and/or chromatin remodelling, it can be expected that cells would not be able to 
repair particularly sterically occluded DNA damage sites, and that their persistence may cause 
sensitivity to DNA damaging agents. These proteins were therefore depleted using siRNA in 
HeLa cells but also in normal lung fibroblasts (AG06173). An siRNA knockdown of either 
HECTD1 and YBX3 (but not YBX1) in normal lung fibroblasts caused a significant delay in the 
repair of SSB and alkali-labile sites following ionising radiation. Interestingly in HeLa cells, a 
lack of HECTD1 and YBX3 only caused a significant difference in the levels of SSB and alkali 
labile sites at later time points post-irradiation compared to the control. I also demonstrated 
that siRNA knockdown of HECTD1, and more so YBX3, caused reduced survival of HeLa 
cells following IR treatment, whereas YBX1 knockdown however had no effect on cell survival 
following IR. Whilst the observed differences in responses between cancer cells and normal 
cells are interesting but require further investigation, but indicates that there are either AP sites 
being formed directly, or formed during the processing of damaged DNA bases, that are 
persistent in cells that don’t contain HECTD1 or YBX3. However whether there are still 
residual damaged DNA bases in more sterically occluded sites within the chromatin that 
haven’t been processed at the later time points, and which are not revealed by the alkaline 
comet assay, is at this stage unknown. This could be investigated using enzyme modified 
comet assays, whereby following cell lysis, the DNA is treated with recombinant DNA repair 
enzymes that incises any residual DNA damage thus creating additional strand breaks that 
can be observed following electrophoresis. Consequently, our data would suggest that 
HECTD1 and YBX3 play an important role in the cellular response to DNA damage following 
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IR induced DNA damage, through modulating the efficiency of BER. I predict that these 
proteins play a role in catalysing BER through histone ubiquitination and chromatin 
remodelling causing sterically occluded sites to become more assessable to BER proteins to 
facilitate efficient DNA damage repair. 
 
YBX1 and YBX3 are Y-box proteins of the cold shock family which are involved in 
transcriptional and translational control. They are predominantly located in the cytoplasm, but 
are expected to localise to the nucleus due to their role in transcription. YBX1 has been the 
most extensively studied and has been found to be involved in the transcription of several 
important genes involved in tumour development (294, 295). YBX1 has also be found to 
protect cells against DNA damaging agents and may have an additional function in DNA repair 
as its truncated form complexes with the MRN complex proteins Mre11 and RAD50 following 
genotoxic stress (296). APE1 specifically has been shown to stably interact with YBX1 to 
increase drug resistance via the regulatory function of acetylated APE1 causing multidrug 
resistance gene (MDR1)-mediated drug resistance. YBX1 has also been shown inhibit AP site 
incision by NEIL1 and APE1 on single stranded DNA, suggesting YBX1 has a direct interaction 
with AP sites (297, 298). The association of YBX1 with APE1, NEIL1 and DNA repair suggests 
that it may be a promising candidate in facilitating APE1 activity towards the THF-IN 
mononucleosome. However, I observed that a YBX1 knockdown did not affect cell survival 
following IR, which would appear to suggest that YBX1 is not involved in increasing 
accessibility to AP sites by histone modifications and/or chromatin remodelling. Nevertheless, 
the role of YBX1 in BER does require further experimentation. 
 
YBX3 has been shown to be a repressor of some growth factors promoter, such are the GM 
PSF promoter and is important for metazoan development and fertility (294, 299). I propose 
that YBX3 is either directly or indirectly affecting the accessibility of BER proteins to occluded 
DNA lesions processed by BER. YBX3 knockdown sensitised cells to IR and delayed repair 
kinetics suggesting its involvement in facilitating BER through histone modifications and/or 
chromatin remodelling. YBX3 has no known E3 ubiquitin ligase activity so it is unlikely that 
YBX3 is ubiquitinating histones alone, but as it is a known transcription factor, it may be 
upregulating the expression of an unknown E3 ubiquitin ligase. YBX3 could also be a novel 
chromatin remodeller, binding to DNA associated with the nucleosome an increasing AP site 
accessibility to APE1. Therefore further studies to establish the impact of YBX3 on 
mononucleosome structure and function during BER are necessary. 
 
The E3 ubiquitin ligase HECTD1 has not been associated with any DNA repair pathway in 
published studies and doesn’t appear to be extensively studied. HECTD1 is required for the 
development of head mesenchyme and neural tube closure and is involved in the 
polyubiquitination of adenomatous polyposis coli (APC) to promote APC-Axin interaction to 
down regulate the Wnt signalling pathway (300, 301). As an active E3 ubiquitin ligase, I now 
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propose that HECTD1 may also ubiquitinate histones required for increasing accessibility of 
DNA base damage during BER. As HECTD1 knockdown both increased cell sensitivity 
towards IR and delayed repair kinetics this makes it a promising candidate for involvement in 
increasing the accessibility of AP sites to APE1, and possibly other BER lesions which have 
not been analysed. If HECTD1 is ubiquitinating histones directly, then this change itself may 
influence histone-histone and/or histone-DNA interactions, making occluded sites more 
accessible. It is also conceivable that HECTD1 may be in association with a chromatin 
remodeller, and therefore ubiquitination of histones could be allowing binding and stimulating 
activity of a chromatin remodeller. However, a chromatin remodeller was not identified in 
active protein fractions purified from HeLa extracts by mass spectrometry. 
 
It is important to highlight that HECTD1 is frequently mutated, deleted and amplified in a wide 
range of cancers. For example it is commonly mutated in prostate cancer, bladder cancer and 
small lung cell carcinoma and amplified in lung adenocarcinoma. YBX3 is also mutated, 
deleted and amplified in a range of cancers, including lung adenocarcinoma and ovarian 
cancers. This suggests that both HECTD1 and YBX3 are import for genome stability and thus 
in the prevention of disease, and I now predict that this could be through controlling BER. 
Whilst there is obviously a large amount of research which needs to be completed to support 
our work, this also further supports the advantage of targeting HECTD1 and YBX3 as a 
therapy for cancer treatment in conjunction with IR (302, 303). 
 
6.5 Future Work 
 
The identification of HECTD1 and YBX3 as candidates for histone modifiers and chromatin 
remodellers to facilitate BER at occluded base damage sites needs further confirmation but 
also that the precise mechanism that they achieve this is currently unknown. In order to 
validate this observation, HECTD1 and YBX3 could be overexpressed and purified from E.coli 
and then the proteins examined in the in vitro BER assay with the THF-IN substrate to confirm 
that they are able to stimulate incision by APE1. It would be interesting to see whether these 
proteins, or active fractions containing these two proteins, also affected incision of THF-OUT 
by APE1. We would expect that the incision of the site would remain similar as histone 
modification or chromatin remodelling activity at this site is not needed for effective APE1 
activity. If processing of this site by APE1 increased then this may suggest that these proteins 
were increasing activity another way, possibly through altered regulation of APE1, but may 
also indicate that these proteins may have an impact on APE1 activity globally throughout the 
genome. However this would seem unlikely based on the observed lack of difference of HeLa 
WCE with and without the ubiquitination and poly(ADP-ribosyl)ation supporting factors have 
on APE1 activity on THF-OUT. I have further shown that knockdown of HECTD1 and YBX3 
delays IR-induced DNA damage repair kinetics in HeLa and AG06173 cells, presumably 
through decreased processing of occluded DNA damage sites, and also lead to increased 
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radiosensitivity of HeLa cells. It would be interesting to establish if these proteins when 
overexpressed in cells cause the opposite effect by increasing DNA damage repair kinetics 
and increasing resistance to IR, which would further validate their role in modulating BER in 
cultured cells. Therefore HECTD1 and YBX3 require cloning into mammalian expression 
plasmids in order to be able to achieve these experiments. As an extension of these 
experiments, it would be interesting to examine by immunofluorescence microscopy whether 
HECTD1 and YBX3 localise to the nucleus following IR- induced DNA damage, as these 
proteins are thought to reside in the cytoplasm, and potentially whether they form discrete foci 
in the nucleus would be an indicator that they were interacting with DNA damage sites in 
histones. 
 
The mechanism in which HECTD1 and YBX3 are functioning needs to be identified. As 
indicated above, recombinant HECTD1 and YBX3 could be overexpressed in E.Coli and then 
added to the BER in vitro assays with THF-IN to confirm increased activity of recombinant 
APE1 on this site, but also the histones themselves could examined in detail. Firstly the 
histones could be extracted and then analysed by Western blotting to determine whether they 
are ubiquitinated directly, particularly by HECTD1. This could be achieved by either using 
antibodies against specific histone ubiquitination sites (eg. H2B lysine 120, H2A lysine K13, 
K15, 119) or by using antibodies against the unmodified histones and examining whether there 
is any protein shift (eg. 8 kDa) equivalent to ubiquitination. Secondly, and as highlighted 
above, a recent study has looked at nucleosome mobilisation efficiency to quantify 
nucleosome sliding (241). It would therefore also be interesting to see if these two candidate 
proteins, YBX3 and HECTD1, in active fractions or as purified proteins are able to induce 
nucleosome sliding as determined by gel analysis which is then providing increased 
accessibility of recombinant APE1 to THF-IN. If recombinant HECTD1 and YBX3 are unable 
to recapitulate our findings of stimulating APE1 to THF-IN in vitro, then further investigations 
into these proteins will have to be undertaken. It is possible that these proteins may require 
post-translational modifications or accessory proteins for histone modification and/or 
chromatin remodelling activity. If this is the case, then the proteins could be overexpressed 
and purified from cultured human cells (or insect cells) and then their activity re-examined, but 
also the interactions of these will other cellular proteins could be determined by mass 
spectrometry analysis. One final point to examine is the possible specificity of HECTD1 and 
YBX3 for stimulating BER in vitro. Whilst I have demonstrated that active fractions containing 
these proteins stimulate APE1 activity on a THF site, it would be interesting to test whether 
this is similarly observed using other BER substrate and protein combinations. For example, 
the activity of specific DNA glycosylases on DNA base damage (eg. OGG1 on 8-oxoG; NTH1 
on thymine glycol), Pol  activity on a single nucleotide gap, and XRCC1-Lig III activity on a 
nicked mononucleosome substrate could be determined.  
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6.6 Concluding remarks 
 
A method was successfully developed and established to produce mononucleosome 
substrates with differently orientated THF sites. I demonstrated that recombinant APE1 activity 
is significantly impeded to the THF site in THF-IN, but efficiently processed the THF-OUT, but 
that APE1 in HeLa WCE with factors supporting ubiquitination and poly(ADP-ribosyl)ation was 
able to efficiently process the THF site in both THF-IN and THF-OUT. Using a fractionation 
approach, I discovered three novel activities to stimulate THF incision of THF-IN through what 
we predicted to be a histone modification and/or chromatin remodelling event. Two candidate 
proteins, HECTD1 and YBX3, were identified in these activity fractions by mass spectrometry 
and further shown to control cellular DNA damage repair kinetics and cell survival following 
ionising radiation. Collectively, the data presented in this thesis strongly suggest that HECTD1 
and YBX3 are novel proteins which are important for facilitating BER by altering chromatin 
structure to make occluded site more accessible. This work provides a solid foundation for 
further analysis of the roles of HECTD1 and YBX3 in BER, but also once validated, these 
proteins could potentially be novel targets for drugs or small molecule inhibitors that can be 
used to increase cancer cell sensitivity to IR. HECTD1 is frequently mutated in prostate 
cancer, bladder cancer and small lung cell carcinoma and amplified in several others, for 
example lung adenocarcinoma. YBX3 is also mutated, deleted and amplified in a range of 
cancers such as lung adenocarcinoma and ovarian cancers. Therefore targeting HECTD1 and 
YBX3, in the future, may provide a novel mode of therapy for cancer treatment in conjunction 
with IR. 
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Appendix I 
 
Mass spectrometry analysis results for activity 1 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step, fraction 
16 (5.3.3.1.2) for activity 1, was analysed by mass spectrometry by Dr Deborah M Simpson 
(Centre for Proteasome Research, University of Liverpool) to identify candidate E3 ubiquitin 
ligases and/or chromatin remodellers. The full list of proteins identified is shown below in 
descending order of mascot score. 
 
Accession Description Mascot  
 
P07900 Heat shock protein HSP 90-alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 - [HS90A_HUMAN] 
3426.13 
P08238 Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 - [HS90B_HUMAN] 
3379.29 
P11021 78 kDa glucose-regulated protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 - [GRP78_HUMAN] 
889 
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 
OS=Homo sapiens GN=CPS1 PE=1 SV=2 - [CPSM_HUMAN] 
879.55 
P13667 Protein disulfide-isomerase A4 OS=Homo sapiens GN=PDIA4 
PE=1 SV=2 - [PDIA4_HUMAN] 
773.18 
Q16543 Hsp90 co-chaperone Cdc37 OS=Homo sapiens GN=CDC37 
PE=1 SV=1 - [CDC37_HUMAN] 
668.43 
P49736 DNA replication licensing factor MCM2 OS=Homo sapiens 
GN=MCM2 PE=1 SV=4 - [MCM2_HUMAN] 
652.36 
P33993 DNA replication licensing factor MCM7 OS=Homo sapiens 
GN=MCM7 PE=1 SV=4 - [MCM7_HUMAN] 
645.29 
Q15042 Rab3 GTPase-activating protein catalytic subunit OS=Homo 
sapiens GN=RAB3GAP1 PE=1 SV=3 - [RB3GP_HUMAN] 
618.74 
P25786 Proteasome subunit alpha type-1 OS=Homo sapiens 
GN=PSMA1 PE=1 SV=1 - [PSA1_HUMAN] 
615.49 
P11142 Heat shock cognate 71 kDa protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 - [HSP7C_HUMAN] 
597.47 
Q9ULT8 E3 ubiquitin-protein ligase HECTD1 OS=Homo sapiens 
GN=HECTD1 PE=1 SV=3 - [HECD1_HUMAN] 
591.28 
P28074 Proteasome subunit beta type-5 OS=Homo sapiens 
GN=PSMB5 PE=1 SV=3 - [PSB5_HUMAN] 
589.67 
P60900 Proteasome subunit alpha type-6 OS=Homo sapiens 
GN=PSMA6 PE=1 SV=1 - [PSA6_HUMAN] 
563.09 
Q9UNE7 E3 ubiquitin-protein ligase CHIP OS=Homo sapiens 
GN=STUB1 PE=1 SV=2 - [CHIP_HUMAN] 
536.44 
O60763 General vesicular transport factor p115 OS=Homo sapiens 
GN=USO1 PE=1 SV=2 - [USO1_HUMAN] 
534.52 
Q14566 DNA replication licensing factor MCM6 OS=Homo sapiens 
GN=MCM6 PE=1 SV=1 - [MCM6_HUMAN] 
534.2 
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Accession  Description Mascot  
 
P34932 Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 
PE=1 SV=4 - [HSP74_HUMAN] 
533.78 
P33991 DNA replication licensing factor MCM4 OS=Homo sapiens 
GN=MCM4 PE=1 SV=5 - [MCM4_HUMAN] 
502.65 
P53621 Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 
SV=2 - [COPA_HUMAN] 
483.73 
P49411 Elongation factor Tu, mitochondrial OS=Homo sapiens 
GN=TUFM PE=1 SV=2 - [EFTU_HUMAN] 
465.39 
P0DMV9 Heat shock 70 kDa protein 1B OS=Homo sapiens 
GN=HSPA1B PE=1 SV=1 - [HS71B_HUMAN] 
464.13 
P07951 Tropomyosin beta chain OS=Homo sapiens GN=TPM2 PE=1 
SV=1 - [TPM2_HUMAN] 
462.39 
P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
454.77 
Q15084 Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 
PE=1 SV=1 - [PDIA6_HUMAN] 
454.07 
Q13409 Cytoplasmic dynein 1 intermediate chain 2 OS=Homo sapiens 
GN=DYNC1I2 PE=1 SV=3 - [DC1I2_HUMAN] 
441.56 
P35998 26S protease regulatory subunit 7 OS=Homo sapiens 
GN=PSMC2 PE=1 SV=3 - [PRS7_HUMAN] 
433.07 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 
- [ACTB_HUMAN] 
426.45 
O14818 Proteasome subunit alpha type-7 OS=Homo sapiens 
GN=PSMA7 PE=1 SV=1 - [PSA7_HUMAN] 
421.41 
Q58FG1 Putative heat shock protein HSP 90-alpha A4 OS=Homo 
sapiens GN=HSP90AA4P PE=5 SV=1 - [HS904_HUMAN] 
420.1 
P35606 Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 
SV=2 - [COPB2_HUMAN] 
416.29 
Q9H3U1 Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A 
PE=1 SV=1 - [UN45A_HUMAN] 
413.96 
P02786 Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC 
PE=1 SV=2 - [TFR1_HUMAN] 
405.71 
Q9H2M9 Rab3 GTPase-activating protein non-catalytic subunit 
OS=Homo sapiens GN=RAB3GAP2 PE=1 SV=1 - 
[RBGPR_HUMAN] 
398.18 
Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15 OS=Homo sapiens 
GN=USP15 PE=1 SV=3 - [UBP15_HUMAN] 
392.58 
P62195 26S protease regulatory subunit 8 OS=Homo sapiens 
GN=PSMC5 PE=1 SV=1 - [PRS8_HUMAN] 
374.86 
P28066 Proteasome subunit alpha type-5 OS=Homo sapiens 
GN=PSMA5 PE=1 SV=3 - [PSA5_HUMAN] 
374.57 
Q9Y230 RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 - 
[RUVB2_HUMAN] 
363.07 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - 
[TBB5_HUMAN] 
362.22 
P38646 Stress-70 protein, mitochondrial OS=Homo sapiens 
GN=HSPA9 PE=1 SV=2 - [GRP75_HUMAN] 
346.75 
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 
SV=1 - [TBB4B_HUMAN] 
340.27 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 
SV=1 - [TBA1C_HUMAN] 
332.82 
P20618 Proteasome subunit beta type-1 OS=Homo sapiens 
GN=PSMB1 PE=1 SV=2 - [PSB1_HUMAN] 
322.96 
P28070 Proteasome subunit beta type-4 OS=Homo sapiens 
GN=PSMB4 PE=1 SV=4 - [PSB4_HUMAN] 
313.83 
P55786 Puromycin-sensitive aminopeptidase OS=Homo sapiens 
GN=NPEPPS PE=1 SV=2 - [PSA_HUMAN] 
312.05 
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Mascot 
Q9BT78 COP9 signalosome complex subunit 4 OS=Homo sapiens 
GN=COPS4 PE=1 SV=1 - [CSN4_HUMAN] 
301.48 
P25788 Proteasome subunit alpha type-3 OS=Homo sapiens 
GN=PSMA3 PE=1 SV=2 - [PSA3_HUMAN] 
301.2 
Q9UBW8 COP9 signalosome complex subunit 7a OS=Homo sapiens 
GN=COPS7A PE=1 SV=1 - [CSN7A_HUMAN] 
290.59 
P07237 Protein disulfide-isomerase OS=Homo sapiens GN=P4HB 
PE=1 SV=3 - [PDIA1_HUMAN] 
289.08 
Q13200 26S proteasome non-ATPase regulatory subunit 2 OS=Homo 
sapiens GN=PSMD2 PE=1 SV=3 - [PSMD2_HUMAN] 
288.25 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
286.19 
Q99436 Proteasome subunit beta type-7 OS=Homo sapiens 
GN=PSMB7 PE=1 SV=1 - [PSB7_HUMAN] 
273.68 
P49327 Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 
- [FAS_HUMAN] 
271.23 
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A 
OS=Homo sapiens GN=PPP4R3A PE=1 SV=1 - 
[P4R3A_HUMAN] 
266.2 
P08195 4F2 cell-surface antigen heavy chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 - [4F2_HUMAN] 
264.7 
Q00839 Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 - [HNRPU_HUMAN] 
264.37 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
262.13 
Q14203 Dynactin subunit 1 OS=Homo sapiens GN=DCTN1 PE=1 SV=3 
- [DCTN1_HUMAN] 
258.74 
Q99961 Endophilin-A2 OS=Homo sapiens GN=SH3GL1 PE=1 SV=1 - 
[SH3G1_HUMAN] 
258.07 
Q96K76 Ubiquitin carboxyl-terminal hydrolase 47 OS=Homo sapiens 
GN=USP47 PE=1 SV=3 - [UBP47_HUMAN] 
257.57 
Q93008 Probable ubiquitin carboxyl-terminal hydrolase FAF-X 
OS=Homo sapiens GN=USP9X PE=1 SV=3 - 
[USP9X_HUMAN] 
255.84 
P61201 COP9 signalosome complex subunit 2 OS=Homo sapiens 
GN=COPS2 PE=1 SV=1 - [CSN2_HUMAN] 
249.14 
P28072 Proteasome subunit beta type-6 OS=Homo sapiens 
GN=PSMB6 PE=1 SV=4 - [PSB6_HUMAN] 
228.7 
Q92905 COP9 signalosome complex subunit 5 OS=Homo sapiens 
GN=COPS5 PE=1 SV=4 - [CSN5_HUMAN] 
224.59 
P25705 ATP synthase subunit alpha, mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 - [ATPA_HUMAN] 
222.15 
Q99460 26S proteasome non-ATPase regulatory subunit 1 OS=Homo 
sapiens GN=PSMD1 PE=1 SV=2 - [PSMD1_HUMAN] 
221.5 
P68366 Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 
SV=1 - [TBA4A_HUMAN] 
220.41 
P48444 Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 
SV=1 - [COPD_HUMAN] 
212.07 
O60664 Perilipin-3 OS=Homo sapiens GN=PLIN3 PE=1 SV=3 - 
[PLIN3_HUMAN] 
210.73 
P14324 Farnesyl pyrophosphate synthase OS=Homo sapiens 
GN=FDPS PE=1 SV=4 - [FPPS_HUMAN] 
209.83 
P17980 26S protease regulatory subunit 6A OS=Homo sapiens 
GN=PSMC3 PE=1 SV=3 - [PRS6A_HUMAN] 
207.88 
P49721 Proteasome subunit beta type-2 OS=Homo sapiens 
GN=PSMB2 PE=1 SV=1 - [PSB2_HUMAN] 
206.68 
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P17812 CTP synthase 1 OS=Homo sapiens GN=CTPS1 PE=1 SV=2 - 
[PYRG1_HUMAN] 
206.63 
P62191 26S protease regulatory subunit 4 OS=Homo sapiens 
GN=PSMC1 PE=1 SV=1 - [PRS4_HUMAN] 
206.39 
P52292 Importin subunit alpha-1 OS=Homo sapiens GN=KPNA2 PE=1 
SV=1 - [IMA1_HUMAN] 
203.75 
P10809 60 kDa heat shock protein, mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 - [CH60_HUMAN] 
199.73 
P48449 Lanosterol synthase OS=Homo sapiens GN=LSS PE=1 SV=1 - 
[ERG7_HUMAN] 
196.75 
P31153 S-adenosylmethionine synthase isoform type-2 OS=Homo 
sapiens GN=MAT2A PE=1 SV=1 - [METK2_HUMAN] 
191.43 
Q9BR76 Coronin-1B OS=Homo sapiens GN=CORO1B PE=1 SV=1 - 
[COR1B_HUMAN] 
189.39 
P28062 Proteasome subunit beta type-8 OS=Homo sapiens 
GN=PSMB8 PE=1 SV=3 - [PSB8_HUMAN] 
187.48 
P17655 Calpain-2 catalytic subunit OS=Homo sapiens GN=CAPN2 
PE=1 SV=6 - [CAN2_HUMAN] 
185.86 
Q9UJU6 Drebrin-like protein OS=Homo sapiens GN=DBNL PE=1 SV=1 
- [DBNL_HUMAN] 
183.42 
Q9Y265 RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 - 
[RUVB1_HUMAN] 
182.18 
O00148 ATP-dependent RNA helicase DDX39A OS=Homo sapiens 
GN=DDX39A PE=1 SV=2 - [DX39A_HUMAN] 
180.68 
Q14974 Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 
SV=2 - [IMB1_HUMAN] 
180.54 
P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 - [1433Z_HUMAN] 
169.65 
Q7L3B6 Hsp90 co-chaperone Cdc37-like 1 OS=Homo sapiens 
GN=CDC37L1 PE=1 SV=1 - [CD37L_HUMAN] 
166.93 
P49321 Nuclear autoantigenic sperm protein OS=Homo sapiens 
GN=NASP PE=1 SV=2 - [NASP_HUMAN] 
162.66 
P30453 HLA class I histocompatibility antigen, A-34 alpha chain 
OS=Homo sapiens GN=HLA-A PE=1 SV=1 - [1A34_HUMAN] 
159.74 
P23396 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 
SV=2 - [RS3_HUMAN] 
158.36 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type 
OS=Homo sapiens GN=PFKP PE=1 SV=2 - [PFKAP_HUMAN] 
157.66 
P31689 DnaJ homolog subfamily A member 1 OS=Homo sapiens 
GN=DNAJA1 PE=1 SV=2 - [DNJA1_HUMAN] 
155.24 
Q92598 Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 
PE=1 SV=1 - [HS105_HUMAN] 
151.98 
O75179 Ankyrin repeat domain-containing protein 17 OS=Homo 
sapiens GN=ANKRD17 PE=1 SV=3 - [ANR17_HUMAN] 
151.76 
P25787 Proteasome subunit alpha type-2 OS=Homo sapiens 
GN=PSMA2 PE=1 SV=2 - [PSA2_HUMAN] 
150.7 
P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform OS=Homo sapiens GN=PPP2R1A 
PE=1 SV=4 - [2AAA_HUMAN] 
150.46 
O95757 Heat shock 70 kDa protein 4L OS=Homo sapiens GN=HSPA4L 
PE=1 SV=3 - [HS74L_HUMAN] 
147.05 
Q9H9Q2 COP9 signalosome complex subunit 7b OS=Homo sapiens 
GN=COPS7B PE=1 SV=1 - [CSN7B_HUMAN] 
143.38 
P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 
SV=2 - [RINI_HUMAN] 
142.72 
P25789 Proteasome subunit alpha type-4 OS=Homo sapiens 
GN=PSMA4 PE=1 SV=1 - [PSA4_HUMAN] 
142.57 
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P01891 HLA class I histocompatibility antigen, A-68 alpha chain 
OS=Homo sapiens GN=HLA-A PE=1 SV=4 - [1A68_HUMAN] 
140.4 
Q13098 COP9 signalosome complex subunit 1 OS=Homo sapiens 
GN=GPS1 PE=1 SV=4 - [CSN1_HUMAN] 
140.15 
P24534 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 
SV=3 - [EF1B_HUMAN] 
135.37 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 
SV=1 - [MEP50_HUMAN] 
132.54 
P47712 Cytosolic phospholipase A2 OS=Homo sapiens GN=PLA2G4A 
PE=1 SV=2 - [PA24A_HUMAN] 
132.11 
O60443 Non-syndromic hearing impairment protein 5 OS=Homo 
sapiens GN=DFNA5 PE=1 SV=2 - [DFNA5_HUMAN] 
131.87 
P10155 60 kDa SS-A/Ro ribonucleoprotein OS=Homo sapiens 
GN=TROVE2 PE=1 SV=2 - [RO60_HUMAN] 
130.34 
O95831 Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens 
GN=AIFM1 PE=1 SV=1 - [AIFM1_HUMAN] 
130.14 
P68104 Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 
PE=1 SV=1 - [EF1A1_HUMAN] 
129.43 
Q99832 T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 
PE=1 SV=2 - [TCPH_HUMAN] 
127.16 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog OS=Homo 
sapiens GN=VAT1 PE=1 SV=2 - [VAT1_HUMAN] 
123.87 
Q9UNS2 COP9 signalosome complex subunit 3 OS=Homo sapiens 
GN=COPS3 PE=1 SV=3 - [CSN3_HUMAN] 
123.46 
P40939 Trifunctional enzyme subunit alpha, mitochondrial OS=Homo 
sapiens GN=HADHA PE=1 SV=2 - [ECHA_HUMAN] 
123.37 
Q9UBE0 SUMO-activating enzyme subunit 1 OS=Homo sapiens 
GN=SAE1 PE=1 SV=1 - [SAE1_HUMAN] 
121.68 
P13639 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - 
[EF2_HUMAN] 
120.59 
P30464 HLA class I histocompatibility antigen, B-15 alpha chain 
OS=Homo sapiens GN=HLA-B PE=1 SV=2 - [1B15_HUMAN] 
118.58 
Q14247 Src substrate cortactin OS=Homo sapiens GN=CTTN PE=1 
SV=2 - [SRC8_HUMAN] 
116.07 
O95816 BAG family molecular chaperone regulator 2 OS=Homo 
sapiens GN=BAG2 PE=1 SV=1 - [BAG2_HUMAN] 
115.37 
P08134 Rho-related GTP-binding protein RhoC OS=Homo sapiens 
GN=RHOC PE=1 SV=1 - [RHOC_HUMAN] 
114.63 
P55072 Transitional endoplasmic reticulum ATPase OS=Homo sapiens 
GN=VCP PE=1 SV=4 - [TERA_HUMAN] 
113.64 
P55060 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 - 
[XPO2_HUMAN] 
113.4 
O60232 Sjoegren syndrome/scleroderma autoantigen 1 OS=Homo 
sapiens GN=SSSCA1 PE=1 SV=1 - [SSA27_HUMAN] 
111.7 
P04792 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 
PE=1 SV=2 - [HSPB1_HUMAN] 
111.62 
P62826 GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN 
PE=1 SV=3 - [RAN_HUMAN] 
111.19 
Q99614 Tetratricopeptide repeat protein 1 OS=Homo sapiens 
GN=TTC1 PE=1 SV=1 - [TTC1_HUMAN] 
110.89 
P21980 Protein-glutamine gamma-glutamyltransferase 2 OS=Homo 
sapiens GN=TGM2 PE=1 SV=2 - [TGM2_HUMAN] 
109.86 
O60884 DnaJ homolog subfamily A member 2 OS=Homo sapiens 
GN=DNAJA2 PE=1 SV=1 - [DNJA2_HUMAN] 
107.05 
P14618 Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 
SV=4 - [KPYM_HUMAN] 
106.33 
   
216 
 
Accession Description Mascot 
 
Q9Y5P4 Collagen type IV alpha-3-binding protein OS=Homo sapiens 
GN=COL4A3BP PE=1 SV=1 - [C43BP_HUMAN] 
105.99 
P62258 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 
SV=1 - [1433E_HUMAN] 
104.21 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA 
PE=1 SV=1 - [PCNA_HUMAN] 
104.21 
O15460 Prolyl 4-hydroxylase subunit alpha-2 OS=Homo sapiens 
GN=P4HA2 PE=1 SV=1 - [P4HA2_HUMAN] 
101.42 
P51784 Ubiquitin carboxyl-terminal hydrolase 11 OS=Homo sapiens 
GN=USP11 PE=1 SV=3 - [UBP11_HUMAN] 
101.03 
P41250 Glycine--tRNA ligase OS=Homo sapiens GN=GARS PE=1 
SV=3 - [SYG_HUMAN] 
100.78 
Q15029 116 kDa U5 small nuclear ribonucleoprotein component 
OS=Homo sapiens GN=EFTUD2 PE=1 SV=1 - 
[U5S1_HUMAN] 
100.23 
P46459 Vesicle-fusing ATPase OS=Homo sapiens GN=NSF PE=1 
SV=3 - [NSF_HUMAN] 
99.01 
P61163 Alpha-centractin OS=Homo sapiens GN=ACTR1A PE=1 SV=1 
- [ACTZ_HUMAN] 
98.11 
O43242 26S proteasome non-ATPase regulatory subunit 3 OS=Homo 
sapiens GN=PSMD3 PE=1 SV=2 - [PSMD3_HUMAN] 
98.08 
Q99627 COP9 signalosome complex subunit 8 OS=Homo sapiens 
GN=COPS8 PE=1 SV=1 - [CSN8_HUMAN] 
97.62 
P27348 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 
SV=1 - [1433T_HUMAN] 
97.16 
Q15018 BRISC complex subunit Abro1 OS=Homo sapiens 
GN=FAM175B PE=1 SV=2 - [F175B_HUMAN] 
96.52 
P43686 26S protease regulatory subunit 6B OS=Homo sapiens 
GN=PSMC4 PE=1 SV=2 - [PRS6B_HUMAN] 
95.59 
P13798 Acylamino-acid-releasing enzyme OS=Homo sapiens 
GN=APEH PE=1 SV=4 - [ACPH_HUMAN] 
95.43 
O00233 26S proteasome non-ATPase regulatory subunit 9 OS=Homo 
sapiens GN=PSMD9 PE=1 SV=3 - [PSMD9_HUMAN] 
94.05 
P31946 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB 
PE=1 SV=3 - [1433B_HUMAN] 
92.62 
Q14160 Protein scribble homolog OS=Homo sapiens GN=SCRIB PE=1 
SV=4 - [SCRIB_HUMAN] 
91.33 
Q9P289 Serine/threonine-protein kinase 26 OS=Homo sapiens 
GN=STK26 PE=1 SV=2 - [STK26_HUMAN] 
91.04 
Q13428 Treacle protein OS=Homo sapiens GN=TCOF1 PE=1 SV=3 - 
[TCOF_HUMAN] 
90.39 
P61981 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 
SV=2 - [1433G_HUMAN] 
90.1 
P51570 Galactokinase OS=Homo sapiens GN=GALK1 PE=1 SV=1 - 
[GALK1_HUMAN] 
90.04 
Q15645 Pachytene checkpoint protein 2 homolog OS=Homo sapiens 
GN=TRIP13 PE=1 SV=2 - [PCH2_HUMAN] 
88.71 
P61586 Transforming protein RhoA OS=Homo sapiens GN=RHOA 
PE=1 SV=1 - [RHOA_HUMAN] 
88.18 
P78344 Eukaryotic translation initiation factor 4 gamma 2 OS=Homo 
sapiens GN=EIF4G2 PE=1 SV=1 - [IF4G2_HUMAN] 
87.77 
P12268 Inosine-5'-monophosphate dehydrogenase 2 OS=Homo 
sapiens GN=IMPDH2 PE=1 SV=2 - [IMDH2_HUMAN] 
87.67 
O95218 Zinc finger Ran-binding domain-containing protein 2 OS=Homo 
sapiens GN=ZRANB2 PE=1 SV=2 - [ZRAB2_HUMAN] 
87.41 
Q8N163 Cell cycle and apoptosis regulator protein 2 OS=Homo sapiens 
GN=CCAR2 PE=1 SV=2 - [CCAR2_HUMAN] 
87.08 
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Q86VP6 Cullin-associated NEDD8-dissociated protein 1 OS=Homo 
sapiens GN=CAND1 PE=1 SV=2 - [CAND1_HUMAN] 
86.97 
P62491 Ras-related protein Rab-11A OS=Homo sapiens GN=RAB11A 
PE=1 SV=3 - [RB11A_HUMAN] 
86.9 
P52294 Importin subunit alpha-5 OS=Homo sapiens GN=KPNA1 PE=1 
SV=3 - [IMA5_HUMAN] 
86.74 
P62495 Eukaryotic peptide chain release factor subunit 1 OS=Homo 
sapiens GN=ETF1 PE=1 SV=3 - [ERF1_HUMAN] 
85.88 
P35613 Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 - 
[BASI_HUMAN] 
84.47 
P46782 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 
SV=4 - [RS5_HUMAN] 
84.31 
Q92928 Putative Ras-related protein Rab-1C OS=Homo sapiens 
GN=RAB1C PE=5 SV=2 - [RAB1C_HUMAN] 
81.29 
Q7L5N1 COP9 signalosome complex subunit 6 OS=Homo sapiens 
GN=COPS6 PE=1 SV=1 - [CSN6_HUMAN] 
80.64 
Q9UNZ2 NSFL1 cofactor p47 OS=Homo sapiens GN=NSFL1C PE=1 
SV=2 - [NSF1C_HUMAN] 
80.11 
P52298 Nuclear cap-binding protein subunit 2 OS=Homo sapiens 
GN=NCBP2 PE=1 SV=1 - [NCBP2_HUMAN] 
78.79 
O14732 Inositol monophosphatase 2 OS=Homo sapiens GN=IMPA2 
PE=1 SV=1 - [IMPA2_HUMAN] 
78.2 
O75832 26S proteasome non-ATPase regulatory subunit 10 OS=Homo 
sapiens GN=PSMD10 PE=1 SV=1 - [PSD10_HUMAN] 
78.16 
P08754 Guanine nucleotide-binding protein G(k) subunit alpha 
OS=Homo sapiens GN=GNAI3 PE=1 SV=3 - [GNAI3_HUMAN] 
77.71 
Q8IZP2 Putative protein FAM10A4 OS=Homo sapiens GN=ST13P4 
PE=5 SV=1 - [ST134_HUMAN] 
77.57 
P26641 Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G 
PE=1 SV=3 - [EF1G_HUMAN] 
77.37 
P04843 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 OS=Homo sapiens GN=RPN1 PE=1 SV=1 - 
[RPN1_HUMAN] 
77.35 
Q9UBT2 SUMO-activating enzyme subunit 2 OS=Homo sapiens 
GN=UBA2 PE=1 SV=2 - [SAE2_HUMAN] 
77.21 
Q8TF09 Dynein light chain roadblock-type 2 OS=Homo sapiens 
GN=DYNLRB2 PE=1 SV=1 - [DLRB2_HUMAN] 
76.82 
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 
OS=Homo sapiens GN=AHSA1 PE=1 SV=1 - 
[AHSA1_HUMAN] 
76.28 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 
PE=1 SV=6 - [K1C10_HUMAN] 
75.66 
P60842 Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 
PE=1 SV=1 - [IF4A1_HUMAN] 
75.45 
P49720 Proteasome subunit beta type-3 OS=Homo sapiens 
GN=PSMB3 PE=1 SV=2 - [PSB3_HUMAN] 
75.43 
Q9UHG3 Prenylcysteine oxidase 1 OS=Homo sapiens GN=PCYOX1 
PE=1 SV=3 - [PCYOX_HUMAN] 
75.27 
P78318 Immunoglobulin-binding protein 1 OS=Homo sapiens 
GN=IGBP1 PE=1 SV=1 - [IGBP1_HUMAN] 
74.69 
P38606 V-type proton ATPase catalytic subunit A OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 - [VATA_HUMAN] 
73.53 
Q13561 Dynactin subunit 2 OS=Homo sapiens GN=DCTN2 PE=1 SV=4 
- [DCTN2_HUMAN] 
73.11 
O14980 Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1 - 
[XPO1_HUMAN] 
72.48 
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P47755 F-actin-capping protein subunit alpha-2 OS=Homo sapiens 
GN=CAPZA2 PE=1 SV=3 - [CAZA2_HUMAN] 
72.26 
Q9H4A6 Golgi phosphoprotein 3 OS=Homo sapiens GN=GOLPH3 PE=1 
SV=1 - [GOLP3_HUMAN] 
71.88 
P11279 Lysosome-associated membrane glycoprotein 1 OS=Homo 
sapiens GN=LAMP1 PE=1 SV=3 - [LAMP1_HUMAN] 
71.59 
Q5JVF3 PCI domain-containing protein 2 OS=Homo sapiens 
GN=PCID2 PE=1 SV=2 - [PCID2_HUMAN] 
71.34 
P55084 Trifunctional enzyme subunit beta, mitochondrial OS=Homo 
sapiens GN=HADHB PE=1 SV=3 - [ECHB_HUMAN] 
71.33 
Q04917 14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 
- [1433F_HUMAN] 
70.07 
Q14697 Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB 
PE=1 SV=3 - [GANAB_HUMAN] 
68.55 
P06576 ATP synthase subunit beta, mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 - [ATPB_HUMAN] 
68.41 
P11586 C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens 
GN=MTHFD1 PE=1 SV=3 - [C1TC_HUMAN] 
68.37 
O00231 26S proteasome non-ATPase regulatory subunit 11 OS=Homo 
sapiens GN=PSMD11 PE=1 SV=3 - [PSD11_HUMAN] 
68.22 
P55884 Eukaryotic translation initiation factor 3 subunit B OS=Homo 
sapiens GN=EIF3B PE=1 SV=3 - [EIF3B_HUMAN] 
68.15 
P60953 Cell division control protein 42 homolog OS=Homo sapiens 
GN=CDC42 PE=1 SV=2 - [CDC42_HUMAN] 
68.01 
P12109 Collagen alpha-1(VI) chain OS=Homo sapiens GN=COL6A1 
PE=1 SV=3 - [CO6A1_HUMAN] 
66.72 
P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 
PE=1 SV=4 - [K1C19_HUMAN] 
66.45 
O60547 GDP-mannose 4,6 dehydratase OS=Homo sapiens GN=GMDS 
PE=1 SV=1 - [GMDS_HUMAN] 
66.1 
P01130 Low-density lipoprotein receptor OS=Homo sapiens GN=LDLR 
PE=1 SV=1 - [LDLR_HUMAN] 
65.13 
P43358 Melanoma-associated antigen 4 OS=Homo sapiens 
GN=MAGEA4 PE=1 SV=2 - [MAGA4_HUMAN] 
64.05 
A4D1P6 WD repeat-containing protein 91 OS=Homo sapiens 
GN=WDR91 PE=1 SV=2 - [WDR91_HUMAN] 
63.97 
Q16186 Proteasomal ubiquitin receptor ADRM1 OS=Homo sapiens 
GN=ADRM1 PE=1 SV=2 - [ADRM1_HUMAN] 
63.88 
P60510 Serine/threonine-protein phosphatase 4 catalytic subunit 
OS=Homo sapiens GN=PPP4C PE=1 SV=1 - [PP4C_HUMAN] 
63.44 
Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 
PE=1 SV=1 - [TEBP_HUMAN] 
63.26 
Q9H269 Vacuolar protein sorting-associated protein 16 homolog 
OS=Homo sapiens GN=VPS16 PE=1 SV=2 - [VPS16_HUMAN] 
63.14 
Q9UPY3 Endoribonuclease Dicer OS=Homo sapiens GN=DICER1 PE=1 
SV=3 - [DICER_HUMAN] 
62.67 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
62.54 
Q04837 Single-stranded DNA-binding protein, mitochondrial OS=Homo 
sapiens GN=SSBP1 PE=1 SV=1 - [SSBP_HUMAN] 
62.44 
P62333 26S protease regulatory subunit 10B OS=Homo sapiens 
GN=PSMC6 PE=1 SV=1 - [PRS10_HUMAN] 
62.07 
P08237 ATP-dependent 6-phosphofructokinase, muscle type 
OS=Homo sapiens GN=PFKM PE=1 SV=2 - [PFKAM_HUMAN] 
61.98 
Q15393 Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 
PE=1 SV=4 - [SF3B3_HUMAN] 
 
61.93 
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P36404 ADP-ribosylation factor-like protein 2 OS=Homo sapiens 
GN=ARL2 PE=1 SV=4 - [ARL2_HUMAN] 
61.69 
P49593 Protein phosphatase 1F OS=Homo sapiens GN=PPM1F PE=1 
SV=3 - [PPM1F_HUMAN] 
61.01 
Q13572 Inositol-tetrakisphosphate 1-kinase OS=Homo sapiens 
GN=ITPK1 PE=1 SV=2 - [ITPK1_HUMAN] 
57.59 
Q9UK59 Lariat debranching enzyme OS=Homo sapiens GN=DBR1 
PE=1 SV=2 - [DBR1_HUMAN] 
56.75 
P04632 Calpain small subunit 1 OS=Homo sapiens GN=CAPNS1 PE=1 
SV=1 - [CPNS1_HUMAN] 
55.9 
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens 
GN=SNRPD2 PE=1 SV=1 - [SMD2_HUMAN] 
55.83 
O43399 Tumor protein D54 OS=Homo sapiens GN=TPD52L2 PE=1 
SV=2 - [TPD54_HUMAN] 
55.74 
P62829 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 
PE=1 SV=1 - [RL23_HUMAN] 
55.33 
Q9HAV4 Exportin-5 OS=Homo sapiens GN=XPO5 PE=1 SV=1 - 
[XPO5_HUMAN] 
54.67 
Q9H4I3 TraB domain-containing protein OS=Homo sapiens 
GN=TRABD PE=1 SV=1 - [TRABD_HUMAN] 
53.83 
Q9NQC3 Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 - 
[RTN4_HUMAN] 
53.35 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - 
[H4_HUMAN] 
53.06 
Q16531 DNA damage-binding protein 1 OS=Homo sapiens GN=DDB1 
PE=1 SV=1 - [DDB1_HUMAN] 
53 
P62633 Cellular nucleic acid-binding protein OS=Homo sapiens 
GN=CNBP PE=1 SV=1 - [CNBP_HUMAN] 
52.46 
P42677 40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 
PE=1 SV=3 - [RS27_HUMAN] 
52.34 
O00487 26S proteasome non-ATPase regulatory subunit 14 OS=Homo 
sapiens GN=PSMD14 PE=1 SV=1 - [PSDE_HUMAN] 
51.67 
P49368 T-complex protein 1 subunit gamma OS=Homo sapiens 
GN=CCT3 PE=1 SV=4 - [TCPG_HUMAN] 
51.53 
P63010 AP-2 complex subunit beta OS=Homo sapiens GN=AP2B1 
PE=1 SV=1 - [AP2B1_HUMAN] 
50.85 
P51149 Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A 
PE=1 SV=1 - [RAB7A_HUMAN] 
50.71 
O14579 Coatomer subunit epsilon OS=Homo sapiens GN=COPE PE=1 
SV=3 - [COPE_HUMAN] 
50.49 
Q00610 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 
SV=5 - [CLH1_HUMAN] 
50.31 
P27708 CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 - 
[PYR1_HUMAN] 
49.76 
P41091 Eukaryotic translation initiation factor 2 subunit 3 OS=Homo 
sapiens GN=EIF2S3 PE=1 SV=3 - [IF2G_HUMAN] 
49.67 
P61221 ATP-binding cassette sub-family E member 1 OS=Homo 
sapiens GN=ABCE1 PE=1 SV=1 - [ABCE1_HUMAN] 
49.51 
O60313 Dynamin-like 120 kDa protein, mitochondrial OS=Homo 
sapiens GN=OPA1 PE=1 SV=3 - [OPA1_HUMAN] 
49.33 
Q9Y678 Coatomer subunit gamma-1 OS=Homo sapiens GN=COPG1 
PE=1 SV=1 - [COPG1_HUMAN] 
48.85 
Q9NR31 GTP-binding protein SAR1a OS=Homo sapiens GN=SAR1A 
PE=1 SV=1 - [SAR1A_HUMAN] 
48.84 
P19623 Spermidine synthase OS=Homo sapiens GN=SRM PE=1 SV=1 
- [SPEE_HUMAN] 
 
48.32 
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Q9NSD9 Phenylalanine--tRNA ligase beta subunit OS=Homo sapiens 
GN=FARSB PE=1 SV=3 - [SYFB_HUMAN] 
47.92 
Q13162 Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 PE=1 SV=1 - 
[PRDX4_HUMAN] 
46.23 
P40227 T-complex protein 1 subunit zeta OS=Homo sapiens 
GN=CCT6A PE=1 SV=3 - [TCPZ_HUMAN] 
46.16 
P53618 Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1 
SV=3 - [COPB_HUMAN] 
45.37 
P42704 Leucine-rich PPR motif-containing protein, mitochondrial 
OS=Homo sapiens GN=LRPPRC PE=1 SV=3 - 
[LPPRC_HUMAN] 
45.37 
P11172 Uridine 5'-monophosphate synthase OS=Homo sapiens 
GN=UMPS PE=1 SV=1 - [UMPS_HUMAN] 
44.93 
P60866 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 
PE=1 SV=1 - [RS20_HUMAN] 
44.89 
O00629 Importin subunit alpha-3 OS=Homo sapiens GN=KPNA4 PE=1 
SV=1 - [IMA3_HUMAN] 
44.62 
Q5VYK3 Proteasome-associated protein ECM29 homolog OS=Homo 
sapiens GN=ECM29 PE=1 SV=2 - [ECM29_HUMAN] 
44.35 
P31350 Ribonucleoside-diphosphate reductase subunit M2 OS=Homo 
sapiens GN=RRM2 PE=1 SV=1 - [RIR2_HUMAN] 
44.34 
Q9NR19 Acetyl-coenzyme A synthetase, cytoplasmic OS=Homo sapiens 
GN=ACSS2 PE=1 SV=1 - [ACSA_HUMAN] 
44.19 
Q9UKV3 Apoptotic chromatin condensation inducer in the nucleus 
OS=Homo sapiens GN=ACIN1 PE=1 SV=2 - [ACINU_HUMAN] 
43.99 
Q9Y223 Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase OS=Homo sapiens GN=GNE PE=1 
SV=1 - [GLCNE_HUMAN] 
43.61 
Q13263 Transcription intermediary factor 1-beta OS=Homo sapiens 
GN=TRIM28 PE=1 SV=5 - [TIF1B_HUMAN] 
43.47 
P62917 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 
SV=2 - [RL8_HUMAN] 
43.28 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial OS=Homo sapiens 
GN=IARS2 PE=1 SV=2 - [SYIM_HUMAN] 
43.14 
P25205 DNA replication licensing factor MCM3 OS=Homo sapiens 
GN=MCM3 PE=1 SV=3 - [MCM3_HUMAN] 
42.94 
P13637 Sodium/potassium-transporting ATPase subunit alpha-3 
OS=Homo sapiens GN=ATP1A3 PE=1 SV=3 - 
[AT1A3_HUMAN] 
42.8 
Q9Y5K5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 OS=Homo 
sapiens GN=UCHL5 PE=1 SV=3 - [UCHL5_HUMAN] 
42.71 
Q05655 Protein kinase C delta type OS=Homo sapiens GN=PRKCD 
PE=1 SV=2 - [KPCD_HUMAN] 
42.49 
P55036 26S proteasome non-ATPase regulatory subunit 4 OS=Homo 
sapiens GN=PSMD4 PE=1 SV=1 - [PSMD4_HUMAN] 
42.4 
P49588 Alanine--tRNA ligase, cytoplasmic OS=Homo sapiens 
GN=AARS PE=1 SV=2 - [SYAC_HUMAN] 
42.12 
Q8IYS1 Peptidase M20 domain-containing protein 2 OS=Homo sapiens 
GN=PM20D2 PE=1 SV=2 - [P20D2_HUMAN] 
42.06 
O00410 Importin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4 - 
[IPO5_HUMAN] 
41.67 
P98170 E3 ubiquitin-protein ligase XIAP OS=Homo sapiens GN=XIAP 
PE=1 SV=2 - [XIAP_HUMAN] 
41.63 
O75436 Vacuolar protein sorting-associated protein 26A OS=Homo 
sapiens GN=VPS26A PE=1 SV=2 - [VP26A_HUMAN] 
41.6 
Q13907 Isopentenyl-diphosphate Delta-isomerase 1 OS=Homo sapiens 
GN=IDI1 PE=1 SV=2 - [IDI1_HUMAN] 
41.34 
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P48556 26S proteasome non-ATPase regulatory subunit 8 OS=Homo 
sapiens GN=PSMD8 PE=1 SV=2 - [PSMD8_HUMAN] 
41.31 
Q9BRP4 Proteasomal ATPase-associated factor 1 OS=Homo sapiens 
GN=PAAF1 PE=1 SV=2 - [PAAF1_HUMAN] 
41.19 
Q14204 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens 
GN=DYNC1H1 PE=1 SV=5 - [DYHC1_HUMAN] 
40.95 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform OS=Homo 
sapiens GN=CPT1A PE=1 SV=2 - [CPT1A_HUMAN] 
40.93 
O00505 Importin subunit alpha-4 OS=Homo sapiens GN=KPNA3 PE=1 
SV=2 - [IMA4_HUMAN] 
40.32 
P61923 Coatomer subunit zeta-1 OS=Homo sapiens GN=COPZ1 PE=1 
SV=1 - [COPZ1_HUMAN] 
40.26 
O94808 Glutamine--fructose-6-phosphate aminotransferase 
[isomerizing] 2 OS=Homo sapiens GN=GFPT2 PE=1 SV=3 - 
[GFPT2_HUMAN] 
40.24 
Q8IWV8 E3 ubiquitin-protein ligase UBR2 OS=Homo sapiens GN=UBR2 
PE=1 SV=1 - [UBR2_HUMAN] 
39.83 
O95777 U6 snRNA-associated Sm-like protein LSm8 OS=Homo 
sapiens GN=LSM8 PE=1 SV=3 - [LSM8_HUMAN] 
39.57 
Q6NXT2 Histone H3.3C OS=Homo sapiens GN=H3F3C PE=1 SV=3 - 
[H3C_HUMAN] 
39.03 
O00232 26S proteasome non-ATPase regulatory subunit 12 OS=Homo 
sapiens GN=PSMD12 PE=1 SV=3 - [PSD12_HUMAN] 
38.99 
P09496 Clathrin light chain A OS=Homo sapiens GN=CLTA PE=1 
SV=1 - [CLCA_HUMAN] 
38.79 
Q15738 Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 
OS=Homo sapiens GN=NSDHL PE=1 SV=2 - 
[NSDHL_HUMAN] 
38.08 
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit 
alpha isoform OS=Homo sapiens GN=PPP2CA PE=1 SV=1 - 
[PP2AA_HUMAN] 
37.64 
Q9UBI6 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-12 OS=Homo sapiens GN=GNG12 PE=1 SV=3 - 
[GBG12_HUMAN] 
37.29 
P12110 Collagen alpha-2(VI) chain OS=Homo sapiens GN=COL6A2 
PE=1 SV=4 - [CO6A2_HUMAN] 
36.98 
Q9H7Z7 Prostaglandin E synthase 2 OS=Homo sapiens GN=PTGES2 
PE=1 SV=1 - [PGES2_HUMAN] 
36.78 
O95817 BAG family molecular chaperone regulator 3 OS=Homo 
sapiens GN=BAG3 PE=1 SV=3 - [BAG3_HUMAN] 
36.74 
P50570 Dynamin-2 OS=Homo sapiens GN=DNM2 PE=1 SV=2 - 
[DYN2_HUMAN] 
36.69 
P48643 T-complex protein 1 subunit epsilon OS=Homo sapiens 
GN=CCT5 PE=1 SV=1 - [TCPE_HUMAN] 
36.57 
P47756 F-actin-capping protein subunit beta OS=Homo sapiens 
GN=CAPZB PE=1 SV=4 - [CAPZB_HUMAN] 
36.24 
P27824 Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 - 
[CALX_HUMAN] 
36.14 
P14209 CD99 antigen OS=Homo sapiens GN=CD99 PE=1 SV=1 - 
[CD99_HUMAN] 
35.75 
Q9NY27 Serine/threonine-protein phosphatase 4 regulatory subunit 2 
OS=Homo sapiens GN=PPP4R2 PE=1 SV=3 - 
[PP4R2_HUMAN] 
35.67 
Q2TAZ0 Autophagy-related protein 2 homolog A OS=Homo sapiens 
GN=ATG2A PE=1 SV=3 - [ATG2A_HUMAN] 
35.47 
Q9UBB4 Ataxin-10 OS=Homo sapiens GN=ATXN10 PE=1 SV=1 - 
[ATX10_HUMAN] 
35.16 
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P06737 Glycogen phosphorylase, liver form OS=Homo sapiens 
GN=PYGL PE=1 SV=4 - [PYGL_HUMAN] 
35.08 
Q32P28 Prolyl 3-hydroxylase 1 OS=Homo sapiens GN=P3H1 PE=1 
SV=2 - [P3H1_HUMAN] 
35 
Q9NZR2 Low-density lipoprotein receptor-related protein 1B OS=Homo 
sapiens GN=LRP1B PE=1 SV=2 - [LRP1B_HUMAN] 
34.98 
Q6PIU2 Neutral cholesterol ester hydrolase 1 OS=Homo sapiens 
GN=NCEH1 PE=1 SV=3 - [NCEH1_HUMAN] 
34.83 
P05362 Intercellular adhesion molecule 1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 - [ICAM1_HUMAN] 
34.76 
O75306 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial OS=Homo sapiens GN=NDUFS2 PE=1 SV=2 - 
[NDUS2_HUMAN] 
34.66 
P32004 Neural cell adhesion molecule L1 OS=Homo sapiens 
GN=L1CAM PE=1 SV=2 - [L1CAM_HUMAN] 
34.32 
Q8TC07 TBC1 domain family member 15 OS=Homo sapiens 
GN=TBC1D15 PE=1 SV=2 - [TBC15_HUMAN] 
33.96 
Q16850 Lanosterol 14-alpha demethylase OS=Homo sapiens 
GN=CYP51A1 PE=1 SV=3 - [CP51A_HUMAN] 
33.93 
Q7L1Q6 Basic leucine zipper and W2 domain-containing protein 1 
OS=Homo sapiens GN=BZW1 PE=1 SV=1 - [BZW1_HUMAN] 
33.87 
Q8TC12 Retinol dehydrogenase 11 OS=Homo sapiens GN=RDH11 
PE=1 SV=2 - [RDH11_HUMAN] 
33.33 
Q9UNH7 Sorting nexin-6 OS=Homo sapiens GN=SNX6 PE=1 SV=1 - 
[SNX6_HUMAN] 
33.09 
Q92616 Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 
PE=1 SV=6 - [GCN1L_HUMAN] 
32.94 
Q9NXR7 BRCA1-A complex subunit BRE OS=Homo sapiens GN=BRE 
PE=1 SV=2 - [BRE_HUMAN] 
32.6 
P12111 Collagen alpha-3(VI) chain OS=Homo sapiens GN=COL6A3 
PE=1 SV=5 - [CO6A3_HUMAN] 
32.58 
P15880 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 
SV=2 - [RS2_HUMAN] 
32.42 
O43852 Calumenin OS=Homo sapiens GN=CALU PE=1 SV=2 - 
[CALU_HUMAN] 
32.38 
Q969Z0 Protein TBRG4 OS=Homo sapiens GN=TBRG4 PE=1 SV=1 - 
[TBRG4_HUMAN] 
32.05 
O75496 Geminin OS=Homo sapiens GN=GMNN PE=1 SV=1 - 
[GEMI_HUMAN] 
30.96 
Q9BPW8 Protein NipSnap homolog 1 OS=Homo sapiens GN=NIPSNAP1 
PE=1 SV=1 - [NIPS1_HUMAN] 
30.87 
O43681 ATPase ASNA1 OS=Homo sapiens GN=ASNA1 PE=1 SV=2 - 
[ASNA_HUMAN] 
30.82 
Q8WY22 BRI3-binding protein OS=Homo sapiens GN=BRI3BP PE=1 
SV=1 - [BRI3B_HUMAN] 
30.71 
Q13085 Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA 
PE=1 SV=2 - [ACACA_HUMAN] 
30.5 
P01374 Lymphotoxin-alpha OS=Homo sapiens GN=LTA PE=1 SV=2 - 
[TNFB_HUMAN] 
30.08 
P31943 Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens 
GN=HNRNPH1 PE=1 SV=4 - [HNRH1_HUMAN] 
30.07 
Q9Y333 U6 snRNA-associated Sm-like protein LSm2 OS=Homo 
sapiens GN=LSM2 PE=1 SV=1 - [LSM2_HUMAN] 
30.01 
Q15008 26S proteasome non-ATPase regulatory subunit 6 OS=Homo 
sapiens GN=PSMD6 PE=1 SV=1 - [PSMD6_HUMAN] 
29.85 
P62249 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 
PE=1 SV=2 - [RS16_HUMAN] 
29.62 
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P11498 Pyruvate carboxylase, mitochondrial OS=Homo sapiens 
GN=PC PE=1 SV=2 - [PYC_HUMAN] 
29.61 
P50990 T-complex protein 1 subunit theta OS=Homo sapiens 
GN=CCT8 PE=1 SV=4 - [TCPQ_HUMAN] 
29.5 
Q9H3P7 Golgi resident protein GCP60 OS=Homo sapiens GN=ACBD3 
PE=1 SV=4 - [GCP60_HUMAN] 
29.39 
Q8TF72 Protein Shroom3 OS=Homo sapiens GN=SHROOM3 PE=1 
SV=2 - [SHRM3_HUMAN] 
29.33 
Q9Y243 RAC-gamma serine/threonine-protein kinase OS=Homo 
sapiens GN=AKT3 PE=1 SV=1 - [AKT3_HUMAN] 
29.26 
Q8WTV0 Scavenger receptor class B member 1 OS=Homo sapiens 
GN=SCARB1 PE=1 SV=1 - [SCRB1_HUMAN] 
29.05 
P51808 Dynein light chain Tctex-type 3 OS=Homo sapiens 
GN=DYNLT3 PE=1 SV=1 - [DYLT3_HUMAN] 
28.93 
Q9Y6E2 Basic leucine zipper and W2 domain-containing protein 2 
OS=Homo sapiens GN=BZW2 PE=1 SV=1 - [BZW2_HUMAN] 
28.92 
Q17RC7 Exocyst complex component 3-like protein 4 OS=Homo 
sapiens GN=EXOC3L4 PE=1 SV=2 - [EX3L4_HUMAN] 
28.28 
Q15181 Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 
PE=1 SV=2 - [IPYR_HUMAN] 
28.14 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 OS=Homo 
sapiens GN=PSMD13 PE=1 SV=2 - [PSD13_HUMAN] 
28.12 
O60814 Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK 
PE=1 SV=3 - [H2B1K_HUMAN] 
27.84 
O95394 Phosphoacetylglucosamine mutase OS=Homo sapiens 
GN=PGM3 PE=1 SV=1 - [AGM1_HUMAN] 
27.8 
Q15365 Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 
PE=1 SV=2 - [PCBP1_HUMAN] 
27.1 
P63173 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 
PE=1 SV=2 - [RL38_HUMAN] 
26.88 
Q9HDC9 Adipocyte plasma membrane-associated protein OS=Homo 
sapiens GN=APMAP PE=1 SV=2 - [APMAP_HUMAN] 
26.77 
P55039 Developmentally-regulated GTP-binding protein 2 OS=Homo 
sapiens GN=DRG2 PE=1 SV=1 - [DRG2_HUMAN] 
26.72 
O60437 Periplakin OS=Homo sapiens GN=PPL PE=1 SV=4 - 
[PEPL_HUMAN] 
26.56 
O75915 PRA1 family protein 3 OS=Homo sapiens GN=ARL6IP5 PE=1 
SV=1 - [PRAF3_HUMAN] 
26.42 
P62877 E3 ubiquitin-protein ligase RBX1 OS=Homo sapiens GN=RBX1 
PE=1 SV=1 - [RBX1_HUMAN] 
26 
O75052 Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase 
protein OS=Homo sapiens GN=NOS1AP PE=1 SV=3 - 
[CAPON_HUMAN] 
25.91 
Q2KHT3 Protein CLEC16A OS=Homo sapiens GN=CLEC16A PE=2 
SV=2 - [CL16A_HUMAN] 
25.44 
Q9UJY1 Heat shock protein beta-8 OS=Homo sapiens GN=HSPB8 
PE=1 SV=1 - [HSPB8_HUMAN] 
24.14 
O14744 Protein arginine N-methyltransferase 5 OS=Homo sapiens 
GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
24.03 
P43246 DNA mismatch repair protein Msh2 OS=Homo sapiens 
GN=MSH2 PE=1 SV=1 - [MSH2_HUMAN] 
24.02 
P13984 General transcription factor IIF subunit 2 OS=Homo sapiens 
GN=GTF2F2 PE=1 SV=2 - [T2FB_HUMAN] 
23.27 
Q86WU2 Probable D-lactate dehydrogenase, mitochondrial OS=Homo 
sapiens GN=LDHD PE=1 SV=1 - [LDHD_HUMAN] 
22.54 
P30622 CAP-Gly domain-containing linker protein 1 OS=Homo sapiens 
GN=CLIP1 PE=1 SV=2 - [CLIP1_HUMAN] 
22.52 
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P28065 Proteasome subunit beta type-9 OS=Homo sapiens 
GN=PSMB9 PE=1 SV=2 - [PSB9_HUMAN] 
22.2 
Q9BVC6 Transmembrane protein 109 OS=Homo sapiens 
GN=TMEM109 PE=1 SV=1 - [TM109_HUMAN] 
22.03 
Q96BN8 Ubiquitin thioesterase otulin OS=Homo sapiens GN=OTULIN 
PE=1 SV=3 - [OTUL_HUMAN] 
20.15 
Q96B36 Proline-rich AKT1 substrate 1 OS=Homo sapiens GN=AKT1S1 
PE=1 SV=1 - [AKTS1_HUMAN] 
18.9 
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Appendix II 
 
Mass spectrometry analysis results for activity 2 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step, fraction 
21 (5.3.3.2.2) for activity 2, was analysed by mass spectrometry by Dr Deborah M Simpson 
(Centre for Proteasome Research, University of Liverpool) to identify candidate E3 ubiquitin 
ligases and/or chromatin remodellers. The full list of proteins identified is shown below in 
descending order of mascot score. 
 
 
Accession Description Mascot 
 
P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - 
[NUCL_HUMAN] 
2355.74 
O00267 Transcription elongation factor SPT5 OS=Homo sapiens 
GN=SUPT5H PE=1 SV=1 - [SPT5H_HUMAN] 
1699.3 
O15355 Protein phosphatase 1G OS=Homo sapiens GN=PPM1G PE=1 
SV=1 - [PPM1G_HUMAN] 
1581.25 
Q7KZ85 Transcription elongation factor SPT6 OS=Homo sapiens 
GN=SUPT6H PE=1 SV=2 - [SPT6H_HUMAN] 
1445.85 
P49792 E3 SUMO-protein ligase RanBP2 OS=Homo sapiens 
GN=RANBP2 PE=1 SV=2 - [RBP2_HUMAN] 
1138.41 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1 OS=Homo sapiens 
GN=HUWE1 PE=1 SV=3 - [HUWE1_HUMAN] 
1040.56 
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 
OS=Homo sapiens GN=CPS1 PE=1 SV=2 - [CPSM_HUMAN] 
891.5 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - 
[TBB5_HUMAN] 
831.35 
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 
SV=1 - [TBB4B_HUMAN] 
760.53 
O43847 Nardilysin OS=Homo sapiens GN=NRD1 PE=1 SV=2 - 
[NRDC_HUMAN] 
739.28 
P55072 Transitional endoplasmic reticulum ATPase OS=Homo sapiens 
GN=VCP PE=1 SV=4 - [TERA_HUMAN] 
736.18 
Q9UNZ2 NSFL1 cofactor p47 OS=Homo sapiens GN=NSFL1C PE=1 
SV=2 - [NSF1C_HUMAN] 
728.8 
P11021 78 kDa glucose-regulated protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 - [GRP78_HUMAN] 
716.35 
O43719 HIV Tat-specific factor 1 OS=Homo sapiens GN=HTATSF1 PE=1 
SV=1 - [HTSF1_HUMAN] 
702.56 
P53621 Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 
SV=2 - [COPA_HUMAN] 
688.71 
Q13885 Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 
SV=1 - [TBB2A_HUMAN] 
664.12 
P29692 Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 
SV=5 - [EF1D_HUMAN] 
 
645.89 
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Q9Y230 RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 - 
[RUVB2_HUMAN] 
636.63 
Q9Y4B6 Protein VPRBP OS=Homo sapiens GN=VPRBP PE=1 SV=3 - 
[VPRBP_HUMAN] 
592.64 
P11142 Heat shock cognate 71 kDa protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 - [HSP7C_HUMAN] 
561 
P26641 Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G 
PE=1 SV=3 - [EF1G_HUMAN] 
550.42 
P0DMV9 Heat shock 70 kDa protein 1B OS=Homo sapiens GN=HSPA1B 
PE=1 SV=1 - [HS71B_HUMAN] 
550.38 
P46060 Ran GTPase-activating protein 1 OS=Homo sapiens 
GN=RANGAP1 PE=1 SV=1 - [RAGP1_HUMAN] 
548.77 
Q07021 Complement component 1 Q subcomponent-binding protein, 
mitochondrial OS=Homo sapiens GN=C1QBP PE=1 SV=1 - 
[C1QBP_HUMAN] 
547.78 
P35606 Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 
SV=2 - [COPB2_HUMAN] 
541.06 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
523.49 
P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
506.97 
P14625 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 - 
[ENPL_HUMAN] 
487.15 
P68366 Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 
SV=1 - [TBA4A_HUMAN] 
487.14 
Q71U36 Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 
SV=1 - [TBA1A_HUMAN] 
486.26 
P05455 Lupus La protein OS=Homo sapiens GN=SSB PE=1 SV=2 - 
[LA_HUMAN] 
465.37 
P14314 Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH 
PE=1 SV=2 - [GLU2B_HUMAN] 
433.44 
Q9BUF5 Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 SV=1 
- [TBB6_HUMAN] 
425.06 
P25705 ATP synthase subunit alpha, mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 - [ATPA_HUMAN] 
408.35 
Q9Y678 Coatomer subunit gamma-1 OS=Homo sapiens GN=COPG1 
PE=1 SV=1 - [COPG1_HUMAN] 
407.45 
Q14697 Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB 
PE=1 SV=3 - [GANAB_HUMAN] 
406.11 
P49411 Elongation factor Tu, mitochondrial OS=Homo sapiens 
GN=TUFM PE=1 SV=2 - [EFTU_HUMAN] 
401.08 
Q99733 Nucleosome assembly protein 1-like 4 OS=Homo sapiens 
GN=NAP1L4 PE=1 SV=1 - [NP1L4_HUMAN] 
392.59 
P08238 Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 - [HS90B_HUMAN] 
378.52 
P48444 Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 
SV=1 - [COPD_HUMAN] 
376.42 
P52292 Importin subunit alpha-1 OS=Homo sapiens GN=KPNA2 PE=1 
SV=1 - [IMA1_HUMAN] 
349.11 
P24534 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 
SV=3 - [EF1B_HUMAN] 
340.94 
P38646 Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 
PE=1 SV=2 - [GRP75_HUMAN] 
337.51 
P07900 Heat shock protein HSP 90-alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 - [HS90A_HUMAN] 
311.22 
P33993 DNA replication licensing factor MCM7 OS=Homo sapiens 
GN=MCM7 PE=1 SV=4 - [MCM7_HUMAN] 
306.52 
227 
 
Accession Description Mascot 
 
P02786 Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC 
PE=1 SV=2 - [TFR1_HUMAN] 
302.96 
P35998 26S protease regulatory subunit 7 OS=Homo sapiens 
GN=PSMC2 PE=1 SV=3 - [PRS7_HUMAN] 
296.87 
P55209 Nucleosome assembly protein 1-like 1 OS=Homo sapiens 
GN=NAP1L1 PE=1 SV=1 - [NP1L1_HUMAN] 
292.32 
P27797 Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 - 
[CALR_HUMAN] 
271.02 
P06748 Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 - 
[NPM_HUMAN] 
268.73 
P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 
SV=1 - [1433Z_HUMAN] 
264.06 
P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 
SV=2 - [RINI_HUMAN] 
258.97 
Q9H3U1 Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A 
PE=1 SV=1 - [UN45A_HUMAN] 
255.96 
Q13200 26S proteasome non-ATPase regulatory subunit 2 OS=Homo 
sapiens GN=PSMD2 PE=1 SV=3 - [PSMD2_HUMAN] 
255.04 
Q9Y265 RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 - 
[RUVB1_HUMAN] 
243.98 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 OS=Homo 
sapiens GN=CAND1 PE=1 SV=2 - [CAND1_HUMAN] 
241.09 
Q8IYB7 DIS3-like exonuclease 2 OS=Homo sapiens GN=DIS3L2 PE=1 
SV=4 - [DI3L2_HUMAN] 
236.34 
P55786 Puromycin-sensitive aminopeptidase OS=Homo sapiens 
GN=NPEPPS PE=1 SV=2 - [PSA_HUMAN] 
230.5 
P23396 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 
SV=2 - [RS3_HUMAN] 
228.54 
Q07020 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 
SV=2 - [RL18_HUMAN] 
213.54 
O00410 Importin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4 - 
[IPO5_HUMAN] 
212.17 
O00148 ATP-dependent RNA helicase DDX39A OS=Homo sapiens 
GN=DDX39A PE=1 SV=2 - [DX39A_HUMAN] 
207.91 
Q9Y4X5 E3 ubiquitin-protein ligase ARIH1 OS=Homo sapiens GN=ARIH1 
PE=1 SV=2 - [ARI1_HUMAN] 
203.5 
Q00839 Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 - [HNRPU_HUMAN] 
202.94 
P48449 Lanosterol synthase OS=Homo sapiens GN=LSS PE=1 SV=1 - 
[ERG7_HUMAN] 
200.39 
P47712 Cytosolic phospholipase A2 OS=Homo sapiens GN=PLA2G4A 
PE=1 SV=2 - [PA24A_HUMAN] 
199.41 
P67809 Nuclease-sensitive element-binding protein 1 OS=Homo sapiens 
GN=YBX1 PE=1 SV=3 - [YBOX1_HUMAN] 
199.23 
Q14974 Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 
SV=2 - [IMB1_HUMAN] 
193.35 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
192.52 
P62195 26S protease regulatory subunit 8 OS=Homo sapiens 
GN=PSMC5 PE=1 SV=1 - [PRS8_HUMAN] 
191.03 
P84098 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 
SV=1 - [RL19_HUMAN] 
190.56 
P30876 DNA-directed RNA polymerase II subunit RPB2 OS=Homo 
sapiens GN=POLR2B PE=1 SV=1 - [RPB2_HUMAN] 
186.46 
P62826 GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN 
PE=1 SV=3 - [RAN_HUMAN] 
 
184.57 
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Q9BW61 DET1- and DDB1-associated protein 1 OS=Homo sapiens 
GN=DDA1 PE=1 SV=1 - [DDA1_HUMAN] 
184.02 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type OS=Homo 
sapiens GN=PFKP PE=1 SV=2 - [PFKAP_HUMAN] 
182.64 
O60884 DnaJ homolog subfamily A member 2 OS=Homo sapiens 
GN=DNAJA2 PE=1 SV=1 - [DNJA2_HUMAN] 
180.11 
P10809 60 kDa heat shock protein, mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 - [CH60_HUMAN] 
178.27 
Q14204 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens 
GN=DYNC1H1 PE=1 SV=5 - [DYHC1_HUMAN] 
170.64 
P31946 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 
SV=3 - [1433B_HUMAN] 
168.78 
Q16531 DNA damage-binding protein 1 OS=Homo sapiens GN=DDB1 
PE=1 SV=1 - [DDB1_HUMAN] 
167.4 
Q8IX15 Homeobox and leucine zipper protein Homez OS=Homo sapiens 
GN=HOMEZ PE=1 SV=2 - [HOMEZ_HUMAN] 
167.33 
P49327 Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 - 
[FAS_HUMAN] 
164.37 
Q01130 Serine/arginine-rich splicing factor 2 OS=Homo sapiens 
GN=SRSF2 PE=1 SV=4 - [SRSF2_HUMAN] 
164.18 
P31153 S-adenosylmethionine synthase isoform type-2 OS=Homo 
sapiens GN=MAT2A PE=1 SV=1 - [METK2_HUMAN] 
155.37 
Q9HAV4 Exportin-5 OS=Homo sapiens GN=XPO5 PE=1 SV=1 - 
[XPO5_HUMAN] 
153.96 
Q5TA31 E3 ubiquitin-protein ligase RNF187 OS=Homo sapiens 
GN=RNF187 PE=1 SV=2 - [RN187_HUMAN] 
153.24 
P17812 CTP synthase 1 OS=Homo sapiens GN=CTPS1 PE=1 SV=2 - 
[PYRG1_HUMAN] 
152.16 
P31689 DnaJ homolog subfamily A member 1 OS=Homo sapiens 
GN=DNAJA1 PE=1 SV=2 - [DNJA1_HUMAN] 
150.81 
O00629 Importin subunit alpha-3 OS=Homo sapiens GN=KPNA4 PE=1 
SV=1 - [IMA3_HUMAN] 
147.29 
P61923 Coatomer subunit zeta-1 OS=Homo sapiens GN=COPZ1 PE=1 
SV=1 - [COPZ1_HUMAN] 
144.22 
P12270 Nucleoprotein TPR OS=Homo sapiens GN=TPR PE=1 SV=3 - 
[TPR_HUMAN] 
142.18 
P55060 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 - 
[XPO2_HUMAN] 
141 
O95373 Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 - 
[IPO7_HUMAN] 
140.76 
P17980 26S protease regulatory subunit 6A OS=Homo sapiens 
GN=PSMC3 PE=1 SV=3 - [PRS6A_HUMAN] 
140.38 
P27348 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 
SV=1 - [1433T_HUMAN] 
139.89 
O14579 Coatomer subunit epsilon OS=Homo sapiens GN=COPE PE=1 
SV=3 - [COPE_HUMAN] 
136.25 
Q9UIA9 Exportin-7 OS=Homo sapiens GN=XPO7 PE=1 SV=3 - 
[XPO7_HUMAN] 
135.43 
P26373 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 
SV=4 - [RL13_HUMAN] 
135.39 
P46779 60S ribosomal protein L28 OS=Homo sapiens GN=RPL28 PE=1 
SV=3 - [RL28_HUMAN] 
134.96 
P68104 Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 
PE=1 SV=1 - [EF1A1_HUMAN] 
133.94 
P62191 26S protease regulatory subunit 4 OS=Homo sapiens 
GN=PSMC1 PE=1 SV=1 - [PRS4_HUMAN] 
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P13639 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - 
[EF2_HUMAN] 
131.18 
P01891 HLA class I histocompatibility antigen, A-68 alpha chain 
OS=Homo sapiens GN=HLA-A PE=1 SV=4 - [1A68_HUMAN] 
129.98 
O60684 Importin subunit alpha-7 OS=Homo sapiens GN=KPNA6 PE=1 
SV=1 - [IMA7_HUMAN] 
128.09 
P41091 Eukaryotic translation initiation factor 2 subunit 3 OS=Homo 
sapiens GN=EIF2S3 PE=1 SV=3 - [IF2G_HUMAN] 
125.57 
P53618 Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1 
SV=3 - [COPB_HUMAN] 
125.01 
P52294 Importin subunit alpha-5 OS=Homo sapiens GN=KPNA1 PE=1 
SV=3 - [IMA5_HUMAN] 
124.29 
P62263 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 
SV=3 - [RS14_HUMAN] 
124 
Q99460 26S proteasome non-ATPase regulatory subunit 1 OS=Homo 
sapiens GN=PSMD1 PE=1 SV=2 - [PSMD1_HUMAN] 
123.91 
P63165 Small ubiquitin-related modifier 1 OS=Homo sapiens 
GN=SUMO1 PE=1 SV=1 - [SUMO1_HUMAN] 
123.56 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 
SV=1 - [MEP50_HUMAN] 
122.68 
P42677 40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 
SV=3 - [RS27_HUMAN] 
120.25 
P10155 60 kDa SS-A/Ro ribonucleoprotein OS=Homo sapiens 
GN=TROVE2 PE=1 SV=2 - [RO60_HUMAN] 
119.32 
P08134 Rho-related GTP-binding protein RhoC OS=Homo sapiens 
GN=RHOC PE=1 SV=1 - [RHOC_HUMAN] 
119.07 
P55084 Trifunctional enzyme subunit beta, mitochondrial OS=Homo 
sapiens GN=HADHB PE=1 SV=3 - [ECHB_HUMAN] 
118.75 
P04792 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 
SV=2 - [HSPB1_HUMAN] 
117.15 
P00367 Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens 
GN=GLUD1 PE=1 SV=2 - [DHE3_HUMAN] 
116.77 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 - [K1C9_HUMAN] 
116.19 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA 
PE=1 SV=1 - [PCNA_HUMAN] 
114.14 
P78318 Immunoglobulin-binding protein 1 OS=Homo sapiens GN=IGBP1 
PE=1 SV=1 - [IGBP1_HUMAN] 
112.67 
P61981 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 
SV=2 - [1433G_HUMAN] 
111.41 
Q02543 60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A 
PE=1 SV=2 - [RL18A_HUMAN] 
108.93 
Q13263 Transcription intermediary factor 1-beta OS=Homo sapiens 
GN=TRIM28 PE=1 SV=5 - [TIF1B_HUMAN] 
105.94 
P40939 Trifunctional enzyme subunit alpha, mitochondrial OS=Homo 
sapiens GN=HADHA PE=1 SV=2 - [ECHA_HUMAN] 
104 
P14324 Farnesyl pyrophosphate synthase OS=Homo sapiens GN=FDPS 
PE=1 SV=4 - [FPPS_HUMAN] 
103.23 
P60900 Proteasome subunit alpha type-6 OS=Homo sapiens 
GN=PSMA6 PE=1 SV=1 - [PSA6_HUMAN] 
101.65 
O00505 Importin subunit alpha-4 OS=Homo sapiens GN=KPNA3 PE=1 
SV=2 - [IMA4_HUMAN] 
101.12 
P62306 Small nuclear ribonucleoprotein F OS=Homo sapiens 
GN=SNRPF PE=1 SV=1 - [RUXF_HUMAN] 
101.12 
P61586 Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 
SV=1 - [RHOA_HUMAN] 
 
99.23 
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O60664 Perilipin-3 OS=Homo sapiens GN=PLIN3 PE=1 SV=3 - 
[PLIN3_HUMAN] 
98.61 
P25788 Proteasome subunit alpha type-3 OS=Homo sapiens 
GN=PSMA3 PE=1 SV=2 - [PSA3_HUMAN] 
97.6 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 - [PABP1_HUMAN] 
96.98 
P39023 60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 
SV=2 - [RL3_HUMAN] 
96.83 
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens 
GN=SNRPD2 PE=1 SV=1 - [SMD2_HUMAN] 
96.57 
P35613 Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 - 
[BASI_HUMAN] 
95.44 
Q5JVF3 PCI domain-containing protein 2 OS=Homo sapiens GN=PCID2 
PE=1 SV=2 - [PCID2_HUMAN] 
95.29 
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A 
OS=Homo sapiens GN=PPP4R3A PE=1 SV=1 - 
[P4R3A_HUMAN] 
95.24 
P42704 Leucine-rich PPR motif-containing protein, mitochondrial 
OS=Homo sapiens GN=LRPPRC PE=1 SV=3 - 
[LPPRC_HUMAN] 
93.66 
O60841 Eukaryotic translation initiation factor 5B OS=Homo sapiens 
GN=EIF5B PE=1 SV=4 - [IF2P_HUMAN] 
93.54 
O14744 Protein arginine N-methyltransferase 5 OS=Homo sapiens 
GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
93.09 
P62491 Ras-related protein Rab-11A OS=Homo sapiens GN=RAB11A 
PE=1 SV=3 - [RB11A_HUMAN] 
93.08 
Q04917 14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 - 
[1433F_HUMAN] 
92.7 
P49588 Alanine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=AARS 
PE=1 SV=2 - [SYAC_HUMAN] 
91.4 
P38606 V-type proton ATPase catalytic subunit A OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 - [VATA_HUMAN] 
90.66 
P36578 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 
SV=5 - [RL4_HUMAN] 
89.68 
Q9NVJ2 ADP-ribosylation factor-like protein 8B OS=Homo sapiens 
GN=ARL8B PE=1 SV=1 - [ARL8B_HUMAN] 
89.48 
P09661 U2 small nuclear ribonucleoprotein A' OS=Homo sapiens 
GN=SNRPA1 PE=1 SV=2 - [RU2A_HUMAN] 
89.28 
O95816 BAG family molecular chaperone regulator 2 OS=Homo sapiens 
GN=BAG2 PE=1 SV=1 - [BAG2_HUMAN] 
89.09 
P62424 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 
SV=2 - [RL7A_HUMAN] 
88.53 
P01111 GTPase NRas OS=Homo sapiens GN=NRAS PE=1 SV=1 - 
[RASN_HUMAN] 
88.06 
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' 
OS=Homo sapiens GN=SNRPB PE=1 SV=2 - [RSMB_HUMAN] 
87.63 
Q15645 Pachytene checkpoint protein 2 homolog OS=Homo sapiens 
GN=TRIP13 PE=1 SV=2 - [PCH2_HUMAN] 
87.37 
P62269 40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 
SV=3 - [RS18_HUMAN] 
86.99 
P62258 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 
SV=1 - [1433E_HUMAN] 
86.31 
Q99832 T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 
PE=1 SV=2 - [TCPH_HUMAN] 
85.87 
P43686 26S protease regulatory subunit 6B OS=Homo sapiens 
GN=PSMC4 PE=1 SV=2 - [PRS6B_HUMAN] 
 
85.42 
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P61026 Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 
PE=1 SV=1 - [RAB10_HUMAN] 
85.29 
P46783 40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 
SV=1 - [RS10_HUMAN] 
85.28 
P63272 Transcription elongation factor SPT4 OS=Homo sapiens 
GN=SUPT4H1 PE=1 SV=1 - [SPT4H_HUMAN] 
85.21 
O00233 26S proteasome non-ATPase regulatory subunit 9 OS=Homo 
sapiens GN=PSMD9 PE=1 SV=3 - [PSMD9_HUMAN] 
84.92 
P25787 Proteasome subunit alpha type-2 OS=Homo sapiens 
GN=PSMA2 PE=1 SV=2 - [PSA2_HUMAN] 
84.86 
P61247 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 
SV=2 - [RS3A_HUMAN] 
84.78 
Q9P2R7 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 
OS=Homo sapiens GN=SUCLA2 PE=1 SV=3 - 
[SUCB1_HUMAN] 
84.58 
P06576 ATP synthase subunit beta, mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 - [ATPB_HUMAN] 
84.23 
P17858 ATP-dependent 6-phosphofructokinase, liver type OS=Homo 
sapiens GN=PFKL PE=1 SV=6 - [PFKAL_HUMAN] 
83.62 
Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 
PE=1 SV=1 - [TEBP_HUMAN] 
83.51 
Q5VYK3 Proteasome-associated protein ECM29 homolog OS=Homo 
sapiens GN=ECM29 PE=1 SV=2 - [ECM29_HUMAN] 
83.24 
P08237 ATP-dependent 6-phosphofructokinase, muscle type OS=Homo 
sapiens GN=PFKM PE=1 SV=2 - [PFKAM_HUMAN] 
82.59 
Q92616 Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 
PE=1 SV=6 - [GCN1L_HUMAN] 
81.5 
P46777 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 
SV=3 - [RL5_HUMAN] 
81.46 
Q06210 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 
1 OS=Homo sapiens GN=GFPT1 PE=1 SV=3 - 
[GFPT1_HUMAN] 
81.34 
Q9H4A6 Golgi phosphoprotein 3 OS=Homo sapiens GN=GOLPH3 PE=1 
SV=1 - [GOLP3_HUMAN] 
81.31 
Q8TEX9 Importin-4 OS=Homo sapiens GN=IPO4 PE=1 SV=2 - 
[IPO4_HUMAN] 
80.48 
Q96P70 Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - 
[IPO9_HUMAN] 
80.04 
P51570 Galactokinase OS=Homo sapiens GN=GALK1 PE=1 SV=1 - 
[GALK1_HUMAN] 
79.61 
O43242 26S proteasome non-ATPase regulatory subunit 3 OS=Homo 
sapiens GN=PSMD3 PE=1 SV=2 - [PSMD3_HUMAN] 
79.5 
P18754 Regulator of chromosome condensation OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 - [RCC1_HUMAN] 
79.24 
Q969Z0 Protein TBRG4 OS=Homo sapiens GN=TBRG4 PE=1 SV=1 - 
[TBRG4_HUMAN] 
78.63 
Q9NZT2 Opioid growth factor receptor OS=Homo sapiens GN=OGFR 
PE=1 SV=3 - [OGFR_HUMAN] 
78.32 
Q9Y285 Phenylalanine--tRNA ligase alpha subunit OS=Homo sapiens 
GN=FARSA PE=1 SV=3 - [SYFA_HUMAN] 
77.1 
Q9BSD7 Cancer-related nucleoside-triphosphatase OS=Homo sapiens 
GN=NTPCR PE=1 SV=1 - [NTPCR_HUMAN] 
76.97 
Q9HDC9 Adipocyte plasma membrane-associated protein OS=Homo 
sapiens GN=APMAP PE=1 SV=2 - [APMAP_HUMAN] 
75.9 
Q92973 Transportin-1 OS=Homo sapiens GN=TNPO1 PE=1 SV=2 - 
[TNPO1_HUMAN] 
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O60547 GDP-mannose 4,6 dehydratase OS=Homo sapiens GN=GMDS 
PE=1 SV=1 - [GMDS_HUMAN] 
75.09 
Q01105 Protein SET OS=Homo sapiens GN=SET PE=1 SV=3 - 
[SET_HUMAN] 
74.88 
P05388 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 
PE=1 SV=1 - [RLA0_HUMAN] 
74.75 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial OS=Homo sapiens 
GN=IARS2 PE=1 SV=2 - [SYIM_HUMAN] 
73.84 
Q13310 Polyadenylate-binding protein 4 OS=Homo sapiens 
GN=PABPC4 PE=1 SV=1 - [PABP4_HUMAN] 
73.51 
P61221 ATP-binding cassette sub-family E member 1 OS=Homo sapiens 
GN=ABCE1 PE=1 SV=1 - [ABCE1_HUMAN] 
73.05 
Q9BTW9 Tubulin-specific chaperone D OS=Homo sapiens GN=TBCD 
PE=1 SV=2 - [TBCD_HUMAN] 
72.93 
P46782 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 
SV=4 - [RS5_HUMAN] 
72.91 
Q9UBF2 Coatomer subunit gamma-2 OS=Homo sapiens GN=COPG2 
PE=1 SV=1 - [COPG2_HUMAN] 
71.55 
P52597 Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens 
GN=HNRNPF PE=1 SV=3 - [HNRPF_HUMAN] 
70.95 
P34932 Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 
PE=1 SV=4 - [HSP74_HUMAN] 
70.74 
Q2TB90 Putative hexokinase HKDC1 OS=Homo sapiens GN=HKDC1 
PE=1 SV=3 - [HKDC1_HUMAN] 
70.7 
P62829 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 
SV=1 - [RL23_HUMAN] 
70.61 
Q9H814 Phosphorylated adapter RNA export protein OS=Homo sapiens 
GN=PHAX PE=1 SV=1 - [PHAX_HUMAN] 
69.14 
P25786 Proteasome subunit alpha type-1 OS=Homo sapiens 
GN=PSMA1 PE=1 SV=1 - [PSA1_HUMAN] 
69.06 
Q14203 Dynactin subunit 1 OS=Homo sapiens GN=DCTN1 PE=1 SV=3 - 
[DCTN1_HUMAN] 
68.05 
P51648 Fatty aldehyde dehydrogenase OS=Homo sapiens 
GN=ALDH3A2 PE=1 SV=1 - [AL3A2_HUMAN] 
66.25 
P60866 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 
SV=1 - [RS20_HUMAN] 
65.92 
P49593 Protein phosphatase 1F OS=Homo sapiens GN=PPM1F PE=1 
SV=3 - [PPM1F_HUMAN] 
65.03 
O14732 Inositol monophosphatase 2 OS=Homo sapiens GN=IMPA2 
PE=1 SV=1 - [IMPA2_HUMAN] 
64.92 
P08195 4F2 cell-surface antigen heavy chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 - [4F2_HUMAN] 
64.91 
P41250 Glycine--tRNA ligase OS=Homo sapiens GN=GARS PE=1 SV=3 
- [SYG_HUMAN] 
64.54 
P17655 Calpain-2 catalytic subunit OS=Homo sapiens GN=CAPN2 PE=1 
SV=6 - [CAN2_HUMAN] 
64.33 
P63173 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 
SV=2 - [RL38_HUMAN] 
64.1 
P0CW18 Serine protease 56 OS=Homo sapiens GN=PRSS56 PE=1 SV=1 
- [PRS56_HUMAN] 
63.93 
P61254 60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 
SV=1 - [RL26_HUMAN] 
63.88 
P46459 Vesicle-fusing ATPase OS=Homo sapiens GN=NSF PE=1 SV=3 
- [NSF_HUMAN] 
63.86 
P36404 ADP-ribosylation factor-like protein 2 OS=Homo sapiens 
GN=ARL2 PE=1 SV=4 - [ARL2_HUMAN] 
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P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 
PE=1 SV=6 - [K1C10_HUMAN] 
63.28 
Q96EY4 Translation machinery-associated protein 16 OS=Homo sapiens 
GN=TMA16 PE=1 SV=2 - [TMA16_HUMAN] 
62.58 
O60313 Dynamin-like 120 kDa protein, mitochondrial OS=Homo sapiens 
GN=OPA1 PE=1 SV=3 - [OPA1_HUMAN] 
62.51 
P62280 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 
SV=3 - [RS11_HUMAN] 
62.04 
P52298 Nuclear cap-binding protein subunit 2 OS=Homo sapiens 
GN=NCBP2 PE=1 SV=1 - [NCBP2_HUMAN] 
60.79 
Q9BRK5 45 kDa calcium-binding protein OS=Homo sapiens GN=SDF4 
PE=1 SV=1 - [CAB45_HUMAN] 
60.73 
Q13572 Inositol-tetrakisphosphate 1-kinase OS=Homo sapiens 
GN=ITPK1 PE=1 SV=2 - [ITPK1_HUMAN] 
60.56 
P35250 Replication factor C subunit 2 OS=Homo sapiens GN=RFC2 
PE=1 SV=3 - [RFC2_HUMAN] 
60.44 
P49736 DNA replication licensing factor MCM2 OS=Homo sapiens 
GN=MCM2 PE=1 SV=4 - [MCM2_HUMAN] 
60.32 
P43358 Melanoma-associated antigen 4 OS=Homo sapiens 
GN=MAGEA4 PE=1 SV=2 - [MAGA4_HUMAN] 
60.11 
P12268 Inosine-5'-monophosphate dehydrogenase 2 OS=Homo sapiens 
GN=IMPDH2 PE=1 SV=2 - [IMDH2_HUMAN] 
59.32 
Q9P289 Serine/threonine-protein kinase 26 OS=Homo sapiens 
GN=STK26 PE=1 SV=2 - [STK26_HUMAN] 
59.07 
Q9HAV0 Guanine nucleotide-binding protein subunit beta-4 OS=Homo 
sapiens GN=GNB4 PE=1 SV=3 - [GBB4_HUMAN] 
58.51 
Q15393 Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 
PE=1 SV=4 - [SF3B3_HUMAN] 
57.89 
Q9BU61 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 3 OS=Homo sapiens GN=NDUFAF3 PE=1 
SV=1 - [NDUF3_HUMAN] 
57.81 
Q99436 Proteasome subunit beta type-7 OS=Homo sapiens GN=PSMB7 
PE=1 SV=1 - [PSB7_HUMAN] 
57.35 
P61353 60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 
SV=2 - [RL27_HUMAN] 
57.32 
O95831 Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens 
GN=AIFM1 PE=1 SV=1 - [AIFM1_HUMAN] 
56.29 
P27824 Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 - 
[CALX_HUMAN] 
56.22 
Q9Y305 Acyl-coenzyme A thioesterase 9, mitochondrial OS=Homo 
sapiens GN=ACOT9 PE=1 SV=2 - [ACOT9_HUMAN] 
55.45 
P50914 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 
SV=4 - [RL14_HUMAN] 
55.41 
P53803 DNA-directed RNA polymerases I, II, and III subunit RPABC4 
OS=Homo sapiens GN=POLR2K PE=3 SV=1 - 
[RPAB4_HUMAN] 
55.31 
Q16790 Carbonic anhydrase 9 OS=Homo sapiens GN=CA9 PE=1 SV=2 - 
[CAH9_HUMAN] 
55.3 
Q99614 Tetratricopeptide repeat protein 1 OS=Homo sapiens GN=TTC1 
PE=1 SV=1 - [TTC1_HUMAN] 
55.19 
Q9UG63 ATP-binding cassette sub-family F member 2 OS=Homo sapiens 
GN=ABCF2 PE=1 SV=2 - [ABCF2_HUMAN] 
55.05 
Q9Y4L1 Hypoxia up-regulated protein 1 OS=Homo sapiens GN=HYOU1 
PE=1 SV=1 - [HYOU1_HUMAN] 
54.76 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 OS=Homo 
sapiens GN=PSMD13 PE=1 SV=2 - [PSD13_HUMAN] 
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P14618 Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 - 
[KPYM_HUMAN] 
54.59 
O60814 Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK PE=1 
SV=3 - [H2B1K_HUMAN] 
54.41 
P48643 T-complex protein 1 subunit epsilon OS=Homo sapiens 
GN=CCT5 PE=1 SV=1 - [TCPE_HUMAN] 
53.88 
P60842 Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 
PE=1 SV=1 - [IF4A1_HUMAN] 
53.84 
P08579 U2 small nuclear ribonucleoprotein B'' OS=Homo sapiens 
GN=SNRPB2 PE=1 SV=1 - [RU2B_HUMAN] 
53.54 
P51153 Ras-related protein Rab-13 OS=Homo sapiens GN=RAB13 
PE=1 SV=1 - [RAB13_HUMAN] 
52.73 
P61313 60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 
SV=2 - [RL15_HUMAN] 
52.73 
Q9H2U1 ATP-dependent RNA helicase DHX36 OS=Homo sapiens 
GN=DHX36 PE=1 SV=2 - [DHX36_HUMAN] 
52.28 
Q7L8L6 FAST kinase domain-containing protein 5 OS=Homo sapiens 
GN=FASTKD5 PE=1 SV=1 - [FAKD5_HUMAN] 
52.17 
P31350 Ribonucleoside-diphosphate reductase subunit M2 OS=Homo 
sapiens GN=RRM2 PE=1 SV=1 - [RIR2_HUMAN] 
51.94 
Q9NUQ8 ATP-binding cassette sub-family F member 3 OS=Homo sapiens 
GN=ABCF3 PE=1 SV=2 - [ABCF3_HUMAN] 
51.83 
P62333 26S protease regulatory subunit 10B OS=Homo sapiens 
GN=PSMC6 PE=1 SV=1 - [PRS10_HUMAN] 
51.79 
O75436 Vacuolar protein sorting-associated protein 26A OS=Homo 
sapiens GN=VPS26A PE=1 SV=2 - [VP26A_HUMAN] 
51.74 
O75607 Nucleoplasmin-3 OS=Homo sapiens GN=NPM3 PE=1 SV=3 - 
[NPM3_HUMAN] 
51.59 
Q9Y3U8 60S ribosomal protein L36 OS=Homo sapiens GN=RPL36 PE=1 
SV=3 - [RL36_HUMAN] 
50.3 
P60953 Cell division control protein 42 homolog OS=Homo sapiens 
GN=CDC42 PE=1 SV=2 - [CDC42_HUMAN] 
49.53 
P27708 CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 - 
[PYR1_HUMAN] 
49.21 
Q8N1F7 Nuclear pore complex protein Nup93 OS=Homo sapiens 
GN=NUP93 PE=1 SV=2 - [NUP93_HUMAN] 
48.9 
P53365 Arfaptin-2 OS=Homo sapiens GN=ARFIP2 PE=1 SV=1 - 
[ARFP2_HUMAN] 
48.87 
P04181 Ornithine aminotransferase, mitochondrial OS=Homo sapiens 
GN=OAT PE=1 SV=1 - [OAT_HUMAN] 
48.75 
P28072 Proteasome subunit beta type-6 OS=Homo sapiens GN=PSMB6 
PE=1 SV=4 - [PSB6_HUMAN] 
48.17 
Q9HD40 O-phosphoseryl-tRNA(Sec) selenium transferase OS=Homo 
sapiens GN=SEPSECS PE=1 SV=2 - [SPCS_HUMAN] 
47.96 
P11279 Lysosome-associated membrane glycoprotein 1 OS=Homo 
sapiens GN=LAMP1 PE=1 SV=3 - [LAMP1_HUMAN] 
47.87 
P50990 T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 
PE=1 SV=4 - [TCPQ_HUMAN] 
47.71 
O00231 26S proteasome non-ATPase regulatory subunit 11 OS=Homo 
sapiens GN=PSMD11 PE=1 SV=3 - [PSD11_HUMAN] 
46.11 
P62249 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 
SV=2 - [RS16_HUMAN] 
45.94 
Q9NR31 GTP-binding protein SAR1a OS=Homo sapiens GN=SAR1A 
PE=1 SV=1 - [SAR1A_HUMAN] 
45.9 
Q9H7Z7 Prostaglandin E synthase 2 OS=Homo sapiens GN=PTGES2 
PE=1 SV=1 - [PGES2_HUMAN] 
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P19367 Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 - 
[HXK1_HUMAN] 
45.8 
Q96D46 60S ribosomal export protein NMD3 OS=Homo sapiens 
GN=NMD3 PE=1 SV=1 - [NMD3_HUMAN] 
44.84 
O14980 Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1 - 
[XPO1_HUMAN] 
44.69 
Q3ZCQ8 Mitochondrial import inner membrane translocase subunit TIM50 
OS=Homo sapiens GN=TIMM50 PE=1 SV=2 - [TIM50_HUMAN] 
44.23 
P62277 40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 
SV=2 - [RS13_HUMAN] 
44.09 
P43246 DNA mismatch repair protein Msh2 OS=Homo sapiens 
GN=MSH2 PE=1 SV=1 - [MSH2_HUMAN] 
44.01 
P62917 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 
SV=2 - [RL8_HUMAN] 
43.82 
Q02878 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 
SV=3 - [RL6_HUMAN] 
43.67 
O00487 26S proteasome non-ATPase regulatory subunit 14 OS=Homo 
sapiens GN=PSMD14 PE=1 SV=1 - [PSDE_HUMAN] 
43.62 
P62877 E3 ubiquitin-protein ligase RBX1 OS=Homo sapiens GN=RBX1 
PE=1 SV=1 - [RBX1_HUMAN] 
43.18 
Q9H5X1 MIP18 family protein FAM96A OS=Homo sapiens GN=FAM96A 
PE=1 SV=1 - [FA96A_HUMAN] 
42.79 
O75489 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial OS=Homo sapiens GN=NDUFS3 PE=1 SV=1 - 
[NDUS3_HUMAN] 
42.29 
Q13619 Cullin-4A OS=Homo sapiens GN=CUL4A PE=1 SV=3 - 
[CUL4A_HUMAN] 
42.19 
Q9BZG1 Ras-related protein Rab-34 OS=Homo sapiens GN=RAB34 
PE=1 SV=1 - [RAB34_HUMAN] 
41.95 
Q9BQ67 Glutamate-rich WD repeat-containing protein 1 OS=Homo 
sapiens GN=GRWD1 PE=1 SV=1 - [GRWD1_HUMAN] 
41.87 
Q15654 Thyroid receptor-interacting protein 6 OS=Homo sapiens 
GN=TRIP6 PE=1 SV=3 - [TRIP6_HUMAN] 
41.7 
Q04837 Single-stranded DNA-binding protein, mitochondrial OS=Homo 
sapiens GN=SSBP1 PE=1 SV=1 - [SSBP_HUMAN] 
41.4 
P62875 DNA-directed RNA polymerases I, II, and III subunit RPABC5 
OS=Homo sapiens GN=POLR2L PE=1 SV=1 - 
[RPAB5_HUMAN] 
41.24 
P50502 Hsc70-interacting protein OS=Homo sapiens GN=ST13 PE=1 
SV=2 - [F10A1_HUMAN] 
40.35 
Q15029 116 kDa U5 small nuclear ribonucleoprotein component 
OS=Homo sapiens GN=EFTUD2 PE=1 SV=1 - [U5S1_HUMAN] 
39.91 
P18124 60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 
SV=1 - [RL7_HUMAN] 
39.68 
P19387 DNA-directed RNA polymerase II subunit RPB3 OS=Homo 
sapiens GN=POLR2C PE=1 SV=2 - [RPB3_HUMAN] 
39.64 
Q96NT1 Nucleosome assembly protein 1-like 5 OS=Homo sapiens 
GN=NAP1L5 PE=2 SV=1 - [NP1L5_HUMAN] 
39.64 
P50897 Palmitoyl-protein thioesterase 1 OS=Homo sapiens GN=PPT1 
PE=1 SV=1 - [PPT1_HUMAN] 
39.6 
P37268 Squalene synthase OS=Homo sapiens GN=FDFT1 PE=1 SV=1 - 
[FDFT_HUMAN] 
39.6 
O43399 Tumor protein D54 OS=Homo sapiens GN=TPD52L2 PE=1 
SV=2 - [TPD54_HUMAN] 
39.29 
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 
OS=Homo sapiens GN=HNRNPUL2 PE=1 SV=1 - 
[HNRL2_HUMAN] 
38.48 
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O15397 Importin-8 OS=Homo sapiens GN=IPO8 PE=1 SV=2 - 
[IPO8_HUMAN] 
38.21 
P25205 DNA replication licensing factor MCM3 OS=Homo sapiens 
GN=MCM3 PE=1 SV=3 - [MCM3_HUMAN] 
38.12 
Q13907 Isopentenyl-diphosphate Delta-isomerase 1 OS=Homo sapiens 
GN=IDI1 PE=1 SV=2 - [IDI1_HUMAN] 
37.97 
Q9UK73 Protein fem-1 homolog B OS=Homo sapiens GN=FEM1B PE=1 
SV=1 - [FEM1B_HUMAN] 
37.91 
Q15365 Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 
SV=2 - [PCBP1_HUMAN] 
37.9 
P18077 60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A 
PE=1 SV=2 - [RL35A_HUMAN] 
37.7 
Q6NVV1 Putative 60S ribosomal protein L13a protein RPL13AP3 
OS=Homo sapiens GN=RPL13AP3 PE=5 SV=1 - 
[R13P3_HUMAN] 
37.61 
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
OS=Homo sapiens GN=IDH3A PE=1 SV=1 - [IDH3A_HUMAN] 
37.54 
Q53GA4 Pleckstrin homology-like domain family A member 2 OS=Homo 
sapiens GN=PHLDA2 PE=1 SV=2 - [PHLA2_HUMAN] 
37.36 
P52657 Transcription initiation factor IIA subunit 2 OS=Homo sapiens 
GN=GTF2A2 PE=1 SV=1 - [T2AG_HUMAN] 
36.45 
Q96BN8 Ubiquitin thioesterase otulin OS=Homo sapiens GN=OTULIN 
PE=1 SV=3 - [OTUL_HUMAN] 
36.23 
Q9H9P8 L-2-hydroxyglutarate dehydrogenase, mitochondrial OS=Homo 
sapiens GN=L2HGDH PE=1 SV=3 - [L2HDH_HUMAN] 
36.22 
P12110 Collagen alpha-2(VI) chain OS=Homo sapiens GN=COL6A2 
PE=1 SV=4 - [CO6A2_HUMAN] 
36.03 
P27635 60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 
SV=4 - [RL10_HUMAN] 
36 
Q9HCE1 Putative helicase MOV-10 OS=Homo sapiens GN=MOV10 PE=1 
SV=2 - [MOV10_HUMAN] 
35.94 
P51149 Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A 
PE=1 SV=1 - [RAB7A_HUMAN] 
35.88 
P18085 ADP-ribosylation factor 4 OS=Homo sapiens GN=ARF4 PE=1 
SV=3 - [ARF4_HUMAN] 
35.64 
Q96MC4 CEP295 N-terminal-like protein OS=Homo sapiens 
GN=CEP295NL PE=2 SV=1 - [C295L_HUMAN] 
35.5 
P11413 Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens 
GN=G6PD PE=1 SV=4 - [G6PD_HUMAN] 
35.29 
P84095 Rho-related GTP-binding protein RhoG OS=Homo sapiens 
GN=RHOG PE=1 SV=1 - [RHOG_HUMAN] 
34.89 
Q7Z4H3 HD domain-containing protein 2 OS=Homo sapiens GN=HDDC2 
PE=1 SV=1 - [HDDC2_HUMAN] 
34.75 
Q6PIU2 Neutral cholesterol ester hydrolase 1 OS=Homo sapiens 
GN=NCEH1 PE=1 SV=3 - [NCEH1_HUMAN] 
34.44 
Q9NPQ8 Synembryn-A OS=Homo sapiens GN=RIC8A PE=1 SV=3 - 
[RIC8A_HUMAN] 
34.34 
P62753 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 
SV=1 - [RS6_HUMAN] 
34.3 
Q9NSD9 Phenylalanine--tRNA ligase beta subunit OS=Homo sapiens 
GN=FARSB PE=1 SV=3 - [SYFB_HUMAN] 
33.86 
Q07002 Cyclin-dependent kinase 18 OS=Homo sapiens GN=CDK18 
PE=1 SV=3 - [CDK18_HUMAN] 
33.65 
P61978 Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens 
GN=HNRNPK PE=1 SV=1 - [HNRPK_HUMAN] 
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Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 
OS=Homo sapiens GN=HNRNPUL1 PE=1 SV=2 - 
[HNRL1_HUMAN] 
32.73 
P21980 Protein-glutamine gamma-glutamyltransferase 2 OS=Homo 
sapiens GN=TGM2 PE=1 SV=2 - [TGM2_HUMAN] 
32.51 
Q16186 Proteasomal ubiquitin receptor ADRM1 OS=Homo sapiens 
GN=ADRM1 PE=1 SV=2 - [ADRM1_HUMAN] 
32.5 
P62906 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A 
PE=1 SV=2 - [RL10A_HUMAN] 
32.32 
Q8NF91 Nesprin-1 OS=Homo sapiens GN=SYNE1 PE=1 SV=4 - 
[SYNE1_HUMAN] 
32.09 
O43681 ATPase ASNA1 OS=Homo sapiens GN=ASNA1 PE=1 SV=2 - 
[ASNA_HUMAN] 
32.06 
P49902 Cytosolic purine 5'-nucleotidase OS=Homo sapiens GN=NT5C2 
PE=1 SV=1 - [5NTC_HUMAN] 
31.92 
P13995 Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial OS=Homo 
sapiens GN=MTHFD2 PE=1 SV=2 - [MTDC_HUMAN] 
31.82 
P11177 Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial OS=Homo sapiens GN=PDHB PE=1 SV=3 - 
[ODPB_HUMAN] 
31.48 
P46781 40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 
SV=3 - [RS9_HUMAN] 
31.33 
Q9Y2I1 Nischarin OS=Homo sapiens GN=NISCH PE=1 SV=3 - 
[NISCH_HUMAN] 
31.31 
P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform OS=Homo sapiens GN=PPP2R1A PE=1 
SV=4 - [2AAA_HUMAN] 
31.22 
P13637 Sodium/potassium-transporting ATPase subunit alpha-3 
OS=Homo sapiens GN=ATP1A3 PE=1 SV=3 - [AT1A3_HUMAN] 
31.17 
P11172 Uridine 5'-monophosphate synthase OS=Homo sapiens 
GN=UMPS PE=1 SV=1 - [UMPS_HUMAN] 
31.16 
Q92598 Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 
PE=1 SV=1 - [HS105_HUMAN] 
31.1 
P61201 COP9 signalosome complex subunit 2 OS=Homo sapiens 
GN=COPS2 PE=1 SV=1 - [CSN2_HUMAN] 
30.65 
P23258 Tubulin gamma-1 chain OS=Homo sapiens GN=TUBG1 PE=1 
SV=2 - [TBG1_HUMAN] 
30.65 
Q9NX14 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 
11, mitochondrial OS=Homo sapiens GN=NDUFB11 PE=1 SV=1 
- [NDUBB_HUMAN] 
30.59 
O75794 Cell division cycle protein 123 homolog OS=Homo sapiens 
GN=CDC123 PE=1 SV=1 - [CD123_HUMAN] 
29.22 
Q9P2R3 Rabankyrin-5 OS=Homo sapiens GN=ANKFY1 PE=1 SV=2 - 
[ANFY1_HUMAN] 
28.97 
O14818 Proteasome subunit alpha type-7 OS=Homo sapiens 
GN=PSMA7 PE=1 SV=1 - [PSA7_HUMAN] 
28.88 
O95757 Heat shock 70 kDa protein 4L OS=Homo sapiens GN=HSPA4L 
PE=1 SV=3 - [HS74L_HUMAN] 
28.83 
P48556 26S proteasome non-ATPase regulatory subunit 8 OS=Homo 
sapiens GN=PSMD8 PE=1 SV=2 - [PSMD8_HUMAN] 
28.68 
P51148 Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C 
PE=1 SV=2 - [RAB5C_HUMAN] 
 
28.31 
P20138 Myeloid cell surface antigen CD33 OS=Homo sapiens GN=CD33 
PE=1 SV=2 - [CD33_HUMAN] 
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P04843 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 OS=Homo sapiens GN=RPN1 PE=1 SV=1 - 
[RPN1_HUMAN] 
27.68 
Q9BW11 Max dimerization protein 3 OS=Homo sapiens GN=MXD3 PE=1 
SV=1 - [MAD3_HUMAN] 
27.54 
Q96MM3 Zinc finger protein 42 homolog OS=Homo sapiens GN=ZFP42 
PE=1 SV=2 - [ZFP42_HUMAN] 
27.53 
Q9Y3D0 Mitotic spindle-associated MMXD complex subunit MIP18 
OS=Homo sapiens GN=FAM96B PE=1 SV=1 - [MIP18_HUMAN] 
27.34 
P31943 Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens 
GN=HNRNPH1 PE=1 SV=4 - [HNRH1_HUMAN] 
26.92 
P35813 Protein phosphatase 1A OS=Homo sapiens GN=PPM1A PE=1 
SV=1 - [PPM1A_HUMAN] 
26.67 
O60232 Sjoegren syndrome/scleroderma autoantigen 1 OS=Homo 
sapiens GN=SSSCA1 PE=1 SV=1 - [SSA27_HUMAN] 
26.37 
Q06828 Fibromodulin OS=Homo sapiens GN=FMOD PE=1 SV=2 - 
[FMOD_HUMAN] 
26.22 
P15880 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 
SV=2 - [RS2_HUMAN] 
26.06 
Q9BUK6 Protein misato homolog 1 OS=Homo sapiens GN=MSTO1 PE=1 
SV=1 - [MSTO1_HUMAN] 
26.06 
P05067 Amyloid beta A4 protein OS=Homo sapiens GN=APP PE=1 
SV=3 - [A4_HUMAN] 
25.78 
P0C0S5 Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2 - 
[H2AZ_HUMAN] 
25.42 
Q0P6H9 Transmembrane protein 62 OS=Homo sapiens GN=TMEM62 
PE=1 SV=1 - [TMM62_HUMAN] 
24.97 
Q96QK1 Vacuolar protein sorting-associated protein 35 OS=Homo 
sapiens GN=VPS35 PE=1 SV=2 - [VPS35_HUMAN] 
24.64 
Q9NZR2 Low-density lipoprotein receptor-related protein 1B OS=Homo 
sapiens GN=LRP1B PE=1 SV=2 - [LRP1B_HUMAN] 
24.31 
P83731 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 
SV=1 - [RL24_HUMAN] 
23.58 
Q9NRG4 N-lysine methyltransferase SMYD2 OS=Homo sapiens 
GN=SMYD2 PE=1 SV=2 - [SMYD2_HUMAN] 
22.79 
Q13098 COP9 signalosome complex subunit 1 OS=Homo sapiens 
GN=GPS1 PE=1 SV=4 - [CSN1_HUMAN] 
22.71 
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1 
OS=Homo sapiens GN=PRKAA1 PE=1 SV=4 - 
[AAPK1_HUMAN] 
22.71 
Q9UNS2 COP9 signalosome complex subunit 3 OS=Homo sapiens 
GN=COPS3 PE=1 SV=3 - [CSN3_HUMAN] 
22.04 
Q13201 Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 - 
[MMRN1_HUMAN] 
20.83 
P05362 Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 
PE=1 SV=2 - [ICAM1_HUMAN] 
20.5 
P15170 Eukaryotic peptide chain release factor GTP-binding subunit 
ERF3A OS=Homo sapiens GN=GSPT1 PE=1 SV=1 - 
[ERF3A_HUMAN] 
17.01 
Q15386 Ubiquitin-protein ligase E3C OS=Homo sapiens GN=UBE3C 
PE=1 SV=3 - [UBE3C_HUMAN] 
0 
 
 
 
 
239 
 
Appendix III 
 
Mass spectrometry analysis results for activity 3 
 
The most active fraction from the final ion exchange (Mono Q) chromatography step, fraction 
29 (5.3.3.3.2) for activity 3, was analysed by mass spectrometry by Dr Deborah M Simpson 
(Centre for Proteasome Research, University of Liverpool) to identify candidate E3 ubiquitin 
ligases and/or chromatin remodellers. The full list of proteins identified is shown below in 
descending order of mascot score. 
 
 
Accession Description 
 
Mascot  
P67809 Nuclease-sensitive element-binding protein 1 OS=Homo sapiens 
GN=YBX1 PE=1 SV=3 - [YBOX1_HUMAN] 
916.92 
P16989 Y-box-binding protein 3 OS=Homo sapiens GN=YBX3 PE=1 
SV=4 - [YBOX3_HUMAN] 
458.57 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 - [PABP1_HUMAN] 
395.36 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 
SV=1 - [TBA1B_HUMAN] 
345.45 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
322.05 
Q9H2U1 ATP-dependent RNA helicase DHX36 OS=Homo sapiens 
GN=DHX36 PE=1 SV=2 - [DHX36_HUMAN] 
319.59 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - 
[TBB5_HUMAN] 
293.16 
P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
286.25 
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 
SV=1 - [TBB4B_HUMAN] 
285.62 
P09132 Signal recognition particle 19 kDa protein OS=Homo sapiens 
GN=SRP19 PE=1 SV=3 - [SRP19_HUMAN] 
263.72 
Q13885 Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 
SV=1 - [TBB2A_HUMAN] 
263.33 
P11021 78 kDa glucose-regulated protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 - [GRP78_HUMAN] 
262.34 
P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - 
[NUCL_HUMAN] 
252.54 
P11142 Heat shock cognate 71 kDa protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 - [HSP7C_HUMAN] 
222.02 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
216.99 
Q13310 Polyadenylate-binding protein 4 OS=Homo sapiens 
GN=PABPC4 PE=1 SV=1 - [PABP4_HUMAN] 
213.52 
P68366 Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 
SV=1 - [TBA4A_HUMAN] 
 
211.15 
240 
 
Accession Description 
 
Mascot  
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
192.57 
O15355 Protein phosphatase 1G OS=Homo sapiens GN=PPM1G PE=1 
SV=1 - [PPM1G_HUMAN] 
155.14 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - 
[H4_HUMAN] 
155.1 
P02786 Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC 
PE=1 SV=2 - [TFR1_HUMAN] 
137.95 
Q9HCE1 Putative helicase MOV-10 OS=Homo sapiens GN=MOV10 
PE=1 SV=2 - [MOV10_HUMAN] 
125.83 
P14314 Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH 
PE=1 SV=2 - [GLU2B_HUMAN] 
118.94 
P49411 Elongation factor Tu, mitochondrial OS=Homo sapiens 
GN=TUFM PE=1 SV=2 - [EFTU_HUMAN] 
112.53 
P62995 Transformer-2 protein homolog beta OS=Homo sapiens 
GN=TRA2B PE=1 SV=1 - [TRA2B_HUMAN] 
108.24 
P08238 Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 - [HS90B_HUMAN] 
107.79 
P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 
SV=1 - [1433Z_HUMAN] 
101.75 
P25705 ATP synthase subunit alpha, mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 - [ATPA_HUMAN] 
96.86 
P09661 U2 small nuclear ribonucleoprotein A' OS=Homo sapiens 
GN=SNRPA1 PE=1 SV=2 - [RU2A_HUMAN] 
96.63 
P08195 4F2 cell-surface antigen heavy chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 - [4F2_HUMAN] 
91.51 
P62826 GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN 
PE=1 SV=3 - [RAN_HUMAN] 
91.36 
P38646 Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 
PE=1 SV=2 - [GRP75_HUMAN] 
76.97 
Q6PKG0 La-related protein 1 OS=Homo sapiens GN=LARP1 PE=1 SV=2 
- [LARP1_HUMAN] 
76.59 
P14324 Farnesyl pyrophosphate synthase OS=Homo sapiens 
GN=FDPS PE=1 SV=4 - [FPPS_HUMAN] 
76.3 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
75.98 
Q99733 Nucleosome assembly protein 1-like 4 OS=Homo sapiens 
GN=NAP1L4 PE=1 SV=1 - [NP1L4_HUMAN] 
72.75 
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 
OS=Homo sapiens GN=CPS1 PE=1 SV=2 - [CPSM_HUMAN] 
71.4 
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' 
OS=Homo sapiens GN=SNRPB PE=1 SV=2 - [RSMB_HUMAN] 
70.18 
P05455 Lupus La protein OS=Homo sapiens GN=SSB PE=1 SV=2 - 
[LA_HUMAN] 
70.13 
P62306 Small nuclear ribonucleoprotein F OS=Homo sapiens 
GN=SNRPF PE=1 SV=1 - [RUXF_HUMAN] 
65.99 
P08579 U2 small nuclear ribonucleoprotein B'' OS=Homo sapiens 
GN=SNRPB2 PE=1 SV=1 - [RU2B_HUMAN] 
65.83 
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 
OS=Homo sapiens GN=HNRNPUL1 PE=1 SV=2 - 
[HNRL1_HUMAN] 
64.84 
P49458 Signal recognition particle 9 kDa protein OS=Homo sapiens 
GN=SRP9 PE=1 SV=2 - [SRP09_HUMAN] 
64.56 
P17980 26S protease regulatory subunit 6A OS=Homo sapiens 
GN=PSMC3 PE=1 SV=3 - [PRS6A_HUMAN] 
61.76 
P62424 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 
SV=2 - [RL7A_HUMAN] 
61.72 
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Accession Description 
 
Mascot  
P01891 HLA class I histocompatibility antigen, A-68 alpha chain 
OS=Homo sapiens GN=HLA-A PE=1 SV=4 - [1A68_HUMAN] 
61 
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens 
GN=SNRPD2 PE=1 SV=1 - [SMD2_HUMAN] 
54.74 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type OS=Homo 
sapiens GN=PFKP PE=1 SV=2 - [PFKAP_HUMAN] 
53.67 
P27824 Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 - 
[CALX_HUMAN] 
50.44 
Q7Z2W4 Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens 
GN=ZC3HAV1 PE=1 SV=3 - [ZCCHV_HUMAN] 
49.93 
P12111 Collagen alpha-3(VI) chain OS=Homo sapiens GN=COL6A3 
PE=1 SV=5 - [CO6A3_HUMAN] 
47.49 
P29692 Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 
SV=5 - [EF1D_HUMAN] 
46.14 
P35052 Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=2 - 
[GPC1_HUMAN] 
44.09 
Q9P015 39S ribosomal protein L15, mitochondrial OS=Homo sapiens 
GN=MRPL15 PE=1 SV=1 - [RM15_HUMAN] 
43.37 
Q92900 Regulator of nonsense transcripts 1 OS=Homo sapiens 
GN=UPF1 PE=1 SV=2 - [RENT1_HUMAN] 
43.3 
A8MWD9 Putative small nuclear ribonucleoprotein G-like protein 15 
OS=Homo sapiens GN=SNRPGP15 PE=5 SV=2 - 
[RUXGL_HUMAN] 
43.07 
P62195 26S protease regulatory subunit 8 OS=Homo sapiens 
GN=PSMC5 PE=1 SV=1 - [PRS8_HUMAN] 
42.81 
P68104 Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 
PE=1 SV=1 - [EF1A1_HUMAN] 
42.39 
Q13200 26S proteasome non-ATPase regulatory subunit 2 OS=Homo 
sapiens GN=PSMD2 PE=1 SV=3 - [PSMD2_HUMAN] 
41.53 
P01889 HLA class I histocompatibility antigen, B-7 alpha chain 
OS=Homo sapiens GN=HLA-B PE=1 SV=3 - [1B07_HUMAN] 
40.22 
P52298 Nuclear cap-binding protein subunit 2 OS=Homo sapiens 
GN=NCBP2 PE=1 SV=1 - [NCBP2_HUMAN] 
40.06 
O00425 Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo 
sapiens GN=IGF2BP3 PE=1 SV=2 - [IF2B3_HUMAN] 
30.95 
P62241 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 
SV=2 - [RS8_HUMAN] 
28.65 
P62318 Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens 
GN=SNRPD3 PE=1 SV=1 - [SMD3_HUMAN] 
28.53 
P55060 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 - 
[XPO2_HUMAN] 
28.5 
P37108 Signal recognition particle 14 kDa protein OS=Homo sapiens 
GN=SRP14 PE=1 SV=2 - [SRP14_HUMAN] 
26.69 
Q9BYD1 39S ribosomal protein L13, mitochondrial OS=Homo sapiens 
GN=MRPL13 PE=1 SV=1 - [RM13_HUMAN] 
25.38 
Q9Y623 Myosin-4 OS=Homo sapiens GN=MYH4 PE=1 SV=2 - 
[MYH4_HUMAN] 
25.11 
Q02878 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 
SV=3 - [RL6_HUMAN] 
24.75 
P62888 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 
SV=2 - [RL30_HUMAN] 
24.43 
P62906 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A 
PE=1 SV=2 - [RL10A_HUMAN] 
23.38 
P84098 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 
SV=1 - [RL19_HUMAN] 
21.01 
Q9H3U1 Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A 
PE=1 SV=1 - [UN45A_HUMAN] 
20.83 
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